TW202315895A - Engineered compositions - Google Patents

Abstract

Provided herein are engineered coronavirus polypeptides, polynucleotides that encode the polypeptides, vectors and host cells that comprise the polynucleotides and/or express the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered spike ectodomains, monomeric receptor binding domains (RBDs), engineered RBDs, and fusion proteins that comprise any one or more of the foregoing.

Description

engineered composition

The present invention relates to engineered compositions.

Background of the invention

A new beta-coronavirus emerged in Wuhan, China, at the end of 2019. As of August 21, 2022, there have been approximately 596 million confirmed cases of infection with this virus (known as SARS-CoV-2, among other names) worldwide, and it has resulted in approximately 6.45 million deaths. Other coronaviruses, such as SARS-CoV, MERS, OC43 and HKU1, also pose health risks to humans and other species. Ways to prevent or treat coronavirus infection are needed.

According to one embodiment of the present invention, a fusion protein is specifically proposed, which includes a first coronavirus receptor binding domain (RBD) polypeptide connected to a second coronavirus RBD polypeptide, wherein optionally ( optionally), the first RBD polypeptide and/or the second RBD polypeptide are from a betacoronavirus, and wherein further optionally, the first RBD polypeptide and the second RBD polypeptide are from different betacoronaviruses.

Detailed description of preferred embodiments

Provided herein are engineered coronavirus polypeptides, polynucleotides encoding the polypeptides, vectors and host cells containing the polynucleotides and/or expressing the polypeptides, and related compositions. Disclosed embodiments include, for example, engineered spike protein ectodomains, monomeric receptor binding domains (RBDs), engineered RBDs, and fusions comprising one or more RBD polypeptides, one or more spike protein ectodomains, or both protein. Engineered peptides have beneficial antigenic and protective properties against coronavirus infections, such as SARS-CoV-2 and its variants, and other coronaviruses. In some embodiments, the engineered polypeptides comprise an element (eg, a peptide tag) that enables binding to a substrate of interest, such as a nanoparticle comprising a cognate binding partner of the element (eg, a peptide tag). In some embodiments, the engineered polypeptides comprise amino acid sequences from two or more (eg, two, three, four, five or more) coronaviruses or coronavirus strains. In some embodiments, the engineered polypeptide comprises one or more copies of a polypeptide comprising a stem-helix antigenic region or motif that is highly conserved across betacoronaviruses, or an engineered polypeptide comprising such a region or motif. ized variants.

Disclosed embodiments include fusion proteins comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second RBD polypeptide via a peptide linker. In certain embodiments, the fusion protein further comprises a third RBD polypeptide. In certain embodiments, the fusion protein further comprises a fourth RBD polypeptide. In certain embodiments, the fusion protein further comprises a fifth RBD polypeptide. In certain other embodiments, the fusion protein includes one or more additional RBD polypeptides. Each of the two, three or five (or more) RBD polypeptides may be different from each other; for example, may be derived from different coronaviruses or different coronavirus strains. Each of the two, three, four or five RBD polypeptides can be linked to one or two other RBD polypeptides in the fusion, such as by a peptide linker. In some embodiments, the peptide linker comprises a stem-helix polypeptide. In other embodiments, non-stem-helical polypeptides are used as linkers.

Isolated polypeptides comprising or consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.: 218 without SEQ ID NO.: 706; (iii) SEQ ID NO.: 218 are also provided. :712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; ( vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:706 without NO.:715; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) No SEQ ID NO. .:706 of SEQ ID NO.:717; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741 ; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Also provided is a fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) one or more peptide tags; (ii) one or more stem- Helical polypeptides, wherein optionally the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Also provided is an isolated polypeptide comprising the following structure: RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 RBD1, RBD2, RBD3, RBD4 and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2β variant; SARS-CoV-2o variant; SARS-CoV-2δ variant; PANG/GX ; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, and each of L1, L2, L3 and L4 is a linker.

Also provided is an isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59.

Also provided is an isolated polypeptide, which includes or consists of the following: the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.:14, and the amino group of SEQ ID NO.:15 The acid sequence, the amino acid sequence of SEQ ID NO.:16 or the amino acid sequence of SEQ ID NO.:17.

Fusion proteins are also provided, which comprise (i) the coronavirus spike protein ectodomain ("S ectodomain"), and (ii) an oligomeric domain at the C-terminus of the S ectodomain, wherein optionally, the oligomeric domain is directly fused to the C terminus of the S extracellular domain. In some embodiments, the oligomeric domain includes a trimeric domain, such as a foldon. In certain other embodiments, the fusion protein comprises: (1) a peptide tag at the C-terminus of the oligomerization domain; (2) a stem-helix polypeptide as provided herein; (3) one or more coronavirus receptor binding domain (RBD) polypeptide, or any combination of (1)-(3). In some embodiments, the peptide tags comprise SpyCatcher tags. In some embodiments, the stem-helix peptide contains an antigenic portion or epitope, and/or can serve as a linker. In some embodiments, one or more (eg, one, two, three or more) RBD polypeptides may be identical to each other, or one or more of the RBD polypeptides may be different from one or more of the other polypeptides. For example, the amino acid sequence of the RBD polypeptide is different or the same as the amino acid sequence of (1) the RBD included in the S extracellular domain and/or (2) another RBD polypeptide included in the fusion. The S ectodomain or RBD of the fusion (the RBD polypeptide or RBD comprised in the S ectodomain) may comprise a wild-type amino acid sequence, or may comprise one or more mutations (substitutions, insertions and/or missing).

Protein trimers comprising three polypeptides are also provided, wherein the three polypeptides each comprise: (i) the coronavirus S ectodomain; and (ii) a trimerization domain at the C terminus of the S ectodomain, wherein the three trimerization domains are associated with each other. combine to form a trimer. In some embodiments, each of the three trimerization domains includes a foldon. In certain embodiments, one, two, or three of the polypeptides in the trimer comprise a fusion protein selected from the fusion proteins disclosed herein.

An isolated coronavirus receptor binding domain (RBD) polypeptide is also provided, wherein the RBD polypeptide is not included in the extracellular domain of the spike protein. Fusion proteins comprising an RBD polypeptide and one or both of: (i) one or more peptide tags; and (ii) one or more stem-helix polypeptides are also provided.

Also provided are engineered variants of the coronavirus receptor binding domain (RBD) and engineered variants of the Sabey coronavirus spike protein extracellular domain, which are relative to the wild-type or parental RBD or spike protein (S). Extracellular domain, respectively, there are one or more modifications in the RBD. In some embodiments, the variant RBD or S ectodomain includes one or more amino acid substitutions, insertions, and/or deletions in the RBD, respectively, compared to the wild-type or parental RBD or S ectodomain. Disclosed embodiments include RBD amino acid sequences engineered to, for example, include non-natural glycosylation motifs, delete two or three amino acids at certain positions, and/or include one or Substitution and/or insertion of multiple amino acids.

In certain embodiments, an isolated and/or engineered polypeptide is provided that includes a conserved antigenic region or motif from the Sabey coronavirus stem-helix region (e.g., the SARS-CoV-2 S2 subunit) , or its antigenic part or epitope-containing part. In some embodiments, the polypeptide contains modifications to, for example, increase the stability of the wild-type stem-helix polypeptide, contains two or more copies of the antigenic region or motif, or the like.

In certain embodiments, there is provided an isolated polypeptide comprising, consisting essentially of, the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699 or consisting of.

In certain embodiments, an isolated polypeptide is provided comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the signal peptide and any Linker sequences selectively adjacent to the signal peptide are removed.

In certain embodiments, there is provided an isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the His tag is different Peptide tag replacement.

In certain embodiments, there is provided an isolated polypeptide comprising the amino acid sequence set forth in any of SEQ ID NOs.: 107-249, 255-565, and 576-699, wherein the His tag is not HHHHHHHH (that is, a His tag that is longer or shorter than HHHHHHHH).

Polynucleotides encoding the disclosed polypeptides, as well as vectors and host cells containing the same, are also provided. In some embodiments, the disclosed compositions are capable of eliciting a protective immune response in a mammal against one or more betacoronaviruses. In some embodiments, the disclosed compositions are capable of inducing activity in mammals against a variety of coronaviruses, such as betacoronaviruses, such as, for example, sarbecovirus, merbecovirus, ebeicoronavirus ( embecovirus), SARS-CoV-2 variants, SARS-CoV or its analogues.

Also provided are methods of using the disclosed polypeptides, RBD polypeptides, fusion proteins, polynucleotides, vectors, host cells, compositions, combinations or mixtures to treat or induce an immune response against coronavirus infection in an individual.

Before the present disclosure is elaborated in more detail, it may be helpful to provide definitions of certain terms that are to be used herein. Additional definitions are set forth throughout this disclosure.

“Coronavirus” refers to a group of related RNA viruses known to cause disease in mammals and birds. Coronavirus can cause respiratory infections in humans. Coronaviruses are enveloped viruses with a positive-sense single-stranded RNA genome and a characteristic spike protein protruding from its surface. Spike protein includes a receptor binding domain (RBD) that interacts with receptors on the host cell surface (eg, with human ACE2).

Coronaviruses include, for example, alphacoronaviruses (species include alphacoronavirus 1 (TGEV, feline coronavirus, canine coronavirus), human coronavirus 229E, human coronavirus NL63, Miniopterus, bat coronavirus 1, Bat coronavirus HKU8 of the genus Winged Bat, porcine epidemic diarrhea virus, bat coronavirus HKU2 of the genus Rhinolophus, bat coronavirus 512 of the genus Scotophilus), betacoronavirus (species include betacoronavirus 1 ( Bovine coronavirus, human coronavirus OC43), hedgehog coronavirus 1, human coronavirus HKU1, Middle East respiratory syndrome-related coronavirus, murine coronavirus, Pipistrellus bat coronavirus HKU5, fruit bat (Rousettus) bat Coronavirus HKU9, severe acute respiratory syndrome-related coronavirus (SARS-CoV, SARS-CoV-2), Tylonycteris bat coronavirus HKU4), gammacoronavirus (species include avian coronavirus, beluga coronavirus SW1 ) and deltavirus (species include Bulbul coronavirus HKU11, porcine coronavirus HKU15). Coronaviruses and coronavirus strains are known in the art and are discussed further herein.

As used in this article, "SARS-CoV-2" is also referred to in this article as "Wuhan Seafood Market Pneumonia Virus" or "Wuhan Coronavirus" or "Wuhan CoV" or "Novel CoV" or "nCoV" or "2019 nCoV" or "Wuhan nCoV", is a betacoronavirus believed to belong to lineage B (Sabe coronavirus). SARS-CoV-2 was first identified in Wuhan City, Hubei Province, China, at the end of 2019, and by the beginning of 2020, it was spreading within China and other parts of the world. Symptoms of SARS-CoV-2 infection include fever, dry cough and difficulty breathing.

The genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 will be provided in Genbank MN908947.3 (January 23, 2020), and the amino acid translation of the genome will be provided in Genbank QHD43416.1 (2020 January 23, 2019). Like other coronaviruses (such as SARS-CoV-1), SARS-CoV-2 contains a "spike" or surface ("S") type I transmembrane glycoprotein containing a receptor-binding domain (RBD). It is believed that RBD mediates entry of lineage B SARS coronavirus into respiratory epithelial cells by binding to the cell surface receptor angiotensin-converting enzyme 2 (ACE2). Specifically, the receptor binding motif (RBM) in the RBD interacts with ACE2.

The amino acid sequence of Wuhan-Hu-1 surface glycoprotein is provided in SEQ ID NO.:1. The Wuhan-Hu-1 RBD amino acid sequence is provided in SEQ ID NO.:2; additional non-limiting examples of Wuhan-Hu-1 RBD polypeptide sequences of the present disclosure are provided in SEQ ID NOs.:722 and 723. . Wuhan-Hu-1 S protein has approximately 73% amino acid sequence identity with SARS-CoV S protein. The amino acid sequence of Wuhan-Hu-1 RBM is provided in SEQ ID NO.:744. Wuhan-Hu-1 RBD has about 75% to 77% amino acid sequence similarity with SARS-CoV RBD, and SARS-CoV-2 RBM has about 50% amino acid sequence similarity with SARS-CoV RBM. Unless otherwise specified herein, Wuhan-Hu-1 refers to a virus comprising the amino acid sequence set forth in SEQ ID NO.: 1, optionally having the amino acid sequence set forth in GenBank MN908947.3 (January 23, 2020) The genome sequence.

Multiple SARS-CoV-2 variants have been identified. Some SARS-CoV-2 variants contain the N439K mutation, which enhances binding affinity to the human ACE2 receptor (Thomson, EC et al., The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity. bioRxiv , 2020). Some SARS-CoV-2 variants contain the N501Y mutation, which is associated with increased transmissibility, including lineage B.1.1.7 found in the United Kingdom (also known as the “alpha” variant, 20I/501Y.V1, and VOC 202012/01; (del69-70, del144, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H mutations)) and B.1.351 found in South Africa (also known as the "beta" variant and 20H/501Y. V2; L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G and A701V mutations) (Tegally, H. et al., Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) ) lineage with multiple spike mutations in South Africa. medRxiv, 2020: p. 2020.12.21.20248640; Leung, K. et al., Early empirical assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020 . medRxiv, 2020: p. 2020.12.20.20248581). B.1.351 includes RBD mutations K417N and E484K (Tegally, H. et al., Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv , 2020: p. 2020.12.21.20248640). SARS-CoV-2 B.1.617.2 (also known as "delta" or Indian variant, and 21A/S:478K; contains T19R, (V70F*), T95I, G142D, E156-, F157-, R158G, ( A222V*), (W258L*), (K417N*), L452R, T478K, D614G, P681R and D950N mutations. B.1.617.2 includes two mutations in the RBD of SARS-CoV2 spike protein: L452R and T478K. SARS- CoV-2 B.1.1.529 (also known as "o") was first identified in South Africa and includes the following mutations in the RBD of the SARS-CoV2 spike protein: G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y and Y505H. Sub-variants of B.1.1.529 may also include R346K or Q493K; o Variants in the pedigree include BA.1, BA.1.1, BA.2, BA. 2. Lineages BA.4 and BA.5. Other SARS-CoV-2 variants include lineage B.1.1.28, which was first reported in Brazil; variant P.1, lineage B.1.1.28 (also known as 20J /501Y.V3 and "γ" variant), which was first reported in Japan; variant L452R, which was first reported in California, United States (Pan American Health Organization, Epidemiological update: Occurrence of variants of SARS-CoV-2 in the Americas , January 20, 2021, available at reliefweb.int/sites/reliefweb.int/files/resources/2021-jan-20-phe-epi-update-SARS-CoV-2.pdf); clade 19A SARS CoV-2 in clade 19B; SARS CoV-2 in clade 20A; SARS CoV-2 in clade 20B; SARS CoV-2 in clade 20C; SARS CoV-2 in clade 20D SARS CoV-2 of clade 20E (EU1); SARS CoV-2 of clade 20F; SARS CoV-2 of clade 20G; and SARS CoV-2 B1.1.207; and Rambaut , A. et al., A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol 5, 1403-1407 (2020). The aforementioned SARS-CoV-2 variants and their amino acid and nucleotide sequences are incorporated herein by reference. Therefore, it should be understood that SARS-CoV-2 includes Wuhan Hu-1 and its variants, including the variants disclosed in the present invention.

SARS-CoV (also known as SARS-CoV-1) is another betacoronavirus that causes respiratory symptoms in infected individuals. The amino acid sequence of SARS-CoV Urbani strain has Genbank accession number AAP13441.1, and the amino acid sequence of the spike protein of SARS-CoV Urbani strain will be provided in SEQ ID NO.:22.

The coronavirus spike protein ectodomain has been observed in an "open" or "upward" conformation, with the RBD (or in the case of a spike protein trimer, at least two RBDs) pointing away from the C-terminus of the spike protein. SARS-CoV-2 RBD and the conformational dynamics of SARS-CoV RBD are discussed, for example, in Yuan et al., Science 368 :630-633 (2020) and Joyce et al., doi: 10.1101/2020.03.15.992883 (2020). Spinin mutations that have been shown to promote the open conformation of the RBD include D614G and K986P with V987P.

In some embodiments, the fusion proteins or polypeptides of the invention comprise the spinin extracellular domain, which includes the RBD in an open conformation. In some embodiments, the polypeptide trimer includes three RBDs (e.g., each is included in the coronavirus spike protein ectodomain of the trimer, wherein one or more of the spike protein ectodomains are each included in the fusion described herein protein), and one or more of the RBDs are in an open configuration. In certain embodiments, an RBD is in an open configuration. In certain embodiments, the two RBDs are in an open configuration. In certain embodiments, the three RBDs are in an open configuration.

Human coronavirus OC43 is also a betacoronavirus. The genome and amino acid sequence of OC43 surface glycoprotein ("S protein") are provided in GenBank AY585229.1. See also SEQ ID No.:23 herein.

MER-CoV is another betacoronavirus. The genome and amino acid sequence of the surface glycoprotein ("S protein") of MERS-CoV strain London 1/2012 are provided in SEQ ID NO.:24 (see also GenBank KC164505).

Human coronavirus HKU1 is another betacoronavirus. The amino acid sequence of the HKU1 surface glycoprotein ("S protein") is provided in SEQ ID NO:25 (see also GenBank YP_173238). Although SARS-CoV and SARS-CoV-2 bind ACE2, it is believed that some other betacoronaviruses enter cells by binding to other receptors. For example, MERS-CoV is believed to bind dipeptidyl peptidase-4 (DPP4), and OC43 and HKU1 are believed to bind the 9-O-acetylated sialic acid (9-O-Ac-Sia) receptor.

In this specification, unless otherwise indicated, any concentration range, percentage range, ratio range or integer range shall be understood to include any integer value and, where appropriate, fractions thereof (such as tenths of an integer) within the recited range. one and one percent). Furthermore, unless otherwise indicated, any numerical range recited herein in relation to any physical characteristic such as polymer subunits, size or thickness is to be understood to include any integer within the recited range. As used herein, unless otherwise specified, the term "about" means ±20% of a specified range, value or structure. “About” includes, for example, ±15%, ±10% and ±5%. It will be understood that the term "a/an" as used herein refers to "one or more" of the listed components. Use of alternatives (eg, "or") should be understood to mean one, both, or any combination of the alternatives. As used herein, the terms "include," "have," and "include" are used synonymously, and these terms and variations thereof are intended to be understood as non-limiting.

"Optional" or "optionally" means that the subsequently described elements, components, events or conditions may or may not occur, and this specification includes the occurrence and eventuality of such elements, components, events or conditions. What happened.

Additionally, it is to be understood that individual constructs or groups of constructs derived from various combinations of structures and subunits described herein are disclosed by this application to the same extent as if each construct or group of constructs were individually set forth. Therefore, the selection of specific structures or specific subunits is within the scope of this disclosure.

The term "consisting essentially of" is different from "comprising" and refers to specified substances or steps of the enumerated subject matter, or substances or steps that do not substantially affect the essential characteristics of the enumerated subject matter. For example, when the amino acid sequence of a domain, region, module, or protein includes up to 20% (e.g., up to 15%, 10%, 8%, 6%) that collectively contributes to the length of the domain, region, module, or protein , 5%, 4%, 3%, 2% or 1%) and does not substantially affect (i.e., does not reduce activity by more than 50%, such as no more than 40%, 30%, 25%, 20%, 15% , 10%, 5%, or 1%) extension, deletion, mutation, or other modification of a domain, region, module, or activity of a protein (e.g., the target binding affinity of a protein, or the ability of a protein to elicit an immune response in a mammalian individual) A protein domain, region or module (e.g. binding domain; coronavirus RBD) or protein "consists essentially of a specific amino acid sequence" when combined (e.g. amino acids at the amino terminus or carboxyl group or between domains) ”.

As used herein, "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code as well as those amino acids that are subsequently modified, such as hydroxyproline, gamma-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids, that is, α-carbon bonded to hydrogen, carboxyl, amine and R groups, such as homoserine and norleucine. , methionine trisulfide, methionine methylsulfonium. These analogs have modified R groups (eg, norleucine) or modified peptide backbones, yet maintain the same basic chemical structure as the naturally occurring amino acid. Amino acid mimetics refer to compounds that have a structure that is different from the general chemical structure of amino acids, but that function in a manner similar to naturally occurring amino acids.

As used herein, "mutation" refers to a change in the sequence of a nucleic acid molecule or polypeptide molecule compared to a reference or wild-type nucleic acid molecule or polypeptide molecule, respectively. Mutations can cause several different types of sequence changes, including substitutions, insertions, or deletions of nucleotides or amino acids.

"Conservative substitutions" refer to amino acid substitutions that do not significantly affect or alter the binding characteristics of a specific protein. Generally speaking, a conservative substitution is one in which a substituted amino acid residue is replaced by an amino acid residue having a similar side chain. Conservative substitutions include substitutions that are present in one of the following groups: Group 1: Alanine (Ala or A), Glycine (Gly or G); Group 2: Aspartic acid (Asp or D) , Glutamic acid (Glu or Z); Group 3: Asparagine (Asn or N), Glutamic acid (Gln or Q), Serine (Ser or S), Threonine (Thr or T ); Group 4: Arginine (Arg or R), Lysine (Lys or K), Histidine (His or H); Group 5: Isoleucine (Ile or I), Leucine (Leu or L), methionine (Met or M), valine (Val or V); and Group 6: phenylalanine (Phe or F), tyrosine (Tyr or Y), tryptophan (Trp or W). Additionally or alternatively, amino acids may be grouped into conserved substitution groups based on similar function, chemical structure, or composition (eg, acidic, basic, aliphatic, aromatic, or sulfur-containing). For example, for purposes of substitution, the aliphatic group may include Gly, Met, Ala, Val, Leu, and Ile. Other conserved substitution groups include: Sulfur-containing: Met and cysteine (Cys or C); Acidic: Asp, Glu; Small aliphatic, non-polar or slightly polar residues: Ala, Ser, Thr, Pro and Gly; Polar , negatively charged residues and their amides: Asp, Asn, Glu and Gln; polar, positively charged residues: His, Arg and Lys; large aliphatic, non-polar residues: Met, Leu, Ile, Val and Cys ; and large aromatic residues: Phe, Tyr and Trp. Additional information can be found in Creighton (1984) Proteins, W.H. Freeman and Company.

As used herein, "protein" or "polypeptide" refers to a polymer of amino acid residues. Protein applies to naturally occurring amino acid polymers, as well as to amino acid polymers in which one or more amino acid residues are artificial chemical mimics of the corresponding naturally occurring amino acids, and to non-naturally occurring amino acid polymers. Amino acid polymers. Variants of the proteins, peptides and polypeptides of the present disclosure are also contemplated. In certain embodiments, variant proteins, peptides and polypeptides comprise an amino acid sequence that is at least 70%, 75%, 80%, 85%, 90%, 91% identical to a defined or reference amino acid sequence described herein. , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.9% identical amino acid sequences or consisting of them.

As used herein, "fusion protein" refers to a protein having at least two distinct domains and/or motifs in a single chain, where the domains or motifs do not naturally co-occur in the protein (e.g., in a given arrangement, order either present in number, or entirely absent). In certain embodiments, a fusion protein contains at least two distinct domains and/or motifs that are not co-occurring in a single naturally occurring peptide or polypeptide. For example, in some embodiments, the fusion protein comprises a spinin ectodomain polypeptide fused (either directly or via a linking amino acid sequence) to one or more of the following: a foldon; a linker; a heterologous RBD (e.g., isolated RBD monomers); peptide tags (eg, SpyTag); and stem-helix polypeptides. In some embodiments, the fusion protein comprises a single (monomeric) isolated RBD fused to one or more of: a linker; a peptide tag (eg, SpyTag); and a stem-helix polypeptide. In some embodiments, a fusion protein includes two or more isolated RBD polypeptides fused via a linker to form a single chain polypeptide (also referred to herein as an RBD concatemer). In certain other embodiments, the fusion protein comprising the RBD concatemer further comprises a peptide tag (e.g., SpyTag, His Tag, or another type of tag); a spinin ectodomain polypeptide with an optional foldon; or any thereof combination.

In certain embodiments, the fusion protein contains one or more additional copies of an amino acid sequence that normally occurs in a reference protein that is otherwise identical or substantially identical to the fusion protein. For example, in some embodiments, a fusion protein of the present disclosure includes (i) a spike protein extracellular domain in which the RBD is naturally included, and (ii) one or more other copies of the RBD amino acid sequence. As another non-limiting example, in some embodiments, a fusion protein of the present disclosure comprises (i) a spike protein ectodomain naturally comprising any of SEQ ID NOs.: 4-14 therein, and (ii) ) one or more other copies of any one or more of SEQ ID NOS.:4-14, and/or may include an engineered version of any one or more of SEQ ID NOS.:4-14 sequence. As another example, in some embodiments, the isolated RBD polypeptide is fused to a stem-helix polypeptide, and neither the RBD polypeptide nor the stem-helix polypeptide is comprised within the spine polypeptide.

"RBD polypeptide" refers to the receptor binding domain (RBD) from the coronavirus spike protein, or a fragment or part of the RBD. RBD polypeptides can be engineered, including having engineered characteristics such as described herein. For example, RBDs can be engineered to replace natural amino acids with amino acids at corresponding positions in different RBDs; for example, using the SARS-CoV-2 Wuhan-Hu-1 RBD polypeptide as a starting point, one or more One or more point mutations of the SARS-CoV-2 variant are introduced into the RBD polypeptide. The RBD polypeptide may be a full-length RBD derived from a source protein, such as the spike protein from a naturally occurring coronavirus, or may be less than a full-length RBD and comprise a length as described herein, or may comprise a full-length RBD and flanking sequences derived from the source protein. . RBD polypeptides will typically have a length of from about 190 to about 230 amino acids, or from about 190 to about 220 amino acids, or a length within the following range (the following ranges are inclusive of the indicated numbers): 190 to 230 amino acids Amino acids; 190 amino acids to 220 amino acids; 190 amino acids to 215 amino acids; 190 amino acids to 210 amino acids; 190 amino acids to 205 amines amino acids; 195 amino acids to 220 amino acids; 195 amino acids to 215 amino acids; 195 amino acids to 210 amino acids; 195 amino acids to 205 amino acids ; 200 amino acids to 220 amino acids; 200 amino acids to 215 amino acids; 200 amino acids to 210 amino acids; or 200 amino acids to 205 amino acids. An RBD polypeptide can have a length of: 190 amino acids to 230 amino acids, or 190 amino acids to 225 amino acids, or 190 amino acids to 220 amino acids, or 190 amino acids. Acid to 215 amino acids, or 190 amino acids to 210 amino acids, or 190 amino acids to 205 amino acids, or 200 amino acids to 230 amino acids, or 200 Amino acid to 225 amino acid, or 200 amino acid to 220 amino acid, or 200 amino acid to 215 amino acid, or 200 amino acid to 210 amino acid, or 200 amino acids to 205 amino acids, or 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208 , 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, or 230 amino acids.

The RBD polypeptide can be derived from or engineered from the coronavirus spike protein. Examples of coronavirus spike proteins include those from viral strains that infect humans, pangolins, palm civets, bats, or any combination thereof. The spike protein can be derived from, for example: SARS-CoV-2 Wuhan-Hu-1; SARS-COV-2α variant (also known as B.1.1.7) and Q lineage; SARS-CoV-2β variant (also known as B .1.351) and descendant lineages); SARS-CoV-2o variant (also known as B.1.1.529) and BA.1, BA.1.1, BA.2, BA.3, BA.4 and BA.5 lineages ; SARS-CoV-2δ variant (also known as B.1.617.2); SARS-CoV-2γ variant (also known as P.1 and its descendant lineage); SARS-CoV-2ε variant (also known as B.1.427 and B.1.429); SARS-CoV-2n variant (also known as B.1.525); SARS-CoV-2ι variant (also known as B.1.526); SARS-CoV-2κ variant (also known as B.1.525); known as B.1.617.1); SARS-CoV-2 1.617.3 variant; SARS-CoV-2μ variant (also known as B.1.621, B.1.621.1); SARS-CoV-2ζ (also known as for P.2); SARS-CoV-2 A.27 (Mayotte); SARS-CoV (also known as SARS-CoV-1); PANG_GX (also known as PCoV_GX-P4L or PCoV_GX-P5L) ;PANG_GD (also known as MP789); RaTG13; RsSHC014; BtKY72; BatCoV/BB9904/BGR/2008; BM48-31/BGR/2008; BtRs-BetaCoV/YN2018B; PC4-241; RmYN02; BtRs-BetaCoV/YN2013; Rp /Shaanxi2011; Longquan-140; Rf1/2004; HKU3-12; BtRf-BetaCoV/JL2012; Rs4231; and ZC45. An RBD polypeptide can be isolated or derived from a clade 1a sabe coronavirus, a clade 1b sabe coronavirus, a clade 2 sabe coronavirus, or a clade 3 sabe coronavirus. Fusion proteins containing multiple RBD polypeptides may include RBD polypeptides from two or more of the following: clade 1a Sabey coronavirus; clade 1b Sabey coronavirus; clade 2 Sabey coronavirus; and clade 3 Sabey coronavirus.

Non-limiting examples of spike proteins from which RBD polypeptides can be obtained are provided in Table A, along with accession numbers (eg, NCBI GenBank) and SEQ ID NOs. Table A. Non-limiting examples of spike proteins virus strain Registration number ; SEQ ID NO. other SARS-CoV-2 Wuhan-Hu-1 QHD43416.1; SEQ ID NO.:1 Exemplary RBD polypeptide sequences in SEQ ID NOs. 2, 722 and 723 SARS-CoV-2 beta variants Amino acid mutations of SARS-CoV-2 beta, delta and o variants compared to Wuhan-Hu-1 are described in this article SARS-CoV-2 delta variants SARS-CoV-2o variants PCoV_GX-P4L QIA48614.1 PCoV_GX-P4L and PCoV_GX-P5L have identical sequences in at least the region shown in SEQ ID NO.:733, and RBD polypeptides from these viruses can be identified by "PANG/GX" herein. PCoV_GX-P5L QIA48632.1 MP789 QIG55945.1 MP789 is also referred to as "PANG/GD" in this article RaTG13 QHR63300.1, QHR63300.2 RsSHC014 AGZ48806.1 BtKY72 APO40579 BatCoV/BB9904/BGR/2008 ALJ94036 BM48-31/BGR/2008 YP_003858584 BtRs-BetaCoV/YN2018B QDF43825 PC4-241 AAV49723 RmYN02 EPI_ISL_412977 BtRs-BetaCoV/YN2013 AIA62330 Rp/Shaanxi2011 AGC74165 Longquan-140 AID16716 Rf1/2004 ABD75323 HKU3-12 ADE34812 BtRf-BetaCoV/JL2012 AIA62277 ZC45 AVP78031.1 Rs4231 ATO98157.1

As a non-limiting illustration, the amino acid sequence of the spike protein of SARS-CoV-2 Wuhan-Hu-1 is shown below, with 232 consecutive amino acids shown in bold; in some embodiments, the RBD polypeptide has as Any length described herein, provided that the RBD polypeptide sequence is contained within the 232 consecutive amino acids shown below. mfvflvllpl vssqcvnltt rtqlppaytn sftrgvyypd kvfrssvlhs tqdlflpffs nvtwfhaihv sgtngtkrfd npvlpfndgv yfasteksni irgwifgttl dsktqslliv nnatnvvikv cefqfcndpf lgvyyhknnk swmesefr vy ssannctfey vsqpflmdle gkqgnfknlr efvfknidgy fkiyskhtpi nlvrdlpqgf saleplvdlp iginitrfqt llalhrsylt pgdsssgwta gaaayyvgyl qprtfllkyn engtitdavd caldplsetk ctlksftvek giyqtsnf rv qptesivrfp nitn lcpfge vfnatrfasv yawnrkrisn cvadysvlyn sasfstfkcy gvsptklndl cftnvyadsf virgdevrqi apgqtgkiad ynyklpddft gcviawnsnn ldskvggnyn ylyrlfrksn lkpferdist eiyqagstpc ngvegfncyf plqsygfqpt ngvgyqpyrv vvlsfellha patvcgpkks tnlvknkcvn fnfngltgtg vltesnkkfl pfqqfgrdia dttdavrdpq tleilditpc sfggvsvitp gtntsnqvav lyqdvnctev pvaihadqlt ptwrvystgs nvfqtragcl igaehvnnsy ec dipigagi casyqtqtns prrarsvasq siiaytmslg aensvaysnn siaiptnfti svtteilpvs mtktsvdctm yicgdstecs nlllqygsfc tqlnraltgi aveqdkntqe vfaqvkqiyk tppikdfggf nfsqilpdps kpskrsfied llfnkvtlad a gfikqygdc lgdiaardli caqkfngltv lpplltdemi aqytsallag titsgwtfga gaalqipfam qmayrfngig vtqnvlyenq klianqfnsa igkiqdslss tasalgklqd vvnqnaqaln tlvkqlssnf gaissvlndi lsrldkveae vqidrlitgr lqslqtyvtq qliraaeira sanlaatkms ecvlgqskrv dfcgkgyhlm sfpqsaphgv vflhvtyvpa qeknfttapa ichdgkahfp regvfvsngt hwfvtqrnfy epqiittdnt fvsgncdvvi givnntvydp lqpeldsfke eld kyfknht spdvdlgdis ginasvvniq keidrlneva knlneslidl qelgkyeqyi kwpwyiwlgf iagliaivmv timlccmtsc csclkgccsc gscckfdedd sepvlkgvkl hyt (SEQ ID NO.:1)

In other embodiments, the RBD polypeptide is from any coronavirus (e.g., any strain listed in Table A) and is of any length as described herein, provided that the RBD polypeptide sequence is comprised of about 230 contiguous stretches of the coronavirus spike protein. In the sequence of amino acids; when the sequences are optimally aligned, the approximately 230 consecutive amino acids of the coronavirus spike protein will preferably correspond or will substantially correspond to those shown in bold in SEQ ID NO.: 1 above Location of amino acids.

Non-limiting examples of RBD polypeptide sequences are provided in SEQ ID NOs.: 2 and 722-737.

As used herein, the term "stem-helix polypeptide" refers to a polypeptide comprising, consisting essentially of, or consisting of: a betacoronavirus stem-helix region comprising a sequence according to the consensus sequence in SEQ ID NO.:4 (located in S2), or optionally retains antigenicity and/or is associated with antibodies, such as antibody S2P6, antibody S2S343, antibody B6 (Sauer et al., Nature Structural & Molecular Biology 28 :478-486 (2021) and/or Or a fragment or sequence variant of SEQ ID NO.:4 that binds antibody 28D9 (Wang et al., Nature Communications 12 :1715 (2021) doi.org/10.1038/s41467-021-21968-w); B6 and 28D9 are Incorporated herein by reference. Stem-helix polypeptides are typically less than 100, less than 90, less than 80, less than 70, less than 60, less than 50, less than 40, less than 30, less than 25, less than 20, or less than 10 amines in length. amino acids (although they may be included within a larger polypeptide, such as a fusion protein as described herein). In some embodiments, the fusion protein contains two, three, four, five, or more in a single chain stem-helix polypeptides linked in a fusion. In some embodiments, the fusion protein contains one, two, three, four, five, six, seven, eight, nine, ten, or more stem-helix polypeptide.

In some embodiments, the stem-helix polypeptide comprises, consists essentially of, or consists of an amino acid sequence according to any of SEQ ID NOs.: 4-19 or 57-59. In some embodiments, the stem-helix polypeptide comprises, consists essentially of, or consists of any of SEQ ID NOs.: 5-12 (or it contains one, two or three amino acids Substituted variants) and one to five, or one to ten, or one to twenty flanking SEQ ID NO.: 5, 6, 7 in the extracellular domain of betacoronavirus spike protein along the N-terminal and/or C-terminal direction , 8, 9, 10, 11 or 12 amino acids, optionally wherein one to five, or one to ten, or one to twenty flanking amino acids comprise the beta coronavirus spike protein extracellular domain sequence One or more amino acid substitutions. In some embodiments, the stem-helix polypeptide comprises, consists essentially of, or consists of: any of SEQ ID NOs.: 5-12 and 1, 2, 3, 4, 5, 6, 7 , 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more from or derived from the N-terminal and/or C-terminal side of the beta coronavirus spike protein extracellular domain Amino acid-linked, stem-helix polypeptides are native to this extracellular domain. Additionally or alternatively, the stem-helix polypeptide may comprise a linker amino acid (e.g., PG, GP, PGP) flanked on one or both ends of an amino acid sequence derived from or engineered from the betacoronavirus spike protein extracellular domain sequence. , GPP, glycine-serine linker (eg GS or GSG or analogs thereof), Townsend linker, whitlow linker or analogs thereof)). In certain embodiments, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). In some embodiments, the stem-helix polypeptide serves as an intermediary between two polypeptides (e.g., between a foldon and an RBD polypeptide, between a first RBD polypeptide and a second RBD polypeptide, between an RBD polypeptide and a peptide tag, between a spinin extracellular domain to a peptide tag, or the like). Stem-helix polypeptides are further described herein.

As used herein, an "oligomeric domain" refers to a polypeptide that mediates or functions together with one or more other similar oligomeric domains to mediate the assembly of polypeptide subunits into polypeptide oligomers. Oligomeric domains may exist, for example, as dimers, trimers, tetramers or pentamers. Non-limiting examples of oligomeric domains include fibrin trimerization domains, collagen helices, coiled-coil structures, and chloramphenicol acetyltransferase (CAT).

Preferred fibrin trimerization domains are foldons found in the C-terminal domain of T4 fibrin (see, eg, Meier et al . J. Mol. Bio. 344 (4):1051-69 (2004)). An example of a foldon sequence is the C-terminal 27 residues from T4 fibrin (GYIPEAPRDGQAYVRKDGEWVLLSTFL; SEQ ID NO.:703), which forms a β-propeller-like structure. The collagen triple helix is the primary secondary structure of various types of fibrillar collagen, including type I collagen. Contemplated examples include natural collagen helices, as well as triple helices derived from synthetic peptides (see, e.g., Kotch and Raines, PNAS 103 (9):3028-3033 (2006), which synthetic helices are incorporated herein by reference ). Coiled coils contain two or more (usually two to seven) α-helices coiled or intertwined like strands (see, e.g., Truebestein and Leonard, Bioessays 38 (9):903-916 (2016) , which describes such coiled coils and methods of using them, is incorporated by reference). It is understood that in certain embodiments, a trimeric domain, such as a foldon, will be connected via a linker, such as a GS linker, a GSG linker, a GPP linker, a Townsend linker (GSGGSGGSGGTG (SEQ ID NO.:702)) , (Gly _x Ser _y ) _n linker or similar linker is connected to another domain or part of the fusion protein.

Certain embodiments include fusion proteins containing one or more peptide tags. Peptide tags can bind specifically to a cognate receptor or binding partner, preferably with high affinity and/or avidity, and will typically be from about five to about twenty amino acids in length. The peptide tag will typically be fused to the polypeptide of interest at the N-terminus and/or C-terminus, and in some cases will be fused to the N-terminus and/or C-terminus of the polypeptide of interest, optionally via an intermediate linker. Peptide tags may additionally or alternatively be included within the polypeptide of interest. Peptide tag:homologous binding partner combinations can be used, for example, to couple a protein of interest to another protein or substrate, such as for assembly of protein delivery vehicles (eg, nanoparticles) or for purification.

Examples of tag:binding partner pairs include the SpyTag:SpyCatcher system (Zakeri et al., PNAS 109 (12):E690-697)) and its derivatives, including SpyTag002/SpyCatcher002 (Keeble et al., Angew Chem Int Ed Engl. 56 (52):16521-16525) and SpyTag003/SpyCatcher003 (Keeble et al., PNAS 116 (52):26523-26533 (2019)). The SpyTag:SpyCatcher system was engineered from the Streptococcus pyogenes fibronectin-binding protein FbaB ation and allows irreversible binding of recombinant proteins via the formation of isopeptide bonds between the SpyTag-bearing protein and the SpyCatcher-bearing protein or structure of interest (e.g., nanoparticles, virus-like particles). Antigens and receptors have been described The combination of the SpyTag:SpyCatcher system (e.g. Cohen et al., PLoS One (2021), https://doi.org/10.1371/journal.pone.0247963) is used. An example of a SpyTag peptide is a SpyTag peptide that contains the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700) or peptides consisting thereof. "SpyCatcher" peptides include any of the aforementioned SpyCatcher peptides. Other exemplary tag cassettes include Strep tag® (which refers to the original Strep tag®, Strep tag® II or any variant thereof; see, e.g., U.S. Patent No. 7,981,632, which Strep tags are incorporated herein by reference), His tags (e.g., HHHHHHHH (SEQ ID NO.:704)), Flag® tags, Xpress tags, Avitag™, Calponin Tag, Polyglutamate Tag, HA Tag, Myc Tag, Nus Tag, S Tag, SBP Tag, Softag® 1, Softag® 3, V5 Tag, CREB Binding Protein (CBP), Gluten Cyst Glypeptide S-transferase (GST), maltose-binding protein (MBP), green fluorescent protein (GFP) and thioredoxin tags.

It will be understood that, although certain exemplary embodiments of the fusion proteins and polypeptides disclosed herein include a peptide tag, such as a SpyTag, a His tag, or both, a peptide tag may not be present, or one or more different peptide tags may be used. The disclosed polypeptides (eg, RBD monomers, fusion proteins) may include a signal peptide (also known as a leader sequence, leader peptide, or transit peptide). Signal peptides target newly synthesized polypeptides to their appropriate location inside or outside the cell. The signal peptide can be located at the N-terminus or C-terminus of the polypeptide, and will typically be located at the N-terminus of the polypeptide. The signal peptide can be removed from the polypeptide during or after localization or secretion is complete. A polypeptide with a signal peptide is referred to herein as a "preprotein" and a polypeptide with the signal peptide removed is referred to herein as a "mature" protein or polypeptide. Therefore, it is contemplated that any of the fusion proteins or polypeptides disclosed herein are provided as preproteins as well as mature proteins.

Non-limiting examples of signal peptides include: signal peptide MNTQILVFALIAIIIPTNADKI (SEQ ID NO.:705; from influenza H7 HA (A/HongKong/125/2017)); signal peptide MAPLLLLLPLLWAGALA (SEQ ID NO.:706; modified from CD33) ; and the signal peptide sequence MFVFLVLLPLVS (SEQ ID NO.:707) or MFVFLVLLPLVSS (SEQ ID NO.:708) from SARS-CoV-2. It will be appreciated that any suitable naturally occurring or engineered signal peptide may be used. Certain signal peptides and their characteristics are described in Owji et al., European Journal of Cell Biology 97 (6):422-441 (2018); these signal peptides are incorporated herein by reference. In certain embodiments, the signal peptide is or is derived from a signal peptide of a viral protein.

It should be understood that any of the polypeptides disclosed herein may include a signal peptide, a peptide tag, both, or neither. Certain disclosed amino acid sequences include a signal peptide; such signal peptides will be recognized by one of ordinary skill in the art, and will also recognize the amino acid sequence resulting from removal of the signal peptide. For example, construct Cov0251 includes the amino acid sequence of SEQ ID NO.:302. It is understood that SEQ ID NO.:302 contains the signal peptide MNTQILVFALIAIIIPTNADKI (SEQ ID NO.:705), and this sequence may be removed (or absent), or may be replaced with a different signal peptide. It should be further understood that in some embodiments, the signal peptide is connected to another sequence (such as a SpyTag sequence, RBD, or analogs thereof) via a linker, and if the signal peptide is removed, the entire linker can also be removed or part of it. In the case of SEQ ID NO.:302, the GSG linker separates the signal peptide from the SpyTag sequence.

It is also understood that linker sequences may be longer, shorter, or present in more or fewer duplicates than shown in the protein constructs exemplified herein.

Polynucleotides encoding polypeptides, such as fusion proteins, may be constructed using PCR, recombinant engineering, or similar methods, or such polypeptides may be synthesized.

啉環)構成之經共價連接的核苷酸的聚合化合物。嘌呤鹼基包括腺嘌呤、鳥嘌呤、次黃嘌呤及黃嘌呤，且嘧啶鹼基包括尿嘧啶、胸腺嘧啶及胞嘧啶。核酸分子包括聚核糖核酸(RNA)，其包括mRNA、微小RNA、siRNA、病毒基因體RNA及合成RNA；及聚脫氧核糖核苷酸(DNA)，其包括cDNA、基因體DNA及合成DNA；其中之任一者可為單股或雙股。若為單股，則核酸分子可為編碼股或非編碼(反義)股。編碼胺基酸序列之核酸分子包括所有編碼相同胺基酸序列之核苷酸序列。核苷酸序列之一些型式亦可包括內含子，其達到經由共轉錄或轉錄後機制移除內含子的程度。換言之，由於遺傳密碼之冗餘或簡併或藉由剪接，不同核苷酸序列可編碼相同胺基酸序列。"Nucleic acid molecule" or "polynucleotide" or "polynucleic acid" means a compound that may be composed of natural subunits (e.g., purine or pyrimidine bases) or non-natural subunits (e.g.,

A polymeric compound composed of covalently linked nucleotides. Purine bases include adenine, guanine, hypoxanthine, and xanthine, and pyrimidine bases include uracil, thymine, and cytosine. Nucleic acid molecules include polyribonucleic acid (RNA), which includes mRNA, microRNA, siRNA, viral genomic RNA, and synthetic RNA; and polydeoxyribonucleotide (DNA), which includes cDNA, genomic DNA, and synthetic DNA; wherein Either one can be a single share or a double share. If single-stranded, the nucleic acid molecule can be a coding strand or a non-coding (antisense) strand. Nucleic acid molecules encoding amino acid sequences include all nucleotide sequences encoding the same amino acid sequence. Some versions of nucleotide sequences may also include introns to the extent that introns are removed via co-transcriptional or post-transcriptional mechanisms. In other words, different nucleotide sequences can encode the same amino acid sequence due to redundancy or degeneracy of the genetic code or through splicing.

Variants of the nucleic acid molecules of the present disclosure are also contemplated. The variant nucleic acid molecule is at least 70%, 75%, 80%, 85%, 90%, and preferably 95%, 96%, 97%, 98%, 99% identical to a nucleic acid molecule as defined or referenced polynucleotide as described herein Or 99.9% consistent, or under the stringent hybridization conditions of 0.015M sodium chloride, 0.0015M sodium citrate, about 65-68℃ or 0.015M sodium chloride, 0.0015M sodium citrate and 50% formamide, about 42℃ Hybridize with polynucleotides. Nucleic acid molecule variants retain encoding binding domains thereof with functionality described herein, such as the ability to bind a target molecule.

"Percent sequence identity" refers to the relationship between two or more sequences as determined by comparing the sequences. Preferred methods of determining sequence identity are designed to give the greatest match between the sequences being compared. For example, sequences are aligned for optimal comparison (eg, gaps may be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment). Additionally, non-homologous sequences can be ignored for comparison purposes. Unless otherwise indicated, percent sequence identity mentioned herein is calculated based on the length of the reference sequence. Methods for determining sequence identity and similarity can be found in publicly available computer programs. Sequence alignment and percent identity calculations can be performed using BLAST programs (eg, BLAST 2.0, BLASTP, BLASTN, or BLASTX). The mathematical algorithms used in the BLAST program can be found in Altschul et al., Nucleic Acids Res. 25 :3389-3402, 1997. Within the context of this disclosure, it will be understood that when sequence analysis software is used for analysis, the analysis results are based on the "default values" of the referenced program. "Default Values" means any set of values or parameters initially loaded with the Software upon first initialization.

The term "isolated" means removal of a substance from its original environment (eg, its natural environment if the substance is naturally occurring). For example, a naturally occurring nucleic acid or polypeptide present in the living animal in which it naturally occurs is unisolated, but the same nucleic acid or polypeptide isolated from some or all coexisting materials in the natural system is isolated. The nucleic acid can be part of a vector and/or such nucleic acid or polypeptide can be part of a composition (e.g., a cell lysate) and still be isolated because such vector or composition is not a nucleic acid or polypeptide. part of the natural environment. As another illustration, an RBD polypeptide or stem-helix polypeptide is "isolated" when it is not present as part of a spike protein or a spike protein extracellular domain; for example, an RBD or stem-helix polypeptide may be present in a spike protein or a spike protein ectodomain. In a separate fragment or portion of the outer realm.

Additionally, in some embodiments, a composition of the present disclosure may be "isolated," meaning that it is physically separate from and not contained in an individual to whom the composition can, has been, or will be administered.

Any of the polypeptides, fusion proteins, polynucleotides, vectors and host cells disclosed herein can be provided in isolated form.

The term "gene" means a segment of DNA or RNA involved in the production of a polypeptide chain; in some cases, it includes the regions preceding and following the coding region (e.g., 5' untranslated region (UTR) and 3' UTR), and intervening sequences (introns) between individual coding segments (exons).

"Functional variant" means a parent or reference compound that is structurally similar or substantially similar in structure to the present disclosure, but differs in composition (e.g., one base, atom or functional group, is added or removed ), such that the polypeptide or encoded polypeptide is capable of producing at least 50% of the activity of the parent polypeptide, preferably at least 55%, 60%, 70%, 75%, 80%, Perform at least one function of the parent polypeptide at the 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9% or 100% level. In other words, when a functional variant is compared to a parent or reference polypeptide in a selected assay, such as an assay used to measure binding affinity (e.g., Biacore® or Biacore® that measures association (Ka) or dissociation ( _KD ) constants Tetramer staining), the polypeptide or functional variant of the encoded polypeptide of the present disclosure has "similar binding", "similar affinity" or "similar activity" when the potency is reduced by no more than 50%.

As used herein, a "functional portion" or "functional fragment" refers to a polypeptide or polynucleotide that contains only a region, portion, or fragment of a parent or reference compound, and the polypeptide or encoded polypeptide retains the same region as the parent or reference compound. , at least 50% activity related to the part or fragment, preferably at least 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97 of the activity of the parent polypeptide %, 98%, 99%, 99.9% or 100% level, or provide biological benefit (e.g., effector function). When a polypeptide of the disclosure, or a functional portion or fragment of an encoded polypeptide, exhibits no more than a 50% reduction in potency in a selected assay compared to a parent or reference polypeptide (with respect to affinity, compared to a parent or reference, Preferably no more than 20% or 10% or no more than a logarithmic difference), the "functional part" or "functional fragment" has "similar binding" or "similar activity".

As used herein, the terms "engineered," "recombinant," or "non-natural" refer to organisms, microorganisms, cells that include at least one genetic alteration or that have been modified by the introduction of exogenous or heterologous nucleic acid molecules , nucleic acid molecules or vectors, wherein such changes or modifications are introduced by genetic engineering (i.e., artificial intervention). Genetic alterations include modifications such as the introduction of expressible nucleic acid molecules encoding functional RNAs, proteins, fusion proteins or enzymes, or the addition, deletion, substitution or other functional disruption of the genetic material of the cell by other nucleic acid molecules. Additional modifications include, for example, noncoding regulatory regions, where the modification alters the expression of the polynucleotide, gene, or operon. Engineered proteins include proteins produced by genetic engineering, for example, by substitution, deletion, insertion, rearrangement, fusion, use of unnatural amino acids, or the like.

As used herein, "heterologous" or "non-endogenous" or "exogenous" refers to any gene, protein, compound, nucleic acid molecule or activity that is not native to the host cell or subject, or Any gene, protein, compound, nucleic acid molecule or activity that is native to the host cell or subject that has been altered. Heterologous, non-endogenous or exogenous includes genes, proteins that have been mutated or otherwise altered such that structure, activity or both differ between native and altered genes, proteins, compounds or nucleic acid molecules , compounds or nucleic acid molecules. In certain embodiments, heterologous, non-endogenous or exogenous genes, proteins or nucleic acid molecules (e.g., receptors, ligands, etc.) may not be endogenous to the host cell or individual, but are actually Above, nucleic acids encoding such genes, proteins or nucleic acid molecules can be added to host cells by conjugation, transformation, transfection, electroporation or similar methods, wherein the added nucleic acid molecules can be integrated into the host cell genome or May exist as extrachromosomal genetic material (eg, as plastids or other self-replicating vehicles). The term "homology" or "homolog" refers to a gene, protein, compound, nucleic acid molecule or activity found in or derived from a host cell, species or strain. For example, a heterologous or exogenous polynucleotide or gene encoding a polypeptide may be homologous to a native polynucleotide or gene and encode a homologous polypeptide or activity, but the polynucleotide or polypeptide may have an altered structure. , sequence, performance level or any combination thereof. The non-endogenous polynucleotide or gene and the encoded polypeptide or activity can be from the same species, different species, or a combination thereof.

In certain embodiments, a nucleic acid molecule, or portion thereof, native to the host cell will be considered heterologous to the host cell if it has been altered or mutated, or if it has heterologously expressed control sequence changes or has not normally been associated with A nucleic acid molecule native to the host cell may be considered heterologous if the sequence changes associated with the endogenous expression of the nucleic acid molecule native to the host cell. Additionally, the term "heterologous" may refer to a biological activity that is different, altered, or not endogenous to the host cell. As described herein, more than one heterologous nucleic acid molecule can be introduced into a host cell as a single nucleic acid molecule, as a plurality of individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a fusion protein, or any combination thereof .

As used herein, the term "endogenous" or "natural" refers to a polynucleotide, gene, protein, compound, molecule or activity normally present in a host cell or subject.

The term "expression" as used herein refers to a method of producing a polypeptide based on the coding sequence of a nucleic acid molecule, such as a gene. Methods may include transcription, post-transcriptional control, post-transcriptional modification, translation, post-translational control, post-translational modification, or any combination thereof. Expressed nucleic acid molecules are typically operably linked to expression control sequences (eg, promoters).

The term "operably linked" refers to the association of two or more nucleic acid molecules on a single nucleic acid fragment such that the function of one is affected by the other. For example, a promoter is operably linked to a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). "Disconnected" means that the related genetic elements are not closely related to each other, and the function of one does not affect the function of the other.

As described herein, more than one heterologous nucleic acid molecule can be introduced into the host cell as a single nucleic acid molecule, as multiple individually controlled genes, as a polycistronic nucleic acid molecule, as a single nucleic acid molecule encoding a polypeptide, or any combination thereof. When two or more heterologous nucleic acid molecules are introduced into a host cell, it will be understood that the two or more heterologous nucleic acid molecules can be administered as single nucleic acid molecules on separate vectors (eg, on a single vector). Introduced, integrated into the host chromosome at a single site or multiple sites, or any combination thereof. References to a number of heterologous nucleic acid molecules or protein activities refer to the number of encoding nucleic acid molecules or protein activities and not to the number of individual nucleic acid molecules introduced into the host cell.

The term "construct" refers to any polynucleotide containing a recombinant nucleic acid molecule (or, when the context clearly indicates, a fusion protein of the present disclosure). The (polynucleotide) construct may be present in a vector (eg, bacterial vector, viral vector) or may be integrated into the genome. A "vector" is a nucleic acid molecule capable of transporting another nucleic acid molecule. The vector may be, for example, a plastid, a myxoid, a virus, an RNA vector or a linear or circular DNA or RNA molecule, which may include chromosomal, non-chromosomal, semi-synthetic or synthetic nucleic acid molecules. Vectors of the present disclosure also include transposon systems (eg, Sleeping Beauty, see, eg, Geurts et al., Mol. Ther. 8 :108, 2003: Mátés et al., Nat. Genet. 41 :753, 2009). Exemplary vectors are vectors that are capable of autonomous replication (episomal vectors), capable of delivering a polynucleotide to the genome of a cell (eg, viral vectors), or capable of expressing the nucleic acid molecule to which it is linked (expression vectors).

As used herein, "expression vector" or "vector" refers to a DNA construct containing a nucleic acid molecule operably linked to suitable control sequences capable of effecting the expression of the nucleic acid molecule in a suitable host. Vectors can also be based on RNA and can contain viral sequences, non-viral sequences, or both (see, eg, Schott et al. Mol Ther. 24 (9):1513-1527 (2016)). Such control sequences include promoters that effect transcription, optional operator sequences that control such transcription, sequences encoding suitable mRNA ribosome binding sites, and sequences that control termination of transcription and translation. The vector may be a plasmid, a phage particle, a virus, or simply a potential gene insert. Once transformed into a suitable host, the vector can replicate and function independently of the host genome, or can in some cases be integrated into the genome itself, or the polynucleotide contained in the vector can be delivered to a site that does not have the vector sequence. in the gene body. In the present invention, "plastid", "expression plasmid", "virus" and "vector" are generally used interchangeably.

In the context of inserting a nucleic acid molecule into a cell, the term "introduction" means "transfection," "transformation" or "transduction" and includes reference to the incorporation of a nucleic acid molecule into a eukaryotic or prokaryotic cell, The nucleic acid molecule can be incorporated into the genome of the cell (eg, chromosome, plastid, chromosomal or mitochondrial DNA), converted into an autonomous replicon or transiently expressed (eg, transfected mRNA).

In certain embodiments, the polynucleotides of the present disclosure are operably linked to certain elements of the vector. For example, a polynucleotide sequence is operably linked that is required to effect expression and processing of the coding sequence to which it is joined. Expression control sequences may include appropriate transcription initiation, termination, promoter, and enhancer sequences; efficient RNA processing signals, such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; and sequences that enhance translation efficiency (i.e., KZA Kozak consensus sequence); sequences that enhance protein stability; and possible sequences that enhance protein secretion. An expression control sequence is operably linked if it is linked to a gene of interest and an expression control sequence that acts in trans or at a distance to control the gene of interest.

In certain embodiments, the vectors comprise plasmid vectors or viral vectors (eg, lentiviral vectors or gamma-retroviral vectors). Viral vectors include retroviruses; adenoviruses; parvoviruses (e.g. adeno-associated virus); coronaviruses; negative-strand RNA viruses such as orthomyxoviruses (e.g. influenza virus), rhabdoviruses (e.g. rabies and vesicular stomatitis virus) , paramyxoviruses (such as measles and Sendai); positive-stranded RNA viruses, such as picornaviruses and alphaviruses; and double-stranded DNA viruses, including adenovirus, herpesviruses (such as herpes simplex virus types 1 and 2, Escherichia coli) Epstein-Barr virus, cytomegalovirus) and poxviruses (such as cowpox, fowlpox and canarypox). Other viruses include, for example, Norwalk virus, togavirus, flavivirus, reovirus, papillomavirus, hepadnavirus and hepatitis virus. Examples of retroviruses include: avian leukemic sarcoid virus, mammalian type C virus, type B virus, type D virus, HTLV-BLV group, lentivirus, foamy virus (Coffin, J. M., Retroviridae: The viruses and their replication , Fundamental Virology, third edition, edited by B.N. Fields et al., Lippincott-Raven Publishers, Philadelphia, 1996).

"Retrovirus" is a virus with an RNA genome that is reverse-transcribed into DNA using reverse transcriptase, and then the reverse-transcribed DNA is incorporated into the host cell genome. "Gammaretrovirus" refers to a genus in the family Retroviridae. Examples of gamma retroviruses include mouse stem cell virus, murine leukemia virus, feline leukemia virus, feline sarcoma virus, and avian reticuloendotheliosis virus.

"Lentiviral vectors" include HIV-based lentiviral vectors used for gene delivery. These lentiviral vectors can be integrated or non-integrating, have relatively large encapsulation capacity, and can transduce a range of different cell types. . Lentiviral vectors are typically generated after transient transfection of three (encapsulation, envelope and transfer) or more plasmids into producer cells. Like HIV, lentiviral vectors enter target cells through the interaction of viral surface glycoproteins with receptors on the cell surface. After entry, viral RNA undergoes reverse transcription, which is mediated by the viral reverse transcriptase complex. The product of reverse transcription is double-stranded linear viral DNA, which is a viral substrate integrated into the DNA of infected cells.

In certain embodiments, the viral vector may be a gamma retrovirus, such as a vector derived from Moloney murine leukemia virus (MLV). In other embodiments, the viral vector may be a more complex retrovirus-derived vector, such as a lentivirus-derived vector. HIV-1 derived vectors fall into this category. Other examples include lentiviral vectors derived from HIV-2, FIV, equine infectious anemia virus, SIV, and Maedi-Visna virus (sheep lentivirus). Methods of using retroviral and lentiviral viral vectors and encapsulated cells to transduce mammalian host cells with viral particles containing transgenes are known in the art and have been previously described, for example, in: U.S. Patent No. 8,119,772 No.; Walchli et al., PLoS One 6 :327930, 2011; Zhao et al., J. Immunol. 174 :4415, 2005; Engels et al., Hum. Gene Ther. 14 :1155, 2003; Frecha et al., Mol. Ther . 18 :1748, 2010; and Verhoeyen et al., Methods Mol. Biol. 506 :97, 2009. Retroviral and lentiviral vector constructs and expression systems are also commercially available. Other viral vectors may also be used for polynucleotide delivery including DNA viral vectors, including, for example, adenovirus-like vectors and adeno-associated virus (AAV)-like vectors; vectors derived from herpes simplex virus (HSV), including amplified Amplifier vectors, replication-defective HSV and attenuated HSV (Krisky et al., Gene Ther. 5 :1517, 1998).

Other vectors useful in the compositions and methods of the present disclosure include vectors derived from baculoviruses and alpha-viruses. (Jolly, D J. 1999. Emerging Viral Vectors. pp. 209-40 in Friedmann T. ed. The Development of Human Gene Therapy. New York: Cold Spring Harbor Lab), or plastid vectors (such as Sleeping Beauty or other seat carrier).

When the viral vector genome contains multiple polynucleotides to be expressed in the host cell as separate transcripts or polypeptides, the viral vector may also contain bicistronic or polypeptides between the two (or more) transcripts. Additional sequences for polycistronic manifestations. Examples of such sequences for use in viral vectors include internal ribosomal entry site (IRES), Furin cleavage site, viral 2A peptide, or any combination thereof.

Further described herein are plastid vectors for direct administration to an individual, including plastid vectors encoding DNA-based polypeptides.

As used herein, the term "host" refers to a cell or microorganism that is targeted genetically modified with a heterologous nucleic acid molecule to produce a polypeptide of interest. The host cell can also be a cell or microorganism that is targeted genetically modified with a heterologous nucleic acid molecule to produce a polynucleotide of interest.

Host cells may include any individual cell or cell culture that accepts a vector or incorporates a nucleic acid or expresses a protein. The term also encompasses progeny of the host cell, whether genetically or phenotypically the same or different. Suitable host cells may depend on the vector and may include mammalian cells, animal cells, human cells, simian cells, insect cells, yeast cells, and bacterial cells. These cells can be induced to incorporate vectors or other substances by using viral vectors, transformation by calcium phosphate precipitation, DEAE-polydextrose, electroporation, microinjection, or other methods. See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 2nd ed. (Cold Spring Harbor Laboratory, 1989).

In the case of coronavirus infection, "host" refers to the cell or individual infected with the coronavirus.

As used herein, "antigen" or "Ag" refers to an immunogenic molecule that elicits an immune response. This immune response may involve antibody production, activation of specific immunologically competent cells, complement activation, antibody-dependent cellular cytotoxicity, or any combination thereof. Antigens (immunogenic molecules) may be, for example, peptides, glycopeptides, polypeptides, glycopolypeptides, polynucleotides, polysaccharides, lipids or the like. It will be readily apparent that the antigen may be synthesized from, recombinantly produced or derived from a biological sample. Exemplary biological samples that may contain one or more antigens include tissue samples, fecal samples, cells, biological fluids, or combinations thereof. Antigens can be produced by cells that have been modified or genetically engineered to express the antigen. Antigens may also be present in betacoronaviruses (eg, surface glycoproteins or portions thereof), such as in virions, or expressed or presented on the surface of betacoronavirus-infected cells.

The term "epitope" or "antigenic epitope" includes any molecule, structure, amino acid sequence or protein determinant recognized by and specifically bound by a cognate binding molecule such as an immunoglobulin or other binding molecule, domain or protein. Epitope determinants typically contain chemically active surface groups of molecules, such as amino acids or sugar side chains, and may have specific three-dimensional structural characteristics as well as charge-to-mass ratio characteristics. When the antigen is or comprises a peptide or protein, the epitope may comprise contiguous amino acids (e.g., a linear epitope), or may comprise amino acids from different portions or regions of the amino acid sequence that are proximate by protein folding ( For example, non-contiguous or conformational epitopes), or closely adjacent non-contiguous amino acids independent of protein folding.

Unless expressly defined herein, terms understood by those skilled in the art of antibodies are each given the meaning acquired in the art. For example, the term "antibody" refers to an intact antibody that contains at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, and has or remains bound to the protein recognized by the intact antibody. Any antigen-binding portion or fragment of an intact antibody, such as a scFv, Fab or Fab'2 fragment, that has the ability to target an antigenic molecule. Therefore, the term "antibody" is used herein in the broadest sense and includes polyclonal and monoclonal antibodies, including intact antibodies and their functional (antigen-binding) antibody fragments, including antigen-binding fragment (Fab) fragments, F( ab')2 fragments, Fab' fragments, Fv fragments, recombinant IgG (rIgG) fragments, single-chain antibody fragments, including single-chain variable fragments (scFv), and single-domain antibody (e.g., sdAb, sdFv, nanobody) fragments . The term encompasses genetically engineered and/or otherwise modified forms of immunoglobulins, such as intrabodies, peptibodies, chimeric antibodies, fully human antibodies, humanized antibodies, and heteroconjugated antibodies, multispecific (eg bispecific) antibodies, bifunctional antibodies, trifunctional antibodies, tetrafunctional antibodies, tandem two scFvs and tandem three scFvs. Unless otherwise stated, the term "antibody" shall be understood to encompass functional antibody fragments thereof. The term also encompasses intact or full-length antibodies, including antibodies of any class or subclass, including IgG and its subclasses (IgG1, IgG2, IgG3, IgG4), IgM, IgE, IgA and IgD.

The terms " _VL " or "VL" and " _VH " or "VH" refer to the variable binding region from the antibody light chain and the antibody heavy chain, respectively. In certain embodiments, VL is a kappa (κ) species (also "VK" herein). In certain embodiments, VL is lambda (λ) type. The variable binding region contains discrete well-defined subregions called "complementarity determining regions" (CDRs) and "framework regions" (FRs). The terms "complementarity determining region" and "CDR" are synonymous with "hypervariable region" or "HVR" and refer to the amino acid sequences within the variable regions of an antibody that together generally confer antigen specificity and/or the antibody Binding affinity in which consecutive CDRs (i.e., CDR1 and CDR2, CDR2 and CDR3) are separated from each other in the primary structure by backbone regions. There are three CDRs in each variable region (HCDR1, HCDR2, HCDR3; LCDR1, LCDR2, LCDR3; also known as CDRH and CDRL, respectively). In certain embodiments, antibody VH includes the following four FRs and three CDRs: FR1-HCDR1-FR2-HCDR2-FR3-HCDR3-FR4; and antibody VL includes the following four FRs and three CDRs: FR1-LCDR1- FR2-LCDR2-FR3-LCDR3-FR4. Generally speaking, VH and VL together form the antigen binding site via their respective CDRs.

Provided herein are the VH and VL amino acid sequences of certain antibodies. engineered peptides

The present invention provides, in part, recombinant polypeptides derived and/or engineered from the coronavirus spike protein extracellular domain (or RBD thereof), and compositions (eg, immunogenic compositions) comprising the same.

In some embodiments, a polypeptide is provided that is derived from the stem-helix portion of the SARS-CoV-2 spike protein polypeptide or an engineered variant thereof. In some cases, the polypeptide is derived or engineered from the antigenic portion of the linker domain or linker domain disposed between the HR2 region and the central helix (CH) region of the S protein. Briefly, as taught in the Examples of the present invention, the antigenic portion of this domain is conserved among multiple beta-coronavirus glycoproteins. Antigenic sequences or (e.g., naturally occurring amino acid sequences or engineered variants thereof) may be present in an immunogenic composition, fusion protein, or analog thereof, including in multiple replicas. From SARS -The antigenic sequences disclosed herein of the CoV-2 stem helix and its engineered variants can be used in various embodiments to connect two or more polypeptides of interest, such as two receptor binding domains ( RBD) polypeptide, thereby forming the linker of the fusion protein. Herein, the references derived from the SARS-CoV-2 S protein stem-helix (and/or engineered variants of the SARS-CoV-2 S protein stem-helix polypeptide) The disclosed antigenic sequence or motif, the polypeptide consisting thereof or consisting essentially of it, may be referred to as a stem-helix polypeptide. However, the full-length SARS-CoV-2S protein naturally containing a stem-helix portion is different from a "stem-helix polypeptide" ; Stem-helix polypeptides will typically be shorter than the S protein, isolated from the S protein, and/or engineered relative to the S protein.

In _{certain embodiments , the stem - helix polypeptide} is comprised _{in the} S _protein amino acid _{sequence FX 1} NO.: 46), or one or more of the S protein amino acids containing the amino acid sequence, wherein: X ₁ is K, E, or Q; X ₂ is E, S, or D; ₃ is D or S; X ₄ is K, Q, H, or E; X ₅ is Y, W, or F; X ₆ is H, Q, or V; X ₇ is _T or S; _L , or T; X ₉ is P, V, L, or S; X ₁₀ is D, A, P, or I; X ₁₁ is V or P; X ₁₂ is D or N; And X ₁₄ is G, S, or T. In a specific embodiment, N at position 11 of SEQ ID NO.:46 is glycosylated.

It is understood that the stem-helix polypeptide may be present in a recombinant (eg, fused or otherwise engineered) protein and/or as a separate or isolated fragment from the spike protein polypeptide. For example, in some embodiments, an isolated polypeptide is provided that has or contains no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than 11 amino acids length, and comprising the amino acid sequence according to SEQ ID NO.:4. In certain other embodiments, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO.:5. In certain embodiments, the stem-helix polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO.:701.

In some embodiments, an isolated polypeptide is provided having or comprising no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino groups acid, no more than about 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than about 10 amino acids, or no More than 6 amino acids in length and comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 4-12 and 14.

In certain embodiments, an isolated polypeptide is provided, the isolated polypeptide comprising any 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, of SEQ ID NO.: 13 or consisting of 17, 18, 19 or 20 consecutive amino acid residues, provided that the isolated peptide contains SEQ ID NO.: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 consecutive amino acids.

In particular embodiments, an isolated polypeptide is provided comprising the amino acid sequence set forth in any of SEQ ID NOs.: 14-19. In some embodiments, a polypeptide is provided comprising: (i) an amino acid sequence according to any of SEQ ID NOs.:4-14; and (ii) set forth in SEQ ID NO.:15 Amino acid sequence. In some embodiments, a polypeptide is provided comprising: (i) any one or more of a plurality of SEQ ID NOs.: 4-14, wherein the plurality is homogeneous, isotypic, heterogeneous or heterotypic; and (ii) A linker sequence disposed between two of the plurality and connecting two of the plurality. Also provided is a polypeptide comprising: (i) two, three, four, five or more copies of SEQ ID NO.:16; (ii) two, three of SEQ ID NO.:17 , four, five or more replicas; and/or (iii) one or more replicas of SEQ ID NO.:16 and one or more replicas of SEQ ID NO.:17. Also provided are polypeptides comprising SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein X is 2 or greater, 3 or greater, 4 or greater, or 5 or greater.

As described herein, stem-helix polypeptides can be included in fusion proteins. In some embodiments, a fusion protein is provided that includes (i) a SARS-CoV-2 spike polypeptide or a portion thereof and (ii) a stem-helix polypeptide as disclosed herein. In certain other embodiments, the SARS-CoV-2 spike polypeptide comprises (i) one or more modifications that promote an open conformation of the receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P, and V987P) and/or or (ii) one or more modifications that promote the stability of the SARS-CoV-2 spike protein trimer.

The fusion protein may comprise a plurality of polypeptides, each independently selected from the polypeptides according to the invention. In some embodiments, one or more polypeptides are disposed in the S2 subunit of the SARS-CoV-2 spike protein.

In some embodiments, the fusion protein comprises SEQ ID NO.:18 or SEQ ID NO.:19, wherein X is 2 or greater, 3 or greater, 4 or greater, or 5 or greater. In some embodiments, the fusion protein includes (i) a (eg, SARS-CoV-2) spike protein receptor binding domain (RBD) polypeptide and (ii) a stem-helix polypeptide as provided herein. In certain embodiments, the RBD is not included in native (eg, SARS-CoV-2) spike polypeptides. In certain embodiments, the fusion protein includes multiple RBD polypeptides of (i) and/or multiple polypeptides of (ii). In certain other embodiments, the fusion protein includes a linker sequence disposed between and connecting two of the plurality of RBD polypeptides.

Fusion proteins may contain any suitable number of linkers, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or more. Where two or more linkers are present, two or more of the linkers may have the same amino acid sequence as each other, or may have different amino acid sequences as compared to each other. Linkers present in fusion proteins of the present disclosure may, for example, comprise or consist of a stem-helix polypeptide. The alternative linker may be selected, for example, based on the following: (1) its ability to assume a flexible extended configuration; (2) its inability or lack of ability to exhibit functions compatible with those on the first and second polypeptides and/or on the target molecule the ability of the secondary structure of the epitope to interact; and/or (3) the lack or relative lack of hydrophobic or charged residues that may react with the polypeptide and/or target molecule. In certain embodiments, the peptide linker sequence contains, for example, Gly, Asn, and Ser residues. Other nearly neutral amino acids such as Thr and Ala may also be included in the linker sequence. Other amino acid sequences suitable for use as linkers include those disclosed in: Maratea et al., Gene 40:39 46 (1985); Murphy et al., Proc. Natl. Acad. Sci. USA 83:8258 8262 ( 1986); U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. Other illustrative and non-limiting examples of linkers may include, for example, Glu-Gly-Lys-Ser-Ser-Gly-Ser-Gly-Ser-Glu-Ser-Lys-Val-Asp (SEQ ID NO: 19) (Chaudhary et al., Proc. Natl. Acad. Sci. USA 87:1066-1070 (1990)) and Lys-Glu-Ser-Gly-Ser-Val-Ser-Ser-Glu-Gln-Leu-Ala-Gln-Phe- Arg-Ser-Leu-Asp (SEQ ID NO: 20) (Bird et al., Science 242:423-426 (1988)) and the pentamer Gly-Gly-Gly-Gly-Ser (SEQ ID NO: 21), or higher when present in a single iteration or repeated 1 to 5 or more times. Any suitable linker can be used, and typically the length can be about 2 (eg, GS, GP, PG, or the like), 3 (eg, GSG, PGP, GPP, or the like), 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100 amino acids, or less than about 200 amino acids in length, and will preferably comprise a flexible structure (which can be two regions, domains, modules connected by a linker) (provide flexibility and space for conformational movement between bodies, segments or modules), and will preferably be bioinert and/or have a low risk of immunogenicity in humans. Non-limiting examples of linkers include those comprising or consisting of the amino acid sequences set forth in any one or more of SEQ ID NOs: 20-21, 97-106, and 702. In certain embodiments, the linker comprises at least 75% (i.e., at least about 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identical amino acid sequence or consisting of it .

The multiple RBD polypeptides present in the fusion proteins or compositions of the invention can be homotypic, heterotypic, homogeneous and/or heterogeneous.

In some embodiments, a fusion protein is provided comprising: ([RBD] -Px- [RBD]) y , wherein each RBD is an RBD polypeptide and the RBD polypeptides may be the same or different from each other, and P is as provided herein Stem-helix polypeptides, x is 1 or greater, and y is 1 or greater. In certain embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:16 or SEQ ID NO.:17. In certain embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:18 or SEQ ID NO.:19, wherein optionally, X is 2, 3, 4, 5, 6, 7, 8, 9, 10 or larger. In certain embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:701.

In any of the embodiments disclosed herein, the spike protein polypeptide may comprise an RBD polypeptide having the following, or the RBD polypeptide may have the following: at least 70%, at least 75% of SEQ ID NO.:2 , at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% consistency. In some embodiments, the fusion protein does not comprise SEQ ID NO.:2 or naturally occurring variants thereof.

Engineered RBD polypeptides and spinin polypeptides comprising the same are also provided. In any of the embodiments disclosed herein, the spike protein and/or RBD may comprise any one or more of (i)-(iv) : (i) One or more of the native RBDs Amino acid substitution; (ii) One or more amino acid deletions relative to the natural RBD; (iii) One or more amino acid insertions relative to the natural RBD; (iv) One or more amino acids relative to the natural RBD a non-natural carbohydrate attachment site, which optionally includes a glycosylation site, wherein optionally, the glycosylation site includes a C-linked glycosylation site, an N-linked glycosylation site, an O Linked glycosylation site, S-linked glycosylation site, or any combination thereof.

In some embodiments, engineered variants of SARS-CoV-2 receptor binding domain (RBD) polypeptides are provided, the variants comprising any one or more of (i)-(iv): (i) One or more amino acid substitutions relative to the natural RBD; (ii) One or more amino acid deletions relative to the natural RBD; (iii) One or more amino acid insertions relative to the natural RBD; (iv) ) one or more non-natural carbohydrate attachment sites relative to the native RBD, which optionally includes a glycosylation site, wherein optionally the glycosylation site includes a C-linked glycosylation site, N Linked glycosylation site, O-linked glycosylation site, S-linked glycosylation site, or any combination thereof.

In other embodiments, engineered variant SARS-CoV-2 spike protein polypeptides are provided that comprise any one or more of (i)-(iv) in the receptor binding domain (RBD): (i) ) One or more amino acid substitutions relative to the natural RBD; (ii) One or more amino acid deletions relative to the natural RBD; (iii) One or more amino acid insertions relative to the natural RBD; ( iv) one or more non-natural carbohydrate attachment sites relative to the native RBD, optionally comprising a glycosylation site, wherein optionally the glycosylation site comprises a C-linked glycosylation site, N-linked glycosylation sites, O-linked glycosylation sites, S-linked glycosylation sites, or any combination thereof, optionally, engineered variant SARS-CoV-2 spike proteins The polypeptide includes (i) one or more modifications that promote the open conformation of the receptor binding domain (RBD) of the spike protein polypeptide (such as D614G, K986P and V987P) and/or (ii) one or more modifications that promote the open conformation of the SARS-CoV-2 spike protein Stable modification of peptide trimers.

It will be appreciated that engineered variant RBD or spike protein polypeptides may, for example, be included in fusion proteins and/or compositions with the stem-helix polypeptides disclosed herein.

Certain embodiments of variant RBD or spike polypeptides provided herein are derived from the "backbone" spike polypeptide of SEQ ID NO.:1. For ease of reference, the amino acid numbering according to SEQ ID NO.: 1 may be used, but it is understood that the present invention includes variant RBDs that can be separated or otherwise isolated from the spike protein polypeptide. Accordingly, reference to an amino acid number according to SEQ ID NO.: 1 does not necessarily mean that the subject RBD or RBD-containing polypeptide is included in the spinin polypeptide of SEQ ID NO.: 1, or is completely included in the spinin polypeptide. In other words, amino acid numbering according to SEQ ID NO.: 1 or any other spike protein polypeptide amino acid sequence can simply provide a reference frame for identifying amino acids.

Additionally, certain embodiments provide variant RBD or spike protein polypeptides that are missing one or more (eg, one, two, three or more) present in a reference sequence (eg, the reference sequence of SEQ ID NO.:1 ), and/or contains one or more additional amino acids that are not present in the reference sequence. For example, certain embodiments provide variant RBD or spike protein polypeptides that comprise one or more deleted and/or inserted amino acids compared to SEQ ID NO.:1. However, for reference in these examples, the amino acid numbering according to SEQ ID NO.:1 will be retained. For example, if the variant RBD includes a deletion of amino acids 444-447 compared to SEQ ID NO.:1, then the numbering of the amino acids downstream of the deletion will remain unchanged relative to SEQ ID NO.:1; for example , according to SEQ ID NO.: 1 numbering, regardless of the presence or absence of amino acids 444-447, amino acid 450 in the variant RBD will be amino acid 450.

It should be understood that an amino acid "substituted by" one or more amino acids may refer to amino acid substitutions, and in some cases may also refer to amino acid deletions and/or insertions. For example, the amino acid sequence N-G-V can be "replaced" with a single G amino acid by deleting the N and V amino acids. In other words, "substituted" may refer to the amino acid difference at the corresponding position or region of the reference sequence (eg, SEQ ID NO.: 1) relative to the subject variant sequence.

In some embodiments, a fusion protein is provided that includes: (i) the coronavirus spike protein ectodomain (S ectodomain); and (ii) an oligomeric domain at the C-terminus of the S ectodomain, wherein optionally, The oligomeric domain is fused or linked to the C-terminus of the S ectodomain, and optionally the coronavirus comprises a betacoronavirus. In some embodiments, the S ectodomain comprises a receptor binding domain (RBD) in an open configuration.

In certain embodiments, the oligomeric domain comprises a trimerization domain. In some embodiments, the trimerization domain comprises a foldon, wherein the foldon optionally comprises or consists of the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO.:703).

In certain other embodiments, the fusion protein further comprises: (i) a peptide tag located at the C-terminus of the oligomerization domain; (ii) one or more stem-helix polypeptides, optionally comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) or consisting of; or (iii) both (i) and (ii). In certain other embodiments, the peptide tag comprises SpyTag, wherein optionally the SPyTag comprises the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700). In certain other embodiments, the fusion protein further comprises a stem-helix polypeptide disposed between (i) an oligomeric domain and a peptide tag or (ii) an oligomeric domain and (iii) one or more stem-helix polypeptides. and connect it to the connector. In certain other embodiments, the linker comprises or consists of the amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GGSGSGSG (SEQ ID NO.:711), PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or the amino acid sequence set forth in any one of SEQ ID NOs.:97-106.

In some embodiments, the fusion protein further comprises a first RBD polypeptide located at the C-terminus of the oligomerization domain. In some embodiments, the fusion protein further comprises a second RBD polypeptide located at the C-terminus of the first RBD polypeptide. In certain other embodiments, the fusion protein further comprises a third RBD polypeptide located at the C-terminus of the second RBD polypeptide.

In some embodiments, the fusion protein further comprises: (a) a linker disposed between and connecting the oligomeric domain and the first RBD polypeptide; and/or (b) disposed between the first RBD polypeptide and the second RBD A linker between and connecting the polypeptides; and/or (c) a linker disposed between and connecting the second RBD polypeptide and the third RBD polypeptide. In certain other embodiments: (i) the linker of (a) comprises, consists essentially of, or consists of the same amino acid sequence as the linker of (b); (ii) the linkage of (a) The linker of (c) contains the same amino acid sequence as the linker of (c), consists essentially of, or consists of; (iii) the linker of (a) contains an amino acid sequence that is different from the linker of (b), Consists essentially of, or consists of; (iv) the linker of (a) contains, consists essentially of, or consists of an amino acid sequence different from that of the linker of (c); (v) (b) The linker of (c) contains the same amino acid sequence as the linker of (c), consists essentially of, or consists of; (vi) the linker of (b) contains an amino acid sequence different from the linker of (c). sequence, consisting essentially of, or consisting of; or (vii) the linker of (a), the linker of (b) and the linker of (c) comprise, consist essentially of, or the same amino acid sequence. consists of. In certain other embodiments, the linker of (a), the linker of (b) and/or the linker of (c) comprises or consists of the following: amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GGSGSGSG (SEQ ID NO.:711), or PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or SEQ ID The amino acid sequence set forth in any one of NOs.: 97-106.

In some embodiments, the fusion protein includes an S ectodomain and a first RBD polypeptide, wherein the first RBD polypeptide includes, consists essentially of, the same amino acid sequence as the amino acid sequence of the RBD included in the S ectodomain. or consisting of. In certain embodiments, the fusion protein comprises a second RBD polypeptide and optionally a third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each comprise an amine group of the RBD contained in the S extracellular domain. An amino acid sequence that has the same acid sequence, consists essentially of, or consists of. In some embodiments, the first RBD polypeptide comprises, consists essentially of, or consists of an amino acid sequence that is different from the amino acid sequence of the RBD contained in the S ectodomain. In some embodiments, the fusion protein comprises a second RBD polypeptide and optionally a third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each independently comprise an amine with the RBD contained in the S extracellular domain. Amino acid sequences that have the same or different amino acid sequences, consist essentially of them, or consist of them. In certain other embodiments, the fusion protein comprises at the C-terminus: a first RBD polypeptide; optionally a second RBD polypeptide; and/or an optional third RBD polypeptide, optionally comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) or a stem-helix polypeptide consisting thereof.

In some embodiments, the fusion protein does not comprise at the C-terminus: a first RBD polypeptide; an optional second RBD polypeptide; and/or an optional third RBD polypeptide, optionally comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) or a stem-helix polypeptide composed thereof.

Polypeptide trimers are also provided, wherein each of the three polypeptides of the trimer includes: (i) the coronavirus spike protein ectodomain (S ectodomain; i.e., natural or engineered); and (ii) the S ectodomain The C-terminal trimerization domain, wherein the three trimerization domains associate with each other to form a trimer, and wherein optionally, each of the three trimerization domains includes a foldon and/or the coronavirus includes a betacoronavirus.

In certain embodiments, one, two, or three of the polypeptides comprise a fusion protein as disclosed herein, wherein two or three fusion proteins, if present, optionally comprise the same amino acid sequence as each other, Consists essentially of or consists of.

An isolated coronavirus receptor binding domain (RBD) polypeptide is also provided, wherein optionally the coronavirus comprises a betacoronavirus.

In some embodiments, the RBD polypeptide is comprised in a fusion protein, wherein the fusion protein further comprises one or both of (i) and (ii): (i) one or more peptide tags; (ii) one or more stem- Helical polypeptides, wherein optionally the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). In certain embodiments, the fusion protein comprises: (a) a peptide tag linked or fused to the first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; (b) linked or fused to the RBD a peptide tag at the second end of the polypeptide, wherein the second end optionally includes the C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to the first end of the RBD polypeptide, wherein the first end optionally includes RBD The N-terminus of the polypeptide; (d) a stem-helix polypeptide linked or fused to the first end of the RBD polypeptide, wherein the first end optionally includes the N-terminus of the RBD polypeptide; or (e) of (a)-(d) Any combination. In some embodiments, the one or more peptide tags comprise SpyTag. In some embodiments, the fusion protein includes a linker disposed between and connecting a peptide tag of (1) an RBD polypeptide and (2) one or more peptide tags. In some embodiments, the fusion protein further comprises two or more linkers that comprise the same amino acid sequence as each other, and/or the linker, or one of the two or more linkers. One or more comprise or consist of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO:702).

In certain embodiments, the fusion protein includes a linker disposed between and connecting (1) an RBD polypeptide and (2) one of one or more stem-helix polypeptides.

In some embodiments, the fusion protein comprises: (i) a peptide tag fused or linked to the N-terminus of the RBD polypeptide; and (ii) a stem-helix polypeptide fused or linked to the C-terminus of the RBD polypeptide. In certain other embodiments, the fusion protein includes an optional signal peptide, an optional linker, an SPyTag (optionally AHIVMVDAYKPTK (SEQ ID NO.:700)), a linker (optionally optionally GSGGSGGSGGTG; SEQ NO.:702), an RBD, a linker (optionally GSGGSGGSGGTG; SEQ ID NO.:702) and a stem-helix polypeptide, wherein optionally the stem-helix polypeptide comprises the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP ( SEQ ID NO.:701) or consisting thereof.

Also provided is a fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein optionally the coronavirus comprises a betacoronavirus. In some embodiments, the fusion protein includes a first RBD polypeptide, a second RBD polypeptide and a third RBD polypeptide, the first RBD polypeptide is linked to the second RBD polypeptide via linker (1), and the second RBD polypeptide is linked to Sub(2) is linked to the third RBD polypeptide. In certain other embodiments, linker (1) and linker (2) comprise, consist essentially of, or consist of the same amino acid sequence. In other embodiments, linker (1) and linker (2) have different amino acid sequences from each other. In some embodiments, the linker of the fusion protein comprises a stem-helix polypeptide. In some embodiments of the fusion protein, linker (1) and linker (2) each comprise a stem-helix polypeptide.

In some embodiments, the fusion protein includes an RBD polypeptide from any one or more of: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 A.27; SARS-like coronavirus ZC45. In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of: SARS-CoV-2 beta variant; SARS-CoV-2 A.2.7 + S494P; SARS-like coronavirus isolate Rs4231. In some embodiments, the fusion protein comprises an RBD polypeptide from any one or more of: SARS-CoV-2 delta variant; GX-pangolin; SARS-like coronavirus isolate Rs4231. In some embodiments, the fusion protein includes an RBD polypeptide from any one or more of: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 beta variant (also known as B.1.351); SARS -CoV-2δ variant (also known as B.1.617.2); and SARS-CoV-2o variant (also known as B.1.1.529). In some embodiments, the fusion protein comprises an RBD polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.: 2 and 722-729. In some embodiments, the fusion protein includes an RBD polypeptide from any one or more of: PANG/GX; MP789; RaTG13; and RsSHC014. In some embodiments, the fusion protein comprises an RBD polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.: 730-737.

In some embodiments, the fusion protein includes three RBD polypeptides, wherein the three RBD polypeptides are from: MP789; RaTG13; and RsSHC014. In some embodiments, the fusion protein comprises three RBD polypeptides, wherein the three RBD polypeptides respectively comprise the amino acid sequences set forth in: (i) SEQ ID NO.: 734 or 735; (ii) SEQ ID NO.: 734 or 735; NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731. In some embodiments, the fusion protein includes three RBD polypeptides, wherein the three RBD polypeptides respectively consist of the amino acid sequences set forth in: (i) SEQ ID NO.: 734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731. In certain embodiments, a stem-helix polypeptide comprises or consists of an amino acid sequence according to any of SEQ ID NOs.: 701, 4-19, 46, and 57-59. In some embodiments, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein comprises three RBD polypeptides, wherein the three RBD polypeptides are from: (i) respectively, SARS-CoV-2 Wuhan-Hu-1, SARS-CoV-2A.27, and SARS-like coronavirus ZC45; (ii) respectively, SARS-CoV-2 beta variant, SARS-CoV-2 A.2.7 + S494P and SARS-like coronavirus isolate Rs4231; or (iii) respectively, SARS-CoV-2 delta variant, GX-pangolin and SARS-like coronavirus isolate Rs4231.

In some embodiments, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein further comprises a fourth RBD polypeptide and a fifth RBD polypeptide, wherein the fourth RBD polypeptide is linked to the third RBD polypeptide via linker (3) and the fifth RBD polypeptide is linked to the third RBD polypeptide via linker (4) Linked to the fourth RBD polypeptide. In certain embodiments, two, three, or all four of linkers (1)-(4) comprise, consist essentially of, or consist of the same amino acid sequence. In other embodiments, two or more of the linkers have different amino acid sequences from each other. In some embodiments, one or more of linkers (1)-(4) comprise or consist of a stem-helix polypeptide, wherein optionally the stem-helix polypeptide comprises the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO .:701) or consisting of. In some embodiments, each of the peptide linkers (1)-(4) comprises or consists of a stem-helix polypeptide, wherein optionally the stem-helix polypeptide comprises the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO. :701) or consisting of.

In some embodiments, the fusion protein comprises an RBD polypeptide from: (i) a SARS-CoV-2β variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (ii) SARS-CoV-2β Variant; SARS-CoV-2o variant; MP789; RaTG13; and RsSHC014; or (iii) SARS-CoV-2o variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (iv) SARS-CoV-2δ Variants; SARS-CoV-2o variants; MP789; RaTG13; and RsSHC014.

In some embodiments, the fusion protein comprises five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequences set forth in the following SEQ ID NO.: (i) respectively, 725, 731, 733, 735 and 737; or (ii) respectively, 725, 731, 729, 735 and 737; or (iii) respectively, 729, 731, 733, 735 and 737; or (iv) respectively, 727, 731, 729, 735 and 737. In certain other embodiments: (1) an RBD polypeptide comprising SEQ ID NO.:725 comprises or consists of SEQ ID NO.:724; (2) an RBD polypeptide comprising SEQ ID NO.:727 comprises SEQ ID NO. .:726 or consisting of it; (3) the RBD polypeptide comprising SEQ ID NO.:729 comprises or consisting of SEQ ID NO.:728; (4) the RBD polypeptide comprising SEQ ID NO.:731 comprises SEQ ID NO. .:730 or consisting of it; (5) an RBD polypeptide comprising SEQ ID NO.:733 comprising or consisting of SEQ ID NO.:732; (6) an RBD polypeptide comprising SEQ ID NO.:735 comprising SEQ ID NO. .:734 or consisting of it; and/or (7) an RBD polypeptide comprising SEQ ID NO.:737 comprising or consisting of SEQ ID NO.:736.

In some embodiments, the fusion protein comprises five RBD polypeptides, wherein the five RBD polypeptides comprise or consist of the amino acid sequences set forth in the following SEQ ID NO.: (i) respectively, 724, 732, 734, 736 and 730; or (ii) respectively, 724, 728, 734, 736 and 730; or (iii) respectively, 728, 732, 734, 736 and 730; or (iv) respectively, 726, 728 , 735, 736 and 730.

In certain embodiments, the fusion protein includes along the N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide from a SARS-CoV-2β variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; An RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (ii) an RBD polypeptide from a SARS-CoV-2 beta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from a SARS-CoV-2o variant; or (ii) an RBD polypeptide from a SARS-CoV-2 beta variant; and an RBD polypeptide from RatG13; or (iii) an RBD polypeptide from a SARS-CoV-2o variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13 RBD polypeptide; or (iv) an RBD polypeptide from a SARS-CoV-2 delta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from a SARS-CoV-2o variant; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13.

In certain embodiments, the fusion protein comprises along the N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising SEQ ID NO.:725; an RBD polypeptide comprising SEQ ID NO.:731; comprising SEQ ID NO. .: The RBD polypeptide of SEQ ID NO.:733; comprising the RBD polypeptide of SEQ ID NO.:735; and comprising the RBD polypeptide of SEQ ID NO.:737; or (ii) comprising the RBD polypeptide of SEQ ID NO.:725; comprising SEQ ID NO. : the RBD polypeptide of SEQ ID NO.:731; comprising the RBD polypeptide of SEQ ID NO.:729; comprising the RBD polypeptide of SEQ ID NO.:735; and comprising the RBD polypeptide of SEQ ID NO.:737; or (iii) comprising SEQ ID NO.: The RBD polypeptide of 729; the RBD polypeptide comprising SEQ ID NO.:731; the RBD polypeptide comprising SEQ ID NO.:733; the RBD polypeptide comprising SEQ ID NO.:735; and the RBD polypeptide comprising SEQ ID NO.:737; or (iv) comprising the RBD polypeptide of SEQ ID NO.:727; comprising the RBD polypeptide of SEQ ID NO.:731; comprising the RBD polypeptide of SEQ ID NO.:729; comprising the RBD polypeptide of SEQ ID NO.:735; and comprising The RBD polypeptide of SEQ ID NO.:737.

In some embodiments, the fusion protein includes along the N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730 or (ii) An RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:728; comprising SEQ ID NO.:728 ID NO.:734 or an RBD polypeptide consisting of; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iii) an RBD polypeptide comprising or consisting of SEQ ID NO.:728; comprising SEQ An RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and comprising SEQ ID NO.: 736 or an RBD polypeptide consisting of; or (iv) an RBD polypeptide comprising or consisting of SEQ ID NO.:726; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; comprising SEQ ID NO.:728 An RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736.

In certain embodiments, the fusion protein includes disposed between a first RBD polypeptide and a second RBD polypeptide, between a second RBD polypeptide and a third RBD polypeptide, between a third RBD polypeptide and a fourth RBD polypeptide, and between a fourth RBD polypeptide and a fourth RBD polypeptide. The amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) between the RBD polypeptide and the fifth RBD polypeptide, wherein the first RBD polypeptide is the N-terminal RBD polypeptide of the fusion protein and the fifth RBD polypeptide is the C-terminal RBD polypeptide of the fusion protein .

In some embodiments, the fusion protein further comprises a peptide tag, wherein optionally the peptide tag is disposed at the C-terminus of the fusion protein, preferably fused to the C-terminus of the C-terminal RBD polypeptide of the fusion protein. In some embodiments, the peptide tag is placed at the C-terminus of the fusion protein. Peptides may contain SpyTag and/or His tags. In some embodiments, the fusion protein does not comprise a peptide tag disposed at the C-terminus of the fusion protein, optionally at the C-terminus of the C-terminal RBD polypeptide.

In certain embodiments, the fusion protein does not include a His tag disposed at the C-terminus of the fusion protein.

In some embodiments, the fusion protein of any one of technical solutions 1 to 34 includes a signal peptide, wherein optionally, the signal peptide is placed at the N-terminus of the fusion protein, and is preferably fused to the N-terminus of the N-terminal RBD polypeptide. end. The signal peptide may comprise or consist of the following: amino acid sequence MAPLLLLLPLLWAGALA (SEQ ID NO.:706), amino acid sequence MNTQILVFALIAIIIPTNADKI (SEQ ID NO.:705), amino acid sequence MFVFLVLLPLVS (SEQ ID NO.: 707) or the amino acid sequence MFVFLVLLPLLVSS (SEQ ID NO.:708), and preferably consists of SEQ ID NO.:706.

In certain embodiments, the fusion protein is administered to a mammal (e.g., a mouse, such as a female BALB/c mouse), optionally twice via intramuscular injection, with the second administration being 20 or 21 days apart. ) elicits, optionally, neutralizing antibodies against any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 B.1.351; SARS-CoV-2 B .1.617.2; SARS-CoV-2 B.1.1.529; and SARS-CoV-1, optionally using serum collected from the mammal 14 days after the second immunization, in vesicular stomatitis virus /Coronavirus pseudovirus system, optionally using Vero-E6 TMPRSS cells to evaluate neutralizing antibodies. In certain embodiments, the fusion protein, when administered to a mammal that has previously received an mRNA SARS-CoV-2 spike protein vaccine, elicits: (i) Against any one or more of the following, and optionally possesses neutralizing antibodies: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 BA1; SARS-CoV-2 BA2; SARS -CoV-2 BA5; and SARS-CoV-1, optionally to a degree greater than that elicited by a third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein optionally: the mammal is Mice, such as female BALB/c mice; the fusion protein is administered intramuscularly and/or once on day 60 and the mammal has received the mRNA spike protein vaccine on day 0 and again on day 14 ; and/or assess neutralizing antibodies on day 67 in a vesicular stomatitis virus/coronavirus pseudovirus system using sera collected from mammals; and/or (ii) Antibodies that bind to RBD from any one or more of the following: SARS-Cov2-Wuhan-Hu-1 (Wu); -B.1.351 (β); SARS-Cov1; Wiv-1; RatG13; PangGD; PANG/GX; Anlog112; wherein optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered intramuscularly and/or once on day 60, and the mammal has received the mRNA spike protein vaccine on day 0 and Re-receive the vaccine on day 14; and/or assess binding antibodies by ELISA on day 67 using sera collected from the mammals.

In certain embodiments, the fusion protein is capable of being bound by any one or more of the following antibodies: S2P6; S2E12; S2K146; S2X259; S309; and S2H97 or an antigen-binding fragment thereof, wherein optionally, the antigen-binding fragment comprises The VH and VL Fab of the antibody further includes IgG1 CH1 and IgG κ CL or IgG λ CL.

Isolated polypeptides comprising or consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.: 218 without SEQ ID NO.: 706; (iii) SEQ ID NO.: 218 are also provided. :712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; ( vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:706 without NO.:715; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) No SEQ ID NO. .:706 of SEQ ID NO.:717; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741 ; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Also provided is a fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) one or more peptide tags; (ii) one or more stem- Helical polypeptides, wherein optionally the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the fusion protein comprises: (a) a peptide tag linked or fused to the first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; (b) linked or fused to the RBD polypeptide a peptide tag at the second end of the RBD polypeptide, wherein the second end optionally includes the C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to the first end of the RBD polypeptide, wherein the first end optionally includes the RBD polypeptide the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to the second end of the RBD polypeptide, wherein the first end optionally includes the C-terminus of the RBD polypeptide; or (e) any combination of (a)-(d) .

In some embodiments, the peptide tag comprises a His tag, wherein optionally the His tag comprises or consists of the amino acid sequence HHHHHHHH (SEQ ID NO.:704). In some embodiments, the peptide tag includes SpyTag. In certain embodiments, the fusion protein includes a linker disposed between and connecting a peptide tag of (1) an RBD polypeptide and (2) one or more peptide tags. In some embodiments, the fusion protein contains two or more linkers that contain the same amino acid sequence as each other. In some embodiments, the linker or one or more of the two or more linkers comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.:702). In some embodiments, the fusion protein includes a linker disposed between and connecting (1) an RBD polypeptide and (2) one of one or more stem-helix polypeptides.

In certain embodiments, the fusion protein includes the following structure: PT1—L1—RBD—L2—SHP—PT2, where: PT1 and PT2 are each an optional peptide tag; L1 and L2 are each an optional linker; RBD is an RBD polypeptide; and SHP is a stem-helix polypeptide.

In some embodiments: PT1 has the amino acid sequence of SEQ ID NO.:700 when present; L1 has the amino acid sequence of SEQ ID NO.:702 when present; L2 is absent or has an amine group when present The acid sequence is GSG, GPP, GS or PGP; SHP has the amino acid sequence of SEQ ID NO.:701; and PT2, when present, has the amino acid sequence of SEQ ID NO.:704. In some embodiments: (i) PT1, L1, SHP, L2, and PT2 are present; (ii) PT1, L1, SHP, and PT2 are present; (iii) L2, SHP, and PT2 are present; (iv) SHP and PT2 are present; (v) SHP and optionally L2 are present; or (vi) L2, SHP and PT2 are present.

In certain embodiments, the fusion protein comprises: (i) a signal peptide fused or linked to the N-terminus of the RBD polypeptide; and (ii) a stem-helix polypeptide fused or linked to the C-terminus of the RBD polypeptide. In some embodiments, the fusion protein includes a signal peptide (optionally MAPLLLLLPLLWAGALA (SEQ ID NO.:706)), an optional linker, an RBD, an optional linker, and a stem- A helical polypeptide, wherein optionally the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

In some embodiments, the RBD polypeptide is from any of the following: SARS-CoV-2-Wuhan-Hu-1; SARS-CoV-2 beta variant; SARS-CoV-2o variant; SARS-CoV-2 delta variant body; PANG_GX; MP789; RatG13; RsSCH014; RmYN02; BM48-31/BGR/2008; PC4-241; Rf1/2004; and Rp/Shaanxi 2011.

In some embodiments, the RBD polypeptide comprises or consists of the amino acid sequence of any of SEQ ID NO.: 724-737.

Also provided is an isolated polypeptide comprising the following structure: RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 RBD1, RBD2, RBD3, RBD4 and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2β variant; SARS-CoV-2o variant; SARS-CoV-2δ variant; PANG/GX ; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, and each of L1, L2, L3 and L4 is a linker. In some embodiments, one or more of L1, L2, L3 and L4 comprise or consist of the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 , and optionally, L1, L2, L3 and L4 each independently comprise or consist of the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59. In certain embodiments, L1, L2, L3 and L4 are the same, and preferably L1, L2, L3 and L4 are SEQ ID NO.:701. In some embodiments, RBD1, RBD2, RBD3, RBD4 and RBD5 are independently selected from the group consisting of: (i) SEQ ID NO.: 724 or 725; (ii) SEQ ID NO.: 726 or 727; (iii) SEQ ID NO.: 728 or 729; (iv) SEQ ID NO.: 730 or 731; (v) SEQ ID NO.: 732 or 733; (vi) SEQ ID NO.: 734 or 735; and ( vii) SEQ ID NO.: 736 or 737, preferably, five of (i)-(vii) are present.

In certain embodiments, RBD1, RBD2, RBD3, RBD4 and RBD5 are from: (i) respectively, SARS-CoV-2 beta variants; RsSHC014; PANG/GX; MP789; and RaTG13; or (ii) respectively, SARS-CoV-2 beta variant; RsSHC014; SARS-CoV-2o variant; MP789; and RaTG13; or (iii) respectively, SARS-CoV-2o variant; RsSHC014; PANG/GX; MP789; and RaTG13; or (iv) Respectively, SARS-CoV-2 delta variant; RsSHC014; SARS-CoV-2o variant; MP789; RaTG13.

In some embodiments, RBD1, RBD2, RBD3, RBD4, and RBD5 comprise the amino acid sequences set forth in the following SEQ ID NO.: (i) 725, 731, 733, 735, and 737, respectively; or (ii) respectively, 725, 731, 729, 735 and 737; or (iii) respectively, 729, 731, 733, 735 and 737; or (iv) respectively, 727, 731, 729, 735 and 737, any of which Specifically, RBD1, RBD2, RBD3, RBD4 and RBD5 comprise or consist of the amino acid sequences set forth in the following SEQ ID NO.: (1) 724, 730, 732, 734 and 736, respectively; or (2) respectively, 724, 730, 728, 734 and 736; or (3) respectively, 728, 730, 732, 734 and 736; or (4) respectively, 726, 730, 728, 734 and 736.

Also provided is an isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59. Also provided is an isolated polypeptide, which includes or consists of the following: the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.:14, and the amino group of SEQ ID NO.:15 The acid sequence, the amino acid sequence of SEQ ID NO.:16 or the amino acid sequence of SEQ ID NO.:17.

In some embodiments, the fusion protein comprises an RBD polypeptide from: (i) SARS-CoV-2 Wuhan-Hu-1, SARS-CoV-2 A.27, SARS-CoV-2 alpha variant+E484K+ S494P, SARS-like coronavirus ZC45 and SARS-CoV-1; or (ii) SARS-CoV-2δ variant, SARS-CoV-2β variant, SARS-CoV-2 A.27+S494P, GX-pangolin and SARS Like coronavirus isolate Rs4231.

In some embodiments, the fusion protein further comprises a peptide tag, wherein optionally the peptide tag is positioned at the C-terminus of the fusion protein.

In certain other embodiments, the peptide tag includes SpyTag and/or His tag.

In any of the disclosed embodiments, the coronavirus may comprise a betacoronavirus, wherein the betacoronavirus comprises a Sabeycoronavirus. In some embodiments, the Sabey coronavirus includes SARS-CoV-2, a SARS coronavirus, a SARS-like coronavirus, or an engineered variant thereof. In certain other embodiments, the Sabey coronavirus includes SARS-CoV-2; Wuhan-Hu-1; A.27 (Mayotte); A.27 with the S494P substitution mutation; AAV49723.1; ATO98157. 1; AVP78031.1; B.1.315; B.167.2; Wuhan-Hu-1 with substitution mutations E484K, S494P and N501Y; QHD43416.1; ADE34812; AIA6227; QIA48632.1; or any combination thereof. In specific embodiments, the Sabey coronavirus includes SARS-CoV-2.

Polypeptides comprising variants of the SARS-CoV-2 receptor binding domain (RBD) are also provided, wherein the variant RBD comprises the following changes (i) relative to the RBD comprising amino acids 328-531 of SEQ ID NO.:1 - any one or more of (xiii) , in which the numbering of the amino acid is according to SEQ ID NO.: 1: (i) replaced by a single P amino acid, a single G amino acid or a single S amino acid Amino acid 444-447 (KVGG); (ii) Amino acid 444-447 (KVGG) substituted by two amino acids PG, two amino acids GG or two amino acids GS; (iii) Y449G Substitution; (iv) Q498A substitution, Q498G substitution or Q498N substitution, optionally further comprising P499A substitution or P499G substitution; (v) P499A substitution or P499G substitution; (vi) T500A substitution; (vii) N450G substitution; (viii) L452A Substitution; (ix) T470N substitution and I472T substitution; (x) V483A substitution; (xi) Amino acid 481-483 (NGV) substituted by a single G amino acid; (xii) E484A substitution; (xiii) Q493A substitution.

Isolated polypeptides comprising variants of the SARS-CoV-2 receptor binding domain (RBD) are also provided, wherein the variant RBD comprises the following changes relative to the RBD comprising amino acids 328-531 of SEQ ID NO.: 1 ( Any one or more of i) - (vi) , wherein the numbering of the amino acid is according to SEQ ID NO.: 1: (i) via a single P amino acid, a single G amino acid or a single S amino acid Substituted amino acid 444-447 (KVGG); (ii) Substituted amino acid 444-447 (KVGG) by two amino acids PG, two amino acids GG or two amino acids GS; (iii ) ) Y449G substitution; (iv) Q498A substitution, Q498G substitution or Q498N substitution, optionally further comprising P499A substitution or P499G substitution; (v) P499A substitution or P499G substitution; (vi) T500A substitution.

Isolated polypeptides comprising variants of the SARS-CoV-2 receptor binding domain (RBD) are also provided, wherein the variant RBD comprises the following changes relative to the RBD comprising amino acids 328-531 of SEQ ID NO.: 1 ( Any one or more of i) - (viii) , wherein the amino acid numbering is according to SEQ ID NO.:1: (i) N450G substitution; (ii) L452A substitution; (iii) T470N substitution; (iv) I472T substitution; (v) V483A substitution; (vi) Amino acid 481-483 (NGV) substituted by a single G amino acid; (vii) K484A substitution; (viii) Q493A substitution.

Isolated polypeptides comprising variants of the SARS-CoV-2 receptor binding domain (RBD) are also provided, wherein the variant RBD comprises the following changes relative to the RBD comprising amino acids 328-531 of SEQ ID NO.:1, The numbering of the amino acids is based on SEQ ID NO.:1: (1) Y449G substitution; or (2) Q498A substitution; or (3) Q498G substitution; or (4) T500A substitution; or (5) Y449G and Q498A substitution ; Or (6) Y449G and Q498G replace; or (7) Y449G and T500A replace; or (8) Q498A and T500A replace; or (9) Q498G and T500A replace; or (10) Y449G, Q498A and T500A replace; or ( 11) Y449G, Q498G and T500A substituted; or (12) Q498N substituted; or (13) Q498N and P499A substituted; or (14) Y449G, Q498N and P499A substituted; or (15) Q498N and P499G substituted; or (16) Y449G , Q498N and P499G substitution; or (17) amino acid 444-447 (KVGG) substituted by a single P amino acid; or (18) amino acid 444-447 (KVGG) substituted by a single G amino acid; or (19) amino acid 444-447 ( KVGG) substituted by a single S amino acid; or (20) amino acid 444-447 (KVGG) substituted by two amino acids PG; or (21 ) ) Amino acid 444-447 (KVGG) substituted by two amino acids GG; or (22) Amino acid 444-447 (KVGG) substituted by two amino acids GS; or (23) (i) Amino acid 444-447 (KVGG) substituted with a single P amino acid, (ii) Q498N substituted, and (iii) P499A substituted; or (24) (i) Amino acid 444 substituted with a single P amino acid -447 (KVGG), (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499A substitution; or (25) (i) amino acid 444-447 (KVGG) substituted with a single P amino acid, (ii) Q498N substitution, and (iii) P499G substitution; or (26) (i) amino acid 444-447 (KVGG) substituted with a single P amino acid, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution; or (27) (i) amino acid 444-447 (KVGG) substituted with a single G amino acid, (ii) Q498N substitution, and (iii) P499A substitution; or (28) ( i) Amino acid 444-447 (KVGG) substituted with a single G amino acid, (ii) Y449G substituted, (iii) Q498N substituted, and (iv) P499A substituted; or (29) (i) Substituted with a single G amine Amino acids 444-447 (KVGG) substituted with amino acids, (ii) Q498N substituted, and (iii) P499G substituted; or (30) (i) Amino acids 444-447 substituted with a single G amino acid (KVGG ), (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution; or (31) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) Q498N Substituted, and (iii) P499A substituted; or (32) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) Y449G substituted, (iii) Q498N substituted, and (iv) P499A substitution; or (33) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) Q498N substitution, and (iii) P499G substitution; or (34) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid Amino acid 444-447 (KVGG) substituted by S amino acid, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution; or (35) (i) substitution by two amino acids PG Amino acid 444-447 (KVGG), (ii) Q498N substituted, and (iii) P499A substituted; or (36) (i) Amino acid 444-447 (KVGG) substituted by two amino acids PG, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499A substitution; or (37) (i) amino acid 444-447 (KVGG) substituted by two amino acids PG, (ii) Q498N substitution , and (iii) P499G substitution; or (38) (i) amino acid 444-447 (KVGG) substituted by two amino acids PG, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution; or (39) (i) amino acid 444-447 (KVGG) substituted by two amino acids GG, (ii) Q498N substitution, and (iii) P499A substitution; or (40) (i) by Amino acid 444-447 (KVGG) substituted by two amino acids GG, (ii) Y449G substituted, (iii) Q498N substituted, and (iv) P499A substituted; or (41) (i) by two amino acids Amino acid 444-447 substituted with GG (KVGG), (ii) substituted with Q498N, and (iii) substituted with P499G; or (42) (i) amino acid 444-447 substituted with two amino acids GG (KVGG) ), (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution; or (43) (i) amino acid 444-447 (KVGG) substituted by two amino acids GS, (ii) Q498N substitution, and (iii) P499A substitution; or (44) (i) amino acid 444-447 (KVGG) substituted by two amino acids GS, (ii) Y449G substitution, (iii) Q498N substitution, and ( iv) P499A substitution; or (45) (i) amino acid 444-447 (KVGG) substituted by two amino acids GS, (ii) Q498N substitution, and (iii) P499G substitution; or (46) (i ) Amino acid 444-447 (KVGG) substituted by two amino acids GS, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution; or (47) N450G substitution; or (48) L452A substituted; or (49) V483A substituted; or (50) K484A substituted; or (51) Q493A substituted; or ( 52) N450G and Q493A substituted; or (53) L452A and Q493A substituted; or (54) N450G, V483A and Q493A substituted; or (55) N450G, K484A and Q493A substituted; or (56) L452A, V483A and Q493A substituted; or (57) L452A, K484A and Q493A substituted; or (58) T470N and I472T substituted; or (59) N450G , T470N and I472T replaced; or (60) L452A, T470N and I472T replaced; or (61) T470N, I472T and V483A replaced; or (62) N450G, T470N, I472T and V483A replaced; or (63) L452A, T470N, I472T and V483A; or (64) T470N, I472T, V483A and Q493A; or (65) N450G, T470N, I472T, V483A and Q493A; or (66) L452A, T470N, I472T, V483A and Q493A; or (67) ) Amino acid 481-483 (NGV) substituted with a single G amino acid; or (68) (i) Amino acid 481-483 (NGV) substituted with a single G amino acid and (ii) K484A substituted; or (69) (i) amino acid 481-483 (NGV) substituted with a single G amino acid, (ii) K484A substitution, and (iii) Q493A substitution; or (70) (i) L452A substitution, (ii) ) Amino acid 481-483 (NGV) substituted with a single G amino acid and (iii) K484A substituted; or (71) (i) L452A substituted, (ii) Amino acid 481 substituted with a single G amino acid -483 (NGV), (iii) K484A substitution, and (iv) Q493A substitution; or (72) (i) T470N substitution, (ii) I472T substitution, and (iii) amino acid substituted by a single G amino acid 481-483 (NGV); or (73) (i) T470N substitution, (ii) I472T substitution, (iii) amino acid 481-483 (NGV) substituted by a single G amino acid and (iv) K484A substitution; or (74) (i) T470N substitution, (ii) I472T substitution, (iii) amino acid 481-483 (NGV) substituted with a single G amino acid, (iv) K484A substitution, and (v) Q493A substitution; or (75) (i) L452A substitution, (ii) T470N substitution, (iii) I472T substitution, and (iv) amino acid 481-483 (NGV) substituted with a single G amino acid; or (76) (i ) L452A substitution, (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid 481-483 (NGV) substituted with a single G amino acid, (v) K484A substitution, and (vi) Q493A substitution; or (77) K484A, Q493A and Q498A replace; or (78) K484A, Q493A and Q498G replace; or (79) Y449G, K484A, Q493A, Q498A, P499A and T500A replace; or (80) Y449G, K484A, Q493A, Q498G , P499A and T500A; or (81) Y449G, L452A, V483A, K484A, Q493A, Q498A, P499A and T500A; or (82) Y449G, L452A, V483A, K484A, Q493A, Q498G, P499A and T500A; or ( 83) T470N, I472T, Q498N and P499A replaced; or (84) Y449G, T470N, I472T, Q498N and P499A replaced; or (85) T470N, I472T, Q493A, Q498N and P499A replaced; or (86) T470N, I472T, K484A , Q498N and P499A; or (87) L452A, T470N, I472T, Q498N and P499A; or (88) Y449G, T470N, I472T, Q493A, Q498N and P499A; or (89) Y449G, T470N, I472T, K484A, Replaced by Q498N and P499A; or (90) Replaced by Y449G, L452A, T470N, I472T, Q493A, Q498N and P499A; or (91 ) Replaced by Y449G, L452A, T470N, I472T, K484A, Q498N and P499A; or (92) Replaced by Y449G, L452 A , T470N, I472T, K484A, Q493A, Q498N and P499A; or (93) T470N, I472T, Q498N and P499G; or (94) Y449G, T470N, I472T, Q498N and P499G; or (95) T470N, I472T, Replaced by Q493A, Q498N and P499G; or (96) Replaced by T470N, I472T, K484A, Q198N and P499G; or (97) Replaced by L452A, T470N, I472T, Q498N and P499G; or (98) Replaced by Y449G, T470N, I472T, Q493A, Q498 N And P499G replacement; or (99) Y449G, T470N, i472T, K484A, Q498N and P499G replacement; or (100) Y449G, L452A, T470N, i472T, Q493A, Q498n and P499G replacement; or (101) Y449G, L452A, T477 0N, I472T, K484A, Q498N and P499G substitution; or (102) Y449G, L452A, T470N, I472T, K484A, Q493A, Q498N and P499G substitution; or (103) (i) Amino acid 444- substituted by a single P amino acid. 447 (KVGG), (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid substituted with a single G amino acid 481-483 (NGV), (v) Q498N substitution, and (vi) P499A substitution ; or (104) (i) amino acid 444-447 (KVGG) substituted with a single G amino acid, (ii) T470N substituted, (iii) I472T substituted, (iv) amine substituted with a single G amino acid Amino acid 481-483 (NGV), (v) Q498N substitution, and (vi) P499A substitution; or (105) (i) Amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid 481-483 (NGV) substituted with a single G amino acid, (v) Q498N substitution, and (vi) P499A substitution; or (106) (i) Amino acids 444-447 substituted with two amino acids PG (KVGG), (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acids 481-483 substituted with a single G amino acid (NGV ), (v) Q498N substitution, and (vi) P499A substitution; or (107) (i) amino acid 444-447 (KVGG) substituted by two amino acids GG, (ii) T470N substitution, (iii) Amino acids 481-483 (NGV) substituted with I472T, (iv) substituted with a single G amino acid, (v) substituted with Q498N, and (vi) substituted with P499A; or (108) (i) substituted with two amino acids GS substituted amino acid 444-447 (KVGG), (ii) T470N substituted, (iii) I472T substituted, (iv) amino acid substituted with a single G amino acid 481-483 (NGV), (v) Q498N Substituted, and (vi) P499A substituted; or (109) (i) amino acid 444-447 (KVGG) substituted with a single P amino acid, (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acids 481-483 (NGV) substituted with a single G amino acid, (v) Q493A substituted, (vi) Q498N substituted, and (vii) P499A substituted; or (110) (i) substituted with a single G amino acid Amino acid 444-447 (KVGG), (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid 481-483 (NGV) substituted with a single G amino acid, (v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution; or (111) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) T470N substitution, (iii) I472T substitution, (iv) Amino acids 481-483 (NGV) substituted with a single G amino acid, (v) substituted with Q493A, (vi) substituted with Q498N, and (vii) substituted with P499A; or (112) (i) substituted with two Amino acid PG substituted amino acid 444-447 (KVGG), (ii) T470N substituted, (iii) I472T substituted, (iv) amino acid 481-483 substituted with a single G amino acid (NGV), ( v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution; or (113) (i) amino acid 444-447 (KVGG) substituted by two amino acids GG, (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid 481-483 (NGV) substituted with a single G amino acid, (v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution; or (114) (i) Amino acid 444-447 (KVGG) substituted by two amino acids GS, (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acid 481- substituted by a single G amino acid 483 (NGV), (v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution; or (115) (i) amino acid 444-447 (KVGG) substituted with a single P amino acid, ( ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (NGV) substituted with a single G amino acid, (vi) Q493A substitution, (vii) Q498N substitution, and (viii) P499A substitution; or (116) (i) amino acid 444-447 (KVGG) substituted with a single G amino acid, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) Amino acids 481-483 (NGV) substituted with a single G amino acid, (vi) Q493A substituted, (vii) Q498N substituted, and (viii) P499A substituted; or (117) (i) Substituted with a single S Amino acid substituted amino acid 444-447 (KVGG), (ii) L452A substituted, (iii) T470N substituted, (iv) I472T substituted, (v) amino acid substituted with a single G amino acid 481-483 (NGV), (vi) Q493A substitution, (vii) Q498N substitution, and (viii) P499A substitution; or (118) (i) amino acid 444-447 (KVGG) substituted by two amino acids PG, ( ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (NGV) substituted with a single G amino acid, (vi) Q493A substitution, (vii) Q498N substitution, and (viii) P499A substitution; or (119) (i) amino acid 444-447 (KVGG) substituted by two amino acids GG, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution , (v) amino acids 481-483 (NGV) substituted with a single G amino acid, (vi) substituted with Q493A, (vii) substituted with Q498N, and (viii) substituted with P499A; or (120) (i) substituted with two Amino acids 444-447 (KVGG) substituted by a single amino acid GS, (ii) L452A substituted, (iii) T470N substituted, (iv) I472T substituted, (v) Amino acid substituted by a single G amino acid 481 -483 (NGV), (vi) Q493A substitution, (vii) Q498N substitution, and (viii) P499A substitution; or (121) (i) amino acid 444-447 (KVGG) substituted with a single P amino acid, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (NGV) substituted with a single G amino acid, (vi) K484A substitution, (vii) Q493A substitution , (viii) Q498N substitution, and (ix) P499A substitution; or (122) (i) amino acid 444-447 (KVGG) substituted with a single G amino acid, (ii) L452A substitution, (iii) T470N substitution , (iv) I472T substitution, (v) amino acid 481-483 (NGV) substituted with a single G amino acid, (vi) K484A substitution, (vii) Q493A substitution, (viii) Q498N substitution, and (ix) P499A substitution; or (123) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) Amino acids 481-483 (NGV) substituted by a single G amino acid, (vi) K484A substituted, (vii) Q493A substituted, (viii) Q498N substituted, and (ix) P499A substituted; or (124) (i) by Amino acid 444-447 (KVGG) substituted by two amino acids PG, (ii) L452A substituted, (iii) T470N substituted, (iv) I472T substituted, (v) amino acid substituted by a single G amino acid 481-483 (NGV), (vi) K484A substitution, (vii) Q493A substitution, (viii) Q498N substitution, and (ix) P499A substitution; or (125) (i) amino group substituted by two amino acids GG Acid 444-447 (KVGG), (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) Amino acid 481-483 (NGV) substituted with a single G amino acid, (vi) K484A substitution, (vii) Q493A substitution, (viii) Q498N substitution, and (ix) P499A substitution; or (126) (i) amino acid 444-447 (KVGG) substituted by two amino acids GS, (ii ) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (NGV) substituted with a single G amino acid, (vi) K484A substitution, (vii) Q493A substitution, ( viii) Q498N substitution, and (ix) P499A substitution; or (127) (i) amino acid 444-447 (KVGG) substituted with a single P amino acid, (ii) Y449G substitution, (iii) L452A substitution, ( iv) T470N substitution, (v) I472T substitution, (vi) amino acid 481-483 (NGV) substituted with a single G amino acid, (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution; or (128) (i) amino acid 444-447 (KVGG) substituted with a single G amino acid, (ii) Y449G substitution, (iii) L452A substitution, (iv) T470N substitution, (v) I472T substitution, (vi) amino acid 481-483 (NGV) substituted with a single G amino acid, (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A Substituted; or (129) (i) amino acid 444-447 (KVGG) substituted with a single S amino acid, (ii) Y449G substituted, (iii) L452A substituted, (iv) T470N substituted, (v) I472T substituted , (vi) amino acids 481-483 (NGV) substituted with a single G amino acid, (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution; or (130 ) (i) Amino acid 444-447 (KVGG) substituted by two amino acids PG, (ii) Y449G substitution, (iii) L452A substitution, (iv) T470N substitution, (v) I472T substitution, (vi) Amino acids 481-483 (NGV) substituted with a single G amino acid, (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution; or (131) (i) Amino acid 444-447 (KVGG) substituted by two amino acids GG, (ii) Y449G substituted, (iii) L452A substituted, (iv) T470N substituted, (v) I472T substituted, (vi) single G amine Amino acids 481-483 (NGV) substituted by amino acids, (vii) K484A substituted, (viii) Q493A substituted, (ix) Q498N substituted, and (x) P499A substituted; or (132) (i) via two amines Amino acid 444-447 (KVGG) substituted by amino acid GS, (ii) Y449G substituted, (iii) L452A substituted, (iv) T470N substituted, (v) I472T substituted, (vi) substituted by a single G amino acid Amino acid 481-483 (NGV), (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution.

In certain embodiments, the polypeptide contains no additional changes relative to amino acids 444-500 of SEQ ID NO.:1 and/or relative to amino acids 328-531 of SEQ ID NO.:1.

In certain embodiments, the polypeptide comprises at most 15, at most 14, at most 13 relative to amino acids 444-500 of SEQ ID NO.:1 and/or at most 13 relative to amino acids 328-531 of SEQ ID NO.:1 , up to 12, up to 11, up to 10, up to 9, up to 8, up to 7, up to 6, up to 5, up to 4, up to 3, up to 2 or up to 1 additional variation, wherein each additional variation independently includes: (i) deletion of one, two or three amino acids; (ii) insertion of one, two or three amino acids; (iii) conservative substitution; or (iv) non-conservative substitution.

In certain embodiments, the polypeptide comprises at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 of amino acids 444-500 of SEQ ID NO.:1 %, at least 97%, at least 98%, or at least 99% of the amino acid sequence.

In certain embodiments, the polypeptide comprises at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96 of amino acids 328-531 of SEQ ID NO.:1 %, at least 97%, at least 98%, or at least 99% of the amino acid sequence.

In certain embodiments, the polypeptide comprises: (i) amino acids 453-469 of SEQ ID NO.:1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (ii) ) Amino acids 473-480 of SEQ ID NO.: 1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (iii) Amino acids 485-492 of SEQ ID NO.:1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (iv) amino acids 501-492 of SEQ ID NO.:1 531, or variant sequences thereof with one, two or three amino acid substitutions; and/or (v) amino acids 328-443 of SEQ ID NO.:1, or amines with SEQ ID NO.:1 Amino acids 328-443 have at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity. mutated sequence. In certain embodiments, the polypeptide includes any one or more of the following amino acids, wherein the amino acids are numbered according to SEQ ID NO.: 1: S443; N448; Y451; E471; Y501. In certain embodiments of the polypeptide: (i) amino acids 498-500 (numbered according to SEQ ID NO.: 1) comprise N-A-T, N-P-T, or N-G-T, respectively; and/or (ii) amino acids 470-472 (numbered according to SEQ ID NO.:1) contains N-X-T, where X is any amino acid, and is preferably E.

In certain embodiments, the polypeptide further comprises: a signal peptide; an SPyTag; a linker; a stem-helix polypeptide; or any combination thereof.

In certain embodiments, the polypeptide consists essentially of or consists of a variant RBD as disclosed herein. In certain embodiments, the polypeptide comprises an amino acid sequence that is at least 80%, at least 85%, or at least 90% identical to the amino acid sequence set forth in SEQ ID NO.:1.

In certain embodiments, the polypeptide is or comprises a variant SARS-CoV-2 spike protein polypeptide. In certain other embodiments, the polypeptide further comprises: a signal peptide; a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof. In certain embodiments, the polypeptide comprises: a SpyTag; a linker; a stem-helix polypeptide; or any combination thereof.

Also provided is an isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids in length. amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than 11 amino acids, and comprising according to SEQ ID NO.:4 The amino acid sequence. In some embodiments, the polypeptide comprises the amino acid sequence set forth in SEQ ID NO.:5.

Also provided is an isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than about 30 amino acids in length. amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than about 10 amino acids, or no more than 6 amino acids , and comprise the amino acid sequence set forth in any one of SEQ ID NO.: 4-12 and 14. Also provided is an isolated polypeptide comprising 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 consecutive amines of SEQ ID NO.: 13 or consisting of amino acid residues, provided that the isolated peptide contains 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 consecutive amines of SEQ ID NO.:5 Basic acid. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.: 14 or 701. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.:15. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in any of SEQ ID NOs.: 16-19. Also provided is an isolated polypeptide comprising: (i) an amino acid sequence according to any one of SEQ ID NO.:4-14; and (ii) an amino acid set forth in SEQ ID NO.:15 sequence. Also provided is an isolated polypeptide comprising: (i) any one or more of a plurality of SEQ ID NO.: 4-14, wherein the plurality is homogeneous, homotypic, heterogeneous or heterotypic; and disposed in the (ii) a linker sequence between two of the plurality and connecting two of the plurality. Also provided is an isolated polypeptide comprising: (i) two, three, four, five or more copies of SEQ ID NO.:16; (ii) two, Three, four, five or more copies; and/or (iii) one or more copies of SEQ ID NO.:16 and one or more copies of SEQ ID NO.:17. Also provided are isolated polypeptides comprising SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein X is 2 or greater, 3 or greater, 4 or greater, or 5 or greater.

Also provided are fusion proteins comprising (i) a SARS-CoV-2 spike polypeptide or a portion thereof and (ii) a stem-helix polypeptide as disclosed herein, wherein optionally the SARS-CoV-2 spike polypeptide comprises (i ) one or more modifications that promote the open conformation of the receptor binding domain (RBD) of the spike protein peptide (such as D614G, K986P and V987P) and/or (ii) one or more modifications that promote the trimerization of the SARS-CoV-2 spike protein peptide stable modification. In certain other embodiments, the fusion protein includes multiple stem-helix polypeptides as disclosed herein. In certain embodiments, one or more stem-helix polypeptides are disposed in the S2 subunit of the SARS-CoV-2 spike polypeptide. In certain embodiments, the fusion protein comprises SEQ ID NO.:18 or SEQ ID NO.:19, wherein X is 2 or greater, 3 or greater, 4 or greater, or 5 or greater.

Fusion proteins are also provided that comprise (i) a SARS-CoV-2 receptor binding domain (RBD) and (ii) a stem-helix polypeptide as disclosed herein. In certain embodiments, the RBD is not included in the betacoronavirus spike protein polypeptide. In certain embodiments, the fusion protein includes multiple RBDs of (i) and/or multiple polypeptides of (ii). In certain embodiments, the fusion protein further comprises a linker disposed between and connecting two of the plurality of RBDs. In certain embodiments, the linker comprises or consists of a stem-helix polypeptide as disclosed herein.

In certain embodiments, multiple RBDs are of the same type. In other embodiments, the plurality of RBDs are heterogeneous.

In certain embodiments , the fusion protein comprises: ([RBD] -P Polypeptide, x is 1 or greater, and y is 1 or greater. In certain other embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:16 or SEQ ID NO.:17 or SEQ ID NO.:701. In certain other embodiments, P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:18 or SEQ ID NO.:19, wherein optionally, X is 2, 3, 4, 5 , 6, 7, 8, 9, 10 or larger.

In certain embodiments, the spike protein polypeptide of the fusion protein, or a portion thereof, comprises an RBD having, or wherein the RBD has, or wherein one of the plurality of RBDs has: and SEQ ID NO. .:2 of at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89 %, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 9%, or 100% consistency.

In some embodiments, the fusion protein does not comprise SEQ ID NO.:2 or naturally occurring variants thereof.

In certain embodiments of the fusion protein, the spike polypeptide or a portion thereof is comprised in an RBD, or the RBD comprises, or one of the plurality of RBDs comprises any one or more of (i)-(iv) Those: (i) One or more amino acid substitutions relative to the natural RBD; (ii) One or more amino acid deletions relative to the natural RBD; (iii) One or more amine groups relative to the natural RBD acid insertion; (iv) one or more non-natural carbohydrate attachment sites relative to the native RBD, optionally comprising a glycosylation site, wherein optionally the glycosylation site comprises a C-linked glycosyl group lation site, N-linked glycosylation site, O-linked glycosylation site, S-linked glycosylation site, or any combination thereof.

Also provided are polypeptides comprising variants of the SARS-CoV-2 receptor binding domain (RBD) that comprise any one or more of (i)-(iv): (i) relative to one of the native RBD or Multiple amino acid substitutions; (ii) one or more amino acid deletions relative to the natural RBD; (iii) one or more amino acid insertions relative to the natural RBD; (iv) one or more amino acids relative to the natural RBD or a plurality of non-natural carbohydrate attachment sites, which optionally comprise glycosylation sites, wherein optionally, the glycosylation sites comprise C-linked glycosylation sites, N-linked glycosylation sites , O-linked glycosylation site, S-linked glycosylation site, or any combination thereof.

Also provided are polypeptides comprising variants of the SARS-CoV-2 receptor binding domain (RBD) that comprise any one or more of (i)-(iv): (i) relative to one of the native RBD or Multiple amino acid substitutions; (ii) one or more amino acid deletions relative to the natural RBD; (iii) one or more amino acid insertions relative to the natural RBD; (iv) one or more amino acids relative to the natural RBD or a plurality of non-natural carbohydrate attachment sites, which optionally comprise glycosylation sites, wherein optionally, the glycosylation sites comprise C-linked glycosylation sites, N-linked glycosylation sites , an O-linked glycosylation site, an S-linked glycosylation site, or any combination thereof, wherein optionally, the engineered variant SARS-CoV-2 spike protein polypeptide comprises (i) one or more Modifications that promote the open conformation of the receptor binding domain (RBD) of the spike polypeptide (such as D614G, K986P and V987P) and/or (ii) one or more modifications that promote the stability of the SARS-CoV-2 spike polypeptide trimer . In certain embodiments, the polypeptide comprises: (i) a SARS-CoV-2 spike protein polypeptide; (ii) a linker, wherein optionally the linker comprises a stem-helix polypeptide; (iii) a peptide tag, wherein optionally Preferably, the peptide tag comprises SpyTag; (iv) another RBD; (v) a stem-helix polypeptide; or (vi) any combination of (i)-(v).

Also provided is an isolated polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any of SEQ ID NOs.: 107-249, 255-565, and 576-699. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in any of SEQ ID NOs.: 107-249, 255-565, and 576-699. Also provided is an isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the signal peptide has been removed, wherein optionally , also remove the linker sequence adjacent to the signal peptide. Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the variation is caused by substitution with a different peptide tag It consists of His tag.

Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the variant consists of a His other than HHHHHHHH tag (that is, a His tag longer or shorter than HHHHHHHH). Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the variant consists of the absence of a His tag . Also provided is an isolated polypeptide comprising a variant of the amino acid sequence set forth in any of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the variant consists of the absence of a peptide tag .

Also provided is an isolated polypeptide, wherein the polypeptide is any of the following: Cov0001-Cov0070, Cov0091-Cov0098, Cov0101, Cov0102, Cov0121-Cov0128, Cov0130, Cov0132, Cov0151-Cov0514, Cov0556-Cov0629, Cov063 1.Cov0633, Cov0662-Cov0690, Cov0693, Cov0722-Cov0739.

Exemplary polypeptides of the present disclosure include: Cov0001, Cov0002, Cov0003, Cov0004, Cov0005, Cov0006, Cov0007, Cov0008, Cov0009, Cov0010, Cov0011, Cov0012, Cov0013, Cov0014, Cov0015, Cov0016, C ov0017, Cov0018, Cov0019, Cov0020, Cov0021 , Cov0022, Cov0023, Cov0024, Cov0025, Cov0026, Cov0027, Cov0028, Cov0029, Cov0030, Cov0031, Cov0032, Cov0033, Cov0034, Cov0035, Cov0036, Cov0037, Cov0038, Cov0 039, Cov0040, Cov0041, Cov0042, Cov0043, Cov0044, Cov0045, Cov0046 , Cov0047, Cov0048, Cov0049, Cov0050, Cov0051, Cov0052, Cov0053, Cov0054, Cov0055, Cov0056, Cov0057, Cov0058, Cov0059, Cov0060, Cov0061, Cov0062, Cov0063, Cov0 064, Cov0065, Cov0066, Cov0067, Cov0068, Cov0069, Cov0070, Cov0091 , Cov0092, Cov0093, Cov0094, Cov0095, Cov0096, Cov0097, Cov0098, Cov0101, Cov0102, Cov0121, Cov0122, Cov0123, Cov0124, Cov0125, Cov0126, Cov0127, Cov0128, Cov0 130. Cov0132, Cov0151, Cov0152, Cov0153, Cov0154, Cov0155, Cov0156 , Cov0157, Cov0158, Cov0159, Cov0160, Cov0161, Cov0162, Cov0163, Cov0164, Cov0165, Cov0166, Cov0167, Cov0168, Cov0169, Cov0170, Cov0171, Cov0172, Cov0173, Cov0 174. Cov0175, Cov0176, Cov0177, Cov0178, Cov0179, Cov0180, Cov0181 , Cov0182, Cov0183, Cov0184, Cov0185, Cov0186, Cov0187, Cov0188, Cov0189, Cov0190, Cov0191, Cov0192, Cov0193, Cov0194, Cov0195, Cov0196, Cov0197, Cov0198, Cov0 199. Cov0200, Cov0201, Cov0202, Cov0203, Cov0204, Cov0205, Cov0206 , Cov0207, Cov0208, Cov0209, Cov0210, Cov0211, Cov0212, Cov0213, Cov0214, Cov0215, Cov0216, Cov0217, Cov0218, Cov0219, Cov0220, Cov0221, Cov0222, Cov0223, Cov0 224. Cov0225, Cov0226, Cov0227, Cov0228, Cov0229, Cov0230, Cov0231 , Cov0232, Cov0233, Cov0239, Cov0240, Cov0241, Cov0242, Cov0243, Cov0244, Cov0245, Cov0246, Cov0247, Cov0248, Cov0249, Cov0250, Cov0592, Cov0593, Cov0594, Cov0 595, Cov0596, Cov0597, Cov0598, Cov0599, Cov0600, Cov0601, Cov0602 , Cov0603, Cov0604, Cov0605, Cov0606, Cov0607, Cov0608, Cov0609, Cov0610, Cov0611, Cov0612, Cov0613, Cov0614, Cov0615, Cov0616, Cov0617, Cov0618, Cov0619, Cov0 620, Cov0621, Cov0622, Cov0623, Cov0624, Cov0625, Cov0626, Cov0627 , Cov0628, Cov0629, Cov0631, Cov0633, Cov0662, Cov0663, Cov0664, Cov0665, Cov0666, Cov0667, Cov0668, Cov0669, Cov0670, Cov0671, Cov0672, Cov0673, Cov0674, Cov0 675, Cov0676, Cov0677, Cov0678, Cov0679, Cov0680, Cov0681, Cov0682 , Cov0683, Cov0684, Cov0685, Cov0686, Cov0687, Cov0688, Cov0689, Cov0690, Cov0693, Cov0722, Cov0723, Cov0724, Cov0725, Cov0726, Cov0727, Cov0728, Cov0729, Cov0 730, Cov0731, Cov0732, Cov0733, Cov0734, Cov0735, Cov0736, Cov0737 , Cov0738, Cov0739, Cov0556, Cov0557, Cov0558, Cov0559, Cov0560, Cov0561, Cov0562, Cov0563, Cov0564, Cov0565, Cov0566, Cov0567, Cov0568, Cov0569, Cov0570, Cov0 571, Cov0572, Cov0573, Cov0574, Cov0575, Cov0576, Cov0577, Cov0578 , Cov0579, Cov0580, Cov0581, Cov0582, Cov0583, Cov0584, Cov0585, Cov0586, Cov0587 Cov0588, Cov0590, Cov0591, Cov0592, Cov0251, Cov0252, Cov0253, Cov0254, Cov02 55. Cov0256, Cov0257, Cov0258, Cov0259, Cov0260, Cov0261, Cov0262, Cov0263, Cov0264, Cov0265, Cov0266, Cov0267, Cov0268, Cov0269, Cov0270, Cov0271, Cov0272, Cov0273, Cov0274, Cov0275, Cov0276, Cov0277, Cov0278, Cov0279, Cov028 0. Cov0281, Cov0282, Cov0283, Cov0284, Cov0285, Cov0286, Cov0287, Cov0288, Cov0289, Cov0290, Cov0291, Cov0292, Cov0293, Cov0294, Cov0295, Cov0296, Cov0297, Cov0298, Cov0299, Cov0300, Cov0301, Cov0302, Cov0303, Cov0304, Cov030 5. Cov0306, Cov0307, Cov0308, Cov0309, Cov0310, Cov0311, Cov0312, Cov0313, Cov0314, Cov0315, Cov0316, Cov0317, Cov0318, Cov0319, Cov0320, Cov0321, Cov0322, Cov0323, Cov0324, Cov0325, Cov0326, Cov0327, Cov0328, Cov0329, Cov033 0. Cov0331, Cov0332, Cov0333, Cov0334, Cov0335, Cov0336, Cov0337, Cov0338, Cov0339, Cov0340, Cov0341, Cov0342, Cov0343, Cov0344, Cov0345, Cov0346, Cov0347, Cov0348, Cov0349, Cov0350, Cov0351, Cov0352, Cov0353, Cov0354, Cov035 5. Cov0356, Cov0357, Cov0358, Cov0359, Cov0360, Cov0361, Cov0362, Cov0363, Cov0364, Cov0365, Cov0366, Cov0367, Cov0368, Cov0369, Cov0370, Cov0371, Cov0372, Cov0373, Cov0374, Cov0375, Cov0376, Cov0377, Cov0378, Cov0379, Cov038 0. Cov0381, Cov0382, Cov0383, Cov0384, Cov0385, Cov0386, Cov0387, Cov0388, Cov0389, Cov0390, Cov0391, Cov0392, Cov0393, Cov0394, Cov0395, Cov0396, Cov0397, Cov0398, Cov0399, Cov0400, Cov0401, Cov0402, Cov0403, Cov0404, Cov040 5. Cov0406, Cov0407, Cov0408, Cov0409, Cov0410, Cov0411, Cov0412, Cov0413, Cov0414, Cov0415, Cov0416, Cov0417, Cov0418, Cov0419, Cov0420, Cov0421, Cov0422, Cov0423, Cov0424, Cov0425, Cov0426, Cov0427, Cov0428, Cov0429, Cov043 0. Cov0431, Cov0432, Cov0433, Cov0434, Cov0435, Cov0436, Cov0437, Cov0438, Cov0439, Cov0440, Cov0441, Cov0442, Cov0443, Cov0444, Cov0445, Cov0446, Cov0447, Cov0448, Cov0449, Cov0450, Cov0451, Cov0452, Cov0453, Cov0454, Cov045 5. Cov0456, Cov0457, Cov0458, Cov0459, Cov0460, Cov0461, Cov0462, Cov0463, Cov0464, Cov0625, Cov0466, Cov0467, Cov0468, Cov0469, Cov0470, Cov0471, Cov0472, Cov0473, Cov0474, Cov0475, Cov0476, Cov0477, Cov0478, Cov0479, Cov048 0. Cov0481, Cov0482, Cov0483, Cov0484, Cov0485, Cov0486, Cov0487, Cov0488, Cov0489, Cov0490, Cov0491, Cov0492, Cov0493, Cov0494, Cov0495, Cov0496, Cov0497, Cov0498, Cov0499, Cov0500, Cov0501, Cov0502, Cov0503, Cov0504, Cov050 5. Cov0506, Cov0507, Cov0508, Cov0509, Cov0510, Cov0511, Cov0512, Cov0513, Cov0514, Cov0746, Cov0747, Cov0748, Cov0749, Cov0750, Cov0751, Cov0758, Cov0759, Cov0761 and Cov0762. The amino acid sequences of these exemplary polypeptides are provided herein. Variants of these polypeptides are also provided in which a different signal peptide is present, a different peptide tag is present, a signal peptide is not present, and/or a peptide tag is not present. Polynucleotides, vectors and host cells

In another aspect, the invention provides an isolated polynucleotide encoding any of the fusion proteins, RBD polypeptides, stem-helix polypeptides, spike polypeptides, polypeptides, or analogs thereof disclosed herein. In certain embodiments, the polynucleotide is codon-optimized for expression in the host cell. Known or identified coding sequences can be codon optimized using known techniques and tools, such as the GenScript® OptimiumGene ^™ tool; see also Scholten et al., Clin. Immunol. 119 :135, 2006). Codon-optimized sequences include sequences that are partially codon-optimized (ie, one or more codons are optimized for expression in the host cell) and sequences that are fully codon-optimized.

It should also be understood that polynucleotides encoding polypeptides of the present disclosure can have different nucleotide sequences while still encoding a polypeptide due to, for example, degeneracy of the genetic code, splicing, and the like.

In any of the disclosed embodiments, the polynucleotide may comprise deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). In some embodiments, the RNA includes messenger RNA (mRNA). In some embodiments, the RNA consists of messenger RNA (mRNA).

In some embodiments, polynucleotides (eg, mRNA) comprise modified nucleosides, cap-1 structures, cap-2 structures, or any combination thereof. In certain embodiments, the polynucleotide comprises pseudouridine, N6-methyladenosine, 5-methylcytidine, 2-thiouridine, or any combination thereof. In some embodiments, the pseudouridine comprises N1-methylpseudouridine. Such features are known in the art and discussed, for example, in Zhang et al. 10.1073/pnas.1821754116 (2019); Nance and Meier, ACS Cent. Sci. 2021, 7, 5, 748-756; doi.org/10.1021/acscentsci.1c00197 (2021) and van Hoecke and Roose, J. Translational Med 17:54 (2019); https://doi.org/10.1186/s12967-019-1804-8, whose modified nucleoside and mRNA characteristics are incorporated herein by reference.

Vectors are also provided, wherein the vectors comprise or contain a polynucleotide as disclosed herein. The vector may include any one or more of the vectors disclosed herein. In certain embodiments, a DNA plasmid construct comprises a single open reading frame encoding two polypeptides or sequences of interest, wherein the sequence encoding the first polypeptide and the sequence encoding the second polypeptide are optionally formed by encoding a protease. The polynucleotide of the cleavage site and/or is isolated from a polynucleotide encoding a self-cleaving peptide. In some embodiments, a polypeptide or a substituent component of a polypeptide complex (eg, a spike protein ectodomain trimer) is encoded by a polynucleotide contained in a single plasmid. In other embodiments, a polypeptide or a substituent component of a polypeptide complex is encoded by a polynucleotide contained in two or more plastids. An exemplary expression vector is pVax1, available from Invitrogen®. The DNA plasmids of the present disclosure can be delivered to an individual by, for example, electroporation (eg, intramuscular electroporation) or by appropriate formulation (eg, hyaluronidase).

In another aspect, the invention also provides a host cell expressing a polypeptide according to the invention; or comprising or containing a vector or polynucleotide according to the invention.

Examples of such cells include, but are not limited to, eukaryotic cells, such as yeast cells, animal cells, insect cells, plant cells; and prokaryotic cells, including E. coli. In some embodiments, the cells are mammalian cells. In certain such embodiments, the cells are mammalian cell lines, such as CHO cells (eg, DHFR-CHO cells (Urlaub et al., PNAS 77:4216 (1980)), human embryonic kidney cells (eg, HEK293T cells) , PER.C6 cells, Y0 cells, Sp2/0 cells. NSO cells, human liver cells such as Hepa RG cells, myeloma cells or fusion tumor cells. Other examples of mammalian host cell lines include mouse Settley cells (such as TM4 cells); monkey kidney CV1 strain transformed from SV40 (COS-7); baby hamster kidney cells (BHK); African green monkey kidney cells (VERO-76); monkey kidney cells (CV1); human cervical cancer Cells (HELA); human lung cells (W138); human liver cells (Hep G2); canine kidney cells (MDCK); buffalo rat liver cells (BRL 3A); mouse mammary tumors (MMT 060562); TRI cells; MRC 5 cells ; and FS4 cells. Mammalian host cell lines suitable for protein production also include, for example, Yazaki and Wu, Methods in Molecular Biology , Volume 248 (BKC Lo, ed., Humana Press, Totowa, NJ), Pages 255-268 (2003 ).

In certain embodiments, the host cell is a prokaryotic cell such as E. coli. The expression of peptides in prokaryotic cells such as E. coli is well established (see, eg, Pluckthun, A. Bio/Technology 9 :545-551 (1991)). For example, polypeptides can be produced in bacteria, especially where sugars are not required When typing. Regarding the expression of polypeptides in bacteria, see, for example, U.S. Patent Nos. 5,648,237; 5,789,199; and 5,840,523.

In certain embodiments, cells can be transfected with vectors and expression vectors according to the present specification. The term "transfection" refers to the introduction of nucleic acid molecules such as DNA or RNA (eg, mRNA) molecules into a cell, such as into a eukaryotic cell. In the context of this specification, the term "transfection" encompasses any method known to those skilled in the art for introducing nucleic acid molecules into cells, such as into eukaryotic cells, including into mammalian cells. Such methods include, for example, electroporation, lipofection, for example based on cationic lipids and/or liposomes, calcium phosphate precipitation, nanoparticle based transfection, virus based transfection or based on cationic polymers such as DEAE-polymer. Glucose or polyethyleneimine, etc.) transfection. In certain embodiments, the introduction is non-viral.

Additionally, host cells of the present disclosure can be stably or transiently transfected with vectors according to the present disclosure, for example, for expressing polypeptides according to the present disclosure. In such embodiments, cells can be stably transfected with vectors as described herein. Alternatively, cells can be transiently transfected with vectors in accordance with the present disclosure encoding polypeptides as disclosed herein. In any of the disclosed embodiments, the polynucleotide may be heterologous to the host cell.

Accordingly, the invention also provides recombinant host cells that heterologously express the polypeptides of the invention. For example, the cell may be a different species or cell strain than the species or cell strain from which the polypeptide was completely or partially obtained or engineered (eg, CHO cells expressing the stem-helix polypeptide). In some embodiments, the host cell is a cell type that does not express the polypeptide in nature. In addition, the host cell can impart post-translational modifications (PTMs; such as glycosylation or fucosylation) to polypeptides that are not present in the native state of the antibody (or in the native state of the parent or reference polypeptide of the engineered or derived polypeptide). )exist. Such PTMs may produce functional differences (eg, reduced immunogenicity). Accordingly, a polypeptide of the invention produced by a host cell disclosed herein may include one or more post-translational modifications that differ from that polypeptide (or a parent or reference polypeptide) in its native state.

Insect cells suitable for expressing polypeptides are known in the art and include, for example, Spodoptera frugipera Sf9 cells, Trichoplusia ni BTI-TN5B1-4 cells, and Spodoptera frugipera SfSWT01" Mimic ^TM ” cells. See, eg, Palmberger et al., J. Biotechnol. 153 (3-4):160-166 (2011). A number of baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.

Eukaryotic microorganisms such as filamentous fungi or yeasts are also suitable hosts for the selection or expression of vectors encoding proteins, and include fungal and yeast strains with "humanized" glycosylation pathways, thereby producing, for example, proteins with partial or Antibodies with fully human glycosylation patterns. See Gerngross, Nat. Biotech. 22:1409-1414 (2004); Li et al., Nat. Biotech. 24:210-215 (2006).

Plant cells can also be used as hosts for expressing polypeptides. For example, PLANTIBODIES™ technology (described in, eg, U.S. Patent Nos. 5,959,177; 6,040,498; 6,420,548; 7,125,978; and 6,417,429) uses transgenic plants to produce antibodies.

In certain embodiments, host cells comprise mammalian cells. In specific embodiments, the host cell is a CHO cell, HEK293 cell, PER.C6 cell, Y0 cell, Sp2/0 cell, NSO cell, human liver cell, myeloma cell, or fusion tumor cell.

In a related aspect, the invention provides methods for producing polypeptides, wherein the methods comprise culturing a host cell of the present disclosure under conditions and for a time sufficient to produce the polypeptide. For example, a method suitable for isolating and purifying a recombinantly produced polypeptide may include obtaining a supernatant from a suitable host cell/vector system that secretes the recombinant polypeptide into the culture medium and subsequently concentrating it using a commercially available filter. culture medium. After concentration, the concentrate can be applied to a single suitable purification matrix or to a series of suitable matrices, such as affinity matrices or ion exchange resins. One or more reverse phase HPLC steps can be used to further purify the recombinant polypeptide. These purification methods can also be used when the immunogen is separated from its natural environment. Methods for large-scale preparation of one or more of the isolated/recombinant polypeptides described herein include batch cell cultures that are monitored and controlled to maintain appropriate culture conditions. Purification of soluble polypeptides may be performed according to methods described herein and known in the art, and consistent with the laws and guidelines of domestic and foreign regulatory agencies. Other components

Also provided herein are any and one or more of the polypeptides, polynucleotides, vectors or host cells disclosed herein, alone or in any combination, and may further include pharmaceutically acceptable carriers, excipients or diluent composition. Carriers, excipients and diluents are discussed in further detail herein.

In certain embodiments, the compositions comprise a polynucleotide (eg, mRNA) coupled to a suitable delivery vehicle or carrier. Exemplary vehicles or carriers for administration to a human subject include lipid or lipid-derived delivery vehicles, such as liposomes, solid lipid nanoparticles, oily suspensions, submicron lipid emulsions, lipid microbubbles, reverse Lipid microcells, cochlear liposomes, lipid microtubules, lipid micropillars or lipid nanoparticles (LNPs) or nanoscale platforms (see e.g. Li et al. Wilery Interdiscip Rev. Nanomed Nanobiotechnol. 11 (2):e1530 (2019) )). Principles, reagents and techniques for designing appropriate mRNAs and formulating and delivering mRNA-LNPs are described, for example, in Pardi et al. ( J Control Release 217 345-351 (2015)); Thess et al. ( Mol Ther 23 :1456-1464) 2015)); Thran et al ( EMBO Mol Med 9 (10):1434-1448 (2017)); Kose et al ( Sci. Immunol. 4 eaaw6647 (2019)); and Sabnis et al ( Mol. Ther. 26 :1509- 1519 (2018)), these techniques include capping, codon optimization, nucleoside modification, mRNA purification, incorporation of mRNA into stable lipid nanoparticles (e.g., ionizable cationic lipids/phosphatidylcholine/cholesterol) /PEG-lipid; ionizable lipid: distearyl PC: cholesterol: polyethylene glycol lipid) and its subcutaneous, intramuscular, intradermal, intravenous, intraperitoneal and intratracheal administration, such technologies Incorporated herein by reference. Methods and Uses

Also provided herein are methods of treating an individual or inducing an immune response in an individual using the fusion proteins, RBD polypeptides, polypeptides, polynucleotides, vectors, host cells, compositions, combinations or mixtures of the present disclosure. In some cases, the individual has, is believed to have, or is at risk of suffering from a coronavirus (such as Sabine coronavirus, eg, SARS-CoV-2) infection. "Treat", "treatment" or "amelioration" refers to an individual (e.g., a human or a non-human mammal such as a primate, horse, cat, dog, goat, mouse or rat) The medical management of a disease, disease or condition. Generally speaking, an appropriate dosage or treatment regimen comprising a composition (fusion protein, polypeptide, RBD polypeptide, polynucleotide, composition, host cell, vector, combination, mixture, or the like) of the present disclosure is sufficient to Administered in an amount that induces a therapeutic or prophylactic benefit. Therapeutic or preventive/preventative benefits include improved clinical outcome; alleviation or relief of symptoms associated with disease; reduced occurrence of symptoms; improved quality of life; prolonged disease-free status; reduced disease severity; stabilization of disease; delayed or prevented disease Progression; remission; survival; prolonged survival; or any combination thereof. In certain embodiments, therapeutic or prophylactic/prophylactic benefits include reducing the frequency, rate, and/or severity of coronavirus infections (i.e., in a statistically significant manner), reducing or preventing the effects of treating Sabine Hospitalization for coronavirus infection, such as SARS-CoV-2 infection (i.e., in a statistically significant manner). In certain embodiments, the therapeutic or prophylactic/prophylactic benefit includes reducing (i.e., in a statistically significant manner) the duration of hospitalization for treatment of a Sabey coronavirus infection, such as a SARS-CoV-2 infection. . In certain embodiments, therapeutic or prophylactic/preventive benefits include reducing or eliminating the need for respiratory intervention, such as intubation and/or use of a ventilator device. In certain embodiments, therapeutic or prophylactic/prophylactic benefits include advanced disease pathology and/or reduced mortality. In certain embodiments, the treatment is administered as pre-exposure prophylaxis, as prophylaxis during exposure, or as post-exposure prophylaxis.

The "therapeutically effective amount" or "effective amount" of the polypeptides, fusion proteins, polynucleotides, vectors, host cells, compositions, combinations or mixtures of this disclosure refers to the amount sufficient to produce a therapeutic effect, including Improved clinical outcome in a statistically significant manner; alleviation or relief of symptoms associated with a disease; reduced occurrence of symptoms; improved quality of life; longer disease-free status; reduced disease severity; stabilization of disease; delayed disease progression ;remission;survival;or prolonged survival. When referring to an individual active ingredient administered alone, a therapeutically effective amount refers to the effect of that ingredient or of cells expressing that ingredient alone. When referring to a combination, a therapeutically effective amount refers to the combined amount of the active ingredient or co-active ingredient of the combination and the cells expressing the active ingredient that produce a therapeutic effect, whether administered continuously, sequentially or simultaneously. Combinations may include, for example, two different constructs that may include the same or different epitopes.

Methods of treatment may include inducing coronavirus infection in an individual by administering to the individual an effective amount of a fusion protein, polypeptide, RBD polypeptide, polynucleotide, vector, host cell, composition, combination or mixture of the present disclosure, and /or have an immune response specific to the infection. The immune response may involve antibody production (e.g., production of coronavirus-binding and optionally coronavirus-neutralizing antibodies), activation of specific immune-competent cells, fixation of complement, antibody-dependent cell-mediated cytotoxicity (also known as antibody-dependent cellular cytotoxicity) toxicity), antibody-dependent phagocytosis, interleukin production, or any combination thereof.

The immune response may include, for example, activated dendritic cells (e.g., as assessed by increased expression of CD80, CD86, CD83, HLA-DR, IL-12, CD40L, CD40, BAFF, April, or any combination thereof), activated host T cells (e.g., CD4+ T cells and/or CD8+ T cells, e.g., by increased expression of CD25, CD137, ICOS, CD4, CD3, CD28, ICOS, CD8, CD69, or any combination thereof, and/or by increased proliferation assessed), proliferation of coronavirus antigen-specific T cells, activation and/or proliferation of host B cells, multi-strain humoral immune response (e.g., production of IgM and/or IgG antibodies), production of one or more interleukins, fever or its likes. In some embodiments, the immune response reduces the intensity of the infection or prevents the infection.

Accordingly, in certain embodiments, methods are provided for treating a coronavirus (e.g., Sabey coronavirus) infection, such as a SARS-CoV-2 infection, in a subject, wherein the methods comprise administering to the subject an effective amount of The disclosed fusion proteins, polypeptides, RBD polypeptides, polynucleotides, vectors, host cells, compositions, combinations or mixtures.

Generally speaking, individuals that may be treated by the present disclosure are humans and other primate individuals, such as monkeys and apes for veterinary purposes. Other model organisms such as mice and rats can also be treated according to the present disclosure. In any of the preceding embodiments, the individual may be a human individual. The subject may be male or female and may be of any appropriate age, including infants, juveniles, young adults, adults and elderly subjects.

Various guidelines are believed to pose a higher risk of severe symptoms or death associated with coronavirus (e.g., Sabey-CoV) infection. These include, but are not limited to, age, occupation, general health, pre-existing health conditions and lifestyle habits. In some embodiments, individuals treated in accordance with the present disclosure contain one or more risk factors.

In certain embodiments, human subjects treated in accordance with the present disclosure are infants, children, adolescents, middle-aged or elderly individuals. In certain embodiments, a human subject treated in accordance with the present disclosure is less than 1 year old, or between 1 and 5 years old, or between 5 and 125 years old (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115 or 125 years of age, including any and all ages therein or therebetween). In certain embodiments, the human subject treated in accordance with the present disclosure is 0-19 years old, 20-44 years old, 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old, or Older age. It is believed that middle-aged individuals, and especially older individuals, are at particular risk. In specific embodiments, the human subject is 45-54 years old, 55-64 years old, 65-74 years old, 75-84 years old, or 85 years old, or older. In some embodiments, the human subject is male. In some embodiments, the human subject is female.

In certain embodiments, a human subject treated in accordance with the present disclosure is a resident of a nursing home or long-term care facility; is a hospice care worker; is a health care provider or health care worker; is a first responder; is Are overweight or clinically obese; are or have been a smoker; have or have had chronic obstructive pulmonary disease (COPD); are asthmatic (e.g., have moderate to severe asthma); have an autoimmune disease or condition (e.g., diabetes); and/or have an impaired or depleted immune system (e.g., due to AIDS/HIV infection, cancer, such as blood cancers, lymphocyte-depleting therapies such as chemotherapy, bone marrow or organ transplantation, or genetic immune diseases condition); have chronic liver disease; have cardiovascular disease; have lung or heart defects; work with or otherwise be in close contact with others, such as in a factory, transportation center, hospital setting, or similar setting. In certain embodiments, the human subject treated in accordance with the present disclosure is a family member or other close contact of any one or more of the above.

In certain embodiments, an individual treated in accordance with the present disclosure has received a coronavirus (such as Sabey coronavirus, eg, SARS-CoV-2) vaccine. In certain embodiments, the individual has a disease that has previously received one or more, two or more, three or more, four or more, or five or more doses of a vaccine composition things. In certain embodiments, the subject has received two or more different coronavirus vaccine compositions. In certain embodiments, the individual has received a coronavirus vaccine composition comprising: at least a portion of the SARS-CoV-2 spike protein (e.g., an RBD polypeptide or holospike protein), encoding at least a portion of the SARS-CoV-2 spike protein (e.g., encoding an RBD polypeptide, or encoding a holospike protein), or a live, attenuated, or inactivated (e.g., heat-inactivated or inactivated with β-propiolactone) virus. In certain embodiments, the individual has received a coronavirus vaccine composition comprising: Comirnaty (Pfizer-BioNTech), Spikevax (Moderna), Janssen Coronavirus Vaccine (Johnson & Johnson), Nuvoxovid/Covavax (Novavax), Vaxzevria ( Oxford-AstraZeneca), Coronavac, also known as BBIBP-CorV, also known as BBIBP (Sinovac), Covaxin, also known as BBV152 (Bharat Biotech), Convidecia, also known as AD5-nCOV (CanSino Biologics), Sputnik V, also known as Known as Gam-COVID-Vac, Sinopharm WIBP, also known as WIBP-CorV (Sinovac), Abdala, Soberana 2, Soberana Plus, ZF2001, also known as Anhui Zhifei Longcom ZifiVax ZF2001, also known as ZF-UZ-VAC-2001 , also known as Zifivax (Anhui Zhifei Longcom Biopharmaceutical), Corbevax (Texas Children's Hospital/Baylor College of Medicine/Dynavax), COVIran Barekat (Sifa Pharmed Industrial Group), VAT00002 or VAT00008 (Sanofi-GSK), SCB-2019 (Clover Biopharmaceuticals) , VLA2001 (Valneva), HIPRA SARS-CoV-2, also known as PHH-1V (HIPRA), mRNA-1273.214 (Moderna), and Sputnik V bivalent (L452R; National Research Center for Epidemiology and Microbiology of Gaimarya) or any combination thereof.

Typical routes of administration of the compositions disclosed herein include, but are not limited to, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques. In certain embodiments, administering includes administering by a route selected from: oral, intravenous, parenteral, intragastric, intrapleural, intrapulmonary, intrarectal, intradermal, intraperitoneal, intratumoral , subcutaneous, local, transcutaneous, intracisternal, intrathecal, intranasal and intramuscular. In certain embodiments, methods comprise orally administering a peptide, polynucleotide, vector, host cell or composition to an individual.

Pharmaceutical compositions according to certain embodiments of the invention are formulated so that the active ingredient contained therein is bioavailable upon administration of the composition to a patient. The compositions for administration to an individual or patient are in the form of one or more dosage units, where, for example, a lozenge can be a single dosage unit and the container can hold multiple dosage units. Practical methods of preparing such dosage forms are known or will be apparent to those skilled in the art; see, for example, Remington: The Science and Practice of Pharmacy , 20th Edition (Philadelphia College of Pharmacy and Science, 2000) . The composition to be administered will in any event contain an effective amount of a polypeptide, fusion protein, RBD polypeptide, polynucleotide, vector, host cell, composition, mixture or combination of the present disclosure for use in accordance with the provisions herein. Teach the treatment of the disease or condition of interest.

The compositions may be in solid or liquid form. In some embodiments, the one or more carriers are particulate, such that the compositions are in the form of a tablet or powder, for example. The carrier or carriers can be a liquid and the composition is, for example, an oral oil, an injectable liquid, or a spray suitable for administration, for example, by inhalation. When intended for oral administration, the pharmaceutical compositions are preferably in solid or liquid form, with semi-solid, semi-liquid, suspension and gel forms being included within what are considered solid or liquid forms herein.

It is a solid composition for oral administration. The pharmaceutical composition can be formulated into powders, granules, compressed tablets, pills, capsules, chewable tablets, powder tablets or the like. Such solid compositions will typically contain one or more inert diluents or edible carriers. Additionally, one or more of the following may be present: a binder, such as carboxymethylcellulose, ethylcellulose, microcrystalline cellulose, tragacanth, or gelatin; an excipient, such as starch, lactose, or dextrin; Disintegrants, such as alginic acid, sodium alginate, sodium starch glycolate (Primogel), corn starch and the like; lubricants, such as magnesium stearate or hydrogenated vegetable oil (Sterotex); slip agents, such as colloidal dihydrogen Silicon oxide; sweeteners such as sucrose or saccharin; flavoring agents such as peppermint, methyl salicylate or citrus flavoring; and coloring agents. When the composition is in the form of a capsule, such as a gelatin capsule, it may contain, in addition to the above types of materials, a liquid carrier such as polyethylene glycol or an oil.

The compositions may be in liquid form such as elixirs, syrups, solutions, emulsions or suspensions. Liquids can be used for oral administration or for delivery by injection, to name two examples. When intended for oral administration, preferred compositions contain, in addition to the compounds of the present invention, one or more of sweeteners, preservatives, dyes/colorants, and flavoring agents. In compositions intended for administration by injection, one or more of surfactants, preservatives, wetting agents, dispersing agents, suspending agents, buffers, stabilizers and isotonic agents may be included. Liquid pharmaceutical compositions, whether in the form of solutions, suspensions or other similar forms, may include one or more of the following: sterile diluents, such as water for injection, saline solution (preferably physiological saline, Ringer's solution, etc. sodium chloride), fixed oils (such as synthetic mono- or diglycerides, which can act as solvents or suspending media), polyethylene glycol, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or p- Methyl hydroxybenzoate; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetate, citrate, or phosphate; and tonicity regulators, such as sodium chloride Or dextrose.

In certain embodiments, the compositions may include a pharmaceutically effective amount of an adjuvant to enhance the prophylactic or therapeutic effects of the treatment. Any suitable adjuvant known to those skilled in the art may be used. Non-limiting examples of suitable adjuvants include: amorphous aluminum hydroxyphosphate sulfate (AAHS), aluminum hydroxide, aluminum phosphate, aluminum potassium sulfate (Alum), AS04 (aluminum salt-containing monophospholipid A (MPL) ), MF59 (oil-in-water emulsion composed of squalene), AF03 (oil-in-water emulsion composed of squalene), AS01B (MPL and QS-21), CpG 1018 (guanine cytosine phosphate), alhydroxiquim -II and AS03 (tocopherol and squalene).

Parenteral preparations may be enclosed in ampoules, disposable syringes or multi-dose vials made of glass or plastic. Physiological saline is the preferred adjuvant. Injectable pharmaceutical compositions are preferably sterile.

Liquid compositions intended for parenteral or oral administration should contain an amount of a construct as disclosed herein such that a suitable dosage will be obtained. Typically, this amount will be at least 0.01% of the construct in the composition. When intended for oral administration, this amount can vary between 0.1% and about 70% by weight of the composition. Certain oral pharmaceutical compositions contain between about 4% and about 75% of the construct. In certain embodiments, pharmaceutical compositions and formulations of the invention are prepared such that parenteral dosage units contain between 0.01% and 10% by weight of the construct prior to dilution.

The composition may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. For example, the base may include one or more of the following: paraffin grease, wool wax, polyethylene glycol, beeswax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in the compositions for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or an iontophoresis device. The pharmaceutical compositions may be intended for rectal administration, for example in the form of suppositories which will melt in the rectum and release the drug. Compositions for rectal administration may contain oily bases as suitable non-irritating excipients. Such bases include, but are not limited to, wool wax, cocoa butter, and polyethylene glycol.

The compositions may include a variety of materials that modify the physical form of solid or liquid dosage units. For example, the composition may include a material that forms a coating around the active ingredient. The material forming the coating shell is generally inert and may be selected from, for example, sugar, shellac and other enteric coating agents. Alternatively, the active ingredients can be enclosed in gelatin capsules. The composition may consist essentially of dosage units that may be administered in aerosol form. The term aerosol is used to refer to a variety of systems ranging from those that are colloidal in nature to those consisting of pressurized encapsulation. Delivery may be by liquefied or compressed gas or by a suitable pump system that dispenses the active ingredient. Aerosols can be delivered as single-phase, bi-phasic or three-phase systems to deliver active ingredients. The delivery of aerosols includes the necessary containers, activators, valves, sub-containers and the like, which together form a kit. Generally, those skilled in the art can determine the preferred aerosol without undue experimentation.

It is understood that carrier molecules (eg, lipid nanoparticles, nanoscale delivery platforms, and the like) for polynucleotides as described herein are also encompassed by the compositions of the present disclosure.

Pharmaceutical compositions can be prepared by methods well known in medical technology. For example, compositions intended for administration by injection can be obtained by combining a composition comprising a construct as described herein and optionally one or more of a salt, buffer, and/or stabilizer with sterile distilled water. Prepare by combining to form a solution. Surfactants may be added to promote the formation of a homogeneous solution or suspension. Surfactants are compounds that interact non-covalently with peptide compositions to promote dissolution or uniform suspension of the construct in an aqueous delivery system.

Generally, appropriate doses and treatment regimens are provided that are sufficient to provide therapeutic and/or preventive benefits such as those described herein, including improved clinical outcomes (e.g., reduction in frequency, duration, or severity of diarrhea or associated dehydration or inflammation, or a longer disease-free period and/or overall survival, or a reduction in the severity of symptoms). For prophylactic uses, the dosage should be sufficient to prevent, delay the onset of, or reduce the severity of illness associated with the disease or condition. The preventive and therapeutic benefits of compositions administered according to the methods described herein can be determined by conducting preclinical (including in vitro and in vivo animal studies) and clinical studies and analyzing by appropriate statistical, biological and clinical methods and techniques. The information obtained confirms that it can be easily implemented by those skilled in the art.

The composition is administered in an effective amount (e.g., to treat a coronavirus infection, such as a SARS-CoV-2 infection), which effective amount will vary depending on a variety of factors including: the activity of the particular compound employed; the metabolic stability of the compound Sex and duration of action; age, weight, general health, gender, and diet of the individual; mode and time of administration; rate of excretion; combination of drugs; severity of the particular disease or condition; and the individual undergoing therapy. In certain embodiments, after administration of therapy according to the formulations and methods of the present disclosure, a test subject will exhibit one or more symptoms associated with the disease or condition compared to a placebo-treated or other suitable control subject. Approximately 10% to approximately 99% reduction in symptoms.

In general, a therapeutically effective daily dose of a construct as disclosed herein can range (for a 70 kg mammal) from about 0.001 mg/kg (i.e., 0.07 mg) to about 100 mg/kg (i.e., 7.0 g) ; Preferably, the therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg (i.e., 0.7 mg) to about 50 mg/kg (i.e., 3.5 g); more preferably, the therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg (i.e., 70 mg) to about 25 mg/kg (i.e., 1.75 g). For the polynucleotides, vectors, host cells and related compositions of the invention, the therapeutically effective dose may differ from that of the polypeptide.

In certain embodiments, methods comprise administering a polypeptide, fusion protein, RBD polypeptide, polynucleotide, vector, host cell, composition, combination or mixture. The time interval between doses can range from 1, 2, 3, 4, 5, 6, or 7 days, to 1, 2, 3, 4, 5, 6, 7, or 8 weeks, to 1, 2, Varying between 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 18 or 24 months. The time interval between single doses can be constant or vary over the course of treatment. In some embodiments, the treatment is administered once a year, twice a year, or about every six months, or about every 12 months, or about every three months. In some embodiments, the treatment is administered before winter.

In certain embodiments, methods comprise administering a polypeptide, fusion protein, polynucleotide, vector, host cell, combination before an individual is exposed to, and optionally infected by, a Sabey coronavirus, such as SARS-CoV-2. , mixture or composition at least once.

Compositions comprising polypeptides, fusion proteins, polynucleotides, vectors, host cells, compositions, mixtures, or combinations of the present disclosure may also be administered simultaneously with, before, or after the administration of one or more other therapeutic agents. give. Such combination therapies may include the administration of a single pharmaceutical dosage form containing a compound of the invention and one or more additional active agents, as well as the administration of compositions comprising a construct of the invention and each active agent in separate dosage forms. For example, a composition as described herein and other active agents may be administered to a patient together in a single oral dosage composition, such as a lozenge or capsule, or each agent may be administered in a separate oral dosage formulation. . Similarly, a composition as described herein and other active agents may be administered to an individual together in a single parenteral dosage composition (such as in physiological saline solution or other physiologically acceptable solution), or each agent may be administered as a Administered as a stand-alone parenteral dosage form. Where separate dosage forms are used, the compositions comprising the composition and one or more additional active agents may be administered at substantially the same time, i.e. concurrently, or at separately staggered times, i.e. sequentially and in any order Administration; it is understood that combination therapy includes all such regimens.

In certain embodiments, a combination therapy is provided that includes a composition as provided herein and one or more of an anti-coronavirus antibody, one or more anti-inflammatory agents, and/or one or more antiviral agents. In some embodiments, the anti-coronavirus antibodies comprise anti-coronavirus antibodies, such as bamlanivimab, etesevimab, casirivimab, emidevir Imdevimab, sotrovimab, or bebtelovimab. In some embodiments, the one or more anti-inflammatory agents include a corticosteroid, such as dexamethasone, prednisone, or the like. In some embodiments, the one or more anti-inflammatory agents comprise an interleukin antagonist, such as, for example, binds to IL6 (such as siltuximab), or binds to IL-6R (such as tocilizumab) )), or binds to IL-1β, IL-7, IL-8, IL-9, IL-10, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP- 1A, MIP1-B, PDGR, TNF-α or VEGF antibodies. In some embodiments, anti-inflammatory agents are used, such as leronlimab, rulitinib, and/or anakinra. In some embodiments, the one or more antiviral agents comprise nucleotide analogs or nucleotide mimetic prodrugs, such as remdesivir, sofosbuvir, acyclovir and zidovudine. In specific embodiments, the antiviral agent includes lopinavir, ritonavir, favipiravir, nirmatrelvir, molnupiravir, or any combination thereof. Other anti-inflammatory agents useful in combination therapies of the present disclosure include non-steroidal anti-inflammatory drugs (NSAIDS). It will be appreciated that in such combination therapies, the compositions of the invention and one or more anti-coronavirus antibodies, one or more anti-inflammatory agents, and/or one or more antiviral agents can be administered in any order and in any sequence or together.

In some embodiments, compositions of the present disclosure are administered to individuals who have previously received one or more anti-coronavirus antibodies, one or more anti-inflammatory agents, and/or one or more anti-viral agents. In some embodiments, one or more anti-coronavirus antibodies, one or more anti-inflammatory agents, and/or one or Various antiviral agents.

In certain embodiments, a combination therapy is provided that includes two or more compositions of the present disclosure. A method may comprise administering a first composition to an individual who has received a second composition, or may comprise administering two or more compositions together. For example, in certain embodiments, a method is provided, comprising administering to an individual (a) a first composition while the individual has received a second composition; (b) a second composition while the individual has received the composition. composition; or (c) the first composition and the second composition.

In a related aspect, uses of the fusion proteins, polypeptides, RBD polypeptides, polynucleotides, vectors, host cells, combinations, mixtures and compositions disclosed herein are provided.

In certain embodiments, polypeptides, fusion proteins, RBD polypeptides, polynucleotides, vectors, host cells, combinations, mixtures, or compositions are provided for treating coronavirus infections in individuals, such as Sabei coronavirus or SARS- Methods of CoV-2 infection.

In certain embodiments, polypeptides, fusion proteins, RBD polypeptides, polynucleotides, vectors, host cells, combinations, mixtures, or compositions are provided for use in the manufacture or preparation for treating a coronavirus infection in a subject, such as coronavirus Methods of using agents for viral or SARS-CoV-2 infection. The following non-limiting examples are also provided:

Example 1. A fusion protein comprising: (i) Coronavirus spike protein extracellular domain (S extracellular domain); and (ii) An oligomeric domain at the C terminus of the S ectodomain, wherein optionally the oligomeric domain is fused or linked to the C terminus of the S ectodomain, and wherein optionally, the coronavirus comprises a betacoronavirus.

Example 2. The fusion protein of Example 1, wherein the S extracellular domain includes a receptor binding domain (RBD) in an open configuration.

Embodiment 3. The fusion protein of embodiment 1 or 2, wherein the oligomeric domain comprises a trimerization domain.

Embodiment 4. The fusion protein of embodiment 3, wherein the trimerization domain comprises a foldon, wherein the foldon optionally comprises or consists of the amino acid sequence GYIPEAPRDGQAYVRKDGEWVLLSTFL (SEQ ID NO.:703).

Embodiment 5. The fusion protein of any one of embodiments 1-4, further comprising: (i) a peptide tag at the C-terminus of the oligomerization domain; (ii) one or more stem-helix polypeptides, optionally Comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701); or (iii) both (i) and (ii).

Embodiment 6. The fusion protein of embodiment 5, wherein the peptide tag comprises SpyTag, wherein optionally, SpyTag comprises the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700).

Embodiment 7. The fusion protein of embodiment 5 or 6, further comprising a stem disposed in (i) an oligomeric domain and a peptide tag or (ii) an oligomeric domain and (iii) one or more stem-helix polypeptides - linkers between and connecting helical polypeptides.

Embodiment 8. The fusion protein of embodiment 7, wherein the linker comprises or consists of the following: amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709) ), GSGSGS (SEQ ID NO.:710), GGSGSGSG (SEQ ID NO.:711), PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701), or any of SEQ ID NOs.:97-106 Amino acid sequence.

Embodiment 9. The fusion protein of any one of embodiments 1-8, further comprising a first RBD polypeptide located at the C-terminus of the oligomerization domain.

Embodiment 10. The fusion protein of embodiment 9, further comprising a second RBD polypeptide located at the C-terminus of the first RBD polypeptide.

Embodiment 11. The fusion protein of embodiment 10, further comprising a third RBD polypeptide located at the C-terminus of the second RBD polypeptide.

Embodiment 12. The fusion protein of any one of embodiments 9-11, comprising: (a) A linker disposed between and connecting the oligomeric domain and the first RBD polypeptide; and/or (b) A linker disposed between and connecting the first RBD polypeptide and the second RBD polypeptide; and/or (c) A linker disposed between and connecting the second RBD polypeptide and the third RBD polypeptide.

Embodiment 13. The fusion protein of embodiment 12, wherein: (i) the linker of (a) contains, essentially consists of, or consists of the same amino acid sequence as the linker of (b); (ii) ) The linker of (a) contains, consists essentially of or consists of the same amino acid sequence as the linker of (c); (iii) the linker of (a) contains a different amino acid sequence than the linker of (b) The amino acid sequence of, consists essentially of or consists of; (iv) the linker of (a) contains, consists essentially of or consists of an amino acid sequence that is different from the linker of (c); (v) The linker of (b) includes, consists essentially of, or consists of the same amino acid sequence as the linker of (c); (vi) The linker of (b) includes a linkage to (c) or (vii) the linker of (a), the linker of (b) and the linker of (c) comprise the same amino acid sequence, Consists essentially of or consists of.

Embodiment 14. The fusion protein of embodiment 12 or 13, wherein the linker of (a), the linker of (b) and/or the linker of (c) includes or consists of the following: amino acid sequence GS, GSG, GPP, GSGGSGGSGGTG (SEQ ID NO.:702), GPPSPPG (SEQ ID NO.:709), GSGSGS (SEQ ID NO.:710), GGSGSGSSG (SEQ ID NO.:711), or PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:711). :701), or the amino acid sequence set forth in any one of SEQ ID NOs.:97-106.

Embodiment 15. The fusion protein of any one of embodiments 9-14, wherein the first RBD polypeptide comprises, and consists essentially of, the same amino acid sequence as the amino acid sequence of the RBD contained in the S extracellular domain. or consisting of.

Embodiment 16. The fusion protein of any one of embodiments 10-15, which includes a second RBD polypeptide and an optional third RBD polypeptide, wherein each of the second RBD polypeptide and the optional third RBD polypeptide includes S An amino acid sequence that is identical to the amino acid sequence of the RBD contained in the extracellular domain, consists essentially of, or consists of.

Embodiment 17. The fusion protein of any one of embodiments 9-14 and 16, wherein the first RBD polypeptide comprises an amino acid sequence different from the amino acid sequence of the RBD contained in the S extracellular domain, consisting essentially of consisting of or consisting of.

Embodiment 18. The fusion protein of any one of embodiments 10-17, which includes a second RBD polypeptide and an optional third RBD polypeptide, wherein the second RBD polypeptide and the optional third RBD polypeptide each independently comprise An amino acid sequence that is the same as or different from, consists essentially of, or consists of an amino acid sequence that is the same as or different from the amino acid sequence of the RBD contained in the S extracellular domain.

Embodiment 19. The fusion protein of any one of embodiments 9-18, comprising at the C-terminus: a first RBD polypeptide; an optional second RBD polypeptide; and/or an optional third RBD polypeptide, optionally A stem-helix polypeptide comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 20. The fusion protein of any one of embodiments 9-19, which does not include at the C-terminus: a first RBD polypeptide; an optional second RBD polypeptide; and/or an optional third RBD polypeptide, any A stem-helix polypeptide selectively comprising or consisting of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Example 21. A polypeptide trimer, wherein each of the three polypeptides of the trimer includes: (i) coronavirus spike protein extracellular domain (S extracellular domain); and (ii) a trimerization domain at the C terminus of the S extracellular domain , wherein the three trimerization domains associate with each other to form a trimer, and wherein optionally, each of the three trimerization domains comprises a foldon, and wherein optionally, the coronavirus comprises a betacoronavirus.

Embodiment 22. A polypeptide trimer as in embodiment 21, wherein one, two or three of the polypeptides comprise a fusion protein as in any one of embodiments 1-20, wherein two or three fusion proteins (if exist) optionally comprise, consist essentially of, or consist of amino acid sequences identical to each other.

Embodiment 23. An isolated coronavirus receptor binding domain (RBD) polypeptide, wherein optionally the coronavirus comprises a betacoronavirus.

Embodiment 24. A fusion protein comprising the RBD polypeptide of Embodiment 23 and one or both of (i) and (ii): (i) one or more peptide tags; (ii) one or more stem-helices A polypeptide, wherein optionally the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 25. The fusion protein of embodiment 24, comprising: (a) a peptide tag connected or fused to the first end of the RBD polypeptide, wherein the first end optionally includes the N-terminus of the RBD polypeptide; (b) connected or a peptide tag fused to the second end of an RBD polypeptide, wherein the second end optionally includes the C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked to or fused to the first end of an RBD polypeptide, wherein the first end optionally includes optionally comprising the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to the first end of the RBD polypeptide, wherein the first end optionally comprises the N-terminus of the RBD polypeptide; or (e) (a)- (d) any combination.

Embodiment 26. The fusion protein of embodiment 24 or 25, wherein the one or more peptide tags comprise SpyTag.

Embodiment 27. The fusion protein of any one of embodiments 24-26, comprising a linker disposed between and connecting a peptide tag of (1) an RBD polypeptide and (2) one or more peptide tags.

Embodiment 28. The fusion protein of embodiment 27, comprising two or more linkers comprising the same amino acid sequence as each other.

Embodiment 29. The fusion protein of embodiment 27 or 28, wherein the linker or one or more of the two or more linkers comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.: 702) .

Embodiment 30. The fusion protein of any one of embodiments 24-29, comprising disposed between and connecting one of (1) an RBD polypeptide and (2) one or more stem-helix polypeptides. connector.

Embodiment 31. The fusion protein of any one of embodiments 24-30, comprising: (i) A peptide tag fused to or linked to the N-terminus of an RBD polypeptide; and (ii) A stem-helix polypeptide fused to or linked to the C-terminus of an RBD polypeptide.

Embodiment 32. The fusion protein of Embodiment 31, which includes an optional signal peptide, an optional linker, SPyTag (optionally AHIVMVDAYKPTK (SEQ ID NO.:700)), a linker along the N-terminal to C-terminal direction. sub (optionally GSGGSGGSGGTG; SEQ NO.:702), RBD, linker (optionally GSGGSGGSGGTG; SEQ ID NO.:702) and a stem-helix polypeptide, wherein optionally the stem-helix polypeptide comprises an amino acid Sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) or consisting of.

Embodiment 33. A fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein optionally the coronavirus comprises a betacoronavirus.

Embodiment 34. The fusion protein of embodiment 33, which includes a first RBD polypeptide, a second RBD polypeptide and a third RBD polypeptide, the first RBD polypeptide is connected to the second RBD polypeptide through the linker (1), and the second The RBD polypeptide is linked to a third RBD polypeptide via linker (2).

Embodiment 35. The fusion protein of embodiment 34, wherein the linker (1) and the linker (2) comprise, essentially consist of, or consist of the same amino acid sequence.

Embodiment 36. The fusion protein of Embodiment 34, wherein the linker (1) and the linker (2) have different amino acid sequences from each other.

Embodiment 37. The fusion protein of any one of embodiments 33-36, wherein the linker comprises a stem-helix polypeptide.

Embodiment 38. The fusion protein of any one of embodiments 34-36, wherein the linker (1) and the linker (2) each comprise a stem-helix polypeptide.

Embodiment 39. The fusion protein of any one of embodiments 33-38, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 A .27; SARS-like coronavirus ZC45.

Embodiment 40. The fusion protein of any one of embodiments 33-39, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2β variant; SARS-CoV-2 A.2.7+ S494P; SARS-like coronavirus isolate Rs4231.

Embodiment 41. The fusion protein of any one of embodiments 33-40, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 delta variant; GX-pangolin; SARS-like coronavirus isolation strain Rs4231.

Embodiment 42. The fusion protein of any one of embodiments 34-41, which includes three RBD polypeptides, wherein the three RBD polypeptides are from: (i) respectively, SARS-CoV-2 Wuhan-Hu-1, SARS -CoV-2A.27 and SARS-like coronavirus ZC45; (ii) SARS-CoV-2 beta variant, SARS-CoV-2 A.2.7 + S494P and SARS-like coronavirus isolate Rs4231, respectively; or (iii) Respectively, SARS-CoV-2 delta variant, GX-pangolin and SARS-like coronavirus isolate Rs4231.

Embodiment 43. The fusion protein of any one of embodiments 37-42, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.: 701).

Embodiment 44. The fusion protein of embodiment 33, further comprising a fourth RBD polypeptide and a fifth RBD polypeptide, wherein the fourth RBD polypeptide is connected to the third RBD polypeptide by linker (3) and the fifth RBD polypeptide is connected by Linker (4) is connected to the fourth RBD polypeptide.

Embodiment 45. The fusion protein of embodiment 44, wherein two, three or all four of the linkers (1)-(4) comprise, essentially consist of, or consist of the same amino acid sequence.

Embodiment 46. The fusion protein of embodiment 44 or 45, wherein two or more of the linkers have amino acid sequences that are different from each other.

Embodiment 47. The fusion protein of any one of embodiments 44-46, wherein one or more of the linkers (1)-(4) comprises or consists of a stem-helix polypeptide, wherein optionally, the stem - The helical polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 48. The fusion protein of embodiment 47, wherein each of the peptide linkers (1)-(4) comprises or consists of a stem-helix polypeptide, wherein optionally, the stem-helix polypeptide comprises an amino acid Sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) or consisting of.

Embodiment 49. The fusion protein of any one of embodiments 44-48, comprising an RBD polypeptide from: (i) SARS-CoV-2 Wuhan-Hu-1, SARS-CoV-2 A.27 , SARS-CoV-2α variant+E484K+S494P, SARS-like coronavirus ZC45 and SARS-CoV-1; or (ii) SARS-CoV-2δ variant, SARS-CoV-2β variant, SARS-CoV-2 A.27+S494P, GX-pangolin and SARS-like coronavirus isolate Rs4231.

Embodiment 50. The fusion protein of any one of embodiments 33-49, further comprising a peptide tag, wherein optionally, the peptide tag is placed at the C-terminus of the fusion protein.

Embodiment 51. The fusion protein of embodiment 50, wherein the peptide tag includes SpyTag and/or His tag.

Embodiment 52. The fusion protein of any one of embodiments 1-21, 24-38, 43-48 and 50-51, the polypeptide trimer of embodiment 21 or 22, or the isolated RBD of embodiment 23 Polypeptides in which coronaviruses include betacoronaviruses and in which betacoronaviruses include Sabeycoronaviruses.

Embodiment 53. The fusion protein of Embodiment 52, the polypeptide trimer of Embodiment 52, or the isolated RBD polypeptide of Embodiment 52, wherein the Sabey coronavirus includes SARS-CoV-2, SARS coronavirus, and SARS-like coronavirus or engineered variants thereof.

Embodiment 54. The fusion protein of embodiment 53, the polypeptide trimer of embodiment 53, or the isolated RBD polypeptide of embodiment 53, wherein the Sabey coronavirus includes SARS-CoV-2; Wuhan-Hu-1; A.27 (Mayotte); A.27 with S494P substitution mutation; AAV49723.1; ATO98157.1; AVP78031.1; B.1.315; B.167.2; Wuhan with substitution mutations E484K, S494P and N501Y -Hu-1; QHD43416.1; ADE34812; AIA6227; QIA48632.1; or any combination thereof.

Embodiment 55. The fusion protein of embodiment 54, the protein trimer of embodiment 54, or the isolated RBD polypeptide of embodiment 54, wherein the Sabey coronavirus comprises SARS-CoV-2.

Embodiment 56. A polypeptide comprising a variant of the SARS-CoV-2 receptor binding domain (RBD), wherein the variant RBD comprises the following changes relative to the RBD comprising amino acids 328-531 of SEQ ID NO.:1 Any one or more of (i)-(xiii) , wherein the number of the amino acid is according to SEQ ID NO.: 1: (i) through a single P amino acid, a single G amino acid or a single S amine group Acid-substituted amino acid 444-447 (KVGG); (ii) Amino acid 444-447 (KVGG) substituted by two amino acids PG, two amino acids GG, or two amino acids GS; ( iii) Y449G substitution; (iv) Q498A substitution, Q498G substitution or Q498N substitution, optionally further comprising P499A substitution or P499G substitution; (v) P499A substitution or P499G substitution; (vi) T500A substitution; (vii) N450G substitution; ( viii) L452A substitution; (ix) T470N substitution and I472T substitution; (x) V483A substitution; (xi) Amino acid 481-483 (NGV) substituted by a single G amino acid; (xii) E484A substitution; (xiii) Replaced by Q493A.

Embodiment 57. An isolated polypeptide comprising a variant of the SARS-CoV-2 receptor binding domain (RBD), wherein the variant RBD comprises RBD relative to an RBD comprising amino acids 328-531 of SEQ ID NO.:1 Any one or more of the following changes (i)-(vi) , in which the number of the amino acid is according to SEQ ID NO.: 1: (i) through a single P amino acid, a single G amino acid or a single S Amino acid 444-447 (KVGG) substituted by amino acid; (ii) Amino acid 444-447 (KVGG) substituted by two amino acids PG, two amino acids GG or two amino acids GS ; (iii) Y449G substitution; (iv) Q498A substitution, Q498G substitution or Q498N substitution, optionally further comprising P499A substitution or P499G substitution; (v) P499A substitution or P499G substitution; (vi) T500A substitution.

Embodiment 58. An isolated polypeptide comprising a variant of the SARS-CoV-2 receptor binding domain (RBD), wherein the variant RBD comprises RBD relative to an RBD comprising amino acids 328-531 of SEQ ID NO.:1 Any one or more of the following changes (i)-(viii) , in which the amino acid numbering is according to SEQ ID NO.: 1: (i) N450G substitution; (ii) L452A substitution; (iii) T470N substitution; (iv) I472T substitution; (v) V483A substitution; (vi) amino acid 481-483 (NGV) substituted with a single G amino acid; (vii) K484A substitution; (viii) Q493A substitution.

Embodiment 59. An isolated polypeptide comprising a variant of the SARS-CoV-2 receptor binding domain (RBD), wherein the variant RBD comprises RBD relative to an RBD comprising amino acids 328-531 of SEQ ID NO.:1 The following changes, where the amino acid number is according to SEQ ID NO.:1: (1) Y449G substitution, or (2) Q498A substitution, or (3) Q498G substitution, or (4) T500A substitution, or (5) Y449G and Q498A replaces; or (6) Y449G and Q498G replaces; or (7) Y449G and T500A replaces; or (8) Q498A and T500A replaces; or (9) Q498G and T500A replaces; or (10) Y449G, Q498A and T500A replaces ; or (11) replaced by Y449G, Q498G and T500A; or (12) replaced by Q498N, or (13) replaced by Q498N and P499A; or (14) replaced by Y449G, Q498N and P499A; or (15) replaced by Q498N and P499G; or ( 16) Y449G, Q498N and P499G substitution; or (17) Amino acid 444-447 (K-V-G-G) substituted by a single P amino acid; or (18) Amino acid 444-447 substituted by a single G amino acid ( K-V-G-G); or (19) Amino acid 444-447 substituted by a single S amino acid (K-V-G-G); or (20) Amino acid 444-447 (K-V-G-G) substituted by two amino acids P-G; or ( 21) Amino acid 444-447 (K-V-G-G) substituted by two amino acids G-G; or (22) Amino acid 444-447 (K-V-G-G) substituted by two amino acids G-S; or (23) (i ) Amino acids 444-447 (K-V-G-G) substituted by a single P amino acid, (ii) Q498N substituted, and (iii) P499A substituted, or (24) (i) Amino acids substituted by a single P amino acid 444-447 (K-V-G-G), (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499A substitution, or (25) (i) amino acid substituted with a single P amino acid 444-447 (K-V-G-G) , (ii) Q498N substitution, and (iii) P499G substitution, or (26) (i) amino acid 444-447 (K-V-G-G) substituted by a single P amino acid, (ii) Y449G substitution, (iii) Q498N substitution , and (iv) P499G substitution, or (27) (i) amino acid 444-447 (K-V-G-G) substituted with a single G amino acid, (ii) Q498N substitution, and (iii) P499A substitution, or (28) (i) Amino acids 444-447 (K-V-G-G) substituted with a single G amino acid, (ii) Y449G substituted, (iii) Q498N substituted, and (iv) P499A substituted, or (29) (i) substituted with a single G Amino acid substituted amino acid 444-447 (K-V-G-G), (ii) Q498N substituted, and (iii) P499G substituted, or (30) (i) Amino acid 444-447 substituted with a single G amino acid ( K-V-G-G), (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution, or (31) (i) amino acid 444-447 (K-V-G-G) substituted with a single S amino acid, (ii) Q498N substitution, and (iii) P499A substitution, or (32) (i) amino acid 444-447 (K-V-G-G) substituted by a single S amino acid, (ii) Y449G substitution, (iii) Q498N substitution, and (iv ) P499A substitution, or (33) (i) amino acid 444-447 (K-V-G-G) substituted with a single S amino acid, (ii) Q498N substitution, and (iii) P499G substitution, or (34) (i) Amino acid 444-447 (K-V-G-G) substituted by a single S amino acid, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution, or (35) (i) by two amino acids P-G Substituted amino acid 444-447 (K-V-G-G), (ii) Q498N substituted, and (iii) P499A substituted, or (36) (i) Amino acid 444-447 substituted by two amino acids P-G (K-V-G-G) , (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499A substitution, or (37) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids P-G, (ii) Q498N Substituted, and (iii) P499G substituted, or (38) (i) Amino acid 444-447 (K-V-G-G) substituted by two amino acids P-G, (ii) Y449G substituted, (iii) Q498N substituted, and (iv ) P499G substitution, or (39) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-G, (ii) Q498N substitution, and (iii) P499A substitution, or (40) (i) Amino acids 444-447 (K-V-G-G) substituted by two amino acids G-G, (ii) Y449G substituted, (iii) Q498N substituted, and (iv) P499A substituted, or (41) (i) substituted by two amine groups Amino acid 444-447 substituted by acid G-G (K-V-G-G), (ii) substituted by Q498N, and (iii) substituted by P499G, or (42) (i) amino acid 444-447 substituted by two amino acids G-G ( K-V-G-G), (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution, or (43) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-S, (ii ) Q498N substitution, and (iii) P499A substitution, or (44) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-S, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499A substitution, or (45) (i) Amino acid 444-447 (K-V-G-G) substituted by two amino acids G-S, (ii) Q498N substitution, and (iii) P499G substitution, or (46) ( i) Amino acid 444-447 (K-V-G-G) substituted by two amino acids G-S, (ii) Y449G substitution, (iii) Q498N substitution, and (iv) P499G substitution, or (47) N450G substitution, or (48 ) L452A substituted, or (49) V483A substituted, or (50) K484A substituted, or (51) Q493A substituted, or (52) N450G and Q493A substituted; or (53) L452A and Q493A substituted; or (54) N450G, V483A and Q493A replaced; or (55) N450G, K484A and Q493A replaced; or (56) L452A, V483A and Q493A replaced; or (57) L452A, K484A and Q493A replaced; or (58) T470N and I472T replaced; or (59) Replaced by N450G, T470N and I472T; or (60) Replaced by L452A, T470N and I472T; or (61) Replaced by T470N, I472T and V483A; or (62) Replaced by N450G, T470N, I472T and V483A; or (63) L452A, T470N, I472T and V483A replace; or (64) T470N, I472T, V483A and Q493A replace; or (65) N450G, T470N, I472T, V483A and Q493A replace; or (66) L452A, T470N, I472T, V483A and Q493A replace; or (66) L452A, T470N, I472T, V483A and Q493A replace; 67) Amino acid 481-483 (N-G-V) substituted by a single G amino acid; or (68) (i) Amino acid 481-483 (N-G-V) substituted by a single G amino acid and (ii) K484A substituted , or (69) (i) Amino acids 481-483 (N-G-V) substituted with a single G amino acid, (ii) K484A substituted, and (iii) Q493A substituted, or (70) (i) L452A substituted, ( ii) Amino acids 481-483 (N-G-V) substituted with a single G amino acid and (iii) K484A substituted, or (71) (i) L452A substituted, (ii) Amino acids substituted with a single G amino acid 481-483 (N-G-V), (iii) K484A substitution, and (iv) Q493A substitution; or (72) (i) T470N substitution, (ii) I472T substitution, and (iii) amino group substituted by a single G amino acid Acid 481-483 (N-G-V); or (73) (i) T470N substitution, (ii) I472T substitution, (iii) amino acid 481-483 (N-G-V) substituted with a single G amino acid and (iv) K484A substitution , or (74) (i) T470N substitution, (ii) I472T substitution, (iii) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (iv) K484A substitution, and (v) Q493A substitution , or (75) (i) L452A substitution, (ii) T470N substitution, (iii) I472T substitution, and (iv) amino acid 481-483 (N-G-V) substituted by a single G amino acid; or (76) ( i) L452A substitution, (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (v) K484A substitution, and (vi) Q493A substitution , or (77) K484A, Q493A and Q498A replace; or (78) K484A, Q493A and Q498G replace; or (79) Y449G, K484A, Q493A, Q498A, P499A and T500A replace; or (80) Y449G, K484A, Q493A, Replaced by Q498G, P499A and T500A; or (81) Replaced by Y449G, L452A, V483A, K484A, Q493A, Q498A, P499A and T500A; or (82) Replaced by Y449G, L452A, V483A, K484A, Q493A, Q498G, P499A and replaced by T500A; or (83) T470N, I472T, Q498N and P499A replace; or (84) Y449G, T470N, I472T, Q498N and P499A replace; or (85) T470N, I472T, Q493A, Q498N and P499A replace; or (86) T470N, I472T , Replaced by K484A, Q498N and P499A; or (87) Replaced by L452A, T470N, I472T, Q498N and P499A; or (88) Replaced by Y449G, T470N, I472T, Q493A, Q498N and P499A; or (89) Replaced by Y449G, T470N, I472T, K4 84A , Q498N and P499A; or (90) Y449G, L452A, T470N, I472T, Q493A, Q498N and P499A; or (91) Y449G, L452A, T470N, I472T, K484A, Q498N and P499A; or (92) Y4 49G, Replaced by L452A, T470N, I472T, K484A, Q493A, Q498N and P499A; or (93) Replaced by T470N, I472T, Q498N and P499G; or (94) Replaced by Y449G, T470N, I472T, Q498N and P499G; or (95) T47 0N、I472T , Q493A, Q498N and P499G replacement; or (96) T470N, i472T, K484A, Q198n and P499G replacement; or (97) L452A, T470N, i472T, Q498N and P499G replacement; As well as Replaced by Q498N and P499G; or (99) Replaced by Y449G, T470N, I472T, K484A, Q498N and P499G; or (100) Replaced by Y449G, L452A, T470N, I472T, Q493A, Q498N and P499G; or (101) Replaced by Y449G, L452A, T4 70N , I472T, K484A, Q498N and P499G substitution; or (102) Y449G, L452A, T470N, I472T, K484A, Q493A, Q498N and P499G substitution; or (103) (i) amino acid 444 substituted by a single P amino acid -447 (K-V-G-G), (ii) T470N substitution, (iii) I472T substitution, (iv) amino acid substituted with a single G amino acid 481-483 (N-G-V), (v) Q498N substitution, and (vi) P499A Substituted; or (104) (i) Amino acid 444-447 (K-V-G-G) substituted with a single G amino acid, (ii) T470N substituted, (iii) I472T substituted, (iv) Substituted with a single G amino acid Amino acid 481-483 (N-G-V), (v) Q498N substitution, and (vi) P499A substitution, or (105) (i) Amino acid 444-447 (K-V-G-G) substituted with a single S amino acid, (ii) ) T470N substitution, (iii) I472T substitution, (iv) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (v) Q498N substitution, and (vi) P499A substitution, or (106) (i ) Amino acids 444-447 substituted by two amino acids P-G (K-V-G-G), (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acids 481-483 substituted by a single G amino acid ( N-G-V), (v) Q498N substitution, and (vi) P499A substitution, or (107) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-G, (ii) T470N substitution, (iii ) I472T substituted, (iv) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (v) Q498N substituted, and (vi) P499A substituted, or (108) (i) with two amine groups Acid G-S substituted amino acid 444-447 (K-V-G-G), (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acid substituted with a single G amino acid 481-483 (N-G-V), (v) Q498N substitution, and (vi) P499A substitution; or (109) (i) amino acid 444-447 (K-V-G-G) substituted with a single P amino acid, (ii) T470N substitution, (iii) I472T substitution, (iv) Amino acids 481-483 (N-G-V) substituted with a single G amino acid, (v) Q493A substituted, (vi) Q498N substituted, and (vii) P499A substituted, or (110) (i) substituted with a single G amino acid Substituted amino acid 444-447 (K-V-G-G), (ii) T470N substitution, (iii) I472T substitution, (iv) Amino acid 481-483 (N-G-V) substituted with a single G amino acid, (v) Q493A substitution , (vi) Q498N substitution, and (vii) P499A substitution, or (111) (i) amino acid 444-447 (K-V-G-G) substituted by a single S amino acid, (ii) T470N substitution, (iii) I472T substitution , (iv) amino acids 481-483 (N-G-V) substituted by a single G amino acid, (v) substituted by Q493A, (vi) substituted by Q498N, and (vii) substituted by P499A, or (112) (i) substituted by two Amino acids 444-447 (K-V-G-G) substituted by a single amino acid P-G, (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acids 481-483 (N-G-V) substituted by a single G amino acid, (v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution, or (113) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-G, (ii) T470N substitution , (iii) I472T substitution, (iv) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution, or (114 ) (i) Amino acid 444-447 substituted by two amino acids G-S (K-V-G-G), (ii) T470N substituted, (iii) I472T substituted, (iv) Amino acid 481 substituted by a single G amino acid -483 (N-G-V), (v) Q493A substitution, (vi) Q498N substitution, and (vii) P499A substitution, or (115) (i) amino acid 444-447 (K-V-G-G) substituted with a single P amino acid, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (vi) Q493A substitution, (vii) Q498N substitution , and (viii) P499A substitution, or (116) (i) amino acid 444-447 (K-V-G-G) substituted with a single G amino acid, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution , (v) amino acids 481-483 (N-G-V) substituted with a single G amino acid, (vi) Q493A substituted, (vii) Q498N substituted, and (viii) P499A substituted, or (117) (i) substituted with a single Amino acid 444-447 substituted with S amino acid (K-V-G-G), (ii) L452A substituted, (iii) T470N substituted, (iv) I472T substituted, (v) Amino acid substituted with a single G amino acid 481- 483 (N-G-V), (vi) Q493A substitution, (vii) Q498N substitution, and (viii) P499A substitution, or (118) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids P-G, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (vi) Q493A substitution, (vii) Q498N substitution , and (viii) P499A substitution, or (119) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-G, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T Substituted, (v) amino acids 481-483 substituted with a single G amino acid (N-G-V), (vi) Q493A substituted, (vii) Q498N substituted, and (viii) P499A substituted, or (120) (i) Amino acids 444-447 substituted by two amino acids G-S (K-V-G-G), (ii) L452A substituted, (iii) T470N substituted, (iv) I472T substituted, (v) amino acids substituted by a single G amino acid 481-483 (N-G-V), (vi) Q493A substitution, (vii) Q498N substitution, and (viii) P499A substitution, or (121) (i) amino acid substituted with a single P amino acid 444-447 (K-V-G-G) , (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (vi) K484A substitution, (vii) Q493A Substitution, (viii) Q498N substitution, and (ix) P499A substitution, or (122) (i) amino acid 444-447 (K-V-G-G) substituted with a single G amino acid, (ii) L452A substitution, (iii) T470N Substituted, (iv) I472T substituted, (v) amino acid 481-483 substituted with a single G amino acid (N-G-V), (vi) K484A substituted, (vii) Q493A substituted, (viii) Q498N substituted, and (ix ) P499A substitution, or (123) (i) amino acid 444-447 (K-V-G-G) substituted with a single S amino acid, (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) Amino acids 481-483 substituted with a single G amino acid (N-G-V), (vi) K484A substitution, (vii) Q493A substitution, (viii) Q498N substitution, and (ix) P499A substitution, or (124) (i) Amino acids 444-447 (K-V-G-G) substituted by two amino acids P-G, (ii) L452A substituted, (iii) T470N substituted, (iv) I472T substituted, (v) Amine substituted by a single G amino acid Acid 481-483 (N-G-V), (vi) K484A substituted, (vii) Q493A substituted, (viii) Q498N substituted, and (ix) P499A substituted, or (125) (i) amine substituted by two amino acids G-G Amino acid 444-447 (K-V-G-G), (ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) Amino acid 481-483 (N-G-V) substituted with a single G amino acid, (vi ) K484A substitution, (vii) Q493A substitution, (viii) Q498N substitution, and (ix) P499A substitution, or (126) (i) amino acid 444-447 (K-V-G-G) substituted by two amino acids G-S, ( ii) L452A substitution, (iii) T470N substitution, (iv) I472T substitution, (v) amino acid 481-483 (N-G-V) substituted with a single G amino acid, (vi) K484A substitution, (vii) Q493A substitution, (viii) Q498N substitution, and (ix) P499A substitution, or (127) (i) amino acid 444-447 (K-V-G-G) substituted with a single P amino acid, (ii) Y449G substitution, (iii) L452A substitution, (iv) T470N substitution, (v) I472T substitution, (vi) amino acid 481-483 (N-G-V) substituted by a single G amino acid, (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution , and (x) P499A substitution, or (128) (i) amino acid 444-447 (K-V-G-G) substituted with a single G amino acid, (ii) Y449G substitution, (iii) L452A substitution, (iv) T470N substitution , (v) I472T substitution, (vi) amino acid 481-483 substituted with a single G amino acid (N-G-V), (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution, or (129) (i) amino acid 444-447 (K-V-G-G) substituted with a single S amino acid, (ii) Y449G substitution, (iii) L452A substitution, (iv) T470N substitution, (v) I472T Substituted, (vi) amino acid 481-483 substituted with a single G amino acid (N-G-V), (vii) K484A substituted, (viii) Q493A substituted, (ix) Q498N substituted, and (x) P499A substituted, or ( 130) (i) Amino acid 444-447 (K-V-G-G) substituted by two amino acids P-G, (ii) Y449G substitution, (iii) L452A substitution, (iv) T470N substitution, (v) I472T substitution, (vi ) Amino acids 481-483 (N-G-V) substituted with a single G amino acid, (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution, or (131) (i ) Amino acids 444-447 (K-V-G-G) substituted by two amino acids G-G, (ii) substituted by Y449G, (iii) substituted by L452A, (iv) substituted by T470N, (v) substituted by I472T, (vi) substituted by a single G Amino acid substituted amino acid 481-483 (N-G-V), (vii) K484A substituted, (viii) Q493A substituted, (ix) Q498N substituted, and (x) P499A substituted, or (132) (i) by two Amino acid G-S substituted amino acid 444-447 (K-V-G-G), (ii) Y449G substituted, (iii) L452A substituted, (iv) T470N substituted, (v) I472T substituted, (vi) substituted with a single G amino acid Amino acid 481-483 (N-G-V), (vii) K484A substitution, (viii) Q493A substitution, (ix) Q498N substitution, and (x) P499A substitution.

Embodiment 60. The polypeptide of any one of embodiments 56-59, relative to amino acid 444-500 of SEQ ID NO.:1 and/or relative to amino acid 328- of SEQ ID NO.:1 531 contains no additional changes.

Embodiment 61. The polypeptide of any one of embodiments 56-60, relative to amino acid 444-500 of SEQ ID NO.:1 and/or relative to amino acid 328- of SEQ ID NO.:1 531 includes at most 15, at most 14, at most 13, at most 12, at most 11, at most 10, at most 9, at most 8, at most 7, at most 6, at most 5, at most 4, at most 3, at most 2 or at most 1 additional variations , where each additional change independently includes: (i) deletion of one, two, or three amino acids; (ii) insertion of one, two, or three amino acids; (iii) conservative substitution; or (ii) insertion of one, two, or three amino acids; iv) Non-conservative substitution.

Embodiment 62. The polypeptide of any one of embodiments 56-61, comprising at least 90%, at least 91%, at least 92%, at least 93%, of amino acids 444-500 of SEQ ID NO.: 1. At least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the amino acid sequence.

Embodiment 63. The polypeptide of any one of embodiments 56-62, comprising at least 90%, at least 91%, at least 92%, at least 93%, of amino acids 328-531 of SEQ ID NO.: 1. At least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the amino acid sequence.

Embodiment 64. The polypeptide of any one of embodiments 56-63, comprising the following amino acid sequence: (i) Amino acids 453-469 of SEQ ID NO.:1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (ii) Amino acids 473-480 of SEQ ID NO.:1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (iii) Amino acids 485-492 of SEQ ID NO.: 1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (iv) Amino acids 501-531 of SEQ ID NO.: 1, or variant sequences thereof with one, two or three amino acid substitutions; and/or (v) Amino acids 328-443 of SEQ ID NO.:1, or at least 90%, at least 91%, at least 92%, at least 93%, or at least Its variant sequence is 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical.

Embodiment 65. The polypeptide of any one of embodiments 56-64, which includes any one or more of the following amino acids, wherein the numbering of the amino acids is according to SEQ ID NO.: 1: S443; N448; Y451; E471; Y501.

Embodiment 66. The polypeptide of any one of embodiments 56-65, wherein: (i) Amino acids 498-500 (numbered according to SEQ ID NO.:1) contain N-A-T, N-P-T or N-G-T respectively; and/or (ii) Amino acids 470-472 (numbered according to SEQ ID NO.:1) comprise N-X-T, where X is any amino acid, and preferably E.

Embodiment 67. The polypeptide of any one of embodiments 56-66, wherein the polypeptide further comprises: signal peptide; SPyTag; linker; stem-helix polypeptide; or any combination thereof.

Embodiment 68. The polypeptide of any one of embodiments 56 to 66, wherein the polypeptide consists essentially of or consists of variant RBD.

Embodiment 69. The polypeptide of any one of embodiments 56-67, comprising an amine having at least 80%, at least 85%, or at least 90% identity with the amino acid sequence set forth in SEQ ID NO.: 1 amino acid sequence.

Embodiment 70. The polypeptide of any one of embodiments 36-67 or the isolated polypeptide of embodiment 68 or 69, which is a variant SARS-CoV-2 spike protein polypeptide.

Embodiment 71. The polypeptide of embodiment 70, further comprising: signal peptide; SPyTag; linker; stem-helix polypeptide; or any combination thereof.

Embodiment 72. The polypeptide of embodiment 71, comprising: SpyTag; linker; stem-helix polypeptide; or any combination thereof.

Example 73. An isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than About 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than 11 amino acids, and comprising according to SEQ ID NO.: 4 amino acid sequence.

Embodiment 74. The polypeptide of embodiment 73, comprising the amino acid sequence set forth in SEQ ID NO.:5.

Example 75. An isolated polypeptide having a length of no more than about 50 amino acids, no more than about 45 amino acids, no more than about 40 amino acids, no more than about 35 amino acids, no more than About 30 amino acids, no more than about 25 amino acids, no more than about 20 amino acids, no more than about 15 amino acids, or no more than about 10 amino acids, or no more than 6 amines amino acid, and comprise the amino acid sequence set forth in any one of SEQ ID NO.: 4-12 and 14.

Embodiment 76. An isolated polypeptide comprising 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 of SEQ ID NO.: 13 or consisting of consecutive amino acid residues, provided that the isolated peptide contains 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 of SEQ ID NO.:5 Continuous amino acids.

Embodiment 77. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.: 14 or 701.

Embodiment 78. An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO.: 15.

Embodiment 79. An isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 16-19.

Example 80. An isolated polypeptide comprising: (i) According to the amino acid sequence of any one of SEQ ID NOs.: 4-14; and (ii) The amino acid sequence set forth in SEQ ID NO.:15.

Embodiment 81. An isolated polypeptide comprising: (i) Any one or more of a plurality of SEQ ID NO.: 4-14, wherein the plurality is homogeneous, isotype, heterogeneous or heterogeneous; and is placed between two of the plurality and connecting two of the plurality of (ii) Linker sequence.

Embodiment 82. An isolated polypeptide comprising: (i) Two, three, four, five or more copies of SEQ ID NO.:16; (ii) two, three, four, five or more copies of SEQ ID NO.:17; and/or (iii) One or more copies of SEQ ID NO.:16 and one or more copies of SEQ ID NO.:17.

Embodiment 83. An isolated polypeptide comprising SEQ ID NO.:18 or SEQ ID NO.:19, wherein X is 2 or greater, 3 or greater, 4 or greater, or 5 or greater.

Embodiment 84. A fusion protein comprising (i) SARS-CoV-2 spike protein polypeptide or a part thereof and (ii) the polypeptide of any one of embodiments 73-83, wherein optionally, SARS-CoV- 2. The spike protein polypeptide includes (i) one or more modifications that promote the open conformation of the receptor binding domain (RBD) of the spike protein polypeptide (such as D614G, K986P and V987P) and/or (ii) one or more modifications that promote the SARS-CoV- 2. Stable modification of the spike protein peptide trimer.

Embodiment 85. The fusion protein of embodiment 84, comprising (ii) a plurality of polypeptides each independently selected from the polypeptides of any one of embodiments 73-83.

Embodiment 86. The fusion protein of embodiment 84 or 85, wherein one or more polypeptides of (ii) are placed in the S2 subunit of the SARS-CoV-2 spike protein polypeptide.

Embodiment 87. The fusion protein of any one of embodiments 84-86, comprising SEQ ID NO.:18 or SEQ ID NO.:19, wherein X is 2 or greater, 3 or greater, 4 or greater Large, or 5 or more.

Embodiment 88. A fusion protein comprising (i) a SARS-CoV-2 receptor binding domain (RBD) and (ii) a polypeptide as in any one of embodiments 73-83.

Embodiment 89. The fusion protein of embodiment 88, wherein the RBD is not included in the betacoronavirus spike protein polypeptide.

Embodiment 90. The fusion protein of embodiment 88 or 89, which includes a plurality of RBD polypeptides of (i) and/or a plurality of polypeptides of (ii).

Embodiment 91. The fusion protein of embodiment 90, further comprising a linker disposed between and connecting two of the plurality of RBDs.

Embodiment 92. The fusion protein of embodiment 91, wherein the linker comprises or consists of the polypeptide of any one of embodiments 73-83.

Embodiment 93. The fusion protein of any one of embodiments 90-92, wherein the plurality of RBDs are of the same type.

Embodiment 94. The fusion protein of any one of embodiments 90-92, wherein the plurality of RBDs are heterotypic.

Embodiment 95. The fusion protein of any one of embodiments 84-94, comprising: ([RBD]-P x -[RBD]) y , wherein P is the polypeptide of any one of embodiments 73-83 , x is 1 or greater, and y is 1 or greater

Embodiment 96. The fusion protein of embodiment 95, wherein P comprises or consists of the amino acid sequence set forth in SEQ ID NO.:16 or SEQ ID NO.:17 or SEQ ID NO.:701.

Embodiment 97. The fusion protein of embodiment 95 or 96, wherein P comprises or consists of the amino acid sequence set forth in SEQ ID NO.: 18 or SEQ ID NO.: 19, wherein optionally, X is 2, 3, 4, 5, 6, 7, 8, 9, 10 or larger.

Embodiment 98. The fusion protein of any one of embodiments 84-97, wherein the spike protein polypeptide or a portion thereof comprises an RBD having the following, or wherein the RBD has the following, or wherein one of the plurality of RBDs The person has the following: at least 70%, at least 75%, at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 9% , or 100% consistency.

Embodiment 99. The fusion protein of any one of embodiments 84-98, which does not comprise SEQ ID NO.: 2 or a naturally occurring variant thereof.

Embodiment 100. The fusion protein of any one of embodiments 84-99, wherein the spike protein polypeptide or a portion thereof is comprised in the RBD, or the RBD comprises, or one of the plurality of RBDs comprises (i)- Any one or more of (iv) : (i) One or more amino acids are substituted relative to the natural RBD; (ii) One or more amino acids are deleted relative to the natural RBD; (iii) One or more amino acids are deleted relative to the natural RBD. one or more amino acid insertions in the native RBD; (iv) one or more non-natural carbohydrate attachment sites relative to the native RBD, which optionally comprise a glycosylation site, wherein optionally, a glycosylation site Glycosylation sites include C-linked glycosylation sites, N-linked glycosylation sites, O-linked glycosylation sites, S-linked glycosylation sites, or any combination thereof.

Embodiment 101. The fusion protein of any one of embodiments 88-100, wherein the RBD comprises or is comprised of the polypeptide of any one of embodiments 56-72.

Example 102. A polypeptide comprising a variant of the SARS-CoV-2 receptor binding domain (RBD), the variant comprising any one or more of (i)-(iv): (i) One or more amino acid substitutions relative to the natural RBD; (ii) One or more amino acids are missing relative to the natural RBD; (iii) Insertion of one or more amino acids relative to the native RBD; (iv) one or more non-natural carbohydrate attachment sites relative to the native RBD, optionally comprising a glycosylation site, wherein optionally the glycosylation site comprises a C-linked glycosylation site , N-linked glycosylation site, O-linked glycosylation site, S-linked glycosylation site, or any combination thereof.

Example 103. A polypeptide comprising a variant of the SARS-CoV-2 receptor binding domain (RBD), the variant comprising any one or more of (i)-(iv): (i) One or more amino acid substitutions relative to the natural RBD; (ii) One or more amino acids are missing relative to the natural RBD; (iii) Insertion of one or more amino acids relative to the native RBD; (iv) one or more non-natural carbohydrate attachment sites relative to the native RBD, optionally comprising a glycosylation site, wherein optionally the glycosylation site comprises a C-linked glycosylation site , N-linked glycosylation site, O-linked glycosylation site, S-linked glycosylation site, or any combination thereof, Optionally, the engineered variant SARS-CoV-2 spike polypeptide includes (i) one or more modifications that promote an open conformation of the receptor binding domain (RBD) of the spike polypeptide (e.g., D614G, K986P, and V987P ) and/or (ii) one or more modifications that promote the stability of the SARS-CoV-2 spike protein trimer.

Embodiment 104. The polypeptide of embodiment 103, wherein the polypeptide comprises: (i) SARS-CoV-2 spike protein polypeptide; (ii) a linker, wherein optionally the linker comprises a stem-helix polypeptide; (iii) a peptide tag, wherein optionally the peptide tag includes SpyTag; (iv) another RBD; (v) stem-helix polypeptide; or (vi) Any combination of (i)-(v).

Embodiment 105. The fusion protein of any one of embodiments 1-20 and 24-55, the polypeptide trimer of embodiment 21 or 22, or the isolated RBD polypeptide of embodiment 23, which is or includes as implemented The polypeptide of any one of Examples 56-72.

Embodiment 106. The fusion protein as in any one of embodiments 1-20, 24-55 and 105 or the polypeptide trimer as in embodiment 21, 22 or 105, which comprises any one of embodiments 73-83 of peptides.

Example 107. An isolated polypeptide comprising, consisting essentially of, or consisting of the amino acid sequence set forth in any of SEQ ID NOs.: 107-249, 255-565, and 576-699 .

Embodiment 108. An isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565, and 576-699.

Embodiment 109. An isolated polypeptide comprising the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the signal peptide is removed, wherein any Optionally, linker sequences adjacent to the signal peptide are also removed.

Example 110. An isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the variation is caused by a different peptide Tag replacement consists of His tags.

Embodiment 111. An isolated polypeptide comprising a variant of the amino acid sequence set forth in any one of SEQ ID NOs.: 107-249, 255-565 and 576-699, wherein the variant is not HHHHHHHH His tag (that is, a His tag longer or shorter than HHHHHHHH).

Embodiment 112. An isolated polypeptide, wherein the polypeptide is any of the following: Cov0001-Cov0070, Cov0091-Cov0098, Cov0101, Cov0102, Cov0121-Cov0128, Cov0130, Cov0132, Cov0151-Cov0514, Cov0556-Cov0629 ,Cov0631, Cov0633, Cov0662-Cov0690, Cov0693, Cov0722-Cov0739.

Embodiment 113. An isolated polypeptide, wherein the polypeptide is: Cov0001, Cov0002, Cov0003, Cov0004, Cov0005, Cov0006, Cov0007, Cov0008, Cov0009, Cov0010, Cov0011, Cov0012, Cov0013, Cov0014, Cov001 5. Cov0016, Cov0017, Cov0018, Cov0019, Cov0020, Cov0021, Cov0022, Cov0023, Cov0024, Cov0025, Cov0026, Cov0027, Cov0028, Cov0029, Cov0030, Cov0031, Cov0032, Cov0033, Cov0034, Cov0035, Cov003 6. Cov0037, Cov0038, Cov0039, Cov0040, Cov0041, Cov0042, Cov0043, Cov0044, Cov0045, Cov0046, Cov0047, Cov0048, Cov0049, Cov0050, Cov0051, Cov0052, Cov0053, Cov0054, Cov0055, Cov0056, Cov0057, Cov0058, Cov0059, Cov0060, Cov006 1. Cov0062, Cov0063, Cov0064, Cov0065, Cov0066, Cov0067, Cov0068, Cov0069, Cov0070, Cov0091, Cov0092, Cov0093, Cov0094, Cov0095, Cov0096, Cov0097, Cov0098, Cov0101, Cov0102, Cov0121, Cov0122, Cov0123, Cov0124, Cov0125, Cov012 6. Cov0127, Cov0128, Cov0130, Cov0132, Cov0151, Cov0152, Cov0153, Cov0154, Cov0155, Cov0156, Cov0157, Cov0158, Cov0159, Cov0160, Cov0161, Cov0162, Cov0163, Cov0164, Cov0165, Cov0166, Cov0167, Cov0168, Cov0169, Cov0170, Cov017 1. Cov0172, Cov0173, Cov0174, Cov0175, Cov0176, Cov0177, Cov0178, Cov0179, Cov0180, Cov0181, Cov0182, Cov0183, Cov0184, Cov0185, Cov0186, Cov0187, Cov0188, Cov0189, Cov0190, Cov0191, Cov0192, Cov0193, Cov0194, Cov0195, Cov019 6. Cov0197, Cov0198, Cov0199, Cov0200, Cov0201, Cov0202, Cov0203, Cov0204, Cov0205, Cov0206, Cov0207, Cov0208, Cov0209, Cov0210, Cov0211, Cov0212, Cov0213, Cov0214, Cov0215, Cov0216, Cov0217, Cov0218, Cov0219, Cov0220, Cov022 1. Cov0222, Cov0223, Cov0224, Cov0225, Cov0226, Cov0227, Cov0228, Cov0229, Cov0230, Cov0231, Cov0232, Cov0233, Cov0239, Cov0240, Cov0241, Cov0242, Cov0243, Cov0244, Cov0245, Cov0246, Cov0247, Cov0248, Cov0249, Cov0250, Cov059 2. Cov0593, Cov0594, Cov0595, Cov0596, Cov0597, Cov0598, Cov0599, Cov0600, Cov0601, Cov0602, Cov0603, Cov0604, Cov0605, Cov0606, Cov0607, Cov0608, Cov0609, Cov0610, Cov0611, Cov0612, Cov0613, Cov0614, Cov0615, Cov0616, Cov061 7. Cov0618, Cov0619, Cov0620, Cov0621, Cov0622, Cov0623, Cov0624, Cov0625, Cov0626, Cov0627, Cov0628, Cov0629, Cov0631, Cov0633, Cov0662, Cov0663, Cov0664, Cov0665, Cov0666, Cov0667, Cov0668, Cov0669, Cov0670, Cov0671, Cov067 2. Cov0673, Cov0674, Cov0675, Cov0676, Cov0677, Cov0678, Cov0679, Cov0680, Cov0681, Cov0682, Cov0683, Cov0684, Cov0685, Cov0686, Cov0687, Cov0688, Cov0689, Cov0690, Cov0693, Cov0722, Cov0723, Cov0724, Cov0725, Cov0726, Cov072 7. Cov0728, Cov0729, Cov0730, Cov0731, Cov0732, Cov0733, Cov0734, Cov0735, Cov0736, Cov0737, Cov0738, Cov0739, Cov0556, Cov0557, Cov0558, Cov0559, Cov0560, Cov0561, Cov0562, Cov0563, Cov0564, Cov0565, Cov0566, Cov0567, Cov056 8. Cov0569, Cov0570, Cov0571, Cov0572, Cov0573, Cov0574, Cov0575, Cov0576, Cov0577, Cov0578, Cov0579, Cov0580, Cov0581, Cov0582, Cov0583, Cov0584, Cov0585, Cov0586, Cov0587 Cov0588, Cov0590, Cov0591, Cov0592, Cov0251, Cov0252 , Cov0253, Cov0254, Cov0255, Cov0256, Cov0257, Cov0258, Cov0259, Cov0260 , Cov0261, Cov0262, Cov0263, Cov0264, Cov0265, Cov0266, Cov0267, Cov0268, Cov0269, Cov0270, Cov0271, Cov0272, Cov0273, Cov0274, Cov0275, Cov0276, Cov0277, Cov0 278. Cov0279, Cov0280, Cov0281, Cov0282, Cov0283, Cov0284, Cov0285 , Cov0286, Cov0287, Cov0288, Cov0289, Cov0290, Cov0291, Cov0292, Cov0293, Cov0294, Cov0295, Cov0296, Cov0297, Cov0298, Cov0299, Cov0300, Cov0301, Cov0302, Cov0 303, Cov0304, Cov0305, Cov0306, Cov0307, Cov0308, Cov0309, Cov0310 , Cov0311, Cov0312, Cov0313, Cov0314, Cov0315, Cov0316, Cov0317, Cov0318, Cov0319, Cov0320, Cov0321, Cov0322, Cov0323, Cov0324, Cov0325, Cov0326, Cov0327, Cov0 328. Cov0329, Cov0330, Cov0331, Cov0332, Cov0333, Cov0334, Cov0335 , Cov0336, Cov0337, Cov0338, Cov0339, Cov0340, Cov0341, Cov0342, Cov0343, Cov0344, Cov0345, Cov0346, Cov0347, Cov0348, Cov0349, Cov0350, Cov0351, Cov0352, Cov0 353, Cov0354, Cov0355, Cov0356, Cov0357, Cov0358, Cov0359, Cov0360 , Cov0361, Cov0362, Cov0363, Cov0364, Cov0365, Cov0366, Cov0367, Cov0368, Cov0369, Cov0370, Cov0371, Cov0372, Cov0373, Cov0374, Cov0375, Cov0376, Cov0377, Cov0 378. Cov0379, Cov0380, Cov0381, Cov0382, Cov0383, Cov0384, Cov0385 , Cov0386, Cov0387, Cov0388, Cov0389, Cov0390, Cov0391, Cov0392, Cov0393, Cov0394, Cov0395, Cov0396, Cov0397, Cov0398, Cov0399, Cov0400, Cov0401, Cov0402, Cov0 403, Cov0404, Cov0405, Cov0406, Cov0407, Cov0408, Cov0409, Cov0410 , Cov0411, Cov0412, Cov0413, Cov0414, Cov0415, Cov0416, Cov0417, Cov0418, Cov0419, Cov0420, Cov0421, Cov0422, Cov0423, Cov0424, Cov0425, Cov0426, Cov0427, Cov0 428, Cov0429, Cov0430, Cov0431, Cov0432, Cov0433, Cov0434, Cov0435 , Cov0436, Cov0437, Cov0438, Cov0439, Cov0440, Cov0441, Cov0442, Cov0443, Cov0444, Cov0445, Cov0446, Cov0447, Cov0448, Cov0449, Cov0450, Cov0451, Cov0452, Cov0 453, Cov0454, Cov0455, Cov0456, Cov0457, Cov0458, Cov0459, Cov0460 , Cov0461, Cov0462, Cov0463, Cov0464, Cov0625, Cov0466, Cov0467, Cov0468, Cov0469, Cov0470, Cov0471, Cov0472, Cov0473, Cov0474, Cov0475, Cov0476, Cov0477, Cov0 478, Cov0479, Cov0480, Cov0481, Cov0482, Cov0483, Cov0484, Cov0485 , Cov0486, Cov0487, Cov0488, Cov0489, Cov0490, Cov0491, Cov0492, Cov0493, Cov0494, Cov0495, Cov0496, Cov0497, Cov0498, Cov0499, Cov0500, Cov0501, Cov0502, Cov0 503, Cov0504, Cov0505, Cov0506, Cov0507, Cov0508, Cov0509, Cov0510 , Cov0511, Cov0512, Cov0513, Cov0514, Cov0746, Cov0747, Cov0748, Cov0749, Cov0750, Cov0751, Cov0758, Cov0759, Cov0761 or Cov0762, or any of the foregoing, in which the signal peptide is removed and the peptide tag is removed, with different Signal peptide, or with different peptide tags.

Embodiment 114. A composition comprising: (1) (i) The fusion protein of any one of Examples 1-20, 24-55, 84-101 and 105-106, (ii) The polypeptide trimer of Example 21 or 22, (iii) An isolated RBD polypeptide as in Example 23, (iv) a polypeptide as in any one of Examples 56-72, (v) an engineered variant RBD as in Example 102, (vi) as in Example 73- The polypeptide of any one of 83, (vii) the polypeptide of 103 or 104; and/or (viii) the polypeptide of any one of embodiments 107-113; and (2) Pharmaceutically acceptable carriers, excipients or diluents.

Embodiment 115. A composition comprising: (1) (i) A plurality of fusion proteins as in any one of embodiments 1-20, 24-55, 84-101 and 105-106, (ii) A plurality of polypeptide trimers as in embodiments 21 or 22, ( iii) a plurality of isolated RBD polypeptides as in embodiment 23, (iv) a plurality of polypeptides as in any one of embodiments 56-72, (v) a plurality of engineered variant RBDs as in embodiment 102, (vi) Polypeptides as in any one of embodiments 73-83, (vii) polypeptides as in 103 or 104; and/or (viii) polypeptides as in any one of embodiments 107-113; and (2) Pharmaceutically acceptable carriers, excipients or diluents.

Embodiment 116. The composition of embodiment 115, wherein multiple (i), multiple (ii), multiple (iii), multiple (iv), multiple (v), multiple (vi) and/or multiple (vii) are Same type or different type.

Embodiment 117. A composition comprising a substrate and disposed on the outer surface of the substrate: (i) a plurality of fusions as in any one of embodiments 1-20, 24-55, 84-101 and 105-106 Protein, (ii) a plurality of polypeptide trimers as in Example 21 or 22, (iii) a plurality of isolated RBD polypeptides as in Example 23, (iv) a plurality of polypeptides as in any one of Embodiments 56-72, ( v) engineered variant RBDs as in embodiment 102, (vi) polypeptides as in any one of embodiments 73-83, (vii) polypeptides as in 103 or 104; and/or (viii) as The polypeptides of any of embodiments 107-113.

Embodiment 118. The composition of Embodiment 117, wherein the plurality of fusion proteins, the plurality of polypeptide trimers, the plurality of isolated RBD polypeptides, the plurality of engineered variant RBDs and/or the plurality of polypeptides are homotypic or heterotypic.

Embodiment 119. A composition comprising a substrate and disposed on the outer surface of the substrate: (i) the fusion protein of any one of embodiments 1-20, 24-55, 84-101 and 105-106 , (ii) the polypeptide trimer of Example 21 or 22, (iii) the isolated RBD polypeptide of Example 23, (iv) the polypeptide of any one of Examples 56-72, (v) as implemented The engineered variant RBD of Example 102, (vi) the polypeptide of any one of Examples 73-83, (vii) the polypeptide of 103 or 104; and/or (viii) the polypeptide of any one of Examples 107-113 A polypeptide.

Embodiment 120. The composition of any one of embodiments 117-119, wherein the substrate includes nanoparticles or virus-like particles.

Embodiment 121. The composition of any one of embodiments 117-120, wherein the substrate further comprises a SpyCatcher polypeptide disposed on the outer surface of the substrate, wherein the fusion protein, polypeptide trimer or polypeptide comprises a SpyCatcher polypeptide coupled to SpyTag.

Embodiment 122. A mixed liquid containing a plurality of compositions as in any one of embodiments 114-121.

Embodiment 123. An isolated polynucleotide encoding: (i) a fusion protein as in any one of embodiments 1-20, 24-55, 84-101 and 105-106, (ii) as in embodiment 21 Or the polypeptide trimer of 22, (iii) the isolated RBD polypeptide of Example 23, (iv) the polypeptide of any one of Examples 56-72, (v) the engineered variation of Example 102 Body RBD, (vi) the polypeptide of any one of embodiments 73-83, (vii) the polypeptide of 103 or 104; and/or (viii) the polypeptide of any one of embodiments 107-113.

Embodiment 124. An isolated polynucleotide encoding the polypeptide of any one of embodiments 107-113.

Embodiment 125. The polynucleotide of embodiment 124, comprising ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA).

Embodiment 126. A vector comprising the polynucleotide of embodiment 124 or 125.

Embodiment 127. The carrier of embodiment 126, which is a living carrier.

Embodiment 128. A host cell comprising the polynucleotide of any one of embodiments 124-125 and/or the vector of embodiment 126 or 127.

Embodiment 129. A composition comprising: (i) The polynucleotide of Example 124 or 125; and/or (ii) The vector of Example 126 or 127; and/or (iii) The host cell of Example 128, and pharmaceutically acceptable carriers, excipients or diluents.

Example 1a. A fusion protein comprising a first coronavirus receptor binding domain (RBD) polypeptide linked to a second coronavirus RBD polypeptide, wherein optionally, the first RBD polypeptide and/or the second RBD polypeptide from a betacoronavirus, and wherein further optionally, the first RBD polypeptide and the second RBD polypeptide are from different betacoronaviruses.

Embodiment 2a. The fusion protein of embodiment 1a, which includes a first RBD polypeptide, a second RBD polypeptide and a third coronavirus (such as beta coronavirus) RBD polypeptide, and the first RBD polypeptide is connected to a second RBD polypeptide, and the second RBD polypeptide is connected to the third RBD polypeptide via linker (2).

Embodiment 3a. The fusion protein of embodiment 2a, wherein the linker (1) and the linker (2) comprise, essentially consist of, or consist of the same amino acid sequence.

Embodiment 4a. The fusion protein of Embodiment 2a, wherein the linker (1) and the linker (2) have different amino acid sequences from each other.

Embodiment 5a. The fusion protein of any one of embodiments 1a-4a, wherein the linker, linker (1) and/or linker (2) comprises a stem-helix polypeptide.

Embodiment 6a. The fusion protein of any one of embodiments 2a-5a, wherein linker (1) and linker (2) each comprise a stem-helix polypeptide.

Embodiment 7a. The fusion protein of any one of embodiments 1a-6a, comprising an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2β variant SARS-CoV-2 delta variant (also known as B.1.351); SARS-CoV-2 delta variant (also known as B.1.617.2); and SARS-CoV-2o variant (also known as B.1.1.529).

Embodiment 8a. The fusion protein of any one of embodiments 1a-7a, which comprises an RBD polypeptide comprising the amino acid sequence of any one of SEQ ID NOs.: 2 and 722-729.

Embodiment 9a. The fusion protein of any one of embodiments 1a-8a, which includes an RBD polypeptide consisting of the amino acid sequence of any one of SEQ ID NOs.: 2 and 722-729.

Embodiment 10a. The fusion protein of any one of embodiments 1a-9a, comprising an RBD polypeptide from any one or more of: PANG/GX; MP789; RaTG13; and RsSHC014.

Embodiment 11a. The fusion protein of any one of embodiments 1a-10a, which comprises an RBD polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.: 730-737.

Embodiment 12a. The fusion protein of any one of embodiments 1a-11a, comprising three RBD polypeptides, wherein the three RBD polypeptides are from: MP789; RaTG13; and RsSHC014.

Embodiment 13a. The fusion protein of any one of embodiments 1a-12a, comprising three RBD polypeptides, wherein the three RBD polypeptides respectively comprise the amino acid sequences set forth in the following: (i) SEQ ID NO .:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731.

Embodiment 14a. The fusion protein of any one of embodiments 1a-13a, comprising three RBD polypeptides, wherein the three RBD polypeptides are composed of the amino acid sequences set forth in: (i) SEQ ID NO .:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731.

Embodiment 15a. The fusion protein of any one of embodiments 5a-14a, wherein the stem-helix polypeptide comprises an amino acid according to any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 sequence or consisting of.

Embodiment 16a. The fusion protein of any one of embodiments 5a-15a, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.: 701).

Embodiment 17a. The fusion protein of any one of embodiments 2a-16a, further comprising a fourth coronavirus (e.g., betacoronavirus) RBD polypeptide and a fifth coronavirus (e.g., betacoronavirus) RBD polypeptide, wherein the fourth The RBD polypeptide is linked to the third RBD polypeptide via linker (3) and the fifth RBD polypeptide is linked to the fourth RBD polypeptide via linker (4).

Embodiment 18a. The fusion protein of Embodiment 17a, wherein two, three or all four of the linkers (1)-(4) comprise, essentially consist of, or consist of the same amino acid sequence.

Embodiment 19a. The fusion protein of Embodiment 17a or 18a, wherein two or more of the linkers (1)-(4) have amino acid sequences that are different from each other.

Embodiment 20a. The fusion protein of any one of embodiments 17a-19a, wherein one or more of the linkers (1)-(4) comprises or consists of a stem-helix polypeptide, wherein optionally, the stem - The helical polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 21a. The fusion protein of embodiment 20a, wherein each of the peptide linkers (1)-(4) comprises or consists of a stem-helix polypeptide, wherein optionally the stem-helix polypeptide comprises an amino acid Sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) or consisting of.

Embodiment 22a. The fusion protein of any one of embodiments 17a-21a, comprising an RBD polypeptide from: (i) a SARS-CoV-2β variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (ii) SARS-CoV-2 beta variant; SARS-CoV-2o variant; MP789; RaTG13; and RsSHC014; or (iii) SARS-CoV-2o variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (iv) SARS-CoV-2 delta variant; SARS-CoV-2o variant; MP789; RaTG13; and RsSHC014.

Embodiment 23a. The fusion protein of any one of embodiments 17a-22a, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequences set forth in the following SEQ ID NO.: (i) respectively, 725, 731, 733, 735 and 737; or (ii) respectively, 725, 731, 729, 735 and 737; or (iii) respectively, 729, 731, 733, 735 and 737; or (iv) ) respectively, 727, 731, 729, 735 and 737.

Embodiment 24a. The fusion protein of embodiment 23a, wherein: (1) the RBD polypeptide comprising SEQ ID NO.:725 comprises or consists of SEQ ID NO.:724; (2) the RBD polypeptide comprising SEQ ID NO.:727 RBD polypeptide comprising SEQ ID NO.:726 or consisting of it; (3) RBD polypeptide comprising SEQ ID NO.:729 comprising SEQ ID NO.:728 or consisting of it; (4) RBD polypeptide comprising SEQ ID NO.:731 An RBD polypeptide comprising or consisting of SEQ ID NO.:730; (5) an RBD polypeptide comprising SEQ ID NO.:733 comprising or consisting of SEQ ID NO.:732; (6) an RBD polypeptide comprising SEQ ID NO.:735 The RBD polypeptide comprises or consists of SEQ ID NO.:734; and/or (7) the RBD polypeptide comprising SEQ ID NO.:737 comprises or consists of SEQ ID NO.:736.

Embodiment 25a. The fusion protein of any one of embodiments 17a-24a, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequences set forth in the following SEQ ID NO.: (i) respectively, 724, 732, 734, 736 and 730; or (ii) respectively, 724, 728, 734, 736 and 730; or (iii) respectively, 728, 732, 734, 736 and 730; or (iv) ) respectively, 726, 728, 735, 736 and 730.

Embodiment 26a. The fusion protein of any one of embodiments 17a-25a, comprising: (i) an RBD polypeptide from a SARS-CoV-2β variant; an RBD from RsSHC014 along the N-terminal to C-terminal direction of the fusion protein polypeptide; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (ii) an RBD polypeptide from a SARS-CoV-2β variant; an RBD polypeptide from RsSHC014; and an RBD polypeptide from SARS-CoV- RBD polypeptides from 2o variants; RBD polypeptides from MP789; and RBD polypeptides from RatG13; or (iii) RBD polypeptides from SARS-CoV-2o variants; RBD polypeptides from RsSHC014; RBD polypeptides from PANG/GX; An RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (iv) an RBD polypeptide from a SARS-CoV-2 delta variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from a SARS-CoV-2o variant; or (iv) an RBD polypeptide from a SARS-CoV-2 delta variant; RBD polypeptides; and RBD polypeptides from RatG13.

Embodiment 27a. The fusion protein of any one of embodiments 17a-26a, which along the N-terminal to C-terminal direction of the fusion protein includes: (i) an RBD polypeptide comprising SEQ ID NO.:725; comprising SEQ ID NO. : the RBD polypeptide of SEQ ID NO.:731; comprising the RBD polypeptide of SEQ ID NO.:733; comprising the RBD polypeptide of SEQ ID NO.:735; and comprising the RBD polypeptide of SEQ ID NO.:737; or (ii) comprising SEQ ID NO.: The RBD polypeptide of 725; the RBD polypeptide comprising SEQ ID NO.:731; the RBD polypeptide comprising SEQ ID NO.:729; the RBD polypeptide comprising SEQ ID NO.:735; and the RBD polypeptide comprising SEQ ID NO.:737; or (iii) comprising the RBD polypeptide of SEQ ID NO.:729; comprising the RBD polypeptide of SEQ ID NO.:731; comprising the RBD polypeptide of SEQ ID NO.:733; comprising the RBD polypeptide of SEQ ID NO.:735; and comprising The RBD polypeptide of SEQ ID NO.:737; or (iv) comprising the RBD polypeptide of SEQ ID NO.:727; comprising the RBD polypeptide of SEQ ID NO.:731; comprising the RBD polypeptide of SEQ ID NO.:729; comprising SEQ ID The RBD polypeptide of NO.:735; and the RBD polypeptide comprising SEQ ID NO.:737.

Embodiment 28a. The fusion protein of any one of embodiments 17a-27a, which includes along the N-terminal to C-terminal direction of the fusion protein: (i) an RBD polypeptide comprising or consisting of SEQ ID NO.: 724; comprising An RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and comprising SEQ ID NO. :736 or an RBD polypeptide consisting of; or (ii) an RBD polypeptide comprising or consisting of SEQ ID NO.:724; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; comprising SEQ ID NO.: 728 or an RBD polypeptide consisting of; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iii) comprising SEQ ID NO.: 728 or an RBD polypeptide consisting of; an RBD polypeptide comprising or consisting of SEQ ID NO.:730; an RBD polypeptide comprising or consisting of SEQ ID NO.:732; comprising or consisting of SEQ ID NO.:734 an RBD polypeptide; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736; or (iv) an RBD polypeptide comprising or consisting of SEQ ID NO.:726; comprising or consisting of SEQ ID NO.:730 An RBD polypeptide comprising or consisting of SEQ ID NO.:728; an RBD polypeptide comprising or consisting of SEQ ID NO.:734; and an RBD polypeptide comprising or consisting of SEQ ID NO.:736.

Embodiment 29a. The fusion protein of any one of embodiments 26a-28a, comprising a third RBD polypeptide disposed between the first RBD polypeptide and the second RBD polypeptide, between the second RBD polypeptide and the third RBD polypeptide, and the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) between the fourth RBD polypeptide and the fourth RBD polypeptide and the fifth RBD polypeptide, wherein the first RBD polypeptide is the N-terminal RBD polypeptide of the fusion protein and the fifth The RBD polypeptide is the C-terminal RBD polypeptide of the fusion protein.

Embodiment 30a. The fusion protein of any one of embodiments 1a-29a, further comprising a peptide tag, wherein optionally, the peptide tag is placed at the C-terminus of the fusion protein, preferably fused to the C-terminus of the fusion protein. The C terminus of RBD polypeptide.

Embodiment 31a. The fusion protein of embodiment 30a, wherein the peptide tag is placed at the C-terminus of the fusion protein.

Embodiment 32a. The fusion protein of embodiment 30a or 31a, wherein the peptide tag includes SpyTag and/or His tag.

Embodiment 33a. The fusion protein of any one of embodiments 1a-32a, wherein the fusion protein does not comprise a peptide tag disposed at the C-terminal end of the fusion protein, optionally disposed at the C-terminal end of the C-terminal RBD polypeptide.

Embodiment 34a. The fusion protein of any one of embodiments 1a-33a, wherein the fusion protein does not comprise a His tag positioned at the C-terminus of the fusion protein.

Embodiment 35a. The fusion protein of any one of embodiments 1a-34a, which includes a signal peptide, wherein optionally, the signal peptide is placed at the N-terminus of the fusion protein, and is preferably fused to the N-terminus of the N-terminal RBD polypeptide. end.

Embodiment 36a. The fusion protein of Embodiment 35a, wherein the signal peptide includes or consists of the following: amino acid sequence MAPLLLLLPLLWAGALA (SEQ ID NO.:706), amino acid sequence MNTQILVFALIAIIIPTNADKI (SEQ ID NO.:705), The amino acid sequence MFVFLVLLPLVS (SEQ ID NO.:707) or the amino acid sequence MFVFLVLLPLVSS (SEQ ID NO.:708), and preferably consists of SEQ ID NO.:706.

Embodiment 37a. The fusion protein of any one of embodiments 1a-36a, which is administered to a mammal (e.g., a mouse, such as a female BALB/c mouse, optionally administered twice via intramuscular injection, in which second doses administered 20 or 21 days apart) elicit, optionally, neutralizing antibodies against any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 B.1.351; SARS-CoV-2 B.1.617.2; SARS-CoV-2 B.1.1.529; and SARS-CoV-1, optionally, from a mammal 14 days after the second immunization Collected sera were optionally used to evaluate neutralizing antibodies in a vesicular stomatitis virus/coronavirus pseudovirus system using Vero-E6 TMPRSS cells.

Embodiment 38a. The fusion protein of any one of embodiments 1a-37a, which elicits when administered to a mammal that has previously received an mRNA SARS-CoV-2 spike protein vaccine: (i) against any of the following or more, and optionally possesses neutralizing antibodies: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 BA1; SARS-CoV-2 BA2; SARS-CoV-2 BA5; and SARS- CoV-1, optionally to a degree that is greater than that elicited by the third administration of the mRNA SARS-CoV-2 spike protein vaccine, wherein optionally: the mammal is a mouse, such as a female BALB/c mouse Mice; the fusion protein is administered intramuscularly and/or once on day 60, and the mammal has received the mRNA spike protein vaccine on day 0 and again on day 14; and/or on day 67 Assessment of neutralizing antibodies in the vesicular stomatitis virus/coronavirus pseudovirus system using sera collected from mammals; and/or (ii) Antibodies that bind to RBD from any one or more of the following: SARS-Cov2-Wuhan-Hu-1 (Wu); -B.1.351 (β); SARS-Cov1; Wiv-1; RatG13; PangGD; PANG/GX; Anlog112; wherein optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered intramuscularly and/or once on day 60, and the mammal has received the mRNA spike protein vaccine on day 0 and Re-receive the vaccine on day 14; and/or assess binding antibodies by ELISA on day 67 using sera collected from the mammals.

Embodiment 39a. The fusion protein of any one of embodiments 1a-38a, which is capable of binding to any one or more of the following antibodies: S2P6; S2E12; S2K146; S2X259; S309; and S2H97 or antigen-binding fragments thereof, Optionally, the antigen-binding fragment includes a Fab having VH and VL of the antibody, and further includes IgG1 CH1 and IgG κ CL or IgG λ CL.

Embodiment 40a. An isolated polypeptide comprising: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.: 218 without SEQ ID NO.: 706; (iii) SEQ ID NO.: 712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:706 without SEQ ID NO.: 715; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) Without SEQ ID NO.:706 SEQ ID NO.:717; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix ) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Embodiment 41a. The polypeptide of Embodiment 40a, consisting of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.: 218 without SEQ ID NO.: 706; (iii) SEQ ID NO.: 218 ID NO.:712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:706 without SEQ ID NO.: 713; (vii) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) without SEQ ID NO.:706 SEQ ID NO.:715; (xi) SEQ ID NO.:716; (xii) None SEQ ID NO.:706, SEQ ID NO.:716; (xiii) SEQ ID NO.:717; (xiv) None SEQ ID NO.:717 of SEQ ID NO.:706; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO. .:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743.

Embodiment 42a. A fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) one or more peptide tags; (ii) one or more Stem-helix polypeptides, wherein optionally the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 43a. The fusion protein of embodiment 42a, comprising: (a) a peptide tag connected or fused to the first end of the RBD polypeptide, wherein the first end optionally includes the N-terminus of the RBD polypeptide; (b) connected or a peptide tag fused to the second end of an RBD polypeptide, wherein the second end optionally includes the C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked to or fused to the first end of an RBD polypeptide, wherein the first end optionally includes optionally comprising the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to the second end of the RBD polypeptide, wherein the first end optionally comprises the C-terminus of the RBD polypeptide; or (e) (a)-( d) any combination.

Embodiment 44a. The fusion protein of embodiment 42a or 43a, wherein the peptide tag comprises a His tag, wherein optionally, the His tag comprises or consists of the amino acid sequence HHHHHHHH (SEQ ID NO.: 704).

Embodiment 45a. The fusion protein of embodiment 44a, wherein the peptide tag comprises SpyTag.

Embodiment 46a. The fusion protein of any one of embodiments 42a-45a, comprising a linker disposed between and connecting a peptide tag of (1) an RBD polypeptide and (2) one or more peptide tags.

Embodiment 47a. The fusion protein of embodiment 46a, comprising two or more linkers comprising the same amino acid sequence as each other.

Embodiment 48a. The fusion protein of embodiment 46a or 47a, wherein the linker or one or more of the two or more linkers comprises or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.: 702) .

Embodiment 49a. The fusion protein of any one of embodiments 42a-48a, comprising disposed between and linking (1) an RBD polypeptide and (2) one of one or more stem-helix polypeptides connector.

Embodiment 50a. The fusion protein of any one of embodiments 42a-49a, comprising the structure PT1—L1—RBD—L2—SHP—PT2, Wherein: PT1 and PT2 are each optional peptide tags; L1 and L2 are each optional linkers; RBD is RBD polypeptide; and SHP is stem-helix polypeptide.

Embodiment 51a. The fusion protein of Embodiment 50a, wherein: PT1 has the amino acid sequence of SEQ ID NO.:700 when present; L1 has the amino acid sequence of SEQ ID NO.:702 when present; L2 does not is present or has the amino acid sequence GSG, GPP, GS or PGP; SHP has the amino acid sequence of SEQ ID NO.:701; and PT2, when present, has the amino acid sequence of SEQ ID NO.:704.

Embodiment 52a. The fusion protein of Embodiment 51a, wherein: (i) PT1, L1, SHP, L2 and PT2 are present; (ii) PT1, L1, SHP and PT2 are present; (iii) L2, SHP and PT2 are present; (iv) SHP and PT2 are present; (v) SHP and optionally L2 are present; or (vi) L2, SHP and PT2 are present.

Embodiment 53a. The fusion protein of any one of embodiments 42a-52a, comprising: (i) a signal peptide fused or connected to the N-terminus of the RBD polypeptide; and (ii) fused or connected to the C-terminus of the RBD polypeptide. of stem-helix polypeptides.

Embodiment 54a. The fusion protein of Embodiment 53a, comprising a signal peptide (optionally MAPLLLLLPLLWAGALA (SEQ ID NO.: 706)), an optional linker, an RBD, and an optional linker along the N-terminal to C-terminal direction. and a stem-helix polypeptide, wherein optionally the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Embodiment 55a. The fusion protein of any one of embodiments 42a-54a, wherein the RBD polypeptide is from any of the following: SARS-CoV-2-Wuhan-Hu-1; SARS-CoV-2β variant; SARS -CoV-2o variant; SARS-CoV-2δ variant; PANG_GX; MP789; RatG13; RsSCH014; RmYN02; BM48-31/BGR/2008; PC4-241; Rf1/2004; and Rp/Shaanxi 2011.

Embodiment 56a. The fusion protein of any one of embodiments 42a-55a, wherein the RBD polypeptide comprises or consists of the amino acid sequence of any one of SEQ ID NO.: 724-737.

Example 57a. An isolated polypeptide comprising the following structure: RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 RBD1, RBD2, RBD3, RBD4 and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2β variant; SARS-CoV-2o variant; SARS-CoV-2δ variant; PANG/GX ; MP789; RaTG13; and RsSHC014, wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, And L1, L2, L3 and L4 are each a linker.

Embodiment 58a. The isolated polypeptide of Embodiment 57a, wherein one or more of L1, L2, L3 and L4 comprise any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 or consisting of an amino acid sequence, and wherein optionally, L1, L2, L3 and L4 each independently comprise the amine group of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 acid sequence or consisting of.

Embodiment 59a. The isolated polypeptide of Embodiment 57a or 58a, wherein L1, L2, L3 and L4 are the same, and L1, L2, L3 and L4 are preferably SEQ ID NO.:701.

Embodiment 60a. The isolated polypeptide of any one of embodiments 57a-59a, wherein RBD1, RBD2, RBD3, RBD4 and RBD5 are independently selected from the group consisting of: (i) SEQ ID NO.: 724 or 725; (ii) SEQ ID NO.: 726 or 727; (iii) SEQ ID NO.: 728 or 729; (iv) SEQ ID NO.: 730 or 731; (v) SEQ ID NO.: 732 or 733; (vi) SEQ ID NO.: 734 or 735; and (vii) SEQ ID NO.: 736 or 737, preferably, five of (i)-(vii) are present.

Embodiment 61a. The isolated polypeptide of any one of embodiments 57a-60a, wherein RBD1, RBD2, RBD3, RBD4 and RBD5 are from: (i) respectively, SARS-CoV-2 beta variant; RsSHC014; PANG/GX ; MP789; and RaTG13; or (ii) respectively, SARS-CoV-2 beta variant; RsSHC014; SARS-CoV-2o variant; MP789; and RaTG13; or (iii) respectively, SARS-CoV-2o variant ; RsSHC014; PANG/GX; MP789; and RaTG13; or (iv) respectively, SARS-CoV-2 delta variant; RsSHC014; SARS-CoV-2o variant; MP789; RaTG13.

Embodiment 62a. The isolated polypeptide of any one of embodiments 57a-61a, wherein RBD1, RBD2, RBD3, RBD4 and RBD5 comprise the amino acid sequence set forth in the following SEQ ID NO.: (i) respectively, 725, 731, 733, 735 and 737; or (ii) respectively, 725, 731, 729, 735 and 737; or (iii) respectively, 729, 731, 733, 735 and 737; or (iv) respectively , 727, 731, 729, 735 and 737, wherein optionally, RBD1, RBD2, RBD3, RBD4 and RBD5 comprise or consist of the amino acid sequence set forth in the following SEQ ID NO.: (1) respectively, 724, 730, 732, 734 and 736; or (2) respectively, 724, 730, 728, 734 and 736; or (3) respectively, 728, 730, 732, 734 and 736; or (4) respectively , 726, 730, 728, 734 and 736.

Embodiment 63a. An isolated polypeptide comprising or consisting of the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59.

Embodiment 64a. An isolated polypeptide comprising or consisting of the following: the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.:14, the amino acid sequence of SEQ ID NO.:15 Amino acid sequence, the amino acid sequence of SEQ ID NO.:16 or the amino acid sequence of SEQ ID NO.:17.

Embodiment 65a. An isolated polynucleotide encoding the fusion protein of any one of embodiments 1a-39a and 42a-56a or the polypeptide of any one of embodiments 40a, 41a and 57a-64a.

Embodiment 66a. The polynucleotide of embodiment 65a, comprising ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA).

Embodiment 67a. The polynucleotide of embodiment 65a or 66a, comprising mRNA.

Embodiment 68a. A vector comprising the polynucleotide of any one of embodiments 65a-67a, wherein optionally the vector is a living vector.

Embodiment 69a. A host cell comprising the polynucleotide of any one of embodiments 65a-67a and/or the vector of embodiment 68a.

Embodiment 70a. A composition comprising: (i) the fusion protein of any one of embodiments 1a-39a and 42a-56a; and/or (ii) any one of embodiments 40a, 41a and 57a-64a The polypeptide of one of the following; and/or (i) the polynucleotide of any one of embodiments 65a-67a; and/or (ii) the carrier excipient of embodiment 68a; and/or (iii) as implemented The host cell of Example 69a, and a pharmaceutically acceptable carrier, excipient or diluent.

Embodiment 71a. The composition of Embodiment 70a, further comprising an adjuvant.

Embodiment 72a. A method of treating a coronavirus infection in an individual or inducing an immune response against the coronavirus infection, the method comprising administering to the individual an effective amount of: any one of embodiments 1a-39a and 42a-56a The fusion protein; the polypeptide of any one of Examples 40a, 41a and 57a-64a; the polynucleotide of any one of Examples 65a-67a; the vector of Example 68a; the host cell of Example 69a ; Or the composition of embodiment 70a or 71a, wherein optionally, the coronavirus infection includes Sabey coronavirus infection.

Embodiment 73a. The fusion protein of any one of Examples 1a-39a and 42a-56a; the polypeptide of any one of Examples 40a, 41a and 57a-64a; the polypeptide of any one of Examples 65a-67a A polynucleotide; a vector as in Embodiment 68a; a host cell as in Embodiment 69a; or a composition as in Embodiment 70a or 71a, which is used to treat a coronavirus infection in an individual or induce an immune response against the coronavirus infection, Optionally, the coronavirus infection includes Sabey coronavirus infection.

Embodiment 74a. The fusion protein of any one of Examples 1a-39a and 42a-56a; the polypeptide of any one of Examples 40a, 41a and 57a-64a; the polypeptide of any one of Examples 65a-67a A polynucleotide; a vector as in Example 68a; a host cell as in Example 69a; or a composition as in Example 70a or 71a, for use in manufacturing a coronavirus infection in an individual or inducing immunity against the coronavirus infection The agent for reacting, wherein optionally, the coronavirus infection includes a Sabey coronavirus infection.

Embodiment 75a. The method of embodiment 72a, or the fusion protein, polypeptide, polynucleotide, vector, host cell or composition of embodiment 73a or 74a, wherein: (i) the treatment includes pre-exposure prophylaxis; (ii) Treatment includes post-exposure prophylaxis; (iii) the individual has previously received one or more, two or more, three or more, four or more or five or more doses of one of the coronavirus A viral vaccine composition, wherein optionally: (1) the individual has received two or more different coronavirus vaccine compositions; (2) the coronavirus vaccine composition includes: a portion of the SARS-CoV-2 spike protein A polynucleotide (eg, mRNA) encoding at least a portion of the SARS-CoV-2 spike protein (e.g., an RBD polypeptide or a holo-spike protein), or a live, attenuated or Inactivated (e.g., heat inactivated or inactivated with beta-propiolactone) virus; and/or (3) the coronavirus vaccine composition includes Comirnaty (Pfizer-BioNTech), Spikevax (Moderna), Janssen Coronavirus Vaccine (Johnson & Johnson), Nuvoxovid/Covavax (Novavax), Vaxzevria (Oxford-AstraZeneca), Coronavac, also known as BBIBP-CorV, also known as BBIBP (Sinovac), Covaxin, also known as BBV152 (Bharat Biotech), Convidecia, also known as For AD5-nCOV (CanSino Biologics), Sputnik V, also known as Gam-COVID-Vac, Sinopharm WIBP, also known as WIBP-CorV (Sinovac), Abdala, Soberana 2, Soberana Plus, ZF2001, also known as Anhui Zhifei Longcom ZifiVax ZF2001, also known as ZF-UZ-VAC-2001, also known as Zifivax (Anhui Zhifei Longcom Biopharmaceutical), Corbevax (Texas Children's Hospital/Baylor College of Medicine/Dynavax), COVIran Barekat (Sifa Pharmed Industrial Group), VAT00002, or VAT00008 (Sanofi-GSK), SCB-2019 (Clover Biopharmaceuticals), VLA2001 (Valneva), HIPRA SARS-CoV-2, also known as PHH-1V (HIPRA), mRNA-1273.214 (Moderna), and Sputnik V bivalent (L452R; cover Maraya National Research Center for Epidemiology and Microbiology) or any combination thereof; (iv) the fusion protein, polypeptide, polynucleotide, vector, host cell or composition is administered once every twelve months or every six months Administer once a month; (v) the coronavirus infection is or includes SARS-CoV-2 infection.

Embodiment 76a. A method comprising introducing into a host cell a polynucleotide as in any one of embodiments 65a-67a or a vector as in embodiment 68a, and optionally in a state sufficient to express an encoded fusion protein or polypeptide or The host cell is cultured for a period of time and under conditions that produce a polynucleotide (eg, mRNA), and the fusion protein, polypeptide, or produced polynucleotide is further optionally isolated. Table 1a. Sequence sequence description SEQ ID NO. sequence Surface glycoprotein [SARS-CoV-2 Wuhan seafood market pneumonia virus]: GenBank: QHD43416.1; January 23, 2020 1 mfvflvllpl vssqcvnltt rtqlppaytn sftrgvyypd kvfrssvlhs tqdlflpffs 61 nvtwfhaihv sgtngtkrfd npvlpfndgv yfasteksni irgwifgttl dsktqslliv 121 nnatnvvikv cefqfcndpf lgvyyhkn nk swmesefrvy ssannctfey vsqpflmdle181 gkqgnfknlr efvfknidgy fkiyskhtpi nlvrdlpqgf saleplvdlp iginitrfqt 241 llalhrsylt pgdsssgwta gaaayyvgyl qprtfllkyn engtitdavd caldplsetk 301 ctlksftvek giy qtsnfrv qptesivrfp nitnlcpfge vfnatrfasv yawnrkrisn 361 cvadysvlyn sasfstfkcy gvsptklndl cftnvyadsf virgdevrqi apgqtgkiad 421 ynyklpddft gcviawnsnn ldskvggnyn ylyrlfrksn lkpferdist eiyqagstpc 481 ngvegfncyf plqsygfqpt ngvgyqpyrv vvlsfellha patvcgpkks tnlvknkcvn 541 fnfngltgtg vltesnkkfl pfqqfgrdia dttdavrdpq tleilditpc sfggvsvitp 601 gtntsnqvav lyqdvnctev pvaihadqlt ptwrvystgs nvfqtragcl igaehvnnsy 661 ecdipigagi casyqtqtns prrarsvasq siiaytmslg aensvaysnn siaiptnfti 721 svtteilpvs mtktsvdctm yicgdstecs nllllqygsfc tqlnraltgi aveqdkntqe 781 vfaqvkqiyk tppikdfggf nfsqilpdps kpskrsfied llfnkvtlad agfikqygdc 841 lgdiaardli caqkfngltv lpplltdemi aqytsallag titsgwtfga gaalqipfam 901 qmayrfngig vtqnvlyenq klianqfnsa igkiqdslss tasalgklqd vvnqnaqaln 961 tlvkqlssnf gaissvlndi lsrldkveae vqidrlitgr lqslqtyvtq qliraaeira 1021 sanlaatkms ecvlgqskrv dfcgkgyhlm sfpqsaphgv vflhvtyvpa qeknfttapa 1081 ichdgkahfp regvfvsngt hwfvtqrnfy epqiittdnt fvsgncdvvi givnntvydp 1141 lqpeldsfke eldkyfknht spdvdlgdis ginasvvniq keidrlneva knlneslidl 1201 qelgkyeqyi kwpwyiwlgf iagliaivmv timlccmtsc csclkgccsc gscckfdedd 1261 sepvlkgvkl hyt Surface glycoprotein RBD [SARS-CoV-2 Wuhan seafood market pneumonia virus]; GenBank: QHD43416.1; January 23, 2020 2 nitnlcpfgevfnatrfasvyawnrkrisncvadysvlynsasfstfkcygvsptklndlcftnvyadsfvirgdevrqiapgqtgkiadynyklpddftgcviawnsnnldskvggnynylyrlfrksnlkpferdisteiyqagstpcngvegfncyfplqsygfqptngvgyqpyrvvvlsfellhapatvcg pkkstnlvknkcvnfnfngltgtg S2 subunit fragment surface glycoprotein [SARS-CoV-2 Wuhan seafood market pneumonia virus]: GenBank: QHD43416.1; January 23, 2020 3 atkmsecvlgqskrvdfcgkgyhlmsfpqsaphgvvflhvtyvpaqeknfttapaichdgkahfpregvfvsngthwfvtqrnfyepqiittdntfvsgncdvvigivnntvydplqpelds f ke eld ky f knhtspdvdlgdisginasvvniqkeidrlnevaknlneslidlqelgky eqyikwpwyiwlgfiagliaivmvtimlccmtsccsclkgccscgscckfdeddsepvlkgvklhyt Polypeptides containing betacoronavirus stem amino acid motifs 4 _{X 1} X ₂ FX ₃ X _{4 ELDX 5} X ₂ is any amino acid, and is preferably not A, V, L, I, F, Y, W, N, K, R, H, E, C or P, and is preferably S; X ₃ is K, D, R or S, and preferably K; X ₄ is E, D, Q, N, S or M, and preferably E; X ₅ is any amino acid except P, and preferably Best is K; and X ₆ is Y or F polypeptide 5 DSFKEELDKYFKNH polypeptide 6 FKEELDKYF polypeptide 7 FKEELDKYFKNH polypeptide 8 FKEELD polypeptide 9 ELDKYF polypeptide 10 DSFKEELD polypeptide 11 ELDKYFKNH polypeptide 12 KEELDKY polypeptide 13 ivnntvydplqpeldsfkeeldkyfknhtspdvdlgdisgin polypeptide 14 Dsfkeeldkyfknhts polypeptide 15 DAASKAGPG polypeptide 16 SFKEELDKYFKNHTSDAASKAGPG polypeptide 17 DSFKEELDKYFKNHTSDAASKAGPG polypeptide 18 (SFKEELDKYFKNHTSDAASKAGPG)x, where X ≥ 1 polypeptide 19 (DSFKEELDKYFKNHTSDAASKAGPG)x, where x ≥ 1 Connector(aa) 20 KESSGSVSSEQLAQFRSLD Connector(aa) twenty one GGGGS SARS-CoV; Urbani strain; surface glycoprotein; GenBank: AAP13441.1 twenty two MFIFLLFLTL TSGSDLDRCT TFDDVQAPNY TQHTSSMRGV YYPDEIFRSD TLYLTQDLFL PFYSNVTGFH TINHTFGNPV IPFKDGIYFA ATEKSNVVRG WVFGSTMNNK SQSVIIINNS TNVVIRACNF ELCDNPFFAV SKPMGTQTHT MIFDNAFNCT FEYISDAFSL DVSEKSGNFK HLREFVFKNK DGFLYVY KGY QPIDVVRDLP SGFNTLKPIF KLPLGINITN FRAILTAFSP AQDIWGTSAA AYFVGYLKPT TFMLKYDENG TITDAVDCSQ NPLAELKCSV KSFEIDKGIY QTSNFRVVPS GDVVRFPNIT NLCPFGEVFN ATKFPSVYAW ERKKISNCVA DYSVLYNSTF FSTFKCYGVS ATKLNDLCFS NVYADSF VVK GDDVRQIAPG QTGVIADYNY KLPDDFMGCV LAWNTRNIDA TSTGNYNYKY RYLRHGKLRP FERDISNVPF SPDGKPCTPP ALNCYWPLND YGFYTTTGIG YQPYRVVVLS FELLNAPATV CGPKLSTDLI KNQCVNFNFN GLTGTGVLTP SSKRFQPFQQ FGRDVSDFTD SVRDPKTSEI LDISPCSFGG VSVITPGTNA SSEVAVLYQD VNCTDVSTAI HADQLTPAWR IYSTGNNVFQ TQAGCLIGAE HVDTSYECDI PIGAGICASY HTVSLLRSTS QKSIVAYTMS LGADSSIAYS NNTIAIPTNF SISIT TEMP IANQFN KAISQIQESL TTTSTALGKL QDVVNQNAQA LNTLVKQLSS NFGAISSVLN DILSRLDKVE AEVQIDRLIT GRLQSLQTYV TQQLIRAAEI RASANLAATK MSECVLGQSK RVDFCGKGYH LMSFPQAAPH GVVFLHVTYV PSQERNFTTA PAICHEGKAY FPREGVFVFN GTSWFITQRN FFSPQIITTD NTFVSGNCDV VIGIINNTVY DPLQPELDSF KEELDKYFKN HTSPDVDLGD ISGINASVVN IQKEIDRLNE VAKNLNESLI DLQELGKYEQ YIKWPWY VWL GFIAGLIAIV MVTILLCCMT SCCSCLKGAC SCGSCCKFDE DDSEPVLKGV KLHYT OC43 indicates glycoprotein; GenBank: AAT84362.1 twenty three MFLILLISLPTAFAVIGDLKCTSDNINDKDTGPPPISTDTVDVTNGLGTYYVLDRVYLNTTLFLNGYYPTSGSTYRNMALKGSVLLSRLWFKPPFLSDFINGIFAKVKNTKVIKDRVMYSEFPAITIGSTFVNTSYSVVVQPRTINSTQDGDNKLQGLLEVSVCQYNMCEYPQTICHPNLGNHRKELWHLDTGVVSCLYKRNFTYDV NADYLYFHFYQEGGTFYAYFTDTGVVTKFLFNVYLGMALSHYYVMPLTCNSKLTLEYWVTPLTSRQYLLAFNQDGIIFNAVDCMSDFMSEIKCKTQSIAPPTGVYELNGYTVQPIADVYRRKPNLPNCNIEAWLNDKSVPSPLNWERKTFSNCNFNMSSLMSFIQADSFTCNNIDAAKIYGMCFSSITIDKFAIPNGRKVDLQ LGNLGYLQSFNYRIDTTATSCQLYYNLPAANVSVSRFNPSTWNKRFGFIEDSVFKPRPAGVLTNHDVVYAQHCFKAPKNFCPCKLNGSCVGSGPGKNNGIGTCPAGTNYLTCDNLCTPDPITFTGTYKCPQTKSLVGIGEHCSGLAVKSDYCGGNSCTCRPQAFLGWSADSCLQGDKCNIFANFILHDVNSGLTCSTDLQKANTDIILGVCVNYDLY GILGQGIFVEVNATYYNSWQNLLYDSNGNLYGFRDYITNRTFMIRSCYSGRVSAAFHANSSEPALLFRNIKCNYVFNNSLTRQLQPINYFDSYLGCVVNAYNSTAISVQTCDLTVGSGYCVDYSKNRRSRGAITTGYRFTNFEPFTVNSVNDSLEPVGGLYEIQIPSEFTIGNMVEFIQTSSPKVTIDCAAFVCGDYAACKSQLVEYGSFCDNILTEVN ELLDTTQLQVANSLMNGVTLSTKLKDGVNFNVDDINFSPVLGCLGSECSKASSRSAIEDLLFDKVKLSDVGFVEAYNNCTGGAEIRDLICVQSYKGIKVLPPLLSENQFSGYTLAATSASLFPPWTAAAGVPFYLNVQYRINGLGVTMDVLSQNQKLIANAFNNALYAIQEGFDATNSALVKIQAVVNANAEALNNLLQQLSNRFGAISASLQ EILSRLDALEAEAQIDRLINGRLTALNAYVSQQLSDSTLVKFSAAQAMEKVNECVKSQSSRINFCGNGNHIISLVQNAPYGLYFIHFSYVPTKYVTARVSPGLCIAGDRGIAPKSGYFVNVNNTWMYTGSGYYYPEPITENNVVVMSTCAVNYTKAPYVMLNTSIPNLPDFKEELDQWFKNQTSVAPDLSLDYINVTFLDLQVEMNRLQEAIKVL NQSYINLKDIGTYEYYVKWPWYVWLLICLAGVAMLVLLFFICCCTGCGTSCFKKCGGCCDDYTGYQELVIKTSHDD MERS-CoV; London 1/2012 strain indicated glycoprotein; GenBank: KC164505 twenty four TGCGTNCMGKLKCNRCCDRYEEYDLEPHKVHVH HKU1 indicates glycoprotein; GenBank: YP173238.1 25 MLLIIFILPTTLAVIGDFNCTNFAINDLNTTVPRISEYVVDVSYGLGTYYILDRVYLNTTILFTGYFPKSGANFRDLSLKGTTYLSTLWYQKPFLSDFNNGIFSRVKNTKLYVNKTLYSEFSTIVIGSVFINNSYTIVVQPHNGVLEITACQYTMCEYPHTICKSKGSSRNESWHFDKSEPLCLFKKNFTYNVSTDWLYFHFYQERGTFYAY YADSGMPTTFLFSLYLGTLLSHYYVLPLTCNAISSNTDNETLQYWVTPLSKRQYLLKFDNRGVITNAVDCSSSFFSEIQCKTKSLLPNTGVYDLSGFTVKPVATVHRRIPDLPDCDIDKWLNNFNVPSPLNWERKIFSNCNFNLSTLLRLVHTDSFSCNNFDESKIYGSCFKSIVLDKFAIPNSRRSDLQLGSSGFLQSSNYKIDTTSSSCQLY YSLPAINVTINNYNPSSWNRRYGFNNFNLSSHSVVYSRYCFSVNNTFCPCAKPSFASSCKSHKPPSASCPIGTNYRSCESTTVLDHTDWCRCSCLPDPITAYDPRSCSQKKSLVGVGEHCAGFGVDEEKCGVLDGSYNVSCLCSTDAFLGWSYDTCVSNNRCNIFSNFILNGINSGTTCSNDLLQPNTEVFTDVCVDYDLYGITGQGIFKEVSAVYYNSWQNL LYDSNGNIIGFKDFVTNKTYNIFPCYAGRVSAAFHQNASSLALLYRNLKCSYVLNNISLTTQPYFDSYLGCVFNADNLTDYSVSSCALRMGSGFCVDYNSPSSSSSRRKRRSISASYRFVTFEPFNVSFVNDSIESVGGLYEIKIPTNFTIVGQEEFIQTNSPKVTIDCSLFVCSNYAACHDLLSEYGTFCDNINSILDEVNGLLDTTQLHVADTLMQGVTLSSNLNT NLHFDVDNINFKSLVGCLGPHCGSSSSRSFFEDLLFDKVKLSDVGFVEAYNNCTGGSEIRDLLCVQSFNGIKVLPPILSESQISGYTTAATVAAMFPPWSAAAGIPFSLNVQYRINGLGVTMDVLNKNQKLIATAFNNALLSIQNGFSATNSALAKIQSVVNSNAQALNSLLQQLFNKFGAISSSLQEILSRLDALEAQVQIDRLTALNAYVSQ Question WLLISFSFIIFLVLLFFICCCTGCGSACFSKCHNCCDEYGGHHDFVIKTSHDD S2P6 VH (aa) 26 EVQLVQSGAEVKKPGASVKVSCKAS GYTFTSQY MHWVRQAPGQGLEWIGI INPSGVHT SYAQKFQGRVTLTRDTSTLYMELSSLRSEDTAVYYC ARGSPKGAFDY WGQGTLVTVSS S2P6 CDRH1 (aa) 27 GYTFTSQY S2P6 CDRH2 (aa) 28 INPSGVHT S2P6 CDRH3 (aa) 29 ARGSPKGAFDY S2P6 VL(VK) (aa) 30 EIVMMQSPGTLSLSPGERATLSCRAS QSVRSNY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPPRFT FGPGTKVEIK S2P6 CDRL1 (aa) 31 QSVRSNY S2P6 CDRL2 (aa) 32 GAS S2P6 CDRL3 (aa) 33 QQYGSSPPRFT S2P6 VH (nt) 34 GAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACCAGCCAATATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATAGGAATAATCAACCCTAGTGGTGTTCACACAAGTTACGCACAGAAATTCCAGGGCAGAGTCACCCTGACCAGGGACACGTCCACGAGCACACTATACATGGAACTGAGCAGCCTGAG ATCTGAAGACACGGGCCGTGTATTACTGTGCGAGAGGGTCTCCCAAAGGGGCCTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCAG S2P6 VL(VK) (nt) 35 GAAATAGTGATGATGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGAAGCAACTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGACTCCTCATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGT ATTACTGTCAGCAGTATGGTAGTTCACCCCCCAGATTCACTTTCGGCCCTGGGACCAAAGTGGAAATCAAAC S2S8 VH (aa) 36 EVQLVESGGGVVQPGRSLRLSCAAS GFTFSDYG MHWVRQAPGKGLEWVAV ISFEGRNE YFADSVKGRFAISRDNSKNTVSLHMNSLRVEDTAVYYC ARDAGYDLIRFFLDS WGQGTRVTVSS S2S8 CDRH1 (aa) 37 GFTFSDYG S2S8 CDRH2 (aa) 38 ISFEGRNE S2S8 CDRH3 (aa) 39 ARDAGYDLIRFFLDS S2S8 VL(VK) (aa) 40 EIVLTQSPGTLSLSPGERATLSCRAS QRIGSTS LAWYQQKPGQAPRLLIY AAS TRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYHSSPLLT FGGGTKVDIK S2S8 CDRL1 (aa) 41 QRIGSTS S2S8 CDRL2 (aa) 42 AAS S2S8 CDRL3 (aa) 43 QQYHSSPLLT S2S8 VH (nt) 44 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGACTACGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATCATTTGAAGGAAGAAATGAATATTTTGCAGACTCCGTGAAGGGCCGATTCGCCATCTCCAGAGACAATTCCAAGAACACGGTGTCTCTGCACATGAACAGCCTGA GAGTTGAGGATACGGCTGTGTATTACTGTGCGAGAGATGCTGGCTACGATTTGATCCGGTTCTTCCTTGACTCCTGGGGCCAGGGAACGCGGGTCACCGTCTCCTCAG S2S8 VL(VK) (nt) 45 GAAATTGTGTTGACACAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGAATTGGCAGCACCTCCTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGCTGCATCCACCAGGGCCACTGGCATCCCAGACAGATTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTCATTATT ACTGTCAGCAGTATCATTCTTCACCCCTGCTCACTTTCGGCGGAGGGACCAAGGTGGATATCAAAC Beta coronavirus partial S protein sequence (aa) 46 _{FX 1 X 2 ELX 3} X ₄ X _{5 FKNX 6} X _{7 X 8 X 9} X ₁₀ X ₁₁ ; X ₃ is D or S; X ₄ is K, Q _, H, or E; X ₅ is Y, W, or F; _{X 6 is} H, Q, or V; S, L, or T; X ₉ is P, V, L, or S; X ₁₀ is D _, A, P, or I; _{X 11 is} V or P; F; and X ₁₄ is G, S, or T S2S43 VH (aa) 47 QVQLVQSGAEVKKPGASVKVSCKAS GYTFTNYY MHWVRQAPGQGLEWMGI INRSGGST IYAQRFQGRVTMTRDTSTSIVYMELSSLRSDDTAVYYC ARGGSHGMDV WGQGTTVTVSS S2S43 CDRH1 (aa) 48 GYTFTNYY S2S43 CDRH2 (aa) 49 INRSGGST S2S43 CDRH3 (aa) 50 ARGGSHGMDV S2S43 VL (aa) 51 QSVLTQPPSVSAAPGQKVTISCSGS TSNIGNNY VSWYQQLPGTAPRLLIF ENN KRPSGIPDRISGSKSGTSATLGITGLQTGDEADYYC GTWDSSLSACV FGTGTKVTVL S2S43 CDRL1 (aa) 52 TSNIGNNY S2S43 CDRL2 (aa) 53 ENN S2S43 CDRL3 (aa) 54 GTWDSSSLSACV S2S43 VH (nt) 55 CAGGTCCAGCTTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTATCCTGCAAGGCATCT GGATACACCTTCACCAATTATTAT ATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAATA ATCAACCGTAGTGGTGGTAGCACA ATCTACGCACAGAGGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCATAGTCTACATGGAGCTGAGCAGCCTG AGATCTGACGACACGGGCCGTGTATTACTGT GCGAGAGGTGGATCCCACGGTATGGACGTC TGGGGCCAAGGGACCACGGTCACCGTCTCCTCA S2S43 VL (nt) 56 CAGTCTGTGCTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGAAGC ACCTCCAACATTGGGAATAATTAT GTATCCTGGTACCAGCAGCTCCCAGGAACAGCCCCCAGACTCCTCATCTTT GAAAATAAT AAGCGACCCTCAGGGATTCCTGACCGTATCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCACCGGACTCCAGACTGGGGACGAGGCCGATTATT ACTGC GGAACATGGGATAGCAGCCTGAGTGCCTGTGTC TTCGGAACTGGGACCAAGGTCACCGTCCTAG SARS-CoV-2 S protein and SARS-CoV S protein peptide 57 F K EELD K YF MERS-CoV S protein peptide 58 GID F Q DELD E FF K HCoV-OC43 S protein peptide 59 DF KEELD Q WF K SARS-CoV-2 S protein and SARS-CoV S protein peptide 60 K RSFIEDLLF N MERS-CoV S protein peptide 61 A RSAIEDLLF D HCoV-OC43 S protein peptide 62 S RSAIEDLLF D HCoV-HKU1 S protein peptide 63 RSFFEDLLF HCoV-NL63 S protein peptide 64 RSALEDLLF SK HCoV-229E S protein peptide 65 G RSAIEDILF S S2P6 UCA VH (aa) 66 QVQLVQSGAEVKKPGASVKVSCKAS GYTFTSYY MHWVRQAPGQGLEWMGI INPSGGST SYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC ARGSPKGAFDY WGQGTLVTVSS S2P6 UCA CDRH1 (aa) 67 GYTFTSYY S2P6 UCA CDRH2 (aa) 68 INPSGGST S2P6 UCA VL(VK) (aa) 69 EIVLTQSPGTLSLSPGERATLSCRAS QSVSSSY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPPRFT FGPGTKVDIK S2P6 UCA CDRL1 (aa) 70 QSVSSSY S2P6 Q32Y VH (aa) 71 EVQLVQSGAEVKKPGASVKVSCKAS GYTFTSYY MHWVRQAPGQGLEWIGI INPSGVHT SYAQKFQGRVTLTRDTSTLYMELSSLRSEDTAVYYC ARGSPKGAFDY WGQGTLVTVSS S2P6 V56G H57S VH (aa) 72 EVQLVQSGAEVKKPGASVKVSCKAS GYTFTSQY MHWVRQAPGQGLEWIGI INPSGGST SYAQKFQGRVTLTRDTSTLYMELSSLRSEDTAVYYC ARGSPKGAFDY WGQGTLVTVSS S2P6 G103V (aa) 73 EVQLVQSGAEVKKPGASVKVSCKAS GYTFTSQY MHWVRQAPGQGLEWIGI INPSGVHT SYAQKFQGRVTLTRDTSTLYMELSSLRSEDTAVYYC ARGSPKVAFDY WGQGTLVTVSS S2P6 G103V CDRH3 (aa) 74 ARGSPKVAFDY S2P6 UCA VL(VK) (aa) 75 EIVLTQSPGTLSLSPGERATLSCRAS QSVSSSY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPPRFT FGPGTKVDIK S2P6 UCA CDRL1 (aa) 76 QSVSSSY S2P6 R30S VL(VK) (aa) 77 EIVMMQSPGTLSLSPGERATLSCRAS QSVSSNY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPPRFT FGPGTKVEIK S2P6 R30S CDRL1 (aa) 78 QSVSSNY S2P6 N32S VL(VK) (aa) 79 EIVMMQSPGTLSLSPGERATLSCRAS QSVRSSY LAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQYGSSPPRFT FGPGTKVEIK S2P6 N32S CDRL1 (aa) 80 QSVRSSY S2S43 UCA VH (aa) 81 QVQLVQSGAEVKKPGASVKVSCKAS GYTFTSYY MHWVRQAPGQGLEWMGI INPSGGST SYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYC ARGGSHGMDV WGQGTTVTVSS S2S43 UCA CDRH1 (aa) 82 GYTFTSYY S2S43 UCA CDRH2 (aa) 83 INPSGGST S2S43 UCA VL (aa) 84 QSVLTQPPSVSAAPGQKVTISCSGS SSNIGNNY VSWYQQLPGTAPKLLIY ENN KRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYC GTWDSSLSACV FGTGTKVTVL S2S43 UCA CDRL1 (aa) 85 SSNIGNNY βcoronavirus stem-helical peptide motif 86 _{X 1 X 2} FX ₃ X ₄ ELDX ₅ YF, wherein is any amino acid, and is preferably not A, V, L, I, F, Y, W, N, K, R, H, E, C or P, and is preferably S; X ₃ is K, D, R or S, and preferably K; X ₄ is E, D, Q, N, S or M, and preferably E; and X ₅ is any amino acid except P, and preferably for K SARS-CoV-2 S309-v2 mAb VH (aa) 87 QVQLVQSGAEVKKPGASVKVSCKAS GYPFTSYG ISWVRQAPGQGLEWMGW ISTYNGNT NYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYC ARDYTRGAWFGESLIGGFDN WGQGTLVTVSS SARS-CoV-2 S309-v2 mAb CDRH1 (aa) 88 GYPFTSYG SARS-CoV-2 S309-v2 mAb CDRH2 (aa) 89 ISTYNGNT SARS-CoV-2 S309-v2 mAb CDRH3 (aa) 90 ARDYTRGAWFGESLIGGFDN SARS-CoV-2 S309-v2 mAb VL (aa) 91 EIVLTQSPGTLSLSPGERATLSCRAS QTVSSTS LAWYQQKPGQAPRLLIY GAS SRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYC QQHDTSLT FGGGTKVEIK SARS-CoV-2 S309-v2 mAb CDRL1 (aa) 92 QTVSSTS SARS-CoV-2 S309-v2 mAb CDRL2 (aa) 93 GAS SARS-CoV-2 S309-v2 mAb CDRL3 (aa) 94 QQHDTSLT SARS-CoV-2 S309-v1.1 mAb (solletvirumab) VH (aa) 95 QVQLVQSGAEVKKPGASVKVSCKAS GYPFTSYG ISWVRQAPGQGLEWMGW ISTYQGNT NYAQKFQGRVTMTTDTSTTTGYMELRRLRSDDTAVYYC ARDYTRGAWFGESLIGGFDN WGQGTLVTVSS SARS-CoV-2 S309-v1.1 mAb (solletvirumab) CDRH2 (aa) 96 ISTYQGNT Connector(aa) 97 GSTSGSGKPGSGEGSTKG Connector(aa) 98 GSGKPGSGEG Connector(aa) 99 GKPGSGEG Connector(aa) 100 SGKPGSGE Connector(aa) 101 BPXXXZ, where each X is independently glycine (G) or serine (S), B is a positively charged amino acid and Z is glycine (G) or a negatively charged amino acid Connector(aa) 102 (GxS)y, where x is 1-10 and y is 1-10 Connector(aa) 103 GGGGSGGGGSGGGGS Connector(aa) 104 GGGGSGGGGSGGGGSGGGGSGGGGS GGGGSGGGGSGGGGSGGGGSGGGGS Connector(aa) 105 GSTSGGGGSGGGSGGGGSS Connector(aa) 106 EGKSSGSGSESKVD Table 1b. Other sequences ＞Cov0001 (SEQ ID NO.:107)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHH ＞Cov0002 (SEQ ID NO.:108)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTGSGHHHHHHHH ＞Cov0003 (SEQ ID NO.:109)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQ STGSGHHHHHHH ＞Cov0004 (SEQ ID NO.:110)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGS GHHHHHHHH ＞Cov0005 (SEQ ID NO.:111)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCG PKLSTGSGHHHHHHHH ＞Cov0006 (SEQ ID NO.:112)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGSGHHHHHHH ＞Cov0007 (SEQ ID NO.:113)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK QSTGSGHHHHHHH ＞Cov0008 (SEQ ID NO.:114)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STGSGHHHHHHH ＞Cov0009 (SEQ ID NO.:115)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLS TGSGHHHHHHHH ＞Cov0010 (SEQ ID NO.:116)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGSGHHHHHHHH ＞Cov0011 (SEQ ID NO.:117)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0012 (SEQ ID NO.:118)MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0013 (SEQ ID NO.:119)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0014 (SEQ ID NO.:120)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0015 (SEQ ID NO.:121)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATTVCGPKLSTGSGHHHHHHHH ＞Cov0016 (SEQ ID NO.:122)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0017 (SEQ ID NO.:123)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0018 (SEQ ID NO.:124)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQ STGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0019 (SEQ ID NO.:125)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGS GHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0020 (SEQ ID NO.:126)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCG PKLSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0021 (SEQ ID NO.:127)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0022 (SEQ ID NO.:128)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK QSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0023 (SEQ ID NO.:129)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0024 (SEQ ID NO.:130)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLS TGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0025 (SEQ ID NO.:131)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0026 (SEQ ID NO.:132)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHGSGGSGGSGG TGAHIVMVDAYKPTK ＞Cov0027 (SEQ ID NO.:133)MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHGSGGSGGSGGTG AHIVMVDAYKPTK ＞Cov0028 (SEQ ID NO.:134)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHHGSGGSG GSGGTGAHIVMVDAYKPTK ＞Cov0029 (SEQ ID NO.:135)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHHGSGGSG GSGGTGAHIVMVDAYKPTK ＞Cov0030 (SEQ ID NO.:136)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATTVCGPKLSTGSGHHHHHHGSGGSG GSGGTGAHIVMVDAYKPTK ＞Cov0031 (SEQ ID NO.:137)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0032 (SEQ ID NO.:138)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0033 (SEQ ID NO.:139)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG YQPYRVVVLSFELLKAPATVCGPKQSTGSGHHHHHHHHH ＞Cov0034 (SEQ ID NO.:140)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVG HQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHHHHH ＞Cov0035 (SEQ ID NO.:141)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTA GVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0036 (SEQ ID NO.:142)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTP TVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGHHHHHHHHH ＞Cov0037 (SEQ ID NO.:143)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQ SSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGHHHHHHHHH ＞Cov0038 (SEQ ID NO.:144)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSS GIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGHHHHHHHHH ＞Cov0039 (SEQ ID NO.:145)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIG YQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0040 (SEQ ID NO.:146)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSG IGYQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0041 (SEQ ID NO.:147)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELL NAPATVCGPKLSTGSGHHHHHHHH ＞Cov0042 (SEQ ID NO.:148)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPA TVCGPKLSTGSGHHHHHHHH ＞Cov0043 (SEQ ID NO.:149)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLS FELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0044 (SEQ ID NO.:150)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLS FELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0045 (SEQ ID NO.:151)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLS FELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0046 (SEQ ID NO.:152)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0047 (SEQ ID NO.:153)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0048 (SEQ ID NO.:154)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVG YQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0049 (SEQ ID NO.:155)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVG HQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0050 (SEQ ID NO.:156)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTA GVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0051 (SEQ ID NO.:157)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTP TVGVGYQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0052 (SEQ ID NO.:158)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQ SSGISFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0053 (SEQ ID NO.:159)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSS GIGFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0054 (SEQ ID NO.:160)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIG YQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0055 (SEQ ID NO.:161)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSG IGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0056 (SEQ ID NO.:162)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELL NAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0057 (SEQ ID NO.:163)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0058 (SEQ ID NO.:164)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0059 (SEQ ID NO.:165)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0060 (SEQ ID NO.:166)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPGHHHHHHHH ＞Cov0151 (SEQ ID NO.:167)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCG PKLSTGGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGS GSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSRFPNITNL CPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITQLCPFNEVF NITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0152 (SEQ ID NO.:168)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCG PKLSTGSGSGSGSGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGS GSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRF PNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGSPFGSGRFPNILC GQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0153 (SEQ ID NO.:169)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGPPSPPGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPP GRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNL CPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGPPSPGRFPNITQLCPFNE VFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0154 (SEQ ID NO.:170)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQ PYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPY GFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGL NCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0155 (SEQ ID NO.:171)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGS RFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGGSRFPNITQ LCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGQVFNASNF PSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0156 (SEQ ID NO.:172)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSG SGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTNIGSGSGSGRFP TNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGFGRFPNITNLCP QVFNASNFPSVYAWERLRISDCVADYAVLYNSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0157 (SEQ ID NO.:173)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPP SPPGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNI TNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITQLCPFNEVF NITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0158 (SEQ ID NO.:174)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK Question ELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGY QPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPY GFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGL NCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0159 (SEQ ID NO.:175)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK QSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGS RFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSPFGSRFPNITNLC GEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGGSGSRFPNITNLCPFGQVFNASNF PSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0160 (SEQ ID NO.:176)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK QSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSG SGSGSGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGS GRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITQ LCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0161 (SEQ ID NO.:177)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPG RFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLC PFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGQVFNASNF PSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0162 (SEQ ID NO.:178)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK QSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPY RVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFY TTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQL GCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0163 (SEQ ID NO.:179)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK QSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGS RFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSRFPNITQ LCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGEVFNATT FPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0164 (SEQ ID NO.:180)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSG SGRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSGRFP NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITKLC PFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0165 (SEQ ID NO.:181)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELL NAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYR VVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTP TVGVGYQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGP NCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0166 (SEQ ID NO.:182)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPF GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNFCPFDKVFNATRFP NVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYG VSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPS KLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0167 (SEQ ID NO.:183)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITN LCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNFCP FDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0168 (SEQ ID NO.:184)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFDKVFNATRFPSV YAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFK CYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYG VSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0169 (SEQ ID NO.:185)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLS TPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHH HHHH ＞Cov0170 (SEQ ID NO.:186)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVF NASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVVLSFELLNGPATVCGPKLSTGSGGSRFPNITNLCPFDKVFNATR FPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTF KCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPS KLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0171 (SEQ ID NO.:187)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITN LCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGSGRFPNITNFCP FDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSV LYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTS FSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0172 (SEQ ID NO.:188)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNRCPFDKVFNATRFPSV YAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFK CYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0173 (SEQ ID NO.:189)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTS DAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPG SFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDVYTLSTYDFYPSVPLDYQATRVENGVVVLSFELLNAPATVCGPKLSTPGSFKEELD KYFKNHTSDAASKPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHH HHHH ＞Cov0174 (SEQ ID NO.:190)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPF GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFDKVFNATRFP SVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFK CYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0175 (SEQ ID NO.:191)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFDKVFNATRFP SVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFS TFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0176 (SEQ ID NO.:192)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNRCPFDKVFNATR FPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFS TFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTF KCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0177 (SEQ ID NO.:193)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEE LDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLS TPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSSPKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHH HHHH ＞Cov0178 (SEQ ID NO.:194)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTGPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNA TRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAW ERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCY GVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0179 (SEQ ID NO.:195)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGSGSSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNASK FASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSGRFPNITNRCPFDKVFNATRFP SVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTS FSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0180 (SEQ ID NO.:196)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLS TPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPACG PKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHH HHHH ＞Cov0181 (SEQ ID NO.:197)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGLSPKTGSG SGSRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0182 (SEQ ID NO.:198)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGS GSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGS GSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0183 (SEQ ID NO.:199)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGP PSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNI TNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSHHHHHHH ＞Cov0184 (SEQ ID NO.:200)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVV VLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQ PYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0185 (SEQ ID NO.:201)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGSGSRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSGSRFPNITN LCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSHHHHHHHH ＞Cov0186 (SEQ ID NO.:202)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTGSGGSGSGRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSGS GSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0187 (SEQ ID NO.:203)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSP PGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0188 (SEQ ID NO.:204)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELL NAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQ PYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0189 (SEQ ID NO.:205)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGSGSGSRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGS GSRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0190 (SEQ ID NO.:206)MapllllPllPllWagalarfpnitQLCPFNEVFNITSFPSVYAWERMRITNCVADYSSSSFSTFQCYGVSPTKLCFSSVVRQIAPGVDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDININ TNSLDSSSSSSSSSNEFRFRHGKKKIKPYGRDLSNVLFNPSGTCSAEGLNCYKPLASYGFTQPYRSFLSFLSFLLLLLNAPKQSgsgsgsgsgsgsgqvFPSAWERRIRI SDCVADYAVLYNSSSSSSSSSSSSSSSSSSSSSSSSSSFKCVSPTKLNDLCFSSVYADYADDDDDVRQIAPAQTGVIDYKLPDDDDDDDDDSVDSKSKYRLFRFRDISAGGTCSSISQL GCYEPLKSYGFTPVGVGYQPyrvVVLSFELLNAPATVCGSGSGSGSGSGSGRCPFGEVFGFPSVYAWERSNCVADSFSTFKCFSNVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVVDDD VRQIAPGQTGVIADYNYKLPDDDFMGCVLAWNTRNIDATSTGNYNYRHGKLRRPFERDISNVPFSPDGPPPAPPPPPPPPPLNGFYRVVVCGPKLSHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHAs place HHH ＞Cov0191 (SEQ ID NO.:207)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGPPSPGRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGPPS PPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHH ＞Cov0192 (SEQ ID NO.:208)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELL NAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQ PYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0193 (SEQ ID NO.:209)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGGSGSRFPNITNRCPFDK VFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVF YNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0194 (SEQ ID NO.:210)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNF CPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADY TVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0195 (SEQ ID NO.:211)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNRCP FDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIA DYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0196 (SEQ ID NO.:212)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGP RFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0197 (SEQ ID NO.:213)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNLCPFD KVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADY TVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0198 (SEQ ID NO.:214)MAPLLLLLPLLWAGALARFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAAS KAGPRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0061 (SEQ ID NO.:215)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGS GSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNI TNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNAS KFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATTFASV YAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH ＞Cov0062 (SEQ ID NO.:216)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCPKLSTGS GSGSGSGRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTNIGSGSGSGRFPTN LCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGGSGSGRFPNITNLC PFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH ＞Cov0063 (SEQ ID NO.:217)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSP PGRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITNLCPFGE VFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGPPSPPGRFPNITNLCPFGEVFNASKFASVY AWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSHHHHHHHH ＞Cov0064 (SEQ ID NO.:218)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTG VNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSY GFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNC YYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0065 (SEQ ID NO.:219)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSR FPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITN LCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFASV YAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH ＞Cov0066 (SEQ ID NO.:220)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGS GSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGS GRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSGSGSGSGRFPNITNLC PFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0067 (SEQ ID NO.:221)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQ STGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVVGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPG RFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVF NASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATR FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0068 (SEQ ID NO.:222)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRV VVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRY GFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYF PLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH ＞Cov0069 (SEQ ID NO.:223)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGS GSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNI TNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPFSGSRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFASV YAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQSTGSHHHHHHHH ＞Cov0070 (SEQ ID NO.:224)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQ STGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGS GSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGRFP NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSNITGSGGSGSGRFP TNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0091 (SEQ ID NO.:225)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLS TGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRF PNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGGSFGSFPNITNLCP QVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSGSGSRFPNITQLCPFNIVFNITS FPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0092 (SEQ ID NO.:226)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSG SGSGSGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSGR FPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGPFSGRFPNITQLC NEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0093 (SEQ ID NO.:227)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTGPPSPPGRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPP GRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCP QVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGPPSPPGRFPNITQLCPFNEVFNI TSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0094 (SEQ ID NO.:228)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPK LSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSF ELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYR VVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSS GIGFQPYRVVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCY EPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0095 (SEQ ID NO.:229)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLS TGSGSGSRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRF PNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSPFGSRFPNITQLC NEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSRFPNITNLCPFGQVFNASNFPSV YAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0096 (SEQ ID NO.:230)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGSG RFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGSGSGSGRFPTN LCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNLCPFGQVF NASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0097 (SEQ ID NO.:231)MAPLLLLLPLLWAGALARFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVC GPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPG RFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLC PFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITQLCPFNEVFNITS FPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGSHHHHHHHH ＞Cov0098 (SEQ ID NO.:232)MAPLLLLLPLLWAGALARFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQ STPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELL NAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYR VVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNG IGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCY EPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0101 (SEQ ID NO.:233)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK Question PNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYRVVVLSFELLNAPATVCGPKQSTGPPSPPGRFPNITNLCPFGE VFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGQVFNASNFPSV YAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCYEPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0102 (SEQ ID NO.:234)MAPLLLLLPLLWAGALARFPNITKLCPFDQVFNASSFPSVYAWERVRITDCVANYAVLYNSSVSFSTFQCYGVSPTKLNDLCFSSVYADYFIVKGDDVRQIAPSQTGVIADYNYKLPDDFTGCVIAWNTNALDSNKDFYYRLFRHGKIKPYGRDLSNIPYSPSGTCSTINNLNCFAPLKSYGFTQSSGISFQPYRVVVLSFELLNAPATVCGPK Question ELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITQLCPFNEVFNITSFPSVYAWERMRITNCVADYSVLYNSSASFSTFQCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVIAWNTNSLDSSNEFFYRRFRHGKIKPYGRDLSNVLFNPSGGTCSAEGLNCYKPLASYGFTQSSGIGFQPYR VVVLSFELLNAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRSLRHGKLRPFERDISNVPFSPDGKPCTPPAFNCYWPLNDYGFFTTNG IGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGQVFNASNFPSVYAWERLRISDCVADYAVLYNSSSSFSTFKCYGVSPTKLNDLCFSSVYADYFVVKGDDVRQIAPAQTGVIADYNYKLPDDFTGCVLAWNTNSVDSKSGNNFYYRLFRHGKIKPYERDISNVLYNSAGGTCSSISQLGCY EPLKSYGFTPTVGVGYQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0121 (SEQ ID NO.:235)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGGSGSRFPNITNRCP FDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGSSFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIA DYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSV YADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNY RLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0122 (SEQ ID NO.:236)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNR CPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKIS DCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLID LCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIAD YNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0123 (SEQ ID NO.:237)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNRCPFDK VFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVF YNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSV YADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADY NYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0124 (SEQ ID NO.:238)MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDA ASKAGPRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRF PNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDK VFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDKVFNATRFP SVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0125 (SEQ ID NO.:239)MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGGSGSRFPNITNRCPFDKVF NVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFY NSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVY ADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADY NYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0126 (SEQ ID NO.:240)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNR CPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNRCPFDSIFNASRFPSVYAWERTKISDC VADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLID LCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIAD YNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0127 (SEQ ID NO.:241)MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNRCPFDKVF NVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFY NSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSV YADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLP DDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0128 (SEQ ID NO.:242)MAPLLLLLPLLWAGALARFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTS DAASKAGPRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGP RFPNITN RCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCPFDKVFNATRFP SVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0130 (SEQ ID NO.:243)MAPLLLLLPLLWAGALARFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDK VFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNFCPFDKVFNATRFPNVYAWQRTKISDCDY TVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFT SVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFPNITNRCPFDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIAD YNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0132 (SEQ ID NO.:244)MAPLLLLLPLLWAGALARFPNITNLCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGSYFYRSHRSSKLKPFERDLSSEENGVRTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFK NHTSDAASKAGPRFPNITNRCPFDKVFNVTRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTAKQDIGNYYYRSHRKTKLKPFERDLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAAS KAGPRFPNITNRCPFDSIFNASRFPSVYAWERTKISDCVADYTVLYNSTLFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGETGVIADYNYRLPDDFTGCVIAWNTANQDVGSYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNRCP FDKVFNATRFPSVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTANQDQGQYYYRSSRKEKLKPFERDLSSDENGVYTLSTYDFYPSVPLDYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNFCPFDKVFNA TRFPNVYAWQRTKISDCIADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQIAPGETGVIADYNYKLPDDFTGCVLAWNTAQQDIGSYFYRSHRAVKLKPFERDLSSDENGVRTLSTYDFNPNVPLDYQATRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0234 (SEQ ID NO.:245)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0235 (SEQ ID NO.:246)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0236 (SEQ ID NO.:247)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0237 (SEQ ID NO.:248)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0238 (SEQ ID NO.:249)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞AAV49723 (SEQ ID NO.:250)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPRE GVFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEPVLKGVKLHYT ＞ADE34812 (SEQ ID NO.:251)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLRSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREG VFVSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEPVLKGVKLHYT ＞AIA62277 (SEQ ID NO.:252)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLRS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFY SPQIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLVGLFMAIILLCYFTSCCSCCKGMCSCGSCCRFDEDDSEPVLKGVKLHYT ＞QIA48632 (SEQ ID NO.:253)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFRSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP QSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIIMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKL HYT ＞SARS-Cov2_South_Africa_variant (SEQ ID NO.:254)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSA PHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHY T ＞Cov0199 (SEQ ID NO.:255)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0200 (SEQ ID NO.:256)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0201 (SEQ ID NO.:257)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0202 (SEQ ID NO.:258)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0203 (SEQ ID NO.:259)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0204 (SEQ ID NO.:260)MFVFLVLVSSSSSSSSSSSSSSFTTRTQLPPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVFHAIHVSGTKRFANPFNDGVYIRGWIFGWIFGTQSLIVNANVVIK VceFQFCNDPFLGYHKNNNNNNNKSWMESEFRVYSSSNCTFEYVSQPFLMDLEGKQGNLREFKNIDGYSKIYSKHTPQGLPLPIGINISYLTPGDSSSSGWT AyyvgylqPrtFllKynengtitDAVDAVDALDPLSETKSFTVEKGIQTSNFRVQPTESIVRFPNITNLCPFGEVFASVALISNSASASASASASVSASFKCYGVSPTKLCCC FtnvyadsfvirgirgevrqiapgqtgniadynyklpdddddftgcvIAWNSNLDSKVGGNYLFRFRKSNLKPFERDIYQAGSTPCNGVKGFPLQPTYRVVVLSFELLHA PATVCGPKKSTNLVKCVNFNFNFNFNGLTGVLTESNKKFLPFQFGRDIDTDAVRDAVRDITPCSFGGVSVSVAVNCTEVNCTEVADQLTPTWRVYSTGSNVFQTRAGC LigaehvnNNNNNNNNSYECAGAGAGAGAGASYQTQTNSPGSASSSQSQSQSQSQSLGVENSNSIAIAIPIPISVTEILPSMTSVCTMYGSFCTQLNRALTGIAVEQDK NTQEVFAQVKQIYDPPIKDFGGFNFSQILPDPSKRSFiedllFNKVTLADAGDCLGDCLGDIAQKFNGLTVLTSALLAGWTFGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGWTS AyrfngigVTQNVTQNQKLIANQFNSAIGKKIQDSLSASASALGLQDVVNQNAQALSSNFGAISSRLLDRLDRLIDRLQSLIRAAAEIRASANLAATKMSEC VLGQSKRVDFCGKKYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAPAHFPREGVFVFVFVTQRNFYEPQIITTDNTFVSGNCDPLDSFKEELDKYFKNHT SPDVDLGDISGINAQKEIDRLNESLIDLIDLIDLGKYEQGYIPRDGQAYVRKDGEWVLLGPPPPPPELDKNHTSKNHTSKSGSGHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH ＞Cov0205 (SEQ ID NO.:261)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKY FKNHTSDAASKAGPGSGSGHHHHHHHH ＞Cov0206 (SEQ ID NO.:262)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKY FKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0207 (SEQ ID NO.:263)MFVFLVLVSSSSSSSSSSSSSSFTTRTQLPPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVFHAIHVSGTKRFANPFNDGVYIRGWIFGWIFGTQSLIVNANVVIK VceFQFCNDPFLGYHKNNNNNNNKSWMESEFRVYSSSNCTFEYVSQPFLMDLEGKQGNLREFKNIDGYSKIYSKHTPQGLPLPIGINISYLTPGDSSSSGWT AyyvgylqPrtFllKynengtitDAVDAVDALDPLSETKSFTVEKGIQTSNFRVQPTESIVRFPNITNLCPFGEVFASVALISNSASASASASASVSASFKCYGVSPTKLCCC FtnvyadsfvirgirgevrqiapgqtgniadynyklpdddddftgcvIAWNSNLDSKVGGNYLFRFRKSNLKPFERDIYQAGSTPCNGVKGFPLQPTYRVVVLSFELLHA PATVCGPKKSTNLVKCVNFNFNFNFNGLTGVLTESNKKFLPFQFGRDIDTDAVRDAVRDITPCSFGGVSVSVAVNCTEVNCTEVADQLTPTWRVYSTGSNVFQTRAGC LigaehvnNNNNNNNNSYECAGAGAGAGAGASYQTQTNSPGSASSSQSQSQSQSQSLGVENSNSIAIAIPIPISVTEILPSMTSVCTMYGSFCTQLNRALTGIAVEQDK NTQEVFAQVKQIYDPPIKDFGGFNFSQILPDPSKRSFiedllFNKVTLADAGDCLGDCLGDIAQKFNGLTVLTSALLAGWTFGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGWTS AyrfngigVTQNVTQNQKLIANQFNSAIGKKIQDSLSASASALGLQDVVNQNAQALSSNFGAISSRLLDRLDRLIDRLQSLIRAAAEIRASANLAATKMSEC VLGQSKRVDFCGKKYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAPAHFPREGVFVFVFVTQRNFYEPQIITTDNTFVSGNCDPLDSFKEELDKYFKNHT SPDVDLGDISGINAQKEIDRLNESLIDLIDLIDLIDLGKYEQGYIPRDGQAYVRKDGEWVLLGSFKNHTSKNHTSKNHTSDAASKSGHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH ＞Cov0208 (SEQ ID NO.:264)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKY FKNHTSDAASKAGPGSGSGHHHHHHHH ＞Cov0209 (SEQ ID NO.:265)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKY FKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0210 (SEQ ID NO.:266)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH HH ＞Cov0211 (SEQ ID NO.:267)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEE LDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0212 (SEQ ID NO.:268)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0213 (SEQ ID NO.:269)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH HH ＞Cov0214 (SEQ ID NO.:270)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEE LDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0215 (SEQ ID NO.:271)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFSSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEE LDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0216 (SEQ ID NO.:272)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0217 (SEQ ID NO.:273)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHHHH ＞Cov0218 (SEQ ID NO.:274)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAAS KAGPGSGHHHHHHHH ＞Cov0219 (SEQ ID NO.:275)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0220 (SEQ ID NO.:276)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0221 (SEQ ID NO.:277)MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKP IFKLPLGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATS TGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPI GAGICASYHTVSSLSSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGA ALQIPFAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREG VFVFNGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAAS KAGPGSGHHHHHHHH ＞Cov0222 (SEQ ID NO.:278)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQ ＞Cov0223 (SEQ ID NO.:279)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHHHH ＞Cov0224 (SEQ ID NO.:280)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASK AGPGSGHHHHHHHH ＞Cov0225 (SEQ ID NO.:281)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0226 (SEQ ID NO.:282)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGGHHHHHHHHH ＞Cov0227 (SEQ ID NO.:283)MKILIFAFLANLAKAQEGCGIISRKPQPKMAQVSSSRRGVYYNDDIFRSDVLHLTQDYFLPFDSNLTQYFSLNVDSDRYTYFDNPILDFGDGVYFAATEKSNVIRGWIFGSSFDNTTQSAVIVNNSTHIIIRVCNFNLCKEPMYTVSRGTQQNAWVYQSAFNCTYDRVEKSFQLDTTPKTGNFKDLREYVFKNRDGFLSVYQTYTAVNLPR GLPTGFSVLKPILKLPFGINITSYRVVMAMFSQTTSNFLPESAAYYVGNLKYSTFMLRFNENGTITDAVDCSQNPLAELKCTIKNFNVDKGIYQTSNFRVSPTQEVIRFPNITNRCPFDKVFNATRFPNVYAWERTKISDCVADYTVLYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRSSEVRQVAPGETGVIADYNYKLPDDFTGCVIAWNTA KHDTGNYYYRSHRKTKLKPFERDLLSSDDGNGVYTLSTYDFNPNVPVAYQATRVVVLSFELLNAPATVCGPKLSTELVKNQCVNFNFNGLKGTGVLTSSSKRFQSFQQFGRDTSDFTDSVRDPQTLEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVPTAIRADQLTPAWRVYSTGVNVFQTQAGCLIGAEHVNASYECDIPIGAGICA SYHTASVLSSTGQKSIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALTGIAIEQDKNTQEVFAQVKQMYKTPAIKDFGGFNFSQILPDPSKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVSARDLICAQKFNGLTVLPPLLTDEMIAAYTAALVSGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPSQEKNFTTAPAICHEGKAYFPREGVF VSNGTSWFITQRNFYSPQLITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASK AGPGSGHHHHHHHH ＞Cov0228 (SEQ ID NO.:284)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0229 (SEQ ID NO.:285)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0230 (SEQ ID NO.:286)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0231 (SEQ ID NO.:287)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0232 (SEQ ID NO.:288)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP QIITTDNTFVAGSCDVVIGIINNTVYDPLQPELDSFKQELDKYFKNHTSPDVDLGDISGINASVVDIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGPGSFKEELDKYFKNHTSDAASKAGPGSPGSFKEELDKYFKNHTSDAASKAGPGSGHHHHHHHH ＞Cov0233 (SEQ ID NO.:289)MFIVFLISYTTFLIPYTATTTCFKGPTTENKLNISSGSRGVYYPDDIFRSNVSVLVTGRFRFNTTLTWYNSWNQAYSSPVLPFGHGVYFSTIDKSNVVRGWIFGTTLDNTTQSALLVNNGSAITIEVCYFQFCDNPAFIIRDGAQINTAIYINLRNCTYVDTLRDLPLSFAEVDGGFKHLREFVFKNSDGFLHIYGAYQPYDLAIGATAALPAQFL PLKPLWKLPLGLNITNYKVVTTLKPTNQAFQAAYIVGNLKHTTMMLSFNENGTMSNAIDCSQDPLAELKCTLKQFDVGKGIYQTSNFRVQPTVDVARFPNITNVCPFDKVFNATRFPSVYAWERTKISDCVADYTVFYNSTSFSTFNCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFIGCVIAWNTAKQDV GSYFYRSHRSSKLKPFERDLSSEENGVLTLSTYDFNQNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPLVKNQCVNFNFNGLKGTGVLTDSSKTFQSFQQFGRDASDFTDSVRDPQTLQILDISPCSFGGVSVITPGTNTSSAVAVLYQDVNCTDVPTTIHADHLTHSWRVYTTGPYVFQTQAGCLIGAEHVNASYQCDIPIGAGICASYHTASLLSS TGQKSIVAYTMSLGAENSVAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSLECSNLLLQYGSFCTQLNRALSGIAVEQDKNTQEVFAQVKQMYKTPTIRDFGGFNFSQILPDPLKPTKRSFIEDLLYNKVTLADAGFMKQYADCLGGINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALISGTATAGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKQIANQFNKAITQIQESLTTTATALGKLQDVVNQNAQALNTLVKQLSSNFGAISSALNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAYFPREGVFVSNGSSWFITQRNFYSP Question ＞Cov0239 (SEQ ID NO.:290)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0240 (SEQ ID NO.:291)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNS ASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0241 (SEQ ID NO.:292)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNS ASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0242 (SEQ ID NO.:293)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSHHHHHHHH ＞Cov0243 (SEQ ID NO.:294)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNS ASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSHHHHHHHH ＞Cov0244 (SEQ ID NO.:295)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVA DYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNS ASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGSHHHHHHHH ＞Cov0245 (SEQ ID NO.:296)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0246 (SEQ ID NO.:297)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPR FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0247 (SEQ ID NO.:298)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPR FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNH TSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHH HHHH ＞Cov0248 (SEQ ID NO.:299)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPGS HHHHHHHH ＞Cov0249 (SEQ ID NO.:300)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPR FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNH TSDAASKAGPGSHHHHHHHH ＞Cov0250 (SEQ ID NO.:301)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPH GVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGPPPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPR FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNH TSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKKSTPGSFK EELDKYFKNHTSDAASKAGPGSHHHHHHHH ＞Cov0251 (SEQ ID NO.:302)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0252 (SEQ ID NO.:303)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0253 (SEQ ID NO.:304)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0254 (SEQ ID NO.:305)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPAYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0255 (SEQ ID NO.:306)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0256 (SEQ ID NO.:307)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0257 (SEQ ID NO.:308)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPAYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0258 (SEQ ID NO.:309)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPAYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0259 (SEQ ID NO.:310)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPAYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0260 (SEQ ID NO.:311)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPAYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0261 (SEQ ID NO.:312)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPAYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0262 (SEQ ID NO.:313)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0263 (SEQ ID NO.:314)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0264 (SEQ ID NO.:315)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0265 (SEQ ID NO.:316)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0266 (SEQ ID NO.:317)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0267 (SEQ ID NO.:318)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0268 (SEQ ID NO.:319)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0269 (SEQ ID NO.:320)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0270 (SEQ ID NO.:321)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0271 (SEQ ID NO.:322)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0272 (SEQ ID NO.:323)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0273 (SEQ ID NO.:324)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0274 (SEQ ID NO.:325)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0275 (SEQ ID NO.:326)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0276 (SEQ ID NO.:327)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0277 (SEQ ID NO.:328)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0278 (SEQ ID NO.:329)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0279 (SEQ ID NO.:330)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0280 (SEQ ID NO.:331)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0281 (SEQ ID NO.:332)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0282 (SEQ ID NO.:333)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0283 (SEQ ID NO.:334)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0284 (SEQ ID NO.:335)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0285 (SEQ ID NO.:336)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0286 (SEQ ID NO.:337)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0287 (SEQ ID NO.:338)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0288 (SEQ ID NO.:339)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0289 (SEQ ID NO.:340)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0290 (SEQ ID NO.:341)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0291 (SEQ ID NO.:342)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0292 (SEQ ID NO.:343)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0293 (SEQ ID NO.:344)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0294 (SEQ ID NO.:345)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0295 (SEQ ID NO.:346)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0296 (SEQ ID NO.:347)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0297 (SEQ ID NO.:348)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYG VGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0298 (SEQ ID NO.:349)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0299 (SEQ ID NO.:350)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0300 (SEQ ID NO.:351)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0301 (SEQ ID NO.:352)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0302 (SEQ ID NO.:353)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0303 (SEQ ID NO.:354)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0304 (SEQ ID NO.:355)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0305 (SEQ ID NO.:356)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0306 (SEQ ID NO.:357)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0307 (SEQ ID NO.:358)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0308 (SEQ ID NO.:359)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0309 (SEQ ID NO.:360)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYG VGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0310 (SEQ ID NO.:361)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0311 (SEQ ID NO.:362)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0312 (SEQ ID NO.:363)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0313 (SEQ ID NO.:364)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0314 (SEQ ID NO.:365)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0315 (SEQ ID NO.:366)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0316 (SEQ ID NO.:367)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0317 (SEQ ID NO.:368)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0318 (SEQ ID NO.:369)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0319 (SEQ ID NO.:370)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0320 (SEQ ID NO.:371)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0321 (SEQ ID NO.:372)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0322 (SEQ ID NO.:373)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0323 (SEQ ID NO.:374)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0324 (SEQ ID NO.:375)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0325 (SEQ ID NO.:376)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0326 (SEQ ID NO.:377)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0327 (SEQ ID NO.:378)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFAPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0328 (SEQ ID NO.:379)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFGPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0329 (SEQ ID NO.:380)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFAAAYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0330 (SEQ ID NO.:381)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFGAAYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0331 (SEQ ID NO.:382)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGAAGFNCYFPLASYGFAAAYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0332 (SEQ ID NO.:383)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGAAGFNCYFPLASYGFGAAYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0333 (SEQ ID NO.:384)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0334 (SEQ ID NO.:385)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0335 (SEQ ID NO.:386)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0336 (SEQ ID NO.:387)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0337 (SEQ ID NO.:388)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0338 (SEQ ID NO.:389)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0339 (SEQ ID NO.:390)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0340 (SEQ ID NO.:391)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0341 (SEQ ID NO.:392)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0342 (SEQ ID NO.:393)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLASYGFNATYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0343 (SEQ ID NO.:394)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0344 (SEQ ID NO.:395)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0345 (SEQ ID NO.:396)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0346 (SEQ ID NO.:397)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0347 (SEQ ID NO.:398)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0348 (SEQ ID NO.:399)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0349 (SEQ ID NO.:400)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0350 (SEQ ID NO.:401)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0351 (SEQ ID NO.:402)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0352 (SEQ ID NO.:403)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLASYGFNGTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0353 (SEQ ID NO.:404)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0354 (SEQ ID NO.:405)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0355 (SEQ ID NO.:406)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0356 (SEQ ID NO.:407)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0357 (SEQ ID NO.:408)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0358 (SEQ ID NO.:409)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0359 (SEQ ID NO.:410)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0360 (SEQ ID NO.:411)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0361 (SEQ ID NO.:412)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0362 (SEQ ID NO.:413)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0363 (SEQ ID NO.:414)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0364 (SEQ ID NO.:415)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0365 (SEQ ID NO.:416)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0366 (SEQ ID NO.:417)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0367 (SEQ ID NO.:418)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0368 (SEQ ID NO.:419)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0369 (SEQ ID NO.:420)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0370 (SEQ ID NO.:421)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0371 (SEQ ID NO.:422)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0372 (SEQ ID NO.:423)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0373 (SEQ ID NO.:424)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0374 (SEQ ID NO.:425)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0375 (SEQ ID NO.:426)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0376 (SEQ ID NO.:427)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0377 (SEQ ID NO.:428)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0378 (SEQ ID NO.:429)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0379 (SEQ ID NO.:430)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSSNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0380 (SEQ ID NO.:431)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSPGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0381 (SEQ ID NO.:432)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0382 (SEQ ID NO.:433)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSGSNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0383 (SEQ ID NO.:434)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0384 (SEQ ID NO.:435)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0385 (SEQ ID NO.:436)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0386 (SEQ ID NO.:437)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0387 (SEQ ID NO.:438)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0388 (SEQ ID NO.:439)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0389 (SEQ ID NO.:440)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0390 (SEQ ID NO.:441)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0391 (SEQ ID NO.:442)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0392 (SEQ ID NO.:443)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFAPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0393 (SEQ ID NO.:444)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFGPAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0394 (SEQ ID NO.:445)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0395 (SEQ ID NO.:446)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0396 (SEQ ID NO.:447)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0397 (SEQ ID NO.:448)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0398 (SEQ ID NO.:449)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0399 (SEQ ID NO.:450)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0400 (SEQ ID NO.:451)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0401 (SEQ ID NO.:452)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0402 (SEQ ID NO.:453)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0403 (SEQ ID NO.:454)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0404 (SEQ ID NO.:455)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0405 (SEQ ID NO.:456)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0406 (SEQ ID NO.:457)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0407 (SEQ ID NO.:458)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0408 (SEQ ID NO.:459)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0409 (SEQ ID NO.:460)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0410 (SEQ ID NO.:461)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0411 (SEQ ID NO.:462)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0412 (SEQ ID NO.:463)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0413 (SEQ ID NO.:464)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0414 (SEQ ID NO.:465)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0415 (SEQ ID NO.:466)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0416 (SEQ ID NO.:467)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0417 (SEQ ID NO.:468)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0418 (SEQ ID NO.:469)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0419 (SEQ ID NO.:470)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0420 (SEQ ID NO.:471)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0421 (SEQ ID NO.:472)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0422 (SEQ ID NO.:473)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0423 (SEQ ID NO.:474)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0424 (SEQ ID NO.:475)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0425 (SEQ ID NO.:476)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0426 (SEQ ID NO.:477)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0427 (SEQ ID NO.:478)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0428 (SEQ ID NO.:479)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0429 (SEQ ID NO.:480)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGS NVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFL HVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0430 (SEQ ID NO.:481)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0431 (SEQ ID NO.:482)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0432 (SEQ ID NO.:483)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0433 (SEQ ID NO.:484)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0434 (SEQ ID NO.:485)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0435 (SEQ ID NO.:486)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0436 (SEQ ID NO.:487)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0437 (SEQ ID NO.:488)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0438 (SEQ ID NO.:489)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0439 (SEQ ID NO.:490)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0440 (SEQ ID NO.:491)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0441 (SEQ ID NO.:492)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPAIHADQLTPTWRVYSTGS NVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFL HVTYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0442 (SEQ ID NO.:493)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0443 (SEQ ID NO.:494)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0444 (SEQ ID NO.:495)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0445 (SEQ ID NO.:496)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0446 (SEQ ID NO.:497)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0447 (SEQ ID NO.:498)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYGYLYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0448 (SEQ ID NO.:499)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGAKGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0449 (SEQ ID NO.:500)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0450 (SEQ ID NO.:501)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0451 (SEQ ID NO.:502)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0452 (SEQ ID NO.:503)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0453 (SEQ ID NO.:504)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISTEIYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0454 (SEQ ID NO.:505)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0455 (SEQ ID NO.:506)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0456 (SEQ ID NO.:507)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0457 (SEQ ID NO.:508)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0458 (SEQ ID NO.:509)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0459 (SEQ ID NO.:510)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFAPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0460 (SEQ ID NO.:511)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFGPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0461 (SEQ ID NO.:512)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFAAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0462 (SEQ ID NO.:513)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVAGFNCYFPLASYGFGAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0463 (SEQ ID NO.:514)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGAAGFNCYFPLASYGFAAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0464 (SEQ ID NO.:515)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISTEIYQAGSTPCNGAAGFNCYFPLASYGFGAAYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0465 (SEQ ID NO.:516)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0466 (SEQ ID NO.:517)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0467 (SEQ ID NO.:518)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0468 (SEQ ID NO.:519)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0469 (SEQ ID NO.:520)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0470 (SEQ ID NO.:521)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0471 (SEQ ID NO.:522)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0472 (SEQ ID NO.:523)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0473 (SEQ ID NO.:524)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0474 (SEQ ID NO.:525)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0475 (SEQ ID NO.:526)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0476 (SEQ ID NO.:527)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0477 (SEQ ID NO.:528)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0478 (SEQ ID NO.:529)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0479 (SEQ ID NO.:530)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKF NGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTY VPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0480 (SEQ ID NO.:531)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0481 (SEQ ID NO.:532)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYLYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0482 (SEQ ID NO.:533)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVKGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0483 (SEQ ID NO.:534)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLQSYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNG LTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYV PTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0484 (SEQ ID NO.:535)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCNGVAGFNCYFPLASYGFNGTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGL TVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPT QYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0485 (SEQ ID NO.:536)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0486 (SEQ ID NO.:537)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0487 (SEQ ID NO.:538)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0488 (SEQ ID NO.:539)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC LIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIALICARDAQKFNGLTV LPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQ YKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0489 (SEQ ID NO.:540)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC LIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIALICARDAQKFNGLTV LPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQ YKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0490 (SEQ ID NO.:541)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLQSYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGC LIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIALICARDAQKFNGLTV LPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQ YKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0491 (SEQ ID NO.:542)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0492 (SEQ ID NO.:543)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0493 (SEQ ID NO.:544)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0494 (SEQ ID NO.:545)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0495 (SEQ ID NO.:546)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0496 (SEQ ID NO.:547)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYLYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0497 (SEQ ID NO.:548)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0498 (SEQ ID NO.:549)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0499 (SEQ ID NO.:550)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0500 (SEQ ID NO.:551)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0501 (SEQ ID NO.:552)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0502 (SEQ ID NO.:553)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGKGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0503 (SEQ ID NO.:554)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0504 (SEQ ID NO.:555)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0505 (SEQ ID NO.:556)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0506 (SEQ ID NO.:557)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0507 (SEQ ID NO.:558)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0508 (SEQ ID NO.:559)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNYNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0509 (SEQ ID NO.:560)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0510 (SEQ ID NO.:561)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0511 (SEQ ID NO.:562)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSSNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQYK NFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0512 (SEQ ID NO.:563)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSPGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0513 (SEQ ID NO.:564)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGGNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞Cov0514 (SEQ ID NO.:565)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSGSNGNYAYRLFRKSNLKPFERDISNETYQAGSTPCGAGFNCYFPLASYGFNATYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLI GAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQKFNGLTV PLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPTQY KNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHHGSGGSGGSGGTGAHIVMVDAYKPTK ＞A.27_[ mayotte ] (SEQ ID NO.:566)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPAIHADQLTPTWRVYSTGS NVFQTRAGCLIGVEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIALICA QKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLVFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLH YT ＞A.27+S494P_[ Engineering ] (SEQ ID NO.:567)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPAIHADQLTPTWRVYSTGS NVFQTRAGCLIGVEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIALICA QKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQ SAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLVFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLH YT ＞AAV49723.1_[SARS_ coronavirus _PC4-241] (SEQ ID NO.:568)MFIFLLFLTLTSGSDLDRCTTFDQAPNYTQSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHTFDNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFVVSKPMGTRTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNTLKPIFKLP LGINITNFRAILTAFSPAQDTWGTSAAAYFVGYLKPTTFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNY KYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTLIHAEQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTICASYECDIPIGAG SYHTVSSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAAEQDRNTREVFVQVKQMYKTPTLKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIP FAMQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVF NGTSWFITQRNFFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQEEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEPVLKGVKLHYT ＞ATO98157.1_[ bat _SARS like _ coronavirus _Rs4231] (SEQ ID NO.:569)MFIFLFFLTLTSGSDLESCTTVQAPPQHSSSRRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGFHTINHRFDNPVIPFKDGVYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNPFFAVSKPTGTQTHTMIFDNAFNCTFEYISDSFSLDVAEKSGNFKHLREFVFKNKDGFLYVYKGYQPIDVVRDLPSGFNILKPIFKLPLGIN ITNFRAILTAFLPAQDTWGTSAAAYFVGYLKPATFMLKYDENGTITDAVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVAPSKEVVRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVR RSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTSSSKRFQPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNTSSEVAVLYQDVNCTDVPVAIHADQLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHT VSSLRSTSQKSIVAYTMSLGADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSGIAVEQDRNTREVFAQVKQMYKTPALKDFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQYGECLGDVNARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFA MQMAYRFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHVTCVPSQERNFTTAPAICHEGKAYFPREGVFVFNG TSWFITQRNFFSPQIITTDNTFVSGSCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKGACSCGSCCKFDEDDSEPVLKGVKLHYT >AVP78031.1_[ bat _SARS like _ coronavirus _ZC45] (SEQ ID NO.:570)LFFLFLQFALVNSQCVNLTGRTPLNPNYTNSSQRGVYYPDTIYRSDTLVLSQGYFLPFYSNVSWYYSLTTNNAATKRTDNPILDFKDGIYFAATEHSNIIRGWIFGTTLDNTSQSLLIVNNATNVIIKVCNFDFCYDPYLSGYYHNNKTWSIREFAVYSSYANCTFEYVSKSFMLNISGNGGLFNTLREFVFRNVDGHFKIYSKFTPVNL NRGLPTGLSVLQPLVELPVSINITKFRTLLTIHRGDPMPNNGWTAFSAAYFVGYLKPRTFMLKYNENGTITDAVDCALDPLSETKCTLKSLTVQKGIYQTSNFRVQPTQSVVRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSSPKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIA WNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTQLVKNQCVNFNFNGLKGTGVLTDSSKRFQSFQQFGKDASDFIDSVRDPQTLEILDITPCSFGGVSVITPGTNTSLEVAVLYQDVNCTDVPTTIHADQLTPAWRIYATGTNVFQTQAGCLIGAEHVNASYECDIPIGA GICASYHTASILRSTSQKAIVAYTMSLGAENSIAYANNSIAIPTNFSISVTTEVMPVSMAKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALSGIAIEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGGISARDLICAQKFNGLTVLPPLLTDEMIAAYTAALISGTATAGWTFGAGAAL QIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQESLTSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYIPSQEKNFTTAPAICHEGKAHFPREGVFVS NGTHWFVTQRNFYEPKIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDIDLGDISGINASVVNIQKEIDRLNEVARNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT ＞B.1.315_[ South Africa ] (SEQ ID NO.:571)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSA PHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHY T >B.167.2[ Indian variants of interest ] (SEQ ID NO.:572)MFVFLVLLPLVSSQCVNLRTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKNNKSWMESGVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSK html DDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVF QTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSRRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQNVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHG VVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT ＞E484K+S494P+N501Y_[ Engineering ] (SEQ ID NO.:573)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYST GSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP QSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKL HYT >QHD43416.1_[SARS-CoV-2] (SEQ ID NO.:574)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQ KFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSA PHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHY T ＞QIA48632.1_[ pangolin _ coronavirus _PANG/GX] (SEQ ID NO.:575)MFVFLFVLPLVSSQCVNLTTRTGIPPGYTNSSTRGVYYPDKVFRSSILHLTQDLFLPFFSNVTWFNTINYQGGFKKFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDARTQSLLIVNNATNVVIKVCEFQFCTDPFLGVYYHNNNKTWVENEFRVYSSANNCTFEYISQPFLMDLEGKQGNFKNLREFVFKNVDGYFKIYSK HTPIDLVRDLPRGFAALEPLVDLPIGINITRFQTLLALHRSYLTPGKLESGWTTGAAAYYVGYLQQRTFLLSYNQNGTITDAVDCSLDPLSETKCTLKSLTVEKGIYQTSNFRVQPTISIVRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADY NYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTTLVKDKCVNFNFNGLTGTGVLTTSKKQFLPFQQFGRDISDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQDVNCTEVPMAIHAEQLTPAWR VYSAGANVFQTRAGCLVGAEHVNNSYECDIPVGAGICASYHSMSSFRSVNQRSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSIECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGLGDCDIALIC AQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFP QSAPHGVVFLHVTYVPAQEKNFTTAPAICHEGKAHFPREGVFVSNGTHWFITQRNFYEPQIITTDNTFVSGSCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIIMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKL HYT ＞Cov0592 (SEQ ID NO.:576)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0593 (SEQ ID NO.:577)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0594 (SEQ ID NO.:578)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0595 (SEQ ID NO.:579)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0596 (SEQ ID NO.:580)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0597 (SEQ ID NO.:581)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0598 (SEQ ID NO.:582)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0599 (SEQ ID NO.:583)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSG IGYQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0600 (SEQ ID NO.:584)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAG VGHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0601 (SEQ ID NO.:585)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELL NAPATVCGPKLSTGSGHHHHHHHH ＞Cov0602 (SEQ ID NO.:586)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY Question SGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSRFPNITNLC GEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0603 (SEQ ID NO.:587)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRV VVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIALD LCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0604 (SEQ ID NO.:588)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY Question VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHA PATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0605 (SEQ ID NO.:589)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVV VLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNG YGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY FPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0606 (SEQ ID NO.:590)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLS TGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLC PFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNAFATR SVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0607 (SEQ ID NO.:591)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPY RVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSF ELLHAPATVCGPKKSTGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDVRTLSTYDFNPNVENGPLEYQATRVVVLSFELLNAPATVCGPKLSNITGSGGSGSGRFP TNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0608 (SEQ ID NO.:592)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYR VVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPF GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0609 (SEQ ID NO.:593)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATR VVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPL NGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0610 (SEQ ID NO.:594)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGLSPKTG SGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPTN LCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATR FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0611 (SEQ ID NO.:595)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYR VVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDVRTLSTYDFNPNVENGPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0612 (SEQ ID NO.:596)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRV VVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPA TVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVF NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0613 (SEQ ID NO.:597)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRV VVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY Question GFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCY FPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0614 (SEQ ID NO.:598)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY Question LSFELLNAPATVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLC PFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0615 (SEQ ID NO.:599)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLS TGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGSGS GSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGRFPTN LCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0616 (SEQ ID NO.:600)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGLSPKTG PPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPN ITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKKSTGPPSPPGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0617 (SEQ ID NO.:601)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY Question GFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNV PLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFPY QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY FPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0618 (SEQ ID NO.:602)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVV LSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATV CGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATR SVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0619 (SEQ ID NO.:603)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGS GSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSNITGGSGSGSGRFP TNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0620 (SEQ ID NO.:604)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSSPKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPN ITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGE VFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0621 (SEQ ID NO.:605)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGF QPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPA PNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSDENGV RTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY FPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0622 (SEQ ID NO.:606)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVV VLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPA TVCGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATR FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0623 (SEQ ID NO.:607)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGS GSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0624 (SEQ ID NO.:608)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGPPSPPGRF PNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPF GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0625 (SEQ ID NO.:609)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGF QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTP PAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSDENG VRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNC YFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0626 (SEQ ID NO.:610)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVV VLSFELLNAPATVCGPKLSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDVRTLSTYDFNPNVENGPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSRFPNITN LCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATR FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0627 (SEQ ID NO.:611)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPK LSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGS GSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKKSTGSGSGSGRFP NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHHHH ＞Cov0628 (SEQ ID NO.:612)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLS TGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRF PNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVF NATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0629 (SEQ ID NO.:613)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNG YGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNP NVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGF QPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCY FPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0631 (SEQ ID NO.:614)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGSGSGS GRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITN LCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0633 (SEQ ID NO.:615)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQPYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPL NGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKERPFDLSSDENGVRTLSTYDF NPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGSYVEGFNCYFPLQ GFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCY FPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0662 (SEQ ID NO.:616)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRV VVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV CGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLS TGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0663 (SEQ ID NO.:617)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNY QPFRVVVLSFELLNGPATVCGPKLSTGGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVV LSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAP ATVCGPKLSTGSGGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHH ＞Cov0664 (SEQ ID NO.:618)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY Question VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHA PATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATV CGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHH HHHHHH ＞Cov0665 (SEQ ID NO.:619)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCY YPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGV KGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPY ERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNRYLDSKVGGNYNYRLFRKSNL KPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0666 (SEQ ID NO.:620)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQ PFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSF ELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPK LSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0667 (SEQ ID NO.:621)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGV NYQPFRVVVLSFELLNGPATVCGPKLSTGGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTGSGGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHH ＞Cov0668 (SEQ ID NO.:622)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY Question VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPA TVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCG PKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHH HHHHHH ＞Cov0669 (SEQ ID NO.:623)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLR PYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCY FPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKPFERDISTEIY QAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFE RDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0670 (SEQ ID NO.:624)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFR VVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHA PATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGLSPKTG SGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0671 (SEQ ID NO.:625)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPY RVVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSF ELLNGPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHH ＞Cov0672 (SEQ ID NO.:626)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQP FRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATV CGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHH HHHHHH ＞Cov0673 (SEQ ID NO.:627)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLR PYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNC YFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTE IYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNL KPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0674 (SEQ ID NO.:628)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVV LSFELLNAPATVCPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSR FPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0675 (SEQ ID NO.:629)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVV VLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHH ＞Cov0676 (SEQ ID NO.:630)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPY RVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLS FELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHH HHHHHH ＞Cov0677 (SEQ ID NO.:631)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPL QPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGV KGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPY ERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNRYLDSKVGGNYNYRLFRKSNL KPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0678 (SEQ ID NO.:632)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVV VLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPA TVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSR FPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0679 (SEQ ID NO.:633)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLS FELLNAPATVCPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCG PKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPK LSTGSGHHHHHHHH ＞Cov0680 (SEQ ID NO.:634)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAP ATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST GPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHH HHHHHH ＞Cov0681 (SEQ ID NO.:635)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPL QPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIY QAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFE RDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0682 (SEQ ID NO.:636)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPY RVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHA PATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGLSPKTG SGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0683 (SEQ ID NO.:637)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPY RVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSF ELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPACG PKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPK LSTGSGHHHHHHHH ＞Cov0684 (SEQ ID NO.:638)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY Question VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPA TVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST GPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHH HHHHHH ＞Cov0685 (SEQ ID NO.:639)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLR PYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCY FPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNG VKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLK PFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0686 (SEQ ID NO.:640)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQ PYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSF ELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPK LSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0687 (SEQ ID NO.:641)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTGSGGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGHHHHHHH ＞Cov0688 (SEQ ID NO.:642)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY Question VLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLS FELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCG PKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHH HHHHHH ＞Cov0689 (SEQ ID NO.:643)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCY YPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSP GGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIY QAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFE RDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0690 (SEQ ID NO.:644)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVV VLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSF ELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPK LSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0693 (SEQ ID NO.:645)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPL QSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVK GFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYER DLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKP FERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0722 (SEQ ID NO.:646)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGSGSRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0723 (SEQ ID NO.:647)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELL NAPATVCGPKLSTGSGGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH ＞Cov0724 (SEQ ID NO.:648)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELL NAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST GPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0725 (SEQ ID NO.:649)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQ PTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPL EYQATRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0726 (SEQ ID NO.:650)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGY Question SGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0727 (SEQ ID NO.:651)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNVCPFHKVFNATRFPSVYAWERTKISDCIADYTVFYNSTSFSTFKCYGVSPSKLIDLCFTSVYADTFLIRFSEVRQVAPGQTGVIADYNYKLPDDFTGCVIAWNTAKQDVGNYFYRSHRSTKLKPFERDLSSDENGVRTLSTYDFNPNVPLEYQATRVVVLSFELLNAPATVCGPK LSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHH HH ＞Cov0728 (SEQ ID NO.:652)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRV VVLSFELLNAPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPA TVCGPKKSTGSGHHHHHHHH ＞Cov0729 (SEQ ID NO.:653)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYR VVVLSFELLNAPATVCGPKLSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0730 (SEQ ID NO.:654)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSG IGYQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYR VVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELL HAPATVCGPKKSTGSGHHHHHHHH ＞Cov0731 (SEQ ID NO.:655)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVG YQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGF QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTP PAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0732 (SEQ ID NO.:656)MNTQILVFALIAIIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGV GYQPYRVVVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRV VVLSFELLHAPATVCGPKKSTGPPSPPGRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELL NAPATVCGPKLSTGSGHHHHHHHH ＞Cov0733 (SEQ ID NO.:657)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSG IGYQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGF QPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNC YFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0734 (SEQ ID NO.:658)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY QPYRVVVLSFELLHAPATVCGPKKSTGSGSGSRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFR VVVLSFELLNGPATVCGPKLSTGSGSGSRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTGSGHHHHHHHH ＞Cov0735 (SEQ ID NO.:659)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAG VGHQPYRVVVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRV VVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVV VLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0736 (SEQ ID NO.:660)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIGPNCYNPLRPYGFFTTAG VGHQPYRVVVLSFELLNAPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNY QPFRVVVLSFELLNGPATVCGPKLSTGPPSPPGRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLS FELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0737 (SEQ ID NO.:661)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPL QSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGG QSCSAIGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTGSGHHHHHHHH ＞Cov0738 (SEQ ID NO.:662)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGY Question VVLSFELLNAPATVCGPKLSTGGSGSGSGRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVV VLSFELLNGPATVCGPKLSTGSGHHHHHHHH ＞Cov0739 (SEQ ID NO.:663)MNTQILVFALIAIIPTNADKIGSGAHIVMVDAYKPTKGSGGSGGSGGTGNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGF HPTTGVNYQPFRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAIG PNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNG VEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGHHHHHHHH ＞Cov0556 (SEQ ID NO.:664)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0557 (SEQ ID NO.:665)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0558 (SEQ ID NO.:666)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0559 (SEQ ID NO.:667)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0560 (SEQ ID NO.:668)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0561 (SEQ ID NO.:669)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0562 (SEQ ID NO.:670)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0563 (SEQ ID NO.:671)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0564 (SEQ ID NO.:672)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATR FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0565 (SEQ ID NO.:673)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNAT KFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0566 (SEQ ID NO.:674)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATR FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTSTGSHHHHHHHH ＞Cov0567 (SEQ ID NO.:675)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATKFP SVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0568 (SEQ ID NO.:676)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATRFASV YAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0569 (SEQ ID NO.:677)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSGSGSGSGRFPNITNLCPFGEVFNATK FPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHHHHHHHH ＞Cov0570 (SEQ ID NO.:678)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATS FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0571 (SEQ ID NO.:679)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATS FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0572 (SEQ ID NO.:680)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATS FASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHHHH ＞Cov0573 (SEQ ID NO.:681)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGSPFGSGRFPNITNLC GEVFNATS FPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTSTGSHHHHHHHH ＞Cov0574 (SEQ ID NO.:682)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHH HH ＞Cov0575 (SEQ ID NO.:683)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGSHH HHHHHH ＞Cov0576 (SEQ ID NO.:684)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHH HHHH ＞Cov0577 (SEQ ID NO.:685)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGSHHHHHH HH ＞Cov0578 (SEQ ID NO.:686)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPACG PKKSTGSHHHHHHHH ＞Cov0579 (SEQ ID NO.:687)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKK STGSHHHHHHHH ＞Cov0580 (SEQ ID NO.:688)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCG PKLSTGGSHHHHHHHH ＞Cov0581 (SEQ ID NO.:689)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSHHHHHHHH ＞Cov0582 (SEQ ID NO.:690)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPACG PKKSTGSHHHHHHHH ＞Cov0583 (SEQ ID NO.:691)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPA TVCGPKLSTGSHHHHHHHH ＞Cov0584 (SEQ ID NO.:692)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTSTGSHHHHHHHH ＞Cov0585 (SEQ ID NO.:693)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCG PKLSTGGSHHHHHHHH ＞Cov0586 (SEQ ID NO.:694)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSFK EELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTGSHHHHHHHH ＞Cov0587 (SEQ ID NO.:695)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTGPPPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATV CGPKLSTGSHHHHHHH ＞Cov0588 (SEQ ID NO.:696)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPACG PKKSTGSHHHHHHHH ＞Cov0589 (SEQ ID NO.:697)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPA TVCGPKKSTGSHHHHHHHH ＞Cov0590 (SEQ ID NO.:698)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPACG PKKSTGSHHHHHHHH ＞Cov0591 (SEQ ID NO.:699)MFVFLVLLPLVSSQCVNFTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIY SKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHISYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNV FQTRAGCLIGAEHVNNSYECDIPIGAGICASYQTQTNSPGSASSVASQSIIAYTMSLGEENSVSYDNNSIAIPTNFTISVTTEIIPVSMQKVSVDCTMYICGDHSECSNLLLQYGSFCTQLNRALHEIAVEQDKNTLEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSAIEDLLFNKVTLADAGFIKGYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAAYTSALLAGTITAGWTFGAGSALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNKAIGAIQDGLDSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLINGRLQALNTYVTQLLIRAAEIRASANLAAEKMSECVLGQSKRVDFCGKGYHLMSFPQAAPHGVVFLHV TYVPTQYKNFTTAPAICHNGKAHFPREGVFVSNGTHWFVTQRNFYEPQPITTDNTFVSGDCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGYIPEAPRDGQAYVRKDGEWVLLSTLFLGPPPGSFKEELDKYFK NHTSDAASKAGPRFPNITNLCPFGEVFNATKFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPAPNCYWPLNGYGFYTTSGIGYQPYRVVVLSFELLNAPATVCGPKLSTGPPPG SFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQPYGFQPTYGVGYQPYRVVVLSFELLHAPATV CGPKKSTSTGSHHHHHHHH ＞SpyTag amino acid sequence (SEQ ID NO.:700)AHIVMVDAYKPTK ＞ engineered stem - helical peptide (SEQ ID NO.:701)PGSFKEELDKYFKNHTSDAASKAGP ＞Townsend Connector (SEQ ID NO.:702)GSGGSGGSGGTG ＞RESERVED (SEQ ID NO.:703) ＞His Tag amino acid sequence (SEQ ID NO.:704)HHHHHHHH ＞ signal peptide (SEQ ID NO.:705)MNTQILVFALIAIIPTNADKI ＞ signal peptide (SEQ ID NO.:706)MAPLLLLLPLLWAGALA ＞ signal peptide (SEQ ID NO.:707)MFVFLVLLPLVS ＞ signal peptide (SEQ ID NO.:708)MFVFLVLLLPLVSS ＞ Connector (SEQ ID NO.:709)GPPSPPG ＞ Connector (SEQ ID NO.:710)GSGSGS ＞ Connector (SEQ ID NO.:711)GSGSGSGSG ＞Cov0746 (SEQ ID NO.:712)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVV VLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGY QPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFY PTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0747 (SEQ ID NO.:713)MAPLLLLLPLLWAGALARFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQP FRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNG VGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLY RYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0748 (SEQ ID NO.:714)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST PGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLS FELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPY RVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDG VGHQPYRVVVLSFELLNAPATVCGPKKSTGSHHHHHHHH ＞Cov0749 (SEQ ID NO.:715)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPK KSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLS FELLNAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVV VLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGY QPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFY PTDGVGHQPYRVVVLSFELLNAPATVCGPKKST ＞Cov0750 (SEQ ID NO.:716)MAPLLLLLPLLWAGALARFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQP FRVVVLSFELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNG VGYQPYRVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLY RYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKST ＞Cov0751 (SEQ ID NO.:717)MAPLLLLLPLLWAGALARFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST PGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELL NAPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLS FELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPY RVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDG VGHQPYRVVVLSFELLNAPATVCGPKKST ＞Cov0758 (SEQ ID NO.:718)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI IVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLP DDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGL TVLPPLLTEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHV TYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0759 (SEQ ID NO.:719)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI IVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLP DDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGL TVLPPLLTEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHV TYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLSPA ＞Cov0761 (SEQ ID NO.:720)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI IVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLP DDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGL TVLPPLLTEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTPSALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFL HVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGRSGHHHHHHHH ＞Cov0762 (SEQ ID NO.:721)MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI IVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLP DDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRA GCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHGSASSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGL TVLPPLLTEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTPSALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFL HVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQGSGYIPEAPRDGQAYVRKDGEWVLLSTFLSPA ＞SEQ ID No.:722 (Wuhan-Hu-1 RBD polypeptide )nitnlcpfgevfnatrfasvyawnrkrisncvadysvlynsasfstfkcygvsptklndlcftnvyadsfvirgdevrqiapgqtgkiadynyklpddftgcviawnsnnldskvggnynylyrlfrksnlkpferdisteiyqagstpcngvegfncyfplqsygfqptngvgyqpyrvvvlsfellhapatvcg pkkst ＞SEQ ID No.:723 (Wuhan-Hu-1 RBD polypeptide )rfpnitnlcpfgevfnatrfasvyawnrkrisncvadysvlynsasfstfkcygvsptklndlcftnvyadsfvirgdevrqiapgqtgkiadynyklpddftgcviawnsnnldskvggnynylyrlfrksnlkpferdisteiyqagstpcngvegfncyfplqsygfqptngvgyqpyrvvvlsfellhapatv cgpkkst ＞SEQ ID NO.:724 (SARS-CoV-2 β variant RBD polypeptide )RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST ＞SEQ ID NO.:725 (SARS-CoV-2 β variant RBD polypeptide )NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKST ＞SEQ ID NO.:726 (SARS-CoV-2 δ variant RBD polypeptide )RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST ＞SEQ ID NO.:727 (SARS-CoV-2 δ variant RBD polypeptide )NITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKST ＞SEQ ID NO.:728 (SARS-CoV-2o variant RBD polypeptide )RFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKST ＞SEQ ID NO.:729 (SARS-CoV-2o variant RBD polypeptide )NITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKST ＞SEQ ID NO.:730 (RsSHC014 RBD polypeptide )RFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLST ＞SEQ ID NO.:731 (RsSHC014 RBD polypeptide )NITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLST ＞SEQ ID NO.:732 (PANG/GX RBD polypeptide )RFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLST ＞SEQ ID NO.:733 (PANG/GX RBD polypeptide )NITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPATVCGPKLST ＞SEQ ID NO.:734 (PANG/GD RBD polypeptide )RFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQST ＞SEQ ID NO.:735 (PANG/GD RBD polypeptide )NITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPATVCGPKQST ＞SEQ ID NO.:736 (RatG13 RBD polypeptide )RFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKST ＞SEQ ID NO.:737 (RatG13 RBD polypeptide )NITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLSFELLNAPATVCGPKKST ＞SEQ ID NO.:738 ( from Cov0064 Of amino acid sequence )RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYF KNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTP GSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLS FELLNGPATVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPY RVVVLSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDG VGHQPYRVVVLSFELLNAPATVCGPKKST ＞SEQ ID NO.:739 ( from Cov0747 Of amino acid sequence )RFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDA ASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEE LDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPNTGVGYQPYRVVV LSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPY RVVVLSFELLNAPATVCGPKKST ＞SEQ ID NO.:740 ( from Cov0748 Of amino acid sequence )RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNH TSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKST PGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPA TVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLS FELLNAPATVCGPKKST ＞SEQ ID NO.:741 ( from Cov0749 The amino acid sequence of )RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYF KNHTSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTP GSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPK KSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELL KAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVV VLSFELLNAPATVCGPKKST ＞SEQ ID NO.:742 ( from Cov0750 Of amino acid sequence )RFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNHTSDA ASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSFKEE LDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNASKFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVKGDEVRQIAPGQTGVIADYNYKLPDDFTGCVIAWNSVKQDALTGGNYGYLYRLFRKSKLKPFERDISTEIYQAGSTPCNGQVGLNCYYPLERYGFHPTTGVNYQPFRVVVLSFELLNGPA TVCGPKLSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPNTGVGYQPYRVVV LSFELLKAPATVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPY RVVVLSFELLNAPATVCGPKKST ＞SEQ ID NO.:743 ( from Cov0751 Of amino acid sequence )RFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTPGSFKEELDKYFKNH TSDAASKAGPRFPNITNLCPFGEVFNATTFPSVYAWERKRISNCVADYSVLYNSTSFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNYKLPDDFLGCVLAWNTNSKDSSTSGNYNYLYRWVRRSKLNPYERDLSNDIYSPGGQSCSAVGPNCYNPLRPYGFFTTAGVGHQPYRVVVLSFELLNAPATVCGPKLSTPGSF KEELDKYFKNHTSDAASKAGPRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKST PGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVVRGDEVRQIAPGQTGRIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFHPTNGVGYQPYRVVVLSFELLKAPA TVCGPKQSTPGSFKEELDKYFKNHTSDAASKAGPRFPNITNLCPFGEVFNATTFASVYAWNRKRISNCVADYSVLYNSTSFSTFKCYGVSPTKLNDLCFTNVYADSFVITGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSKHIDAKEGGNFNYLYRLFRKANLKPFERDISTEIYQAGSKPCNGQTGLNCYYPLYRYGFYPTDGVGHQPYRVVVLS FELLNAPATVCGPKKST ＞SEQ ID NO.:744 (Wuhan-Hu-1 RBM)NSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPY ＞SEQ ID NO.:745 ( Connector )GPPPGSFKEELDKYFKNHTSDAASKAGP ＞SEQ ID NO.:746 (Ace2 Forward introduction )CAAGAGCAAACGGTTGAACAC ＞SEQ ID NO.:747 (Ace2 reverse primer )CCAGAGCCTCTCATTGTAGTCT ＞SEQ ID NO.:748 (HPRT Forward introduction )CCTGGCGTCGTGATTAGTG ＞SEQ ID NO.:749 (HPRT reverse primer )ACACCCTTTCCAAATCCTCAG ＞SEQ ID NO.:750 (TMPRSS2 Forward introduction )CAAGTGCTCCRACTCTGGGAT ＞SEQ ID NO.:751 (TMPRSS2 reverse primer )AACACACCGRTTCTCGTCCTC ＞SEQ ID NO.:752 (S gene forward primer )CGAGAAAAAGGCATCTGGAG ＞SEQ ID NO.:753 (S gene reverse primer )CATTGAACTCGTCGGTCTC ＞SEQ ID NO.:754 (S2E12 VH)QVQLVQSGPEVKKPGTSVRVSCKASGFFTTSSAVQWVRQARGQRLEWVGWIVVGSGNTNYAQKFHERVTITRDMSSTAYMELSSLRSEDTAVYYCASPYCSGGSCSDGFDIWGQGTMVTVSS ＞SEQ ID NO.:755 (S2E12 VL)DIVLTQTPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYVGLTGWTFGQGTKVEIK ＞SEQ ID NO.:756 (S2X259 VH)QVQLVQSGAEVKKPGSSVKVSCKASGGIFNTYTISWVRQAPGQGLEWMGRIILMSGMANYAQKIQGRVTITADKSTSTAYMELTSLRSDDTAVYYCARGFNGNYYGWGDDDAFDISGQGTLVTVYS ＞SEQ ID NO.:757 (S2X259 VL)QTVLTQPPSVSGAPGQRVTISCTGSNSNIGAGYDVHWYQQLPGTAPKLLICGNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGPNWVFGGGTKLTVL ＞SEQ ID NO.:758 (S2K146 VH)QVQLVESGGVVVQPGGSLRLSCAASGFTFHDHTMHWVRQAPGKGLEWVSLITWNGGTIHYSDSVKGRFTISRDNSKNSLYLQMNSLRTEDTALYYCAKDLGRGGWYLPSDAWGQGTLVTVSS ＞SEQ ID NO.:759 (S2K146 VL)QSVLTQPPSASGTPGQRVTISSCSGSSANIGSNTVNWYQHLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDSLKGVFGGGTKLTVL ＞SEQ ID NO.:760 (S2L20 VH)EVQLVESGGGVVQPGGSLRLSCAASGFTFNSYGMHWVRQAPGKGLEWVAFIRYDGGNKYYADSVKGRFTISRDNSKNTLYLQMKSLRAEDTAVYYCANLKDSRYSGSYYDYWGQGTLVTVSS ＞SEQ ID NO.:761 (S2L20 VL)VIWMTQSPSSSLSASVGDRVTITCQASQDIRFYLNWYQQKPGKAPKLLISDASNMETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYDNLPFTFGPGTKVDFK ＞SEQ ID NO.:762 (S2H97 VH)QVRLVQSGAEVKKSGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTVYLQWSSLKASDTAMYYCARQWSHYTYDYYYWGQGTLVTISS ＞SEQ ID NO.:763 (S2H97 VL)QSVLTQPASVSGSPGQSITISCTGISSDVGGYNSVSWYQQHPGKAPKLMIYDVTNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYTSSSTPPYVFGTGTKVSVL ＞SEQ ID NO.:764 (S2X333 VH)EVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAVIWYDGSNKFYADSVKGRFTISRDNSKNSLYLQMNSLRAEDTAVYFCARAFPDSSSWSGFTIDYWGQGTLVTVSS ＞SEQ ID NO.:765 (S2X333 VL)SYELTQPPSVSVAPGQTARITCGGNNIERKSVHWCQQKPGQAPALVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSGSDQVIFGGGTKLTVL Example Example 1 Design and testing of SARS-COV-2 protein constructs

Protein constructs were generated using the spike (S) protein ectodomain, or RBD, from the South African variant of SARS-CoV-2. Spinin ectodomain constructs, RBD monomeric constructs (ie, containing a single RBD polypeptide), and mixed spinin:RBD constructs were prepared. As discussed herein, three spike protein ectodomain constructs preferably associate to form a trimer.

The spike protein extracellular domain construct includes: (Figure 1A) wild-type spike protein extracellular domain connected to the foldon; (Figure 1B) wild-type spike protein extracellular domain connected to the foldon, and the trimeric foldon connected to the SpyTag The Townsend linker; and (Figure 1C) the wild-type spike protein ectodomain connected to the foldon (three spike protein ectodomains associate to form a trimer), and one at the C terminus of the foldon of the trimer , two or less than three copies of: a linker (GSG or GPP) attached to a stem-helix polypeptide engineered from an epitope recognized by antibody S2P6 ( see Example 9 ).

The RBD monomer construct includes: (Fig. 2A) an RBD polypeptide; (Fig. 2B) a wild-type RBD polypeptide linked to SpyTag at the N-terminus or at the C-terminus via a Townsend linker; and (Fig. 2C) at the N-terminus via a Townsend linker. An RBD polypeptide linked to SpyTag and C-terminally linked to a stem-helix polypeptide via a GSG or GPP linker.

The hybrid spine/RBD construct is (Figure 3A) a trimer of the wild-type spine ectodomain fused at the C terminus to a foldon trimer; each foldon of the trimer is linked to the (first) RBD polypeptide. In some constructs, each first RBD polypeptide is linked to a second RBD polypeptide. In some constructs, each second RBD polypeptide is linked to a third RBD polypeptide; and (Figure 3B) A construct of the same design as outlined in Figure 3A, except for each linker (between the foldon and the first RBD polypeptide , between consecutive RBD polypeptides) comprising a stem-helix polypeptide, another stem-helix polypeptide linked to the C-terminal RBD polypeptide (whether first, second or third).

The constructs were tested for performance (yes or no), purification yield (high or low), biophysical properties (assessed using SDS-PAGE, SEC-HPLC and DSF) and antigen binding characteristics (assessed using BLI).

For spinin ectodomain constructs, required biophysical properties include the formation of soluble trimers over aggregates and monomers. The desired antigen binding characteristic is equivalent or increased binding (relative to the comparative wild-type spike protein trimer) of a panel of SARS-CoV-2 binding antibodies (among these including antibody S2P6, which requires increased binding), and Equivalent binding to human ACE2 (relative to wild-type spike protein trimer). For SpyTag-containing constructs, the binding of nanoparticles to surface SpyCatchers was studied.

For RBD monomeric constructs, the required biophysical properties include the formation of soluble monomers over aggregates. Desired antigen binding characteristics of the fusion (Figures 2B and 2C) include equivalent binding of a panel of SARS-CoV-2 binding antibodies (relative to the comparative isolated RBD; Figure 2A) (and for stem-helix containing constructs, Binding of antibody S2P6). Combination with human ACE2 is also studied. For SpyTag-containing constructs, the binding of nanoparticles to surface SpyCatchers was studied.

For mixed spike protein:RBD constructs, the required biophysical properties include the formation of soluble trimers over aggregates, monomers, and soluble oligomers. Desired antigen binding characteristics include increased binding of a panel of SARS-CoV-2 binding antibodies relative to the wild-type spike protein trimer (including increased binding of antibody S2P6 for stem-helix containing constructs). Combination with human ACE2 is also studied. Example 2 Design and testing of protein constructs based on zoonotic coronavirus strains

Protein constructs were generated using the extracellular domain of spike protein and the RBD polypeptide from zoonotic coronavirus strains as the backbone. Prepare the spinin extracellular domain construct, RBD monomer construct and RBD concatemer construct.

The spike protein ectodomain construct is of the design shown in Figures 1A, 1B, and 1C (e.g., some embodiments include one, two, or three copies of the following at the C-terminus of the foldon of the foldon trimer: attached to the stem- Helical polypeptide linker (GSG or GPP)).

The RBD monolithic construct is the design shown in Figures 2A-2C.

The RBD concatemer constructs are: the designed constructs shown in Figure 4A, each containing three isotypic (i.e., each RBD is different from the other RBD) RBD polypeptides selected from three groups of zoonotic strains, and the RBD polypeptides are linked to form a single chain, wherein the linker is (GlySer)n (e.g., SEQ ID NO.:710), GPPSPPG (SEQ ID NO.:709), or a stem-helix polypeptide; and the designed construct shown in Figure 4B, Some contain five heterotypic RBD polypeptides selected from three groups of zoonotic strains, the RBD polypeptides linked to each other to form a single chain (where the linker is: (GlySer)n (e.g., SEQ ID NO.:710), GPPSPPG (SEQ ID NO. .:709) or stem-helix polypeptide); and others include five heterotypic RBD polypeptides selected from two groups of zoonotic virus strains, with the RBD polypeptides linked to each other to form a single chain; these thirty constructs include two groups of ten Five different constructs where the linker is: (GlySer)n (eg SEQ ID NO.:710), GPPSPPG (SEQ ID NO.:709) or a stem-helix polypeptide.

Test construct performance (yes or no), purification yield (high or low; for RBD monomeric constructs, higher or lower compared to independent zoonotic RBD), biophysical properties (using SDS-PAGE, SEC-HPLC and DSF assessment) and antigen-binding characteristics (assessed using BLI).

For spinin ectodomain constructs, required biophysical properties include the formation of soluble trimers over aggregates and monomers. The desired antigen binding characteristics are equivalent binding of a panel of SARS-CoV-2 binding antibodies relative to the comparative wild-type spike protein trimer, and increased binding of the S2P6 antibody. Study the combination with human ACE2. For SpyTag-containing constructs, the binding of nanoparticles to surface SpyCatchers was studied.

For RBD monomeric constructs, required biophysical properties include the formation of soluble monomers over aggregates and soluble oligomers. Required antigen binding characteristics include equivalent binding of a panel of SARS-CoV-2 binding antibodies relative to an independent WT zoonotic RBD (and for stem-helix containing constructs, binding of antibody S2P6). Combination with human ACE2 is also studied. For SpyTag-containing constructs, the binding of nanoparticles to surface SpyCatchers was studied.

For RBD concatemer constructs, required biophysical properties include the formation of soluble monomers over aggregates and soluble oligomers. Desired antigen binding characteristics include increased binding of a panel of SARS-CoV-2 binding antibodies relative to an independent WT zoonotic RBD (and for stem-helix containing constructs, binding of antibody S2P6). Combination with human ACE2 is also studied. For SpyTag-containing constructs, the binding of nanoparticles to surface SpyCatchers was studied. Example 3 Design and testing of protein constructs based on zoonotic coronavirus strains

Selected constructs from Examples 1 and 2 that met respective quality criteria were tested in animal models. Example 4 Engineering of SARS-COV-2 RBD

A modified form of the extracellular domain of the SARS-CoV-2 South African variant spike protein was selected as the backbone for RBD engineering. Generate constructs (RBD (monomeric) fusion containing SpyTag (Figure 6, left), and Spinin ectodomain fusion containing SpyTag (Figure 6, right)) with respect to the selected RBD position/region The backbone contains one or more amino acid substitutions, deletions and/or insertions. Engineering particularly contemplates the creation of one or more glycosylation sites, deletions of loop regions, certain point mutations, and combinations of these. The RBD mutations of selected constructs ("Cov0251"-"Cov0382") are summarized in Tables 2A and 2B below, and Figures 5A-5G (as "251"-"382"). Table 2A. Overview of mutations in constructs Cov0251-Cov0326 construct RBD position (Wuhan 1 number ) 443 444 445 446 447 448 449 498 499 500 WT S K V G G N Y Q P T Cov0251 - - - - - - G - - - Cov0252 - - - - - - - A - - Cov0253 - - - - - - - G - - Cov0254 - - - - - - - - A Cov0255 - - - - - - G A - - Cov0256 - - - - - - G G - - Cov0257 - - - - - - G - - A Cov0258 - - - - - - - A - A Cov0259 - - - - - - - G - A Cov0260 - - - - - - G A - A Cov0261 - - - - - - G G - A Cov0262 - - - - - - - N - - Cov0263 - - - - - - - N A Cov0264 - - - - - - G N A - Cov0265 - - - - - - - N G - Cov0266 - - - - - - G N G - Cov0267 - Δ444-447 + P - - - - - Cov0268 - Δ444-447+G - - - - - Cov0269 - Δ444-447+S - - - - - Cov0270 - Δ444-447 + PG - - - - - Cov0271 - Δ444-447 + GG - - - - - Cov0272 - Δ444-447 +GS - - - - - Cov0273 - Δ444-447 + P - - N A - Cov0274 - Δ444-447 + P - G N A - Cov0275 - Δ444-447 + P - - N G - Cov0276 - Δ444-447 + P - G N G - Cov0277 - Δ444-447+G - - N A - Cov0278 - Δ444-447+G - G N A - Cov0279 - Δ444-447+G - - N G - Cov0280 - Δ444-447+G - G N G - Cov0281 - Δ444-447+S - - N A - Cov0282 - Δ444-447+S - G N A - Cov0283 - Δ444-447+S - - N G - Cov0284 - Δ444-447+S - G N G - Cov0285 - Δ444-447 + PG - - N A - Cov0286 - Δ444-447 + PG - G N A - Cov0287 - Δ444-447 + PG - - N G - Cov0288 - Δ444-447 + PG - G N G - Cov0289 - Δ444-447 + GG - - N A - Cov0290 - Δ444-447 + GG - G N A - Cov0291 - Δ444-447 + GG - - N G - Cov0292 - Δ444-447 + GG - G N G - Cov0293 - Δ444-447 +GS - - N A - Cov0294 - Δ444-447 +GS - G N A - Cov0295 - Δ444-447 +GS - - N G - Cov0296 - Δ444-447 +GS - G N G - construct RBD position (Wuhan 1 number ) 450 452 470 472 481 482 483 484 493 WT N L T I N G V E Q Cov0297 G - - - - - - - - Cov0298 - A - - - - - - - Cov0299 - - - - - - A - - Cov0300 - - - - - - - A - Cov0301 - - - - - - - - A Cov0302 G - - - - - - - A Cov0303 - A - - - - - - A Cov0304 G - - - - - A - A Cov0305 G - - - - - - A A Cov0306 - A - - - - A - A Cov0307 - A - - - - - A A Cov0308 - - N T - - - - - Cov0309 G - N T - - - - - Cov0310 - A N T - - - - - Cov0311 - - N T - - A - - Cov0312 G - N T - - A - - Cov0313 - A N T - - A - - Cov0314 - - N T - - A - A Cov0315 G - N T - - A - A Cov0316 - A N T - - A - A Cov0317 - - - - Δ481-483+G - - Cov0318 - - - - Δ481-483+G A - Cov0319 - - - - Δ481-483+G A A Cov0320 - A - - Δ481-483+G A - Cov0321 - A - - Δ481-483+G A A Cov0322 - - N T Δ481-483+G - - Cov0323 - - N T Δ481-483+G A - Cov0324 - - N T Δ481-483+G A A Cov0325 - A N T Δ481-483+G - - Cov0326 - A N T Δ481-483+G A A Table 2B. Overview of mutations in constructs Cov0327-Cov0382 construct 444 445 446 447 449 452 470 472 481 482 483 484 493 498 499 500 WT K V G G Y L T I N G V E Q Q P T Cov0327 - - - - - - - - - - - A A A - - Cov0328 - - - - - - - - - - - A A G - - Cov0329 - - - - G - - - - - - A A A A A Cov0330 - - - - G - - - - - - A A G A A Cov0331 - - - - G A - - - - A A A A A A Cov0332 - - - - G A - - - - A A A G A A Cov0333 - - - - - - N T - - - - - N A - Cov0334 - - - - G - N T - - - - - N A - Cov0335 - - - - - - N T - - - - A N A - Cov0336 - - - - - - N T - - - A - N A - Cov0337 - - - - - A N T - - - - - N A - Cov0338 - - - - G - N T - - - - A N A - Cov0339 - - - - G - N T - - - A - N A - Cov0340 - - - - G A N T - - - - A N A - Cov0341 - - - - G A N T - - - A - N A - Cov0342 - - - - G A N T - - - A A N A - Cov0343 - - - - - - N T - - - - - N G - Cov0344 - - - - G - N T - - - - - N G - Cov0345 - - - - - - N T - - - - A N G - Cov0346 - - - - - - N T - - - A - N G - Cov0347 - - - - - A N T - - - - - N G - Cov0348 - - - - G - N T - - - - A N G - Cov0349 - - - - G - N T - - - A - N G - Cov0350 - - - - G A N T - - - - A N G - Cov0351 - - - - G A N T - - - A - N G - Cov0352 - - - - G A N T - - - A A N G - Cov0353 Δ444-447 + P - - N T Δ481-483+G - - N A - Cov0354 Δ444-447+G - - N T Δ481-483+G - - N A - Cov0355 Δ444-447+S - - N T Δ481-483+G - - N A - Cov0356 Δ444-447 + PG - - N T Δ481-483+G - - N A - Cov0357 Δ444-447 + GG - - N T Δ481-483+G - - N A - Cov0358 Δ444-447 +GS - - N T Δ481-483+G - - N A - Cov0359 Δ444-447 + P - - N T Δ481-483+G - A N A - Cov0360 Δ444-447+G - - N T Δ481-483+G - A N A - Cov0361 Δ444-447+S - - N T Δ481-483+G - A N A - Cov0362 Δ444-447 + PG - - N T Δ481-483+G - A N A - Cov0363 Δ444-447 + GG - - N T Δ481-483+G - A N A - Cov0364 Δ444-447 +GS - - N T Δ481-483+G - A N A - Cov0365 Δ444-447 + P - A N T Δ481-483+G - A N A - Cov0366 Δ444-447+G - A N T Δ481-483+G - A N A - Cov0367 Δ444-447+S - A N T Δ481-483+G - A N A - Cov0368 Δ444-447 + PG - A N T Δ481-483+G - A N A - Cov0369 Δ444-447 + GG - A N T Δ481-483+G - A N A - Cov0370 Δ444-447 +GS - A N T Δ481-483+G - A N A - Cov0371 Δ444-447 + P - A N T Δ481-483+G A A N A - Cov0372 Δ444-447+G - A N T Δ481-483+G A A N A - Cov0373 Δ444-447+S - A N T Δ481-483+G A A N A - Cov0374 Δ444-447 + PG - A N T Δ481-483+G A A N A - Cov0375 Δ444-447 + GG - A N T Δ481-483+G A A N A - Cov0376 Δ444-447 +GS - A N T Δ481-483+G A A N A - Cov0377 Δ444-447 + P G A N T Δ481-483+G A A N A - Cov0378 Δ444-447+G G A N T Δ481-483+G A A N A - Cov0379 Δ444-447+S G A N T Δ481-483+G A A N A - Cov0380 Δ444-447 + PG G A N T Δ481-483+G A A N A - Cov0381 Δ444-447 + GG G A N T Δ481-483+G A A N A - Cov0382 Δ444-447 +GS G A N T Δ481-483+G A A N A -

Test constructs for performance (yes or no), purification yield (high or low; for the spike protein ectodomain fusion trimer, higher or lower compared to the wild-type spike protein trimer), biophysical properties (using SDS- PAGE, SEC-HPLC and DSF assessment) and antigen binding characteristics (assessed using BLI).

For RBD fusions, desired biophysical properties include the formation of soluble monomers over aggregates. Desired antigen binding characteristics include equivalent binding (relative to WT South African variant RBD monomer) and reduced binding to human ACE2 (relative to WT South African variant RBD monomer) for a panel of SARS-CoV-2 binding antibodies. The combination of nanoparticles and surface SpyCatchers is also studied.

For spinin ectodomain fusions, required biophysical properties include the formation of soluble trimers over aggregates and monomers. Desired antigen binding characteristics include equivalent or increased binding (relative to WT South African spike protein trimer) and reduced binding to human ACE2 (relative to WT South African variant spike protein trimer) for a panel of SARS-CoV-2 binding antibodies. polymer). The combination of nanoparticles and surface SpyCatchers is also studied. Example 5 Design and testing of additional coronavirus fusion proteins

The S ectodomain of the SARS-CoV-2 South African variant was used as the backbone for engineering. Mutations are made to increase prefusion stability and promote an "up" or "open" conformation of the RBD. In the preferred trimer containing constructs, two of the three RBs are in an upward or open configuration. Constructs were generated, all of which had a foldon added to the C-terminus and a SpyTag attached to the foldon for nanoparticle binding (Figure 7). A control spike protein construct was also prepared: SARS-CoV-2 Wuhan S-2P (S-2P = spike protein containing two proline substitutions in the S2 subunit; Wrapp et al. Science 367 (6483): 1260- 1263(2020)); SARS-CoV-2 Wuhan Hexapro (Hexapro=S-2P variant containing six proline substitutions (F817P, A892P, A899P, A942P plus S-2P); described in Hsieh et al . Science 369 (6510):1501-1505 (2020)); SARS-CoV-2 South Africa Hexapro; SARS-CoV-2 Indian variant S-2P; SARS-CoV-2 Indian variant HexaPro-like; and SARS-CoV- 1.

Test constructs for performance (yes or no), purification yield (increase or decrease relative to WT South African variant spike protein trimer containing S-2P), biophysical properties (assessed using SDS-PAGE, SEC-HPLC and DSF ) and antigen binding characteristics (assessed using BLI).

Desired biophysical properties include the formation of soluble trimers over aggregates and monomers. Required antigen binding characteristics include equivalent or increased binding of a panel of SARS-CoV-2 binding antibodies (relative to the WT South African variant spike protein trimer) and equivalent binding of antibody S2P6 (relative to the WT South African variant spike protein). protein trimer). Combination with human ACE2 is also studied. The combination of nanoparticles and surface SpyCatchers is also studied. Example 6 Design and testing of additional SARS-COV-2 RBD concatemers

Construction of heterotypic SARS-CoV-2 RBD concatemer constructs using selected virus strains. The construct has the design shown in Figures 4B (5 RBD polypeptides connected by a stem-helix polypeptide or other linker) and 4A (3 RBD polypeptides connected by a stem-helix polypeptide or other linker). Escape mutations from SARS-CoV-2 variants and phylogenetically distinct strains were distributed among the five constructs. In this regard, the construct is as follows: "2×5" multiplex ● Group 1 (30 constructs): Wuhan-Hu-1 / A.27 / α + E484K + S494P / ZC45 / SARS-CoV-1 ● Group 2 (30 constructs): δ / β / A.27 + S494P / GX-Pangolin / Rs4231. "3×3" multiplex ● Group 1 (6 structures): Wuhan-Hu-1 / A.27 / ZC45 ● Group 2 (6 constructs): β / A.27 + S494P / Rs4231 ● Group 3 (6 constructs): δ / GX-Pangolin / Rs4231 All constructs were designed with SPyTag for nanoparticle binding.

The constructs were tested for performance (yes or no), purification yield (high or low), biophysical properties (assessed using SDS-PAGE, SEC-HPLC and DSF) and antigen binding characteristics (assessed using BLI).

Desired biophysical properties include the formation of soluble monomers over soluble oligomers and aggregates. Desired antigen binding characteristics include increased binding (relative to an independent RBD) of a panel of SARS-CoV-2 binding antibodies (and for stem-helix containing constructs, binding of antibody S2P6). Combination with human ACE2 is also studied. For SpyTag-containing constructs, the binding of nanoparticles to surface SpyCatchers was studied. Example 7 Design and testing of additional coronavirus spike proteins:RBD fusions

A modified form of the spike protein ectodomain of the SARS-CoV-2 South African variant was used as a scaffold to construct the heterotypic spike protein ectodomain:RBD hybrid construct. RBD lines are selected from Wuhan-Hu-1, β, δ, A.27 + S494P and SARS-CoV-1: Single RBD fusions (Figure 8A; 8 constructs) ● Foldon-RBD linker=(GS)n ● Foldon-RBD linker = stem-helix polypeptide Double RBD fusions (Figure 8B; 28 constructs) ● Foldon-RBD linker=(GS)n ● Foldon-RBD linker = stem-helix polypeptide The dual RBD fusions tested included combinations of all five RBD types.

The constructs were tested for performance (yes or no), purification yield (high or low), biophysical properties (assessed using SDS-PAGE, SEC-HPLC and DSF) and antigen binding characteristics (assessed using BLI).

Desired biophysical properties include the formation of soluble trimers over soluble oligomers, aggregates and monomers. Desired antigen binding characteristics include increased binding of a panel of SARS-CoV-2 binding antibodies relative to the WT South African variant spike protein trimer (and for stem-helix containing constructs, binding of antibody S2P6). Combination with human ACE2 is also studied. Example 8 Further description of certain constructs

The following provides additional information about some of the constructs described in Examples 1, 2, and 4-7. The structures are "Cov0001" - "Cov0060", "Cov0061" - "Cov0070", "Cov0091" - "Cov0098", "Cov0101" - "Cov0102", "Cov0121" - "Cov0128", "Cov0130", "Cov0132" , "Cov0199" - "Cov0514", "Cov0556" - "Cov0629", "Cov0631", "Cov0633", "Cov0662" - "Cov0690", "Cov0693", and "Cov0722" - "Cov0739". Table 3. Overview of RBD monomer constructs "Cov0001" - "Cov0060" Virus strain N° Identification code virus strain animal origin independent structure RBD construct of SpyTag fusion C- terminal SpyTag N- terminal SpyTag N terminus + S2P6 C terminus 1 SAR-Cov2 (internal sequence) B.1.351 (South African variant) human Cov0001 Cov0016 Cov0031 Cov0046 2 QIA48614 PCoV_GX-P4L pangolin Cov0002 Cov0017 Cov0032 Cov0047 3 QIG55945 MP789 pangolin Cov0003 Cov0018 Cov0033 Cov0048 4 QHR63300 RaTG13 bat Cov0004 Cov0019 Cov0034 Cov0049 5 AGZ48806 RsSHC014 bat Cov0005 Cov0020 Cov0035 Cov0050 6 APO40579 BtKY72 bat Cov0006 Cov0021 Cov0036 Cov0051 7 ALJ94036 BatCoV/BB9904/BGR/2008 bat Cov0007 Cov0022 Cov0037 Cov0052 8 YP_003858584 BM48-31/BGR/2008 bat Cov0008 Cov0023 Cov0038 Cov0053 9 QDF43825 BtRs-BetaCoV/YN2018B bat Cov0009 Cov0024 Cov0039 Cov0054 10 AAV49723 PC4-241 coconut cat Cov0010 Cov0025 Cov0040 Cov0055 11 EPI_ISL_412977 RmYN02 bat Cov0011 Cov0026 Cov0041 Cov0056 12 AIA62330 BtRs-BetaCoV/YN2013 bat Cov0012 Cov0027 Cov0042 Cov0057 13 AGC74165 Rp/Shaanxi2011 bat Cov0013 Cov0028 Cov0043 Cov0058 14 AID16716 Longquan-140 bat Cov0014 Cov0029 Cov0044 Cov0059 15 ABD75323 Rf1/2004 bat Cov0015 Cov0030 Cov0045 Cov0060

Taking Cov001 as an example, the "independent" constructs Cov0001-Cov0015 are the processes shown in Figure 9A. Taking Cov0016 as an example, the "C-terminal SpyTag" construct Cov00016-Cov0030 is the process shown in Figure 9B. Taking Cov0031 as an example, the "N-terminal SpyTag" construct Cov00031-Cov0045 is the process shown in Figure 9C. Taking Cov0046 as an example, the "N-terminal + S2P6 C-terminal" construct Cov00046-Cov0060 is the process shown in Figure 9D. Table 4. Virus strains selected for RBD 3x5 constructs “Cov0061”-“Cov0070” Virus strain N° Identification code virus strain animal origin 1 SAR-Cov2 (internal sequence) B.1.351 (South African variant) human 2 QIA48614 PCoV_GX-P4L pangolin 3 QIG55945 MP789 pangolin 4 QHR63300 RaTG13 bat 5 AGZ48806 RsSHC014 bat

The virus strain numbers in Table 4 are represented by the 5 RBDs of the constructs in Table 5. Table 5. Overview of RBD 3x5 constructs "Cov0061"-"Cov0070" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0061 4 5 1 2 3 GSGSGS (SEQ ID NO.:710) Cov0062 1 5 4 2 3 GSGSGSGSG (SEQ ID NO.:711) Cov0063 1 5 4 3 2 GPPSPPG (SEQ ID NO.:709) Cov0064 1 5 2 3 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0065 1 5 2 4 3 GSGSGS (SEQ ID NO.:710) Cov0066 4 5 3 2 1 GSGSGSGSG (SEQ ID NO.:711) Cov0067 3 5 4 2 1 GPPSPPG (SEQ ID NO.:709) Cov0068 2 5 1 4 3 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0069 4 5 2 1 3 GSGSGS (SEQ ID NO.:710) Cov0070 3 5 1 2 4 GSGSGSGSG (SEQ ID NO.:711) Table 6. Virus strains selected for RBD 3x5 constructs “Cov0091”-“Cov0098” and “Cov0101”-“Cov0102” Virus strain N° Identification code virus strain animal origin 6 APO40579 BtKY72 bat 7 ALJ94036 BatCoV/BB9904/BGR/2008 bat 8 YP_003858584 BM48-31/BGR/2008 bat 9 QDF43825 BtRs-BetaCoV/YN2018B bat 10 AAV49723 PC4-241 coconut cat

The virus strain numbers in Table 6 are represented by the 5 RBDs of the constructs in Table 7. Table 7. Overview of RBD 3x5 constructs "Cov0091"-"Cov0098" and "Cov0101"-"Cov0102" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0091 9 7 10 6 8 GSGSGS (SEQ ID NO.:710) Cov0092 6 10 7 9 8 GSGSGSGSG (SEQ ID NO.:711) Cov0093 10 7 9 6 8 GPPSPPG (SEQ ID NO.:709) Cov0094 10 7 9 8 6 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0095 9 7 10 8 6 GSGSGS (SEQ ID NO.:710) Cov0096 8 9 7 10 6 GSGSGSGSG (SEQ ID NO.:711) Cov0097 6 9 7 10 8 GPPSPPG (SEQ ID NO.:709) Cov0098 8 10 7 9 6 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0101 7 9 8 10 6 GPPSPPG (SEQ ID NO.:709) Cov0102 7 10 8 9 6 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Table 8. Virus strains selected for RBD 3x5 constructs “Cov0121”-“Cov0132” Virus strain N° Identification code virus strain animal origin 11 EPI_ISL_412977 RmYN02 bat 12 AIA62330 BtRs-BetaCoV/YN2013 bat 13 AGC74165 Rp/Shaanxi2011 bat 14 AID16716 Longquan-140 bat 15 ABD75323 Rf1/2004 bat

The virus strain numbers in Table 8 are represented by the 5 RBDs of the constructs in Table 9. Table 9. Overview of RBD 3x5 constructs "Cov0121"-"Cov0132" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0121 15 14 11 13 12 GSGSGS (SEQ ID NO.:710) Cov0122 15 14 11 12 13 GSGSGSGSG (SEQ ID NO.:711) Cov0123 11 14 15 13 12 GPPSPPG (SEQ ID NO.:709) Cov0124 12 14 11 13 15 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0125 12 14 15 13 11 GSGSGS (SEQ ID NO.:710) Cov0126 15 14 12 11 13 GSGSGSGSG (SEQ ID NO.:711) Cov0127 12 14 15 11 13 GPPSPPG (SEQ ID NO.:709) Cov0128 11 14 15 12 13 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0130 12 14 11 15 13 GSGSGSGSG (SEQ ID NO.:711) Cov0132 15 14 12 13 11 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)

The constructs summarized in Tables 5, 7 and 9 include an N-terminally modified signal peptide based on the CD33 signal peptide and a C-terminal linker-His tag sequence GSHHHHHHHH. Table 10. Virus strains selected for use in RBD 2x5 constructs “Cov0151”-“Cov0165” Virus strain N° Identification code virus strain animal origin 1 AGZ48806 RsSHC014 bat 2 APO40579 BtKY72 bat 3 ALJ94036 BatCoV/BB9904/BGR/2008 bat 4 YP_003858584 BM48-31/BGR/2008 bat 5 AAV49723 PC4-241 coconut cat

The virus strain numbers in Table 10 are represented by the 5 RBDs of the constructs in Table 11. Table 11. Overview of RBD 2x5 constructs "Cov0151"-"Cov0165" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0151 1 3 5 2 4 GSGSGS (SEQ ID NO.:710) Cov0152 1 3 5 4 2 GSGSGSGSG (SEQ ID NO.:711) Cov0153 5 3 1 2 4 GPPSPPG (SEQ ID NO.:709) Cov0154 2 5 3 1 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0155 5 3 1 4 2 GSGSGS (SEQ ID NO.:710) Cov0156 4 5 3 1 2 GSGSGSGSG (SEQ ID NO.:711) Cov0157 2 1 3 5 4 GPPSPPG (SEQ ID NO.:709) Cov0158 3 5 2 1 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0159 3 5 4 1 2 GSGSGS (SEQ ID NO.:710) Cov0160 3 1 2 5 4 GSGSGSGSG (SEQ ID NO.:711) Cov0161 4 1 3 5 2 GPPSPPG (SEQ ID NO.:709) Cov0162 3 1 4 5 2 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0163 3 5 2 4 1 GSGSGS (SEQ ID NO.:710) Cov0164 4 5 2 1 3 GSGSGSGSG (SEQ ID NO.:711) Cov0165 4 5 3 2 1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Table 12. Virus strains selected for use in RBD 2x5 constructs " Cov0166 " - " Cov0180 " Virus strain N° Identification code virus strain animal origin 6 SAR-Cov2 (internal sequence) B.1.351 (South African variant) human 7 QIA48614 PCoV_GX-P4L pangolin 8 EPI_ISL_412977 RmYN02 bat 9 AGC74165 Rp/Shaanxi2011 bat 10 ABD75323 Rf1/2004 bat

The virus strain numbers in Table 12 are represented by the 5 RBDs of the constructs in Table 13. Table 13. Overview of RBD 2x5 constructs "Cov0166"-"Cov0180" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0166 10 6 8 7 9 GSGSGS (SEQ ID NO.:710) Cov0167 10 7 8 6 9 GSGSGSGSG (SEQ ID NO.:711) Cov0168 8 6 10 7 9 GPPSPPG (SEQ ID NO.:709) Cov0169 9 6 8 7 10 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0170 8 7 10 6 9 GSGSGS (SEQ ID NO.:710) Cov0171 9 7 8 6 10 GSGSGSGSG (SEQ ID NO.:711) Cov0172 8 6 9 7 10 GPPSPPG (SEQ ID NO.:709) Cov0173 8 7 9 6 10 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0174 9 6 10 7 8 GSGSGS (SEQ ID NO.:710) Cov0175 7 8 6 10 9 GSGSGSGSG (SEQ ID NO.:711) Cov0176 10 6 9 7 8 GPPSPPG (SEQ ID NO.:709) Cov0177 6 8 7 10 9 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0178 7 8 6 9 10 GPPSPPG (SEQ ID NO.:709) Cov0179 6 8 7 9 10 GSGSGSGSG (SEQ ID NO.:711) Cov0180 9 7 10 6 8 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)

The constructs summarized in Tables 11 and 13 include a modified signal peptide based on the CD33 signal peptide and a C-terminal linker-His tag sequence GSHHHHHHHH. Table 14. Virus strains selected for RBD 3x3 constructs “Cov0181”-“Cov0186” Virus strain N° Identification code virus strain animal origin 1 SAR-Cov2 (internal sequence) B.1.351 (South African variant) human 2 QIA48614 PCoV_GX-P4L pangolin 3 QHR63300 RaTG13 bat

The virus strain numbers in Table 14 are represented by the 3 RBDs of the constructs in Table 15. Table 15. Overview of RBD 3x3 constructs "Cov0181"-"Cov0186" construct RBD1 RBD2 RBD3 Connector Cov0181 1 2 3 GSGSGS (SEQ ID NO.:710) Cov0182 3 2 1 GSGSGSGSG (SEQ ID NO.:711) Cov0183 3 1 2 GPPSPPG (SEQ ID NO.:709) Cov0184 2 1 3 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0185 1 3 2 GSGSGS (SEQ ID NO.:710) Cov0186 2 3 1 GSGSGSGSG (SEQ ID NO.:711) Table 16. Virus strains selected for use in RBD 3x3 constructs “Cov0187”-“Cov0192” Virus strain N° Identification code virus strain animal origin 4 APO40579 BtKY72 bat 5 YP_003858584 BM48-31/BGR/2008 bat 6 AAV49723 PC4-241 coconut cat

The virus strain numbers in Table 16 are represented by the 3 RBDs of the constructs in Table 17. Table 17. Overview of RBD 3x3 constructs "Cov0187"-"Cov0192" construct RBD1 RBD2 RBD3 Connector Cov0187 4 6 5 GPPSPPG (SEQ ID NO.:709) Cov0188 5 6 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0189 6 4 5 GSGSGS (SEQ ID NO.:710) Cov0190 5 4 6 GSGSGSGSG (SEQ ID NO.:711) Cov0191 4 5 6 GPPSPPG (SEQ ID NO.:709) Cov0192 6 5 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Virus strain / isolate NCBI registration number origin S2P6 replica number Connector Folder - S2P6 Replica 1 construct B.1.351 SARS-Cov2 South Africa N/A (internal) human 1 GPP Cov0204 2 GPP Cov0205 3 GPP Cov0206 1 GSG Cov0207 2 GSG Cov0208 3 GSG Cov0209 PCoV_GX-P5L QIA48632 pangolin 1 GPP Cov0210 2 GPP Cov0211 3 GPP Cov0212 1 GSG Cov0213 2 GSG Cov0214 3 GSG Cov0215 PC4-241 AAV49723 coconut cat 1 GPP Cov0216 2 GPP Cov0217 3 GPP Cov0218 1 GSG Cov0219 2 GSG Cov0220 3 GSG Cov0221 HKU3-12 ADE34812 bat 1 GPP Cov0222 2 GPP Cov0223 3 GPP Cov0224 1 GSG Cov0225 2 GSG Cov0226 3 GSG Cov0227 BtRf-BetaCoV/JL2012 AIA62277 bat 1 GPP Cov0228 2 GPP Cov0229 3 GPP Cov0230 1 GSG Cov0231 2 GSG Cov0232 3 GSG Cov0233 Table 18. Virus strains selected for use in RBD 3x3 constructs “Cov0193”-“Cov0198” Virus strain N° Identification code virus strain animal origin 7 EPI_ISL_412977 RmYN02 bat 8 AGC74165 Rp/Shaanxi2011 bat 9 ABD75323 Rf1/2004 bat

The virus strain numbers in Table 18 are represented by the 3 RBDs of the constructs in Table 19. Table 19. Overview of RBD 3x3 constructs "Cov0193"-"Cov0198" construct RBD1 RBD2 RBD3 Connector Cov0193 7 8 9 GSGSGS (SEQ ID NO.:710) Cov0194 9 7 8 GSGSGSGSG (SEQ ID NO.:711) Cov0195 9 8 7 GPPSPPG (SEQ ID NO.:709) Cov0196 8 7 9 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0197 7 9 8 GSGSGSGSG (SEQ ID NO.:711) Cov0198 8 9 7 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)

The constructs summarized in Tables 15, 17 and 19 include a modified signal peptide based on the CD33 signal peptide and a C-terminal linker-His tag sequence GSHHHHHHHH. Table 20. Summary of constructs "Cov0204"-"Cov0233" containing part of the extracellular domain of spike protein and one or more copies of engineered sequences based on the S2P6 antibody epitope Virus strain / isolate NCB registration number origin S2P6 replica number Connector Folder - S2P6 Replica 1 construct B.1.351 SARS-Cov2 South Africa N/A (internal) human 1 GPP Cov0204 2 GPP Cov0205 3 GPP Cov0206 1 GSG Cov0207 2 GSG Cov0208 3 GSG Cov0209 PCoV_GX-P5L QIA48632 pangolin 1 GPP Cov0210 2 GPP Cov0211 3 GPP Cov0212 1 GSG Cov0213 2 GSG Cov0214 3 GSG Cov0215 PC4-241 AAV49723 coconut cat 1 GPP Cov0216 2 GPP Cov0217 3 GPP Cov0218 1 GSG Cov0219 2 GSG Cov0220 3 GSG Cov0221 HKU3-12 ADE34812 bat 1 GPP Cov0222 2 GPP Cov0223 3 GPP Cov0224 1 GSG Cov0225 2 GSG Cov0226 3 GSG Cov0227 BtRf-BetaCoV/JL2012 AIA62277 bat 1 GPP Cov0228 2 GPP Cov0229 3 GPP Cov0230 1 GSG Cov0231 2 GSG Cov0232 3 GSG Cov0233

All four zoonotic spike protein sequences contain a substitution mutation to proline at the equivalent position before fusion (see the rectangle in the partial sequence alignment in Figure 50A), and at the S1/S2 cleavage site, Arg is replaced by Ser (See the rectangle in the partial sequence alignment in Figure 50B).

The engineered sequence based on the S2P6 epitope is: PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) ("S2P6" in Table 20). The linker that separates different copies of SEQ ID NO.:701 is -GS-. The Cov0222 sequence is incomplete due to an error resulting in the absence of the C-terminal foldon, followed by a copy of reengineered S2P6. Some constructs (e.g. Cov0204, Cov0205, Cov0207, Cov0208) contain an additional, unexpected -GS- between the last S2P6 sequence copy and the GSG-His-tag sequence, namely GSGSGHHHHHHHHH . Table 21. Overview of Spinin-RBD fusion construct “Cov0239”-“Cov0250” construct RBDs fused to spinin Linker Foldon -RBD1 Connector between RBDs C- terminal S2P6 Cov0239 1 GSGSGSGSG (SEQ ID NO.:711) GSGSGSGSG (SEQ ID NO.:711) no Cov0240 2 GSGSGSGSG (SEQ ID NO.:711) GSGSGSGSG (SEQ ID NO.:711) no Cov0241 3 GSGSGSGSG (SEQ ID NO.:711) GSGSGSGSG (SEQ ID NO.:711) no Cov0242 1 GSGSGSGSG (SEQ ID NO.:711) GSGSGSGSG (SEQ ID NO.:711) yes Cov0243 2 GSGSGSGSG (SEQ ID NO.:711) GSGSGSGSG (SEQ ID NO.:711) yes Cov0244 3 GSGSGSGSG (SEQ ID NO.:711) GSGSGSGSG (SEQ ID NO.:711) yes Cov0245 1 GPPPGSFKEELDKYFKNHTSDAASKAGP PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) no Cov0246 2 GPPPGSFKEELDKYFKNHTSDAASKAGP PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) no Cov0247 3 GPPPGSFKEELDKYFKNHTSDAASKAGP PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) no Cov0248 1 GPPPGSFKEELDKYFKNHTSDAASKAGP PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) yes Cov0249 2 GPPPGSFKEELDKYFKNHTSDAASKAGP PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) yes Cov0250 3 GPPPGSFKEELDKYFKNHTSDAASKAGP PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) yes

For constructs "Cov0239"-"Cov0250", the spike protein extracellular domain and RBD are from the SARS-CoV-2 South African variant backbone. The sequence based on the S2P6 epitope (PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)) is used in constructs Cov0245-Cov0250 as part of the linker between the foldon and the first RBD and as a linker between the two RBDs, and C-terminal elements in Cov0242-0244 and Cov0248-Cov0250.

Constructs Cov0251-Cov0382 are discussed in Example 4; see also Table 2 and partial sequences/mutations summarized in Figures 5A-5G. Taking Cov0251 as an example, these structures are the processes shown in Figure 10. Table 22. Overview of SpyTag-RBD fusion construct "Cov0592"-"Cov0601" Virus strain N° Identification code virus strain animal origin construct 1 QHD43416.1 Wuhan human Cov0592 2 internal sequence B.1.617.2 (India) human Cov0593 3 internal sequence A.27 (Mayotte) human Cov0594 4 internal sequence B.1.351 (South Africa) human Cov0595 5 N/A A.27+S494P Engineering Cov0596 6 N/A B1.1.7 + E484K + S494P Engineering Cov0597 7 QIA48632.1 GX-Pangolin pangolin Cov0598 8 AAV49723.1 SARS-CoV1 PC4-241 human Cov0599 9 ATO98157.1 Rs4231 bat Cov0600 10 AVP78031.1 ZC45 bat Cov0601

Constructs Cov0592-Cov0601 contain the general organization shown in Figure 11 (the amino acid numbers in Figure 11 are irrelevant to all such constructs and can be ignored for the purpose of illustrating the general organization of the construct). Table 23. Virus strains selected for RBD 2x5 concatemer constructs “Cov0602”-“Cov0631” and “Cov0633” Virus strain N° Identification code virus strain animal origin 1 QHD43416.1 Wuhan human 3 internal sequence A.2 (Mayotte) human 6 N/A B1.1.7 + E484K + S494P Engineering 10 AVP78031.1 ZC45 bat 8 AAV49723.1 SARS-Cov1PC4-241 human

The virus strain numbers in Table 23 are represented by the 5 RBDs of the constructs in Table 24. Table 24. Overview of RBD 2x5 concatemer construct "Cov0602" - "Cov0631" and "Cov0633" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0602 1 10 3 8 6 GSGSGS (SEQ ID NO.:710) Cov0603 1 8 3 10 6 GSGSGSGSG (SEQ ID NO.:711) Cov0604 1 8 6 10 3 GPPSPPG (SEQ ID NO.:709) Cov0605 1 10 6 8 3 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0606 6 10 1 8 3 GSGSGS (SEQ ID NO.:710) Cov0607 6 8 1 10 3 GSGSGSGSG (SEQ ID NO.:711) Cov0608 6 8 3 10 1 GPPSPPG (SEQ ID NO.:709) Cov0609 6 10 3 8 1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0610 3 10 6 8 1 GSGSGS (SEQ ID NO.:710) Cov0611 3 8 6 10 1 GSGSGSGSG (SEQ ID NO.:711) Cov0612 3 8 1 10 6 GPPSPPG (SEQ ID NO.:709) Cov0613 3 10 1 8 6 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0614 1 8 10 3 6 GSGSGS (SEQ ID NO.:710) Cov0615 1 10 8 3 6 GSGSGSGSG (SEQ ID NO.:711) Cov0616 1 10 8 6 3 GPPSPPG (SEQ ID NO.:709) Cov0617 1 8 10 6 3 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0618 1 6 8 10 3 GSGSGS (SEQ ID NO.:710) Cov0619 1 6 10 8 3 GSGSGSGSG (SEQ ID NO.:711) Cov0620 6 1 10 8 3 GPPSPPG (SEQ ID NO.:709) Cov0621 6 1 8 10 3 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0622 6 3 8 10 1 GSGSGS (SEQ ID NO.:710) Cov0623 6 3 10 8 1 GSGSGSGSG (SEQ ID NO.:711) Cov0624 3 6 10 8 1 GPPSPPG (SEQ ID NO.:709) Cov0625 3 6 8 10 1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0626 3 8 10 6 1 GSGSGS (SEQ ID NO.:710) Cov0627 3 10 8 6 1 GSGSGSGSG (SEQ ID NO.:711) Cov0628 3 10 8 1 6 GPPSPPG (SEQ ID NO.:709) Cov0629 3 8 10 1 6 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0631 3 1 10 8 6 GSGSGSGSG (SEQ ID NO.:711) Cov0633 6 8 10 1 3 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Table 25. Virus strains selected for RBD 2x5 concatemer constructs “Cov0662”-“Cov0690” and “Cov0693” Virus strain N° Identification code virus strain animal origin 2 internal sequence B.1.617.2 (India) human 4 internal sequence B.1.351 (South Africa) human 5 N/A A.27+S494P Engineering 7 QIA48632.1 GX-Pangolin pangolin 9 ATO98157.1 Rs4231 bat

The virus strain numbers in Table 25 are represented by the 5 RBDs of the constructs in Table 26. Table 26. Overview of RBD 2x5 concatemer constructs "Cov0662" - "Cov0690" and "Cov0693" construct RBD1 RBD2 RBD3 RBD4 RBD5 Connector Cov0662 4 9 2 7 5 GSGSGS (SEQ ID NO.:710) Cov0663 5 7 2 9 4 GSGSGSGSG (SEQ ID NO.:711) Cov0664 2 9 4 7 5 GPPSPPG (SEQ ID NO.:709) Cov0665 5 7 4 9 2 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0666 4 7 5 9 2 GSGSGS (SEQ ID NO.:710) Cov0667 4 7 2 9 5 GSGSGSGSG (SEQ ID NO.:711) Cov0668 2 9 5 7 4 GPPSPPG (SEQ ID NO.:709) Cov0669 5 9 2 7 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0670 2 7 5 9 4 GSGSGS (SEQ ID NO.:710) Cov0671 4 9 5 7 2 GSGSGSGSG (SEQ ID NO.:711) Cov0672 2 7 4 9 5 GPPSPPG (SEQ ID NO.:709) Cov0673 5 9 4 7 2 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0674 2 9 4 5 7 GSGSGS (SEQ ID NO.:710) Cov0675 7 2 9 4 5 GSGSGSGSG (SEQ ID NO.:711) Cov0676 7 2 9 5 4 GPPSPPG (SEQ ID NO.:709) Cov0677 7 5 4 9 2 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0678 5 4 9 2 7 GSGSGS (SEQ ID NO.:710) Cov0679 4 5 9 2 7 GSGSGSGSG (SEQ ID NO.:711) Cov0680 4 2 9 5 7 GPPSPPG (SEQ ID NO.:709) Cov0681 7 5 9 2 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0682 7 5 2 9 4 GSGSGS (SEQ ID NO.:710) Cov0683 4 9 2 5 7 GSGSGSGSG (SEQ ID NO.:711) Cov0684 2 9 5 4 7 GPPSPPG (SEQ ID NO.:709) Cov0685 5 9 2 4 7 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0686 7 4 5 9 2 GSGSGS (SEQ ID NO.:710) Cov0687 7 4 2 9 5 GSGSGSGSG (SEQ ID NO.:711) Cov0688 2 9 7 5 4 GPPSPPG (SEQ ID NO.:709) Cov0689 5 7 9 2 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0690 4 5 7 9 2 GSGSGS (SEQ ID NO.:710) Cov0693 7 2 4 9 5 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)

Constructs "Cov0662" - "Cov0690" and "Cov0693" contain the signal peptide from H7 HA (A/HongKong/125/2017), followed by the GSG linker, then the SpyTag, then the Townsend linker (GSGGSGGSGGTG), then for polylinked RBDs. A C-terminal GS-His tag (GSHHHHHHHH) is included for purification purposes. Table 27. Virus strains selected for RBD 3x3 concatemer construct “Cov0722”-“Cov0727” Virus strain N° Identification code virus strain animal origin 1 QHD43416.1 Wuhan human 3 internal sequence A.27 (Mayotte) human 9 AVP78031.1 ZC45 bat

The virus strain numbers in Table 27 are represented by the 3 RBDs of the constructs in Table 28. Table 28. Overview of RBD 3x3 concatemer constructs "Cov0722"-"Cov0727" construct RBD1 RBD2 RBD3 Connector Cov0722 1 3 9 GSGSGS (SEQ ID NO.:710) Cov0723 9 3 1 GSGSGSGSG (SEQ ID NO.:711) Cov0724 9 1 3 GPPSPPG (SEQ ID NO.:709) Cov0725 3 1 9 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0726 1 9 3 GSGSGS (SEQ ID NO.:710) Cov0727 3 9 1 GSGSGSGSG (SEQ ID NO.:711) Table 29. Virus strains selected for RBD 3x3 construct “Cov0728”-“Cov0733” Virus strain N° Identification code virus strain animal origin 4 internal sequence B.1.351 (South Africa) human 5 N/A A.27+S494P Engineering 7 AAV49723.1 SARS-Cov1 PC4-241 human

The virus strain numbers in Table 29 are represented by the three RBDs of the constructs in Table 30. Table 30. Overview of RBD 3x3 concatemer construct "Cov0728"-"Cov0733" construct RBD1 RBD2 RBD3 Connector Cov0728 4 7 5 GSGSGS (SEQ ID NO.:710) Cov0729 5 7 4 GSGSGSGSG (SEQ ID NO.:711) Cov0730 7 4 5 GPPSPPG (SEQ ID NO.:709) Cov0731 5 4 7 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0732 4 5 7 GPPSPPG (SEQ ID NO.:709) Cov0733 7 5 4 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Table 31. Virus strains selected for RBD 3x3 concatemer construct “Cov0734”-“Cov0739” Virus strain N° Identification code virus strain animal origin 2 internal sequence B.1.617.2 (India) human 6 QIA48632.1 GX-Pangolin pangolin 8 ATO98157.1 Rs4231 bat

The virus strain numbers in Table 31 are represented by the three RBDs of the construct in Table 32. Table 32. Overview of RBD 3x3 concatemer constructs "Cov0734"-"Cov0739" Project ID RBD1 RBD2 RBD3 Connector Cov0734 2 6 8 GSGSGS (SEQ ID NO.:710) Cov0735 8 2 6 GSGSGSGSG (SEQ ID NO.:711) Cov0736 8 6 2 GPPSPPG (SEQ ID NO.:709) Cov0737 6 2 8 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0738 2 8 6 GSGSGSGSG (SEQ ID NO.:711) Cov0739 6 8 2 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)

Constructs "Cov0722" - "Cov0739" contain the signal peptide from H7 HA (A/HongKong/125/2017), followed by the GSG linker, followed by SpyTag, followed by the Townsend linker (GSGGSGGSGGTG), followed by concatenated RBDs . A C-terminal GS-His tag (GSHHHHHHHH) is included for purification purposes. Table 33. Overview of Spinin-RBD-Hybrid Constructs "Cov0556"-"Cov0592" construct RBD1 RBD2 Connector Cov0556 India - GSGSGSGSG (SEQ ID NO.:711) Cov0557 SARS-Cov1 - GSGSGSGSG (SEQ ID NO.:711) Cov0558 A.27-S494P - GSGSGSGSG (SEQ ID NO.:711) Cov0559 Wuhan - GSGSGSGSG (SEQ ID NO.:711) Cov0560 Wuhan SA GSGSGSGSG (SEQ ID NO.:711) Cov0561 Wuhan India GSGSGSGSG (SEQ ID NO.:711) Cov0562 Wuhan SARS-Cov1 GSGSGSGSG (SEQ ID NO.:711) Cov0563 Wuhan A.27-S494P GSGSGSGSG (SEQ ID NO.:711) Cov0564 SA India GSGSGSGSG (SEQ ID NO.:711) Cov0565 SA SARS-Cov1 GSGSGSGSG (SEQ ID NO.:711) Cov0566 SA A.27-S494P GSGSGSGSG (SEQ ID NO.:711) Cov0567 India SARS-Cov1 GSGSGSGSG (SEQ ID NO.:711) Cov0568 India A.27-S494P GSGSGSGSG (SEQ ID NO.:711) Cov0569 A.27-S494P SARS-Cov1 GSGSGSGSG (SEQ ID NO.:711) Cov0570 SARS-Cov1 Wuhan GSGSGSGSG (SEQ ID NO.:711) Cov0571 SARS-Cov1 SA GSGSGSGSG (SEQ ID NO.:711) Cov0572 SARS-Cov1 India GSGSGSGSG (SEQ ID NO.:711) Cov0573 SARS-Cov1 A.27-S494P GSGSGSGSG (SEQ ID NO.:711) Cov0574 India - PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0575 SARS-Cov1 - PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0576 A.27-S494P - PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0577 Wuhan - PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0578 Wuhan SA PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0579 Wuhan India PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0580 Wuhan SARS-Cov1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0581 Wuhan A.27-S494P PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0582 SA India PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0583 SA SARS-Cov1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0584 SA A.27-S494P PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0585 India SARS-Cov1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0586 India A.27-S494P PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0587 A.27-S494P SARS-Cov1 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0588 SARS-Cov1 Wuhan PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0590 SARS-Cov1 SA PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0591 SARS-Cov1 India PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Cov0592 SARS-Cov1 A.27-S494P PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) Example 9 Neutralizing antibodies against the conserved antigenic region in the stem helix of the beta coronavirus S protein

To identify mAbs targeting a highly conserved region of the S glycoprotein, human IgG ⁺ memory B cells from COVID-19 convalescent donors were queried. Identification of mAbs that bind to viruses belonging to all three subgenus beta-coronaviruses that infect humans (i.e., SARS-CoV and SARS-CoV-2), MERS-CoV and E. The prefusion-stabilized S ectodomain trimer of shellfish coronaviruses (OC43 and HKU1) but does not bind to human alpha-coronaviruses (229E and NL63). The binding of monoclonal antibody S2P6 to the spike proteins of different human beta-coronaviruses was tested by enzyme-linked immunosorbent assay (ELISA; Figure 12). S2P6 contains a VH comprising the sequence provided in SEQ ID NO:26 and a VL comprising the sequence provided in SEQ ID NO:30. Coated at 1 µg/ml from SARS-CoV (Urbani strain, GenBank: AAP13441; ncbi.nlm.nih.gov/protein/30027620), SEQ ID NO:22, SARS-CoV-2 (BetaCoV/Wuhan-Hu -1/2019, GenBank: MN908947), SEQ ID NO:3, MERS (Lundon1/2012; GenBank: KC164505), SEQ ID NO:24, OC43 (GenBank AAT84362.1), SEQ ID NO:23 and HKU1 (GenBank YP_173238.1), SEQ ID NO:25 pre-fusion stabilized spike protein, and only PBS was used as a negative control. The half-maximal effective concentration (EC50) is determined and reported in ng/ml. Antibody binding to alpha-coronavirus was also measured by ELISA; no binding was observed (data not shown).

Additional monoclonal antibodies S2S40, S2S41, S2S42, S2S43 and S2X529 were tested for binding to the spike proteins of different human beta-coronaviruses and to the spike protein subunit S2 of SARS-CoV-2, as described above. The results are shown in Table 34. Table 34. antibody SARS-CoV-2 spike protein SARS-CoV-2 S2 SARS spike protein MERS spike protein OC43 spike protein HKU-1 spike protein S2S40 + + + - + - S2S41 + + + + + - S2S42 + - - - + + S2S43 + + + + + - S2X529 + nd + + + -

The binding of S2P6 (represented as recombinant IgG1 carrying the M428L/N434S Fc mutation; "MLNS") to the spike proteins of different human betacoronaviruses expressed on the surface of mammalian cells was measured by flow cytometry. Briefly, Expi-CHO cells were transiently transfected with phCMV1 expression plasmid encoding the full-length spike protein from human betacoronavirus. Measures binding to spike proteins from SARS-CoV-2 (BetaCoV/Wuhan-Hu-1/2019), SARS-CoV (Urbani strain, AAP13441), OC43, and MERS-CoV (London1/2012).

In addition, the binding of S2P6 to S1, S2 and receptor-binding domain (RBD) from SARS-CoV-2 (BetaCoV/Wuhan-Hu-1/2019) S protein was measured by ELISA. Coat protein at 1 µg/ml. The results indicate that S2P6 binds in S2.

The neutralizing activity of S2P6 against SARS-CoV-2 virus infection was assessed using a luciferase reporter assay. VeroE6 cells were infected with SARS-CoV-2-luciferase reporter virus at a magnification of infection (MOI) of 0.01 for 24 hours. A curve was generated showing the percent neutralization as the antibody concentration increased and the calculated IC50 value (ng/ml). The neutralizing effect of comparative antibody "S309" was also tested (see Pinto et al., Cross-neutralizaiton of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , Nature 583:290-295 (July 2020)); in In this analysis, S2P6 was a less potent neutralizer than S309.

Neutralization of pseudotyped viruses by S2P6 was assessed by luciferase reporter assay. S2P6 neutralization of MERS-CoV in Huh7 cells and SARS-CoV-2 in Vero E6 cells was examined. The neutralizing effects of antibodies LCA60 (anti-MERS; Corti et al., PNAS 122 (33):10473-10478 (2015)) and S309 were also measured and compared. Neutralization IC50 values (reported in µg/ml) are: for MERS PVs, LCA60=0.01246, S2P6=6.328; for SARS-CoV-2 PVs, S309=0.2649, S2P6=4.679.

Conduct further research. Another antibody, S2S8, but not S2P6, was cross-reactive against alpha-coronavirus. In the Syrian hamster model, S2P6 can activate human FcγRIIa (H131 allele) and FcγRIIIa (V158 allele), trigger effector functions, and prevent SARS-CoV-2 infection (Figures 18, 26, and 27). S2P6 binding does not block SARS-CoV-2 RBD binding to human ACE2. S2P6 uses Vero-E6 cells transfected with SARS-CoV-2 S to inhibit cell-cell fusion.

Peptide mapping studies were performed to identify epitope regions. See Figures 17, 27 and 22. According to these studies, S2P6 binds to conserved epitopes in the stem helix region of β-coronavirus (Figure 22; for example, the SARS-CoV-2 motif F ₁₁₄₈ KEELDKYF ₁₁₅₆ located in the stem helix within the S2 subunit, which is found in human β -highly conserved in coronaviruses).

S2P6 was shown to bind to all full-length SARS-CoV-2 S variants tested and to 24 S glycoproteins representing all SARS-CoV-2 clade transiently expressed on the surface of ExpiCHO cells (Figures 20, 29A-29C and 30). S2P6 binds equally well to the stem-helical peptides of the five beta-coronaviruses that infect humans (albeit with a faster dissociation rate for HKU1) as well as MERS-CoV-related bat viruses (HKU4 and HKU5) and murine hepatitis virus (MHV) (data not shown). S2P6 also exhibits binding to the fused SARS-CoV-2 spike protein, even though its epitope appears to be buried at the interface between the targeting protomer and the other two protomers of the rod trimer of spike protein, and therefore, May not be expected to be fully accessible (data not shown). Other discussions

S2P6 activates immune cell-dependent effector functions in vitro and protects hamsters challenged with SARS-CoV-2 Wuhan-1 and B.1.351 strains. Serology and B-cell lineage analysis, as well as germline reversal of the cross-reactive mAbs identified here, indicate that the generation of pan-β-coronavirus mAbs requires rare events of somatic mutation. The S2P6 and S2S43 mAbs were derived from two donors and used the VH1-46*01 and D5-12*01 genes. Overall, the level of somatic mutations in the variable regions of these mAbs is limited. The mAb binds to prefusion and postfusion SARS-CoV-2 S with comparable apparent affinities, indicating that its homologous epitope is available in two conformational states of the S glycoprotein.

S2P6 was selected for further characterization and demonstrated that S2P6 binds to all full-length SARS-CoV-2 S variants tested and to 24 S sugars representing all Sabey coronavirus clades transiently expressed on the surface of ExpiCHO cells protein. Using surface plasmon resonance (SPR), it was found that the S2P6 Fab fragment has the highest affinity for SARS-CoV-2 S and SARS-CoV S, followed by MERS-CoV S and OC43 S, with equilibrium dissociation constants (KD) of 7 respectively. , 7, 12 and 16 nM. S2P6 also binds to HKU1 S, albeit with reduced affinity (K _D of approximately 120 nM). Recognition of prefusion SARS-CoV-2 S by this mAb is pH-dependent, with higher binding affinity at pH 7 relative to pH 5 in both IgG and Fab formats. These data demonstrate the unique and potent cross-reactivity of S2P6 against all beta-coronaviruses infecting humans.

To evaluate the neutralization potency and breadth of S2P6, its ability to inhibit the entry of true SARS-CoV-2 into Vero-E6 cells in the presence or absence of S-activated protease TMPRSS2 was studied. S2P6 completely neutralized infection of TMPRSS2-positive Vero-E6 cells but was less effective in neutralizing infection of Vero-E6 cells. Previous studies determined that the primary route of entry of SARS-CoV-2 into cultured lung cells occurs via activating fusion of TMPRSS2 with the plasma membrane (Hoffmann, Mösbauer et al. 2020; Hoffmann, Kleine-Weber et al. 2020; Hoffmann, Kleine-Weber and Pöhlmann 2020). More efficient S2P6-mediated neutralization of SARS-CoV-2 entry into Vero-E6 cells expressing TMPRSS2 relative to cells lacking this protease is consistent with inhibitory binding at endosomal pH and suggests that S2P6 is responsible for lung cell infection The relevant virus entry paths are as effective as possible. Assessment of S2P6-mediated resistance to vesicular stomatitis virus (VSV) pseudotyped with SARS-CoV-2 S and several variants of interest (VOC), including B.1.1.7, B.1.351, and P.1 ) and (Kaname et al. 2010). Similar potency was observed against the parental SARS-CoV-2 D614G S. In addition, S2P6 inhibited SARS-CoV S, Guangdong Pangolin 2019 (P-GD) S, MERS-CoV S and OC43 S VSV pseudotypes with IC50 values ranging from 0.02 to 17 μg/ml. S2P6 thus features unprecedented neutralizing activity against a broad range of beta-coronaviruses, including SARS-CoV-2 and circulating VOCs.

To define the epitopes recognized by the identified mAbs, peptide mapping experiments were performed using 15-mer linear overlapping peptides. All mAbs were found to bind to a peptide containing the SARS-CoV-2 motif F1148KEELDKYF1156, which is located in the stem helix within the S2 subunit. This region is highly conserved among beta-coronaviruses and overlaps with the epitopes of B6 and 28D9, two mAbs previously identified after immunization of mice (Sauer et al. 2020; Wang et al. 2021) . S2P6 binds in similar amounts to the stem helices of five beta-coronaviruses that infect humans (albeit with a faster dissociation rate for HKU1) as well as MERS-CoV-related bat viruses (HKU4 and HKU5) and murine hepatitis virus (MHV) Peptides. S2S43 exhibits similar overall binding to S2P6, with significantly less reactivity to HKU1, HKU4 and HKU5 peptides.

Viral escape mutation selection was performed in vitro using replication-competent VSV-SARS-CoV-2 S chimeric viruses in the presence of S2P6 (Case et al. 2020). After the second passage, virus neutralization by S2P6 was completely eliminated and deep sequencing analysis revealed the emergence of five different resistance mutations: L1152F, D1153N/G/A and F1156L. These mutations are consistent with reduced binding by S2P6 in substitution scanning analysis. The cumulative frequency of these mutations is greater than 90% after the second passage and they appear as quasispecies (i.e., they are not visible within the same sequenced read). Isolation of neutralization escape mutants at key interface residues highlights the critical role of the identified interactions for S2P6 mAb binding. However, such mutations have been detected in circulating SARS-CoV-2 isolates at a very low prevalence (0.01%, 146 of 1,217,814 sequences as of April 30, 2021).

To verify the inferred mechanism of S2P6-mediated broad coronavirus neutralization, we first demonstrated using ELISA that S2P6 binding does not block the engagement of SARS-CoV-2 S by ACE2. However, S2P6 blocks cell-cell fusion between Vero-E6 cells transfected with full-length SARS-CoV-2 S, which is as effective as the S2M11 mAb that locks SARS-CoV-2 S in the closed state (M. A. Tortorici et al. People. 2020). mAbs targeting RBD antigenic sites Ia (e.g., S2E12) and IIa (e.g., S2X259 or S2X35) have been described that can mimic receptor attachment and prematurely trigger profusion S conformational changes (A. C. Walls et al. 2019; Lempp et al. 2021; Piccoli et al. 2020). Thus, S2P6 eliminates the formation of fused cells mediated by S2E12 at concentrations as low as 1 ng/ml. Overall, these results suggest that the primary mechanism of S2P6 neutralization is prevention of viral entry via inhibition of membrane fusion resulting from blocking S-fusogenic rearrangements. S2P6-mediated protection against SARS-CoV-2 challenge is enhanced by Fc-mediated effector functions in hamsters

Fc-mediated effector functions may contribute to in vivo protection by promoting viral clearance and antiviral immune responses (Schäfer et al. 2021; Bournazos, Wang, and Ravetch 2016; Bournazos et al. 2020; Winkler et al. 2020) . Analyze the potential of S2P6 to trigger the activation of FcγRIIa and FcγRIIIa and exert Fc effector functions in vitro. S2P6 promotes moderate dose-dependent FcγRIIa- and FcγRIIIa-mediated signaling using a luciferase reporter assay. After incubation of ExpiCHO target cells (CHO-S) expressing SARS-CoV-2 S with human NK cells, S2P6 promotes robust activation of Ab-dependent cellular cytotoxicity (ADCC) to a level comparable to that observed with the S309 mAb level (Pinto et al. 2020). Using Cell-Trace-Violet labeled peripheral blood mononuclear cells (PBMC) as phagocytes and CHO-S cells, S2P6 also exhibited Ab-dependent cellular phagocytosis (ADCP) activity. Finally, S2P6 does not promote complement-dependent cytotoxicity (CDC), indicating that S2P6 Fc-mediated effector functions, rather than complement activation, may be involved in viral control in vivo.

To evaluate the protective activity of S2P6 (containing fully human IgG1 or hamster IgG2a constant regions) against challenge with prototype (Wuhan-1 related) SARS-CoV-2 in a Syrian hamster model (Boudewijns et al. 2020). Previous findings showed that human IgG1 mAb does not recognize hamster FcgRs (Lempp et al. 2021); therefore S2P6 was also produced in a hamster IgG2 format to provide optimal interaction with hamster FcgRs. Two different doses of human IgG1 (Hu-S2P6) or hamster IgG2 (Hm-S2P6) were administered 24 hours before intranasal SARS-CoV-2 challenge, and the animals' lungs were assessed for viral RNA load and 4 days postinfection. Replicate the virus. Hm-S2P6 administered at 20 mg/kg reduced viral RNA replicas and replicating virus titers in hamster lungs by two orders of magnitude relative to the control (irrelevant) mAb. Furthermore, 20 mg/kg Hm-S2P6 reduced viral RNA copies detected in the lungs to levels significantly lower than those observed with Hu-S2P6, indicating a beneficial role for S2P6 effector function in vivo. Based on the comparable S2P6 neutralizing potency observed in vitro against SARS-CoV-2 VOCs, the protective efficacy of S2P6 in hamsters challenged with SARS-CoV-2 B.1.351 was evaluated. Prophylactic administration of Hu-S2P6 at 20 mg/kg reduced the titer of replicating virus (but not the number of RNA copies) in the lungs by approximately 1.5 orders of magnitude relative to the control group, consistent with the stem-helix table among all VOCs identified to date. Strict conservation of bits.

Collectively, these findings indicate that Abs targeting highly conserved epitopes in the S fusion machinery can trigger Fc-mediated ADCC and ADCP in vitro and protect against SARS-CoV-2 via both neutralization and effector functions in vivo attack. Natural infection or vaccination primarily elicits stem-helix-directed Abs with narrow specificity

To understand the frequency of triggering stem-helix-specific Abs, serological analyzes were performed using plasma samples from pre-pandemic, convalescent, and vaccinated individuals. The binding potency of plasma IgG to stem-helical peptides of SARS-CoV-2/SARS-CoV (SARS-CoV/-2), OC43, MERS-CoV, HKU1, HKU4 and HKU5 was determined. Overall, plasma Ab binding to stem-helical peptides was not found in pre-pandemic samples, with the exception of HKU1, possibly reflecting previous infection with this virus in this cohort. In contrast, low frequencies of stem-helix-specific Ab were found in individuals previously infected with SARS-CoV-2 or who received a second dose of the mRNA vaccine. Overall, these data demonstrate that plasma Ab responses to stem helices are induced following SARS-CoV-2 infection or vaccination but are relatively rare.

Stems in the memory B cell lineage of 21 convalescent and 17 vaccinated individuals were studied using a lineage analysis based on in vitro multiline stimulation, termed here antigen-specific B cell memory lineage analysis (AMBRA). Frequency of helix-specific Abs (Pinna et al. 2009). In both cohorts, stem-helix-specific IgGs frequencies in the range 0.1-2.5% were observed, except for one individual (infected and vaccinated with a single dose of mRNA vaccine), for which 97% was measured Frequency of SARS-CoV/-2-specific Abs. Most SARS-CoV-2 stem helix-specific Abs were found to cross-react with OC43, consistent with the higher sequence identity of the stem helices of these two viruses. Abs specific for the HKU1 S stem helix were found in some individuals but did not cross-react with other b-coronaviruses. This analysis revealed a single instance of cross-reactivity to all stem-helix b-coronavirus peptides tested.

These findings indicate that stem-helix Abs are rarely induced following SARS-CoV-2 infection or vaccination and appear to have limited cross-reactivity among b-coronaviruses. Broadly reactive b-coronavirus Abs gain affinity and breadth through somatic mutation

To define the ontogeny of S2P6, a set of germline variants was generated. Two of the seven S2P6 heavy chain residues mutated relative to the germline contribute to epitope recognition (Q32 and H57), whereas none of the five light chain mutated residues are involved in S binding. In response to the effects of somatic mutations in VH and VK, a set of heavy or light chains or two variable regions (VH and VK) of S2P6 germline variants are generated. Complete germline S2P6 (UCA) binds to OC43 and MERS-CoV stem-helix peptides (with an EC50 approximately 1 order of magnitude higher than mutant mAbs) but not to SARS-CoV/-2 or HKU1 peptides. Somatic mutations in VH are sufficient for high-affinity binding to SARSCoV/-2, while VH and VK mutations are required for optimal binding to HKU1. The presence of residue G103 in CDRH3 was found to be necessary for binding to all b-coronaviruses. Collectively, these findings indicate that the S2P6 mAb may be generated in response to OC43 infection and have its specificity expanded to SARS-CoV-2 through somatic mutations selected during natural infection with one or both of these betacoronaviruses. 2 and HKU1. Together with serology and B-cell lineage analyses, these findings suggest that pan-beta-coronavirus antibodies can be generated by priming specific B cells with affinity and breadth through somatically mutated viruses in response to heterotypic coronavirus exposure.

The coronavirus S ₂ subunit (the so-called fusion mechanism) contains several important antigenic sites, including the fusion peptide and the heptapeptide repeat 2 region, and is more conserved than the S ₁ subunit (Daniel et al. 1993; Zhang et al. 2004; Poh et al. 2020; Elshabrawy et al. 2012; Zheng et al. 2020). Therefore, it is an attractive target for widespread coronavirus detection and neutralization (AC Walls et al. 2016). The recent identification of three cross-reactive mAbs targeting the stem helix revealed this previously unknown S2 subunit epitope, which is conserved in the β-coronavirus S glycoprotein (Sauer et al. 2020; C. Wang et al. 2021; Song et al. 2020), although none of them inhibited members of all three betacoronavirus subgenus (lineage). Here, mAbs targeting overlapping epitopes in the S stem helix and cross-reactive with human and animal b-coronaviruses were identified. S2P6 broadly neutralized all Sabe, Mobe, and Ebbe coronaviruses evaluated via inhibition of membrane fusion and provided evidence that S2 subunit-directed mAb protected hamsters from SARS-CoV-2 challenge, including SARS-CoV-2 B.1.351 VOC challenge has beneficial effects on Fc-mediated effector functions. These data extend the description of effector functions involved in SARS-CoV-2 RBD-specific mAbs (Schäfer et al. 2021; Winkler et al. 2020) as well as influenza A hemagglutinin stem-specific broadly neutralizing mAbs (Corti et al. 2011; DiLillo et al. 2014). This observation suggests similar findings for mAbs for a highly conserved epitope on the stem of influenza hemagglutinin, and indicates that the combination of cross-reactivity plus effector function may provide specific potency for antibodies against these infections (Ref.).

The exceptionally broad cross-reactivity and neutralization breadth of S2P6 can be explained by the conserved properties of the stem helix in b-coronaviruses. Within SARS-CoV-2, mutations between S residues 1146 and 1159 have been reported in less than 0.01% of the sequences in more than 1.3 million genomes deposited in GISAID (date) and there are no SARS-CoV-2 VOCs in this region There are residue substitutions within.

It is believed that the stem helix forms a 3-helix bundle in pre-fusion SARS-CoV-2 S and may require dynamic conformational changes to expose the originally buried hydrophobic epitope, which is surrounded by conserved glycans and may further shield this conserved sites. The results presented here provide evidence that stem-helix-targeting Abs are more effective after natural infection with endemic (OC43 or HKU1) or pandemic (SARS-CoV-2) coronaviruses and via COVID-19 mRNA. Triggered by vaccines. However, possibly due to limited epitope exposure, stem-helix-specific Abs are present at lower titers in plasma samples of convalescent or vaccinated individuals and at low frequencies in their memory B cell lineages.

Abs targeting the stem-helix mainly have narrow specificity and only a few of them mediate broad β-coronavirus neutralization and protection via accumulation of somatic mutations. Example 10 Analysis of human beta-coronavirus spike protein

Part of the S2 segment from human beta-coronavirus spike protein is shown in Figure 13. It was determined that the region in the C-terminal part of the prefusion extracellular domain (Fig. 14A) has certain conservation. A model illustrating the helical structure of the surface-exposed linker region at the tail of the prefusion ectodomain is provided in Figure 14B. Figure 14C shows a close-up view of the exposed surface linker region and indicates certain amino acid residues. Structural analysis provides the following: Table 35. Structural characterization of amino acids in the helix characteristics of the β-coronavirus linker (amino acid numbering is as in pre-fusion configuration) residue Observations F1148 not exposed K1149 Partially exposed (side chain) E1150 Complete exposure (S in HKU1 and D in MERS-CoV) E1151 fully exposed and fully conserved L1152 not exposed D1153 Completely exposed (S in HKU1) K1154 Extreme exposure (Q in OC43, H in HKU1 and E in MERS-COV) Y1155 Partial exposure (W in OC43 and HKU1, and F in MERS-COV) F1156 not exposed K1157 fully exposed and fully conserved N1158 Fully exposed and fully conserved (glycosylation site conserved in all Sabey coronaviruses)

The structure of the post-fusion spike protein was also examined (Fig. 15A). Detailed views of the linker region (Figure 15B and Figure 15C (the pre-fusion configuration shown at the bottom of 15C for comparison)) show partial rearrangement and exposure of residues 1148-1158. The numbering of residues in Figures 15A-15C after fusion does not take into account the signal peptide, which adds an additional 18 residue positions. Example 11 Materials and methods used in Examples 9 and 10 For the experiments described in Examples 9 and 10, the following materials and methods were used: Generation of stable overexpressing cell lines

Lenti-X 293T was obtained by co-transfection with lentiviral expression plasmids encoding DC-SIGN (CD209), L-SIGN (CLEC4M), SIGLEC1, TMPRSS2, or ACE2 (all obtained from Genecopoeia) and respective lentiviral helper plasmids. (Takara) cells to produce lentivirus. Forty-eight hours after transfection, lentivirus in the supernatant was harvested and concentrated by ultracentrifugation at 20,000 rpm for 2 hours. Lenti-X 293T (Takara), Vero E6 (ATCC), MRC5 (Sigma-Aldrich), A549 (ATCC) were transduced in the presence of 6 μg/mL polybrene (Millipore) for 24 hours. Cell lines overexpressing both transgenes were then transduced. Selection with puromycin and/or blasticidin (Gibco) was initiated two days after transduction and the selection reagents were maintained in the growth medium for all subsequent cultures. Single cell lines are derived from the A549-ACE2-TMPRSS2 cell line, all other cell lines represent cell pools. SARS-CoV-2 neutralization

Vero E6 or Vero E6-TMPRSS2 cells cultured in DMEM supplemented with 10% FBS (VWR) and 1× penicillin/streptomycin (Thermo Fisher Scientific) were seeded into black 96-well plates at 20,000 cells/well. Serial 1:4 dilutions of monoclonal antibodies were mixed with 200 pfu SARS-CoV-2 (isolate USA-WA1/2020, passage 3, passaged in Vero E6 cells) in a BSL-3 facility at 37°C. Incubate together for 30 minutes. The cell supernatant was removed and the virus-antibody mixture was added to the cells. After 24 hours of infection, cells were fixed with 4% paraformaldehyde for 30 minutes, washed twice with PBS (pH 7.4), and permeabilized with PBS containing 0.25% Triton X-100 for 30 minutes. After blocking for 30 minutes in 5% milk powder/PBS, cells were incubated for 1 hour with a primary antibody targeting the SARS-CoV-2 nucleocapsid protein (Sino Biological, Cat. No. 40143-R001) at a dilution of 1:2000. . After washing and incubation for 1 hour with secondary Alexa647-labeled antibody mixed with 1 μg/ml Hoechst 33342, the plates were imaged on an automated cell imaging reader (Cytation 5, Biotek) and using the manufacturer's software Nucleocapsid-positive cells were counted. SARS-CoV-2-Nluc neutralization

Neutralization was determined using SARS-CoV-2-Nluc, an infectious pure strain of SARS-CoV-2 encoding a nanoluciferase (based on strain 2019-nCoV/USA_WA1/2020), instead of viral ORF7, which Exhibits growth kinetics comparable to wild-type virus (Xie et al., Nat Comm, 2020, https://doi.org/10.1038/s41467-020-19055-7). Cells were seeded into black-walled, clear-bottomed 96-well dishes at 20,000 cells/well (293T cells were seeded at 35,000 cells/well into poly-L-lysine-coated wells) and incubated at 37°C. Incubate overnight. The next day, 9-point, 4-fold serial dilutions of the antibodies were prepared in infection medium (DMEM + 10% FBS). SARS-CoV-2-Nluc was diluted in infection medium at the indicated MOI, added to the antibody diluent and incubated at 37°C for 30 minutes. Medium was removed from the cells, mAb-virus complexes were added, and cells were incubated at 37°C for 24 hours. Medium was removed from cells, Nano-Glo luciferase substrate (Promega) was added according to manufacturer's recommendations, incubated for 10 min at room temperature and luciferin was quantified on a VICTOR Nivo plate reader (Perkin Elmer) enzyme signal. Generation and neutralization of SARS-CoV-2 pseudotyped VSV

To generate SARS-CoV-2 pseudotyped vesicular stomatitis virus, Lenti-X 293T cells (Takara) were inoculated into 10 cm culture dishes at a confluence rate of 80% the next day. The next day, cells were transfected with a plasmid encoding a C-terminal 19 aa truncated SARS-CoV-2 S-glycoprotein (YP_009724390.1) using TransIT-Lenti (Mirus Bio) according to the manufacturer's instructions. One day after transfection, cells were infected with VSV (G*ΔG-luciferase) (Kerafast) at an MOI of 3 infectious units/cell. After one hour the viral inoculum was washed away and cells were incubated for an additional day at 37°C. Cell supernatants containing SARS-CoV-2 pseudotyped VSV were collected on day 2 after transfection, centrifuged at 1000 x g for 5 minutes to remove cell debris, aliquoted, and frozen at -80°C.

For virus neutralization, cells were seeded at 20,000 cells/well into black-walled, clear-bottomed 96-well dishes (293T cells were seeded at 35,000 cells/well into poly-L-lysine-coated wells) and incubate overnight at 37°C. The next day, prepare 9-point 4-fold serial dilutions of the antibody in culture medium. SARS-CoV-2 pseudotyped VSV was diluted 1:30 in culture medium in the presence of 100 ng/mL anti-VSV-G antibody (pure line 8G5F11, Absolute Antibody), and added 1:1 to each antibody dilution. The virus:antibody mixture was incubated at 37°C for 1 hour. Medium was removed from the cells and 50 μL of virus:antibody mixture was added to the cells. One hour after infection, 100 μL of medium was added to all wells and incubated at 37°C for 17-20 hours. Medium was removed and 50 μL of Bio-Glo reagent (Promega) was added to each well. The disks were shaken on a disk shaker at 300 RPM for 15 minutes at room temperature, and the RLUs were read on an EnSight disk reader (Perkin-Elmer). Transfection-based attachment receptor screening

Lenti-X 293T cells (Takara) were transfected with plasmids encoding the following receptor candidates (all purchased from Genecopoeia): ACE2 (NM_021804), DC-SIGN (NM_021155), L-SIGN (BC110614), LGALS3 (NM_002306) , SIGLEC1 (NM_023068), SIGLEC3 (XM_057602), SIGLEC9 (BC035365), SIGLEC10 (NM_033130), MGL (NM_182906), MINCLE (NM_014358), CD147 (NM_198589), ASGR1 (NM_001671.4), ASGR2 (NM_080913), NRP1 ( NM_003873). One day after transfection, cells were infected with SARS-CoV-2 pseudotyped VSV at a 1:20 dilution in the presence of 100 ng/ml anti-VSV-G antibody (clone 8G5F11, Absolute Antibody) at 37°C. One hour after infection, 100 μL of medium was added to all wells and incubated at 37°C for 17-20 hours. Medium was removed and 50 μL of Bio-Glo reagent (Promega) was added to each well. The disks were shaken on a disk shaker at 300 RPM for 15 minutes at room temperature, and the RLUs were read on an EnSight disk reader (Perkin-Elmer). Anti-infection

Parental HeLa cells or HeLa cells stably expressing DC-SIGN, L-SIGN or SIGLEC1 were seeded into a black-walled, transparent-bottomed 96-well plate at 5,000 cells/well. One day later, cells reached approximately 50% confluence and were inoculated with SARS-CoV-2 pseudotyped VSV at a 1:10 dilution at 37°C in the presence of 100 ng/mL anti-VSV-G antibody (clone 8G5F11, Absolute Antibody) 2 hours. For antibody-mediated inhibition of counter-infection, cells were preincubated with 10 ug/mL anti-SIGLEC1 antibody (Biolegend, pure line 7-239) for 30 minutes. After 2 hours of seeding, cells were washed four times with complete medium and 10,000 VeroE6-TMPRSS2 cells/well were added and incubated at 37°C for 17-20 hours for counter-infection. Medium was removed and 50 μL of Bio-Glo reagent (Promega) was added to each well. The disks were shaken on a disk shaker at 300 RPM for 15 minutes at room temperature, and the RLUs were read on an EnSight disk reader (Perkin-Elmer). Cell-cell fusion of CHO-S cells

CHO cells stably expressing SARS-CoV-2 S glycoprotein were seeded in 96-well plates at 12,500 cells/well for microscopy (Thermo Fisher Scientific), and on the next day, different concentrations mAb and nuclear marker Hoechst (final dilution 1:1000) were added to cells and incubated for an additional 24 hours. The degree of fusion was established using Cytation 5 Imager (BioTek), and nuclei were detected as objects and measured using an object detection protocol. The nuclei of fused cells (i.e., syncytia) were found to cluster in the center of the fused cells and were identified as unique larger objects that were gated based on their size. The area of the objects in the fused cell is divided by the total area of all objects multiplied by 100 to get the percentage of fused cells. Immunofluorescence analysis

After inoculation with 4% paraformaldehyde for 30 minutes, HEK 293T cells were seeded onto poly-D-lysine-coated 96-well plates (Sigma-Aldrich) and fixed for 24 hours, followed by secondary PBS (pH 7.4) Wash and permeate with PBS containing 0.25% Triton X-100 for 30 minutes. Cells were incubated with primary antibodies anti-DC-SIGN/L-SIGN (Biolegend, Cat. No. 845002, 1:500 dilution), anti-DC-SIGN (Cell Signaling, Cat. No. 13193S, 1:500 dilution), anti-SIGLEC1 (Biolegend, Cat. No. 346002, 1:500 dilution), or anti-ACE2 (R&D Systems, Cat. No. AF933, 1:200 dilution) were incubated for 2 hours. After washing and incubation for 1 hour with secondary Alexa647-labeled antibody mixed with 1 ug/mL Hoechst 33342, the plates were imaged on a reverse fluorescence microscope (Echo Revolve). ACE2/TMPRSS2 RT-qPCR

RNA was extracted from cells using the NucleoSpin RNA Plus Kit (Macherey-Nagel) according to the manufacturer's protocol. RNA was reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems) according to the manufacturer's instructions. Luna Universal qPCR Master Mix (New England Biolabs) was used according to the manufacturer's protocol to quantify ACE2 (forward primer: CAAGAGCAAACGGTTGAACAC, reverse primer: CCAGAGCCTCTCATTGTAGTCT), HPRT (forward primer: CCTGGCGTCGTGATTAGTG, reverse primer: ACACCCTTTCCAAATCCTCAG) and TMPRSS2 (forward primer: The intracellular level of the forward primer: CAAGTGCTCCRACTCTGGGAT and the reverse primer: AACACACCGRTTCTCGTCCTC). The levels of ACE2 and TMPRSS2 are normalized to HPRT. HeLa cells were used as reference samples. All qPCR were run on a QuantStudio 3 Real-Time PCR System (Applied Biosystems). SARS2 D614G spike protein production and biotin labeling

Using 293fectin as the transfection agent, the prefusion-stabilized SARS2 D614G spike protein (containing the amino acid sequence Q14 to K1211) was transfected into HEK293 Freestyle cells. The cells were allowed to rest at 37°C for three days to produce protein. Subsequently, the supernatant was harvested by centrifuging the cells at 500 xg for 30 minutes, followed by spinning at 4000 xg for an additional 30 minutes. Cell culture supernatant was filtered through a 0.2 μm filter and loaded onto a 5 mL C-tag affinity matrix column, pre-equilibrated with 50 mM Tris pH 8 and 200 mM NaCl. SARS2 D614G spike protein was eluted using 10 column volumes of 100 mM Tris, 200 mM NaCl, and 3.8 mM SEPEA peptide. The eluted peak was concentrated and injected on a Superose 6 Plus 10/300 GL gel filtration column using 50 mM Tris pH 8 and 200 mM NaCl as working buffer. SEC fractions corresponding to the monodisperse SARS2 D614G spike protein were collected and flash frozen in liquid nitrogen for storage at -80°C. Purified SARS2 D614G spike protein was biotin-labeled using the BirA500 biotin labeling kit with self-affinity. Add 5 μg BirA and 11 μL BiomixA and BiomixB to 50 μg spike protein. The final spike protein concentration during the biotin labeling reaction was approximately 1 μM. The reaction was allowed to proceed at 4°C for 16 hours. Next, the proteins were desalted using two Zeba spin columns pre-equilibrated in 1× PBS pH 7.4. Flow cytometric analysis of DC-SIGN, L-SIGN, SIGLEC1 and ACE-2

HEK 293T cells expressing DC-SIGN, L-SIGN, SIGLEC1 or ACE2 were resuspended at 4×10 ⁶ cells/mL and 100 μL/well were seeded into V-bottom 96-well plates (Corning, 3894). The plate was centrifuged at 2,000 rpm for 5 minutes and washed with PBS (pH 7.4). Cells were resuspended in 200 μL of PBS containing Ghost violet 510 viability dye (Cell Signaling, Cat. No. 13-0870-T100, 1:1,000 dilution), incubated on ice for 15 minutes and then washed. Cells were resuspended in 100 μL of FACS buffer prepared with 0.5% BSA (Sigma-Aldrich) in PBS containing a 1:100 dilution of the following primary antibody: mouse anti-DC/L-SIGN (Biolegend , Cat. No. 845002), rabbit anti-DC-SIGN (Cell Signaling, Cat. No. 13193), mouse anti-SIGLEC1 (Biologend, Cat. No. 346002), or goat anti-ACE2 (R&D Systems, Cat. No. AF933). After 1 hour of incubation on ice, cells were washed twice and resuspended in FACS buffer containing a 1:200 dilution of the following Alexa Fluor-488-labeled secondary antibody: goat anti-mouse (Invitrogen Cat. No. A11001) , goat anti-rabbit (Invitrogen Cat. No. A11008) or donkey anti-goat (Invitrogen Cat. No. A11055). After incubation on ice for 45 min, cells were washed three times with 200 μL of FACS buffer and fixed with 200 μL of 4% PFA (Alfa Aesar) for 15 min at room temperature. Cells were washed three times, resuspended in 200 μL of FACS buffer and analyzed by flow cytometry using a CytoFLEX flow cytometer (Beckman Coulter). Flow cytometry of SARS-CoV-2 spike protein and RBD bound to cells

Biotin-labeled SARS-CoV-2 spike protein D614G protein (Spikebiotin, produced in-house) or biotin-labeled SARS-CoV-2 spike protein receptor binding domain (RBDbiotin, Sino Biological, 40592-V08B) was added at room temperature. Incubate with Alexa Fluor® 647 Streptavidin (AF647-strep, Invitrogen, S21374) at a 1:20 ratio by volume for 20 minutes. The labeled proteins were then stored at 4°C until further use. Cells were dissociated using TrpLE Express (Gibco, 12605-010) and 10 ⁵ cells were transferred to each well of a 96-well V-chassis (Corning, 3894). Cells were washed twice in flow cytometry buffer (PBS with 2% FBS (Ca/Mg-free)) and stained with Spikebiotin-AF647-strep at a final concentration of 20 µg/ml on ice or Stain with RBDbiotin-AF647-strep at a final concentration of 7.5 µg/ml for 1 hour. Stained cells were washed twice with flow cytometry buffer, resuspended in 1% PFA (Electron Microscopy Sciences, 15714-S) and analyzed with Cytoflex LX (Beckman Coulter). Recombinant performance of SARS-CoV-2-specific mAb

Human mAbs were isolated from plasma cells or memory B cells of SARS-CoV-2 immune donors as previously described. Recombinant antibodies were expressed in ExpiCHO cells at 37°C and 8% _CO2 . Cells were transfected using ExpiFectamine. Transfected cells were replenished 1 day after transfection with ExpiCHO Feed and ExpiFectamine CHO enhancer. Cell culture supernatants were collected eight days after transfection and filtered through a 0.2 µm filter. Recombinant antibodies were affinity purified on an ÄKTA xpress FPLC device using a 5 mL HiTrap™ MabSelect™ PrismA column, followed by a HiPrep 26/10 desalted column with histidine buffer (20 mM histidine, 8% sucrose, pH 6) Perform buffer exchange. SARS-CoV-2 infection model virus preparation in hamsters

The SARS-CoV-2 strain used for this study, BetaCov/Belgium/GHB-03021/2020, was recovered from nasopharyngeal swabs obtained from asymptomatic patients confirmed by RT-qPCR who returned from Wuhan, China in February 2020 ( EPI ISL 109 407976|2020-02-03). The close relationship with the prototype Wuhan-Hu-1 2019-nCoV (GenBank registration number MN908947.3) was confirmed through phylogenetic analysis. Infectious virus was isolated by serial passage on HuH7 and Vero E6 cells; passage 6 viruses were used in the studies described herein. The titer of virus stocks was determined by endpoint dilution on Vero E6 cells using the Reed and Muench method. cells

Vero E6 cells (African green monkey kidney, ATCC CRL-1586). Endpoint titrations were performed using media containing 2% rather than 10% fetal calf serum. SARS-CoV-2 infection model in hamsters

(xylazine)/阿托品麻醉且鼻內接種50 μL含有2×10 ⁶TCID50 SARS-CoV-2 (第0天)。 治療方案 The hamster infection model of SARS-CoV-2 has been described previously. The specific study design is presented in the schematic below. Briefly, wild-type Syrian golden hamsters (Mesocricetus auratus) were purchased from Janvier Laboratories and housed in ventilated isolation cages (IsoCage N Biocontainment System, Tecniplast) with ad libitum access to food and water. With cage enrichment (wooden blocks). Animals were allowed to acclimate for 4 days before the start of the study. The feeding conditions and experimental procedures were approved by the Animal Experimentation Ethics Committee of the University of Leuven (permit P065-2020). Ketamine/xylethyl for female 6-8 week old hamsters

(xylazine)/atropine anesthesia and intranasal inoculation of 50 μL containing 2×10 ⁶ TCID50 SARS-CoV-2 (day 0). treatment plan

Animals were treated with prophylaxis by intraperitoneal (i.p.) administration 48 hours prior to infection, and appearance, behavior, and body weight were monitored. On day 4 post-infection (p.i.), hamsters were euthanized by intraperitoneal injection of 500 μL Dolethal (200 mg/mL sodium pentobarbital, Vétoquinol SA). Lungs were collected and viral RNA and infectious virus were quantified by RT-qPCR and endpoint viral titration, respectively. Blood samples were collected prior to infection for PK analysis. SARS-CoV-2 RT-qPCR

Collected lung tissue was homogenized in 350 μL RLT buffer (RNeasy Minikit, Qiagen) using bead disruption (Precellys) and centrifuged (10.000 rpm, 5 min) to assemble cell debris. Extract RNA according to the manufacturer's instructions. In 50 μL eluate, 4 μL was used as template in RT-qPCR reaction. RT-qPCR was performed on the LightCycler96 platform (Roche) using the iTaq universal probe one-step RT-qPCR kit (BioRad) with N2 primers and probes targeting nucleocapsids. SARS-CoV-2 cDNA (IDT) standards are used to represent viral genome copies per mg of tissue or per mL of serum. Endpoint virus titration

Lung tissue was homogenized in 350 μL of minimum essential medium using bead disruption (Precellys) and centrifuged (10.000 rpm, 5 min, 4°C) to assemble cellular debris. To quantify infectious SARS-CoV-2 particles, endpoint titrations were performed on confluent Vero E6 cells in 96-well plates. Viral titers were calculated by the method of Reed and Muench using a Lindenbach calculator and expressed as 50% tissue culture infectious dose (TCID50) per mg of tissue. Histology

For histological examination, lungs were fixed in 4% formaldehyde overnight and embedded in paraffin. Tissue sections (5 μm) were analyzed after staining with hematoxylin and eosin, and lung lesions were scored blindly by a dedicated pathologist. The scoring parameters with a cumulative score of 1 to 3 are as follows: congestion, intra-alveolar hemorrhage, apoptotic bodies in the bronchial wall, necrotizing bronchiolitis, perivascular edema, bronchopneumonia, perivascular inflammation, peribronchial inflammation and vasculitis. Binding of immune complexes to hamster monocytes

Immune complexes (ICs) were generated by combining S309 mAb (hamster IgG, wt or N297A) with biotinylated anti-idiotypic Fab fragments and Alexa-488- Streptavidin complex is produced. Pre-generated fluorescent ICs were incubated with serial dilutions of fresh viable hamster splenocytes obtained from untreated animals for 3 hours at 4°C. Cell binding was then assessed by cytometry while excluding dead cells and physically gating on the mononuclear spheroid population. Results are expressed as the average Alexa-488 fluorescence intensity of the entire mononuclear population. Bioinformatics analysis

Download the processed Human Lung Cell Atlas (HLCA) data and cell type annotations from Github (github.com/krasnowlab/HLCA). Download the processed single cell transcriptome data and annotations of lung epithelial and immune cells from SARS-CoV-2 infected individuals from the NCBI GEO database (ID: GSE158055) and Github (github.com/zhangzlab/covid_balf). Available sequence data from the second single-cell transcriptomic study by Liao et al. were downloaded from the NCBI SRA (ID: PRJNA608742) for examination of reads corresponding to viral RNA. The ratio of sgRNA relative to genome RNA was estimated by counting TRS-containing reads supporting the leader-TRS junction. Criteria and methods for detecting leader-TRS junction reads were adapted from Alexandersen et al. The viral genome reference and TRS annotation are based on Wuhan-Hu-1 NC_045512.2/MN908947 ⁴⁹ . Only 2 samples from individuals with severe COVID-19 had detectable leader-TRS junction reads (SRR11181958, SRR11181959). cell lines

Cell lines used in this study were obtained from ATCC (HEK293T and Vero-E6) or ThermoFisher Scientific (Expi CHO cells, FreeStyle™ 293-F cells, and Expi293F™ cells). sample donor

The review was conducted under the supervision of local institutional review boards (Canton Ticino Ethics Committee, Switzerland, the Ethical committee of Luigi Sacco Hospital, Milan, Italy) and WCG North America ( Under a research protocol approved by WCG North America (Princeton, NJ, US), samples were obtained from individuals recruited before June 2019 (pre-pandemic), SARS-CoV-2 infected individuals, or Groups of vaccinated individuals immunized with Moderna or Pfizer/BioNTech BNT162b2 vaccine. All donors provided written informed consent for the use of blood and blood components (such as PBMC, serum or plasma) and were recruited in hospital or as an outpatient setting. PBMCs were isolated from blood by Ficoll density gradient centrifugation and used fresh or stored in liquid nitrogen for subsequent use. Serum was obtained from blood collected using tubes containing coagulation activator, then centrifuged and stored at -80°C. AMBRA for IgG antibodies (antigen-specific memory B cell lineage analysis)

Replicate cultures of PBMC were plated in 96 U chassis (Corning) and stimulated with 2.5 μg/ml R848 (3 M) and 1000 U/ml human recombinant IL-2 for 10 days at 37°C, 5% CO2. Cell culture supernatants were collected for further analysis. Antibody discovery and performance

Isolation and selection of antigen-specific IgG+ memory B cells from total PBMC of convalescent individuals. The antibody VH and VL sequences were obtained by reverse transcription PCR (RT-PCR), and the mAb appeared to be a recombinant human IgG1 carrying the half-life extending M428L/N434S (LS) mutation in the Fc region or Fab fragment. ExpiCHO cells were transiently transfected with heavy and light chain expression vectors as previously described (Pinto et al. 2020). For in vivo experiments in Syrian hamsters, S2P6 was generated using Syrian hamster IgG2 Fc. IMGT/V-QUEST was used to construct UCA sequences and recombine to generate VH and VL with somatic mutations. PBS was used as the mobile phase, HiTrap Protein A column (Cytiva) for full-length human and hamster mAbs and CaptureSelect CH1-XL MiniChrom column (ThermoFisher Scientific) for Fab fragments, operated by UNICORN software version 5.11 (Build 407) MAb affinity purification was performed on ÄKTA Xpress FPLC (Cytiva). Buffer exchange of appropriately prepared buffers was performed using a HiTrap rapid desalting column (Cytiva). The final product was sterilized by filtration through a 0.22 µm filter and stored at 4°C. Flow cytometry of antibodies on ExpiCHO-S cells expressing spike protein

For transient transfection of Expi-CHO cells, S plasmid (Pinto et al. 2020; M. Alejandra Tortorici et al. 2021) was diluted in cold OptiPRO SFM, mixed with ExpiFectamine CHO reagent (Life Technologies, A29130) and incubated in 50 ml Add to a volume of 5 ml seeded cells at 6 × 10 ⁶ cells/ml in the bioreactor. The transfected cells were incubated at 37°C, 8% CO2 at an orbital shaking speed of 209 rpm (25 mm orbital diameter) for 42 hours. To test mAb binding, transfected ExpiCHO cells were harvested, washed twice in wash buffer (bovine serum albumin (BSA; Sigma) 1% w/v in PBS, 2 mM EDTA), and incubated at 60,000 Cells/well were distributed into 96 U-shaped chassis (Corning). Serial dilutions of mAb at 10 µg/ml were added to the cells on ice for 30 minutes, and after a second wash, an Alexa Fluot647-labeled goat anti-human IgG secondary Ab (Jackson Immunoresearch, 109-606- 098) perform detection. After incubation on ice for 15 minutes, cells were washed twice and mAb binding was analyzed by flow cytometry using a ZE5 Cell Analyzer (Biorard). Enzyme-linked immunosorbent assay (ELISA)

Plate with recombinant stable fusion prefusion spike protein trimer or S2 subunit at 1 µg/ml or coronavirus stem-helical peptide at 8 µg/ml (all diluted in phosphate buffered saline (PBS)) at 4°C. Spectraplate-384 (Perkin Elmer) or 96-well plate (Corning) with high protein binding treatment overnight. Plates were blocked with a 1% w/v solution of bovine serum albumin (BSA; Sigma) in PBS or, for ELISAs using plasma, in PBS supplemented with 0.05% Tween 20 (Thermo Fisher Scientific). Blocked with casein (1% w/v). Serial dilutions of mAb or plasma were added and maintained at room temperature for 1 hour. After further washing, mAb binding was revealed using anti-human IgG coupled to alkaline phosphatase (Jackson Immunoresearch) incubated for 1 hour. Color development was performed using substrate (p-NPP, Sigma) and the plates were read by a microplate reader (Biotek) at 405 nm. The data has been plotted using Graph Prism software. Blockade of SARS-CoV-2 spike protein to ACE2

SARS-CoV-2 S prefusion (final concentration 300 ng/ml) was incubated with 1 µg/ml S309 mouse Fc-tagged mAb (S309-mFc) for 30 minutes at 37°C, followed by the addition of serial dilutions of S2P6 ( from 20 µg/ml) and incubate for an additional 30 minutes at 37°C. Complex Spinin:S309:S2P6 was then added to pre-coated hACE2 (2 µg/ml in PBS) 96-well MaxiSorp (Nunc) plates and incubated for 1 hour at room temperature. Subsequently, the plates were washed and secondary Ab goat anti-mouse IgG (Southern Biotech) was added to detect SARS-CoV-2 spike protein:S309-mFc binding. After further washing, substrate (p-NPP, Sigma) was added and the plates were read using a microplate reader (Biotek) at 405 nm. Calculate percent inhibition as follows: (1-((OD sample-OD negative control)/(OD positive control-OD negative control))*100. Epitope identification and substitution scanning

PEPperMAP epitope mapping (PEPperPRINT GmbH, Heidelberg, Germany) was performed to determine mAb epitopes via a pan-coronavirus spike protein microarray covering the spike proteins of all betacoronaviruses. Briefly, microarrays containing 15-mer peptides (overlapping 13-mers) were incubated with 10 µg/ml mAb for 16 h at 4°C with shaking at 140 rpm, followed by secondary and control Ab at room temperature. Stain for 45 minutes. Microarray readout was performed with a LI-COR Odyssey imaging system at a scan intensity of 7/7 (red/green). An epitope substitution scan was performed on the identified epitopes based on stepwise single amino acid exchange at all amino acid positions. Binding of mAbs to the resulting microarrays was performed as above. SPR combined measurement

SPR binding measurements were performed using a Biacore T200 instrument using anti-AviTag pAb covalently immobilized on a CM5 chip to capture S ECD, except that a Cytiva biotin capture kit was used to capture biotin-labeled OC43 S ECD. For neutral or acidic pH experiments, the operating buffer is Cytiva HBS-EP+ (pH 7.4) or 20 mM phosphate pH 5.4, 150 mM NaCl, 0.05% P-20. All measurements were performed at 25°C. S2P6 Fab or IgG concentrations were 11, 33, 100, and 300 nM as single-cycle kinetics. The dual reference-subtracted data were fit to the combined model using Biacore evaluation software. All data of SARS-CoV-2 S, SARS-CoV S and OC43 S were fitted to a 1:1 binding model. Fitting MERS S data to a heterogeneous ligand binding model is assumed to be an artifact because the kinetic phase has extremely slow dissociation; the lower affinity of the two KDs obtained from the fit is reported as the S2P6:MERS S interaction KD and are indicated as approximations (Rmax associated with higher affinity kinetics is proportional to the magnitude of the final signal above baseline). The HKU1 S data were fit to a steady-state binding model because of the low signal and rapid approach to equilibrium during each association phase; the reported KD indications are approximate. IgG binding data yields the "apparent KD" due to avidity. Neutralizes true SARS-CoV-2 virus

For SARS-CoV-2 neutralization experiments, DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 lot number 345K19) and 100 U/ml penicillin-streptomycin (Gibco 15140-122) culture cells. Cells were seeded in a black, 96-well glass bottom plate (Cellvis P96-1.5H-N) at a density of 20,000 cells/well. Serial dilutions (1:4) of the mAb were mixed with 200 PFU (plaque forming units, corresponding to a magnification of infection of 0.01) of authentic SARS-CoV-2 (isolate USA-WA1) at 37°C in a BSL3 facility. /2020, passage 3, subcultured in Vero-E6 cells) and incubated together for 30 minutes. After removal of cell culture supernatant, cells were infected with virus:antibody mixture and incubated at 37°C for 20 hours. Cells were then fixed with 4% paraformaldehyde (Electron Microscopy Sciences, 15714-S) in PBS (Gibco 10010-031) for 30 minutes, permeabilized with 0.1% Triton X-100 (Sigma, X100-500ML) for 30 minutes, and Human SARS coronavirus nucleoprotein/NP antibody, rabbit Mab (Sino Biological, 40143-R001) was stained in 2% milk (RPI, M17200-500.0) at a dilution of 1:2000 for 1 hour. Subsequently, cells were stained with goat anti-rabbit IgG (H+L) AF647 (Invitrogen, catalog number A21245 lot 223 2862) at a 1:1000 dilution and 2 μg/mL Hoechst 33342 in 2% milk for 1 hour. Discs were imaged with an automated microscope (Cytation5, Biotek), and nuclei and cells positive for SARS-CoV-2 nucleoprotein were quantified using the provided Gen5 software. SARS-CoV-2 Nluc virus neutralization

Cells were cultured in DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 Lot No. 345K19) and 100 U/ml penicillin-streptomycin (Gibco 15140-122). For neutralization experiments, cells were plated at 20,000 cells/well in black, 96-well glass bottom plates (Corning, 3904) and transferred to a BSL3 facility. Serial 1:4 dilution series of mAb were incubated with 200 PFU of SARS-CoV-2 Nluc (infectious pure strain of SARS-CoV-2 (virus strain 2019-nCoV/USA_WA1/2020)), in which the viral ORF7 gene was expressed m luciferase reporter replacement (Xie et al. 2020). After incubation at 37°C for 30 minutes, the virus:antibody mixture was used to infect target cells at an infection magnification of 0.01. Twenty hours after infection, cells were allowed to equilibrate to room temperature and cell culture supernatants were aspirated. A 1:1 mixture of Nano-Glo® Live Cell Analysis System (Promega N2012) reagent and DPBS with Ca/Mg (Gibco 14040-133) was added to the cells. After 10 minutes of incubation at room temperature, the luciferase signal was read using a luminescent disk reader (PerkinElmer VICTOR Nivo™). VSV pseudotype virus generation and neutralization

The Sabey coronavirus spike protein cassette lacking 19 amino acids (D19) at the C terminus was synthesized and cloned into a mammalian expression construct (pcDNA3.1(+) or pTwist-CMV) for use in the following Sabey coronavirus : SARS-CoV-2 (registration number QOU99296.1), SARS-CoV-1 (registration number AAP13441.1), hCoV-19/pangolin/Guangdong/1/2019 (GD19, registration number QLR06867.1) and Middle East respiratory tract Syndrome-associated coronavirus (MERS, registration number YP_009047204). To generate pseudotyped VSV, 293T Lenti-X encapsulated cells (Takara, 632180) were seeded in 15 cm dishes so that the cells would be 80% confluent the next day. The cultures were then transfected with various spike protein expressing plasmids using TransIT-Lenti transfection reagent (Mirus, 6600) according to the manufacturer's instructions. 24 hours after transfection, the encapsulated cells were infected with VSV-G*ΔG-luciferase (Kerafast, EH1020-PM). 48 hours after infection, the supernatant containing Sabey coronavirus pseudotype VSV-luc was collected, centrifuged at 1000 × g for 5 min, aliquoted and frozen at -80°C. For pseudovirus neutralization assays, the following cells that support stable pseudoviruses were used: VeroE6-TMPRSS2 cells for VSV-SARS-CoV-2, VSV-SARS-CoV-1, and VSV-GD19 and Huh7 cells for VSV-MERS . Cells were seeded at 20,000 cells/well into clear-bottom, white-walled 96-well plates. The next day, 1:3 serial dilutions of Ab were prepared in triplicate in basic DMEM. Pseudotyped VSV was diluted in base DMEM and added to each Ab dilution such that the final dilution of pseudovirus was 1:20. Pseudovirus:antibody mixture was incubated at 37°C for 1 hour. Medium was removed from cells seeded the day before and replaced with 50 μl of pseudovirus:Ab mixture and incubated at 37°C. One hour after infection, 50 μl of complete medium was added to each well and cells were incubated at 37°C overnight. The medium was then removed from the infected cells and 100 μl of 1:1 diluted PBS:Bio-Glo (Promega, G7940) luciferase substrate was added to each well. The disk was shaken at 300 rpm for 10 min at room temperature and then the relative light units (RLU) were read on an EnSight microplate reader (Perkin Elmer). Percent neutralization was determined by subtracting the average background (uninfected cells with luciferase substrate alone) value from 6 wells per plate from all data points. The percent neutralization of each antibody concentration was calculated relative to the control wells that received no antibody for each plate. Neutralization percentage data were analyzed using Prism (GraphPad, v9.0.1). Absolute EC50 values were calculated by fitting the curve using a variable slope 4-parameter nonlinear regression model and interpolating each value from the curve at y=50. Selection of VSV-SARS-CoV-2 mAb escape mutants Resistant virus options:

Cells were cultured in DMEM (Gibco 11995-040) supplemented with 10% FBS (VWR 97068-085 Lot No. 345K19) and 100 U/ml penicillin-streptomycin (Gibco 15140-122). The day before infection, 250,000 VeroE6-TMPRSS2 cells were cultured in 2 ml DMEM (Gibco 11995) supplemented with 10% FBS (VWR 97068-085 batch number 345K19) and 100 U/ml penicillin-streptomycin (Gibco 15140-122). -040) in a 12-well plate and incubated overnight at 37°C. The next day, S2P6 was serially diluted 1:4 starting from 80 μg/ml in infection medium (DMEM (supplemented with 2% FBS and 20mM HEPES (Gibco, 15630-080))) and replicated at MOI 2 at 37°C. Competent VSV-SARS-CoV-2 (Case et al. 2020) were incubated together for 1 h. Ab controls were not included to account for any tissue culture adaptation and quasi-species variability that may occur during viral replication. At 37°C, The mAb-virus complexes were adsorbed to the cells for 1 hour while shaking manually every 15 minutes. After adsorption, the cells were washed with PBS and overlaid with infection medium containing the same amount of S2P6 as used for the initial infection. Post-infection On days 1 and 3, the infection was visually observed with a microscope for GFP expression and cytopathic effect (CPE) of the cells. On day 3 after infection, when the no-mAb control wells reached >50% CPE, select to display >20% CPE. The well with the highest Ab concentration (80 μg/ml well in this case) was subcultured. The cell supernatant was centrifuged to remove cell debris, diluted 1:10 in infection medium and added to the same concentration as the initial subculture. in fresh VeroE6-TMPRRS2 cells in the same S2P6 concentration range and treatment. After the second passage, selection was stopped after no viral neutralization was observed at the highest concentration tested. Sequencing of S gene:

Viral RNA was extracted from viral passage supernatants using the QIAamp Viral RNA Mini Kit (Qiagen, 52904) according to the manufacturer's instructions without adding carrier RNA. According to the manufacturer's instructions, the NEB ProtoScript II first-strand cDNA synthesis kit (NEB, E6560S) was used to perform the reverse transcription reaction with 6 μl of purified RNA and random primers. Using the KapaBio system polymerase (KAPA HiFi HotStart Ready PCR Kit KK2601) with primers 5'- CGAGAAAAGGCATCTGGAG -3' and 5'- CATTGAACTCGTCGGTCTC -3', the obtained cDNA was used as a template for PCR amplification of the spike protein gene. Amplification conditions included an initial 3 minutes at 95°C, followed by 28 cycles of 20 seconds at 98°C, 15 seconds at 59°C and 72°C for 2 minutes, and a final 4 minutes at 72°C. PCR products were purified using AMPure XP beads (Beckman Coulter, A63881) following the manufacturer's instructions. The size of the amplicon was confirmed by analyzing 2 μl of PCR product using the Agilent D5000 ScreenTap system (Agilent D5000 ScreenTap, 5067-5588, Agilent D5000, reagent 5067-5589). The product was quantified by analyzing 2 μl with the Quant-iT dsDNA High Sensitivity Assay Kit (Thermo Fisher, Q331120). Twenty ng of purified PCR product was used as input for library construction using the NEBNext Ultra II FS DNA library preparation kit (NEB, E6177S) following the manufacturer's instructions. DNA fragmentation was performed for 13 minutes. NEBNext multiplex oligonucleotide (NEB, E7600S) of Illumina dual index primer set 1 was used for library construction with a total of 6 PCR cycles. Library size was determined using the Agilent D1000 ScreenTape system (Agilent D1000 ScreenTape, 5067-5582, Agilent D5000 reagents, 5067-5583) and quantified using the Quant-iT dsDNA High Sensitivity Assay Kit. Equal amounts of each library were pooled for multiplexing and the Illumina library preparation guide "Protocol A: Standard Normalization Method" was used to prepare an 8 pM final multiplex with 1% PhiX spikes. The library is used for sequencing. Illumina MiSeq Reagent Kit v3 (600-cycle) (Illumina, MS-102-300) was used to sequence libraries on the Illumina MiSeq platform, including 300 cycles for read 1 and 300 cycles for read 2. 300 cycles, 8 cycles for index 1 and 8 cycles for index 2. Bioinformatics analysis:

The average read length after running Illumina's Bcl2fastq command ranged from 149 to 188 bp per sample. For consistency across the sample, paired-end reads were initially trimmed to 2 × 150 bp and further cleaned using Trimmomatic (Bolger, Lohse, and Usadel 2014) to remove Illumina adapters and low-quality bases. Read alignment was performed with the Burrows-Wheeler aligner (BWA (Li 2013)) using custom reference sequences. LoFreq was used to identify variants during indel re-alignment and base quality recalibration using a frequency threshold of 1% (Wilm et al. 2012). Two consecutive rounds of alignment and variant identification were performed, in which variants identified with >50% allele frequency during the first round were integrated against the reference in the second round to facilitate comparison ratio and variant identification accuracy. Variants were annotated using SnpEff (Cingolani et al. 2012). The reference sequence coordinates were mapped back to the SARS-CoV-2 Wuhan-Hu-1 sequence (NCBI: NC_045512.2) to match the reference sequence nomenclature. Extensive QC on reads, alignments and variant levels using FastQC, samtools, picard, mosdepth (Pedersen and Quinlan 2018), bcftools (Danecek et al. 2021), MultiQC (Ewels et al. 2016) and in-house scripts , in particular, variants that are consistently identified by removing static positions within the reads, such as the beginning or end of the reads that carry them, rather than being randomly distributed throughout them. Automate end-to-end workflows using NextFlow (Di Tommaso et al. 2017). All programs are available through the Bioconda Initiative (Grüning et al. 2018) (bioconda.github.io). MAb-dependent activation of human FcγRIIIa and FcγRIIa

Assays for mAb-dependent activation of human FcγRIIIa and FcγRIIa were performed using ExpiCHO cells (target cells) stably expressing full-length wild-type SARS-CoV-2 spike protein (S). Cells were incubated with varying amounts of mAb for 10 minutes and subsequently treated with cells stably expressing FcγRIIIa receptor (V158 variant) or FcγRIIa receptor ( H131 variant) and Jurkat cells with NFAT-driven luciferase gene (effector cells) were cultured together. Activation of human FcγRs was quantified by the luciferase signal generated based on activation of the NFAT pathway. Bio-Glo-TM Luciferase Assay Reagent (Promega, catalog numbers: G7018 and G9995) was used according to the manufacturer's instructions, and luminescence was measured after incubation with a photometer for 21 hours at 37°C and 5% CO2. Antibody-dependent cellular cytotoxicity (ADCC)

ADCC analysis was performed at an E:T ratio of 33:1 using SARS-CoV2 CHO-K1 cells (genetically engineered to stably express the HaloTag-HiBit tag) as target cells and PBMC as effector cells. HiBit cells were seeded at 3,000 cells/well and incubated at 37°C for 16 hours, while PBMC (VV donor) isolated from fresh blood were incubated at 37°C in the presence of 5 ng/ml IL-2 Incubate overnight. After one day, the medium was removed and titrated concentrations of mAb were added, followed by PBMC at 100,000 cells/well. For 100% specific dissolution, use 100 μg/ml of digitonin. After 4 hours of incubation at 37°C, ADCC was measured using a Nano-Glo HiBiT Extracellular Detection System (Promega; catalog number: N2421) using a photometer (integration time 00:30). Antibody-dependent cellular phagocytosis (ADCP)

ADCP was performed using CHO cells (target cells) that stably express the full-length wild-type SARS-CoV-2 S glycoprotein fluorescently labeled with the PKH67 fluorescent cell linker kit (Sigma Aldrich; catalog number: MINI67). Target cells were incubated with titrated concentrations of mAb for 10 minutes, followed by overnight incubation in 5 ng/ml IL-2 (recombinant human interleukin-2; ImmunoTools, Inc.; Cat. No. 11340027) and then incubated with Cell Trace Violet ( Invitrogen, Cat. No. C34557) were cultured with fluorescently labeled PBMC. Use a 20:1 effect:target ratio. After overnight incubation at 37°C, cells were stained with anti-human CD14-APC antibody (BD Pharmingen, catalog number 561708, pure line M5E2) to stain mononuclear spheres. ADCP was measured by flow cytometry, gated on CD14+ cells that were double positive for cell trace violet and PKH67. Complement-dependent cytotoxicity (CDC)

CDC was performed on CHO cells (target cells) stably expressing the SARS-CoV-2 S glycoprotein, which was incubated with serial dilutions of mAb for 10 minutes, followed by pre-adsorbed Low at a final dilution of 1:12. - Tox M rabbit complement (Cederlane Laboratories Limited; catalog number: CL3051). CDC was measured photometrically using the CytoTox-Glo Cytotoxicity Assay (Promega; catalog number: G9291) according to the manufacturer's instructions after 3 hours of incubation at 37°C, 5% CO2. S2P6 binding and S2P6/B6 competition experiments of different synthetic coronavirus S-stem peptides

All biotinylated coronavirus S-stem helix peptide binding experiments were performed on an Octet Red instrument (Fortebio) at 30°C and shaking at 1,000 rpm in PBS supplemented with 0.005% Tween20 (PBST). For S2P6 binding to different stem-helical peptides, 1 µg/ml of biotin-labeled stem peptides (15-residue or 16-residue long stem peptide-PEG6-Lys-biotin synthesis from Genscript) was loaded on the SA biosensing on the device up to the threshold of 0.5 nm. Next, the system was equilibrated in PBST for 300 seconds, and then the sensors were immersed in 0.1 µM S2P6 mAb for 300 seconds, followed by dissociation in buffer for 300 seconds. For S2P6-B6 competition, 1 µg/ml biotinylated SARS CoV-2 peptide was loaded onto the SA biosensor up to the 0.5 nm threshold. The system was equilibrated in PBST for 180 seconds and each subsequent step was monitored for 900 seconds. The first sample biosensor was immersed in 0.1 µM mAb S2P6, and then the sample biosensors were immersed in 0.1 µM mAb S2P6 and B6 solutions respectively. The second sample biosensor was immersed in PBST and then in 0.1 µM mAb B6. To monitor nonspecific binding, the same experiment was performed without loading the stem peptide to the biosensor. Fusion inhibition analysis

To test inhibition of spinin-mediated cell-cell fusion, VeroE6 cells were seeded in 96-well plates at 20,000 cells/well in 70 μl of DMEM with high glucose and 2.4% FBS (Hyclone). After 16 hours, cells were transfected with SARS-CoV-2-S-D19_pcDNA3.1 as follows: for 10 wells, mix 0.57 µg plasmid SARS-CoV-2-S-D19_pcDNA3.1 with 1.68 µl X-tremeGENE HP at 30 Mix in µl OPTIMEM. After incubation for 15 minutes, the mixture was diluted 1:10 in DMEM medium and 30 μl was added to each well. 4-fold serial dilutions of mAb were prepared and added to cells starting at a concentration of 20 μg/ml. The next day, 30 μl of DMEM containing 5× concentrated DRAQ5 was added to each well and incubated at 37°C for 2 hours. Nine images of each well were acquired with Cytation 5 equipment for analysis. In vivo mAb testing using the Syrian hamster model

KU LEUVEN R&D has developed and validated the SARS-CoV-2 Syrian golden hamster infection model (Boudewijns et al. 2020). SARS-CoV-2 virus generation

The wild-type SARS-CoV-2 strain used in this study, BetaCov/Belgium/GHB- 03021/2020 (EPI ISL 109 407976|2020-02-03). The close relationship with the prototype Wuhan-Hu-1 2019-nCoV (GenBank registration number MN908947.3) was confirmed through phylogenetic analysis. Infectious virus was isolated by serial passage on HuH7 and VeroE6 cells (Boudewijns et al. 2020); passage 6 virus was used in the studies described here. The titer of virus stocks was determined by endpoint dilutions on Vero-E6 cells using the method of Reed and Muench (Reed and Muench 1938). Variant strain B.1.351 (hCoV-19/Belgium/rega-1920/2021; EPI_ISL_896474, 2021-01-11) was isolated from a nasopharyngeal swab obtained from a traveler who returned to Belgium and suffered from respiratory symptoms . The patient's nasopharyngeal swabs were sequenced directly on the MinION platform (Oxford Nanopore) (Abdelnabi et al. https://www.biorxiv.org/content/10.1101/ 2021.02.26.433062v1).

Live virus-related work (3CAPS) is performed in the high containment A3 and BSL3+ facilities of KU Leuven Rega Institute under licenses AMV 30112018 SBB 219 2018 0892 and AMV 23102017 SBB 219 20170589 according to institutional guidelines. SARS-CoV-2 infection model in hamsters

/阿托品麻醉且鼻內接種50 μl，對於野生型或B.1.351變異體分別含有2×106或1×104 TCID50。在藉由腹膜內注射感染之前24小時或48小時開始單株抗體(人類或倉鼠S2P6 (2-20 mg/kg))處理。監測倉鼠之外觀、行為及體重。在感染後第4天，藉由腹膜內注射500 μL Dolethal (200 mg/mL戊巴比妥鈉，Vétoquinol SA)使倉鼠安樂死。收集肺且分別藉由RT-qPCR及終點病毒滴定來定量病毒RNA及感染性病毒。在感染之前收集血液樣品用於藥物動力學分析。 SARS-CoV-2 RT-qPCR： Wild-type Syrian hamsters (golden hamsters) were purchased from Janvier Laboratories, and each pair was housed in a ventilated isolation cage (IsoCage N Biocontainment System, Tecniplast) with ad libitum access to food and water and cage enrichment. (wooden block). The feeding conditions and experimental procedures were approved by the Animal Experimentation Ethics Committee of the University of Leuven (permit P065-2020). Ketamine/xylethyl for female hamsters aged 6-10 weeks

/Atropine anesthesia and intranasal inoculation of 50 μl containing 2 × 106 or 1 × 104 TCID50 for wild type or B.1.351 variant, respectively. Monoclonal antibody (human or hamster S2P6 (2-20 mg/kg)) treatment was initiated 24 or 48 hours before infection by intraperitoneal injection. Monitor the hamster's appearance, behavior and weight. On day 4 post-infection, hamsters were euthanized by intraperitoneal injection of 500 μL Dolethal (200 mg/mL sodium pentobarbital, Vétoquinol SA). Lungs were collected and viral RNA and infectious virus were quantified by RT-qPCR and endpoint viral titration, respectively. Blood samples were collected before infection for pharmacokinetic analysis. SARS-CoV-2 RT-qPCR:

Hamster tissue was collected after sacrifice and homogenized in 350 μl RLT buffer (RNeasy Mini Kit, Qiagen) using bead disruption (Precellys) and centrifuged (10,000 rpm, 5 min) to assemble cellular debris. Extract RNA according to the manufacturer's instructions. For RNA extraction from serum, the NucleoSpin kit (Macherey-Nagel) was used. 4 μL of the 50 μL eluate was used as template in the RT-qPCR reaction. RT-qPCR was performed on the LightCycler96 platform (Roche) using the iTaq universal probe one-step RTqPCR kit (BioRad) with N2 primers and probes targeting nucleocapsids (Boudewijns et al. 2020). SARS-CoV-2 cDNA (IDT) standards are used to represent viral genome copies per mg of tissue or per ml of serum. Endpoint virus titration

Lung tissue was homogenized in 350 μL of minimum essential medium using bead disruption (Precellys) and centrifuged (10.000 rpm, 5 min, 4°C) to assemble cellular debris. To quantify infectious SARS-CoV-2 particles, endpoint titrations were performed on confluent Vero-E6 cells in 96-well plates. Viral titers were calculated by the method of Reed and Muench (Reed and Muench 1938) using a Lindenbach calculator and expressed as 50% tissue culture infectious dose (TCID50) per mg of tissue. References

Anderson, Elizabeth M., Eileen C. Goodwin, Anurag Verma, Claudia P. Arevalo, Marcus J. Bolton, Madison E. Weirick, Sigrid Gouma, et al. 2021. “Seasonal Human Coronavirus Antibodies Are Boosted upon SARS-CoV-2 Infection but Not Associated with Protection.” Cell 184 (7): 1858-1864.e10. Azoitei, ML, BE Correia, YE Ban, C. Carrico, O. Kalyuzhniy, L. Chen, A. Schroeter, et al. 2011 . “Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold.” Science 334 (6054): 373–76. Bolger, Anthony M., Marc Lohse, and Bjoern Usadel. 2014. “Trimmomatic: A Flexible Trimmer for Illumina Sequence Data." Bioinformatics (Oxford, England) 30 (15): 2114–20. Boudewijns, R., HJ Thibaut, SJF Kaptein, R. Li, V. Vergote, L. Seldeslachts, J. Van Weyenbergh, et al. 2020. “STAT2 Signaling Restricts Viral Dissemination but Drives Severe Pneumonia in SARS-CoV-2 Infected Hamsters.” Nature Communications 11 (1): 5838. Bournazos, S., D. Corti, HW Virgin, and JV Ravetch. 2020. “ Fc-Optimized Antibodies Elicit CD8 Immunity to Viral Respiratory Infection.” Nature 588 (7838): 485–90. Bournazos, S., TT Wang, and JV Ravetch. 2016. “The Role and Function of Fcγ Receptors on Myeloid Cells.” Microbiol Spectr 4 (6). https://doi.org/10.1128/microbiolspec.MCHD-0045-2016. Boyoglu-Barnum, Seyhan, Daniel Ellis, Rebecca A. Gillespie, Geoffrey B. Hutchinson, Young-Jun Park, Syed M. Moin, Oliver J. Acton, et al. 2021. "Quadrivalent Influenza Nanoparticle Vaccines Induce Broad Protection." Nature , March. https://doi.org/10.1038/s41586-021-03365-x. Cai, Y. , J. Zhang, T. Xiao, H. Peng, SM Sterling, RM Walsh, S. Rawson, S. Rits-Volloch, and B. Chen. 2020. “Distinct Conformational States of SARS-CoV-2 Spike Protein.” Science 369 (6511): 1586–92. Case, JB, PW Rothlauf, RE Chen, Z. Liu, H. Zhao, AS Kim, LM Bloyet, et al. 2020. “Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication- Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2.” Cell Host & Microbe 28 (3): 475-485.e5. Chen, S., G. McMullan, AR Faruqi, GN Murshudov, JM Short, SH Scheres, and R. Henderson. 2013. “High-Resolution Noise Substitution to Measure Overfitting and Validate Resolution in 3D Structure Determination by Single Particle Electron Cryomicroscopy.” Ultramicroscopy 135 (December): 24–35. Cingolani, Pablo, Adrian Platts, Le Lily Wang, Melissa Coon, Tung Nguyen, Luan Wang, Susan J. Land, Xiangyi Lu, and Douglas M. Ruden. 2012. “A Program for Annotating and Predicting the Effects of Single Nucleotide Polymorphisms, SnpEff: SNPs in the Genome of Drosophila Melanogaster Strain W1118; Iso-2; Iso-3.” Fly 6 (2): 80–92. Correia, BE, JT Bates, RJ Loomis, G. Baneyx, C. Carrico, JG Jardine, P. Rupert, et al. 2014. “Proof of Principle for Epitope-Focused Vaccine Design.” Nature 507 (7491): 201–6. Corti, D., J. Voss, SJ Gamblin, G. Codoni, A. Macagno, D . Jarrossay, SG Vachieri, et al. 2011. “A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins.” Science 333 (6044): 850–56. Danecek, Petr, James K. Bonfield , Jennifer Liddle, John Marshall, Valeriu Ohan, Martin O. Pollard, Andrew Whitwham, et al. 2021. “Twelve Years of SAMtools and BCFtools.” GigaScience 10 (2). https://doi.org/10.1093/gigascience/ giab008. Daniel, C., R. Anderson, MJ Buchmeier, JO Fleming, WJ Spaan, H. Wege, and PJ Talbot. 1993. “Identification of an Immunodominant Linear Neutralization Domain on the S2 Portion of the Murine Coronavirus Spike Glycoprotein and Evidence That It Forms Part of Complex Tridimensional Structure." Journal of Virology 67 (3): 1185–94. Di Tommaso, Paolo, Maria Chatzou, Evan W. Floden, Pablo Prieto Barja, Emilio Palumbo, and Cedric Notredame. 2017. "Nextflow Enables Reproducible Computational Workflows." Nature Biotechnology 35 (4): 316–19. DiLillo, DJ, GS Tan, P. Palese, and JV Ravetch. 2014. "Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Require FcγR Interactions for Protection against Influenza Virus in Vivo." Nature Medicine 20 (2): 143–51. Elshabrawy, HA, MM Coughlin, SC Baker, and BS Prabhakar. 2012. "Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing." PloS One 7 (11): e50366. Ewels, Philip, Måns Magnusson, Sverker Lundin, and Max Käller. 2016. "MultiQC: Summarize Analysis Results for Multiple Tools and Samples in a Single Report." Bioinformatics 32 ( 19): 3047–48. Fan, X., D. Cao, L. Kong, and X. Zhang. 2020. “Cryo-EM Analysis of the Post-Fusion Structure of the SARS-CoV Spike Glycoprotein.” Nature Communications 11 (1): 3618. Grüning, Björn, Ryan Dale, Andreas Sjödin, Brad A. Chapman, Jillian Rowe, Christopher H. Tomkins-Tinch, Renan Valieris, Johannes Köster, and Bioconda Team. 2018. “Bioconda: Sustainable and Comprehensive Software Distribution for the Life Sciences." Nature Methods 15 (7): 475–76. Gui, M., W. Song, H. Zhou, J. Xu, S. Chen, Y. Xiang, and X. Wang. 2017. “Cryo-Electron Microscopy Structures of the SARS-CoV Spike Glycoprotein Reveal a Prerequisite Conformational State for Receptor Binding.” Cell Research 27 (1): 119–29. Hoffmann, M., H. Kleine-Weber, and S. Pöhlmann. 2020. “A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells.” Molecular Cell 78 (4): 779-784.e5. Hoffmann, M., H. Kleine-Weber , S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, TS Schiergens, et al. 2020. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.” Cell 181 (2): 271-280.e8. Hoffmann, M., K. Mösbauer, H. Hofmann-Winkler, A. Kaul, H. Kleine-Weber, N. Krüger, NC Gassen, MA Müller, C. Drosten, and S. Pöhlmann. 2020. “Chloroquine Does Not Inhibit Infection of Human Lung Cells with SARS-CoV-2.” Nature 585 (7826): 588–90. Kallewaard, NL, D. Corti, PJ Collins, U. Neu, JM McAuliffe, E. Benjamin, L. Wachter-Rosati, et al. 2016. “Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes.” Cell 166 (3): 596–608. Kaname, Y., H. Tani, C. Kataoka, M. Shiokawa, S. Taguwa, T. Abe, K. Moriishi, T. Kinoshita, and Y. Matsuura. 2010. “Acquisition of Complement Resistance through Incorporation of CD55/Decay-Accelerating Factor into Viral Particles Bearing Baculovirus GP64." Journal of Virology 84 (7): 3210–19. Kanekiyo, M., MG Joyce, RA Gillespie, JR Gallagher, SF Andrews, HM Yassine, AK Wheatley, et al. 2019. "Mosaic Nanoparticle Display of Diverse Influenza Virus Hemagglutinins Elicits Broad B Cell Responses.” Nature Immunology 20 (3): 362–72. Kanekiyo, M., CJ Wei, HM Yassine, PM McTamney, JC Boyington, JR Whittle, SS Rao, WP Kong, L. Wang, and GJ Nabel. 2013. “Self-Assembling Influenza Nanoparticle Vaccines Elicit Broadly Neutralizing H1N1 Antibodies.” Nature 499 (7456): 102–6. Kirchdoerfer, RN, N. Wang, J. Pallesen, D. Wrapp, HL Turner , CA Cottrell, KS Corbett, BS Graham, JS McLellan, and AB Ward. 2018. “Stabilized Coronavirus Spikes Are Resistant to Conformational Changes Induced by Receptor Recognition or Proteolysis.” Scientific Reports 8 (1): 15701. Lempp, Florian A. , Leah Soriaga, Martin Montiel-Ruiz, Fabio Benigni, Julia Noack, Young-Jun Park, Siro Bianchi, et al. 2021. “Membrane Lectins Enhance SARS-CoV-2 Infection and Influence the Neutralizing Activity of Different Classes of Antibodies.” BioRxiv . bioRxiv. https://doi.org/10.1101/2021.04.03.438258. Li, Heng. 2013. "Aligning Sequence Reads, Clone Sequences and Assembly Contigs with BWA-MEM." ArXiv [q-Bio.GN] . arXiv . http://arxiv.org/abs/1303.3997. Marcandalli, J., B. Fiala, S. Ols, M. Perotti, W. de van der Schueren, J. Snijder, E. Hodge, et al. 2019. “Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.” Cell 176 (6): 1420-1431 e17. Pedersen, Brent S., and Aaron R. Quinlan. 2018. “Mosdepth: Quick Coverage Calculation for Genomes and Exomes." Bioinformatics 34 (5): 867–68. Piccoli, L., YJ Park, MA Tortorici, N. Czudnochowski, AC Walls, M. Beltramello, C. Silacci-Fregni, et al. 2020. " Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.” Cell 183 (4): 1024-1042.e21. Pinna, Debora, Davide Corti, David Jarrossay, Federica Sallusto, and Antonio Lanzavecchia. 2009. “Clonal Dissection of the Human Memory B-Cell Repertoire Following Infection and Vaccination.” European Journal of Immunology 39 (5): 1260–70. Pinto, D., YJ Park, M. Beltramello, AC Walls, MA Tortorici, S. Bianchi, S. Jaconi, et al. 2020. “Cross-Neutralization of SARS-CoV-2 by a Human Monoclonal SARS-CoV Antibody.” Nature 583 (7815): 290–95. Poh , CM, G. Carissimo, B. Wang, SN Amrun, CY Lee, RS Chee, SW Fong, et al. 2020. “Two Linear Epitopes on the SARS-CoV-2 Spike Protein That Elicit Neutralising Antibodies in COVID-19 Patients ." Nature Communications 11 (1): 2806. Punjani, A., JL Rubinstein, DJ Fleet, and MA Brubaker. 2017. "CryoSPARC: Algorithms for Rapid Unsupervised Cryo-EM Structure Determination." Nature Methods 14 (3): 290 –96. Reed, LJ, and H. Muench. 1938. “A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS12.” American Journal of Epidemiology 27 (3): 493–97. Sauer, Maximilian M., M. Alexandra Tortorici, Young-Jun Park, Alexandra C. Walls, Leah Homad, Oliver Acton, John Bowen, et al. 2020. “Structural Basis for Broad Coronavirus Neutralization.” BioRxiv : The Preprint Server for Biology , December. https://doi.org /10.1101/2020.12.29.424482. Schäfer, A., F. Muecksch, JCC Lorenzi, SR Leist, M. Cipolla, S. Bournazos, F. Schmidt, et al. 2021. “Antibody Potency, Effector Function, and Combinations in Protection and Therapy for SARS-CoV-2 Infection in Vivo." The Journal of Experimental Medicine 218 (3). https://doi.org/10.1084/jem.20201993. Sesterhenn, F., C. Yang, J. Bonet, JT Cramer, X. Wen, Y. Wang, CI Chiang, et al. 2020. “De Novo Protein Design Enables the Precise Induction of RSV-Neutralizing Antibodies.” Science 368 (6492). https://doi.org/10.1126 /science.aay5051. Song, Ge, Wan-Ting He, Sean Callaghan, Fabio Anzanello, Deli Huang, James Ricketts, Jonathan L. Torres, et al. 2020. “Cross-Reactive Serum and Memory B Cell Responses to Spike Protein in SARS-CoV-2 and Endemic Coronavirus Infection." BioRxiv , 2020.09.22.308965. Tegunov, D., and P. Cramer. 2019. "Real-Time Cryo-Electron Microscopy Data Preprocessing with Warp." Nature Methods 16 (11): 1146–52. Tortorici, MA, M. Beltramello, FA Lempp, D. Pinto, HV Dang, LE Rosen, M. McCallum, et al. 2020. “Ultrapotent Human Antibodies Protect against SARS-CoV-2 Challenge via Multiple Mechanisms. Science 370 (6519): 950–57. Tortorici, M. Alejandra, Nadine Czudnochowski, Tyler. 2019. “Structural Insights into Coronavirus Entry.” Advances in Virus Research 105: 93–116. N. Starr, Roberta Marzi, Alexandra C. Walls, Fabrizia Zatta, John E. Bowen, et al. 2021. “Structural Basis for Broad Sarbecovirus Neutralization by a Human Monoclonal Antibody.” BioRxiv.Org: The Preprint Server for Biology , April . https://doi.org/10.1101/2021.04.07.438818. Walls, AC, B. Fiala, A. Schäfer, S. Wrenn, MN Pham, M. Murphy, LV Tse, et al. 2020. “Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2.” Cell 183 (5): 1367-1382.e17. Walls, AC, YJ Park, MA Tortorici, A. Wall, AT McGuire, and D. Veesler. 2020. “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.” Cell 181 (2): 281-292.e6. Walls, AC, MA Tortorici, BJ Bosch, B. Frenz, PJM Rottier, F . DiMaio, FA Rey, and D. Veesler. 2016. “Cryo-Electron Microscopy Structure of a Coronavirus Spike Glycoprotein Trimer.” Nature 531 (7592): 114–17. Walls, AC, MA Tortorici, J. Snijder, X. Xiong, BJ Bosch, FA Rey, and D. Veesler. 2017. “Tectonic Conformational Changes of a Coronavirus Spike Glycoprotein Promote Membrane Fusion.” Proceedings of the National Academy of Sciences of the United States of America 114 (42): 11157–62 Walls, AC, X. Xiong, YJ Park, MA Tortorici, J. Snijder, J. Quispe, E. Cameroni, et al. 2019. “Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion.” Cell 176 (5): 1026-1039.e15. Walls, Alexandra C., Marcos C. Miranda, Minh N. Pham, Alexandra Schäfer, Allison Greaney, Prabhu S. Arunachalam, Mary-Jane Navarro, et al. 2021. “Elicitation of Broadly Protective Sarbecovirus Immunity by Receptor-Binding Domain Nanoparticle Vaccines." BioRxiv.Org: The Preprint Server for Biology , March. https://doi.org/10.1101/2021.03.15.435528. Wang, Chunyan, Rien van Haperen, Javier Gutiérrez-Álvarez, Wentao Li , Nisreen MA Okba, Irina Albulescu, Ivy Widjaja, et al. 2021. “A Conserved Immunogenic and Vulnerable Site on the Coronavirus Spike Protein Delineated by Cross-Reactive Monoclonal Antibodies.” Nature Communications 12 (1): 1715. Wilm, Andreas, Pauline Poh Kim Aw, Denis Bertrand, Grace Hui Ting Yeo, Swee Hoe Ong, Chang Hua Wong, Chiea Chuen Khor, Rosemary Petric, Martin Lloyd Hibberd, and Niranjan Nagarajan. 2012. “LoFreq: A Sequence-Quality Aware, Ultra-Sensitive Variant Caller for Uncovering Cell-Population Heterogeneity from High-Throughput Sequencing Datasets." Nucleic Acids Research 40 (22): 11189–201. Winkler, Emma S., Pavlo Gilchuk, Jinsheng Yu, Adam L. Bailey, Rita E. Chen, Seth J. Zost, Hyesun Jang, et al. 2020. “Human Neutralizing Antibodies against SARS-CoV-2 Require Intact Fc Effector Functions and Monocytes for Optimal Therapeutic Protection.” BioRxiv , 2020.12.28.424554. Wrapp, D., N. Wang , KS Corbett, JA Goldsmith, CL Hsieh, O. Abiona, BS Graham, and JS McLellan. 2020. “Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation.” Science 367 (6483): 1260–63. Xie, Xuping, Antonio E. Muruato, Xianwen Zhang, Kumari G. Lokugamage, Camila R. Fontes-Garfias, Jing Zou, Jianying Liu, et al. 2020. “A Nanoluciferase SARS-CoV-2 for Rapid Neutralization Testing and Screening of Anti-Infective Drugs for COVID-19." Nature Communications 11 (1): 5214. Yuan, Y., D. Cao, Y. Zhang, J. Ma, J. Qi, Q. Wang, G. Lu, et al . 2017. "Cryo-EM Structures of MERS-CoV and SARS-CoV Spike Glycoproteins Reveal the Dynamic Receptor Binding Domains." Nature Communications 8: 15092. Zhang, H., G. Wang, J. Li, Y. Nie, X . Shi, G. Lian, W. Wang, et al. 2004. “Identification of an Antigenic Determinant on the S2 Domain of the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Capable of Inducing Neutralizing Antibodies.” Journal of Virology 78 (13): 6938–45. Zheng, Z., VM Monteil, S. Maurer-Stroh, CW Yew, C. Leong, NK Mohd-Ismail, S. Cheyyatraivendran Arularasu, et al. 2020. “Monoclonal Antibodies for the S2 Subunit of Spike of SARS-CoV-1 Cross-React with the Newly-Emerged SARS-CoV-2.” Euro Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin 25 (28). https://doi.org/10.2807/1560 -7917.ES.2020.25.28.2000291. Zhou, P., XL Yang, XG Wang, B. Hu, L. Zhang, W. Zhang, HR Si, et al. 2020. “A Pneumonia Outbreak Associated with a New Coronavirus of Probable Bat Origin." Nature , February. https://doi.org/10.1038/s41586-020-2012-7. Example 12 Stem-helix polypeptide containing amino acids from the epitope recognized by antibody S2P6

A recombinant polypeptide is generated comprising an amino acid sequence according to any of SEQ ID NOs.: 4-19. The polypeptide comprises and/or is engineered from a portion of the stem region of the SARS-CoV-2 spike protein polypeptide. The following table shows the amino acid sequence of the SARS-CoV-2 subunit and its fragments containing the S2P6 epitope region or a portion thereof, and engineered polypeptides containing the S2P6 epitope region at the C-terminus of the S2P6 epitope region has stabilizing mutations in the S2 flanking sequence. Table 36. describe sequence S2 subunit fragment surface glycoprotein [SARS-CoV-2 Wuhan Seafood Market Pneumonia Virus]; Genbank: QHD43416.1; January 23, 2020, the S2P6 epitope region is underlined and the key amino acid residues bound are shown in bold body display Atkmsecvlgqskrvdfcgkgyhlmsfpqsaphgvvflhvtyvpaqeknfttapaichdgkahfpregvfvsngthwfvtqrnfyepqiittdntfvsgncdvvigivnntvydplqpel ds f ke eld ky f knh tspdvdlgdisginasvvniqkeidrlnevaknlneslidlqel gkyeqyikwpwyiwlgfiagliaivmvtimlccmtsccsclkgccscgscckfdeddsepvlkgvklhyt (SEQ ID NO.:3) SARS-CoV-2 S2 fragment with S2P6 epitope region (underlined, key residues for S2P6 binding shown in bold) QPEL DS F KE ELD KY F KNH TSP SARS-CoV-2 S2 fragment with truncated S2P6 epitope region (N-terminal D and C-terminal H amino acids are missing, key residues for S2P6 binding are shown in bold) S F KE ELD KY F KN SARS-CoV-2 S2 fragment with truncated S2P6 epitope region (underlined, key residues for S2P6 binding in bold; C-terminal NH missing) EL DS F KE ELD KY F K SARS-CoV-2 S2 fragment with S2P6 epitope region (underlined, key residues for S2P6 binding shown in bold) and C-terminal flanking amino acids (TS) DS F KE ELD KY F KNH TS SARS-CoV-2 S2 fragment with truncated S2P6 epitope region (underlined, critical residues for S2P6 binding in bold; N-terminal D amino acid missing) and including C-terminal flanking amino acids (T) S F KE ELD KY F KNH T Contains a truncated S2P6 epitope region (underlined, residues critical for S2P6 binding in bold; N-terminal D amino acid missing) and two native C-terminal acids from S2 (TS in italics), followed by Engineered peptides of stable and engineered S2 sequences (lower case letters) S F KE ELD KY F KNH TSdaaskagpg engineered peptides PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)

Other engineered polypeptides can be made, for example, by including more or less flanking sequences on either side of the S2P6 epitope region from SARS-CoV-2 or another coronavirus that contains the S2P6 epitope region. (In the case of SARS-CoV-2, SEQ ID NO.: 5) (and optionally introducing mutations, such as stabilizing mutations, into the flanking sequences); including a portion, but not all, of the S2P6 epitope region, preferably provided that one or more, two or more, three or more or four or more key residues for S2P6 binding are retained and the polypeptide maintains an overall structure capable of being recognized by S2P6 ; Mutation of one or more amino acids in the S2P6 epitope region, preferably, the restriction is to retain one or more, two or more, three or more or four S2P6 binding or more key residues, and the polypeptide maintains an overall structure that can be recognized by S2P6; one or more amino acids in the S2P6 epitope region are mutated, or the like. In some embodiments, the engineered polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701).

Fusion proteins containing two or more polypeptides are generated; some fusion proteins further include the SARS-CoV-2 spike protein or its receptor binding domain (RBD). In some embodiments, the polypeptide links together two or more RBDs that comprise variant (ie, engineered) RBDs and/or RBDs that comprise naturally occurring RBD amino acid sequences.

Certain embodiments of constructs comprising engineered stem-helix polypeptides are illustrated, for example, in Figures 1C, 2C, 3A, 3B, 4A (lower construct), 4B (lower construct), 8A (lower construct), 8B (lower construct) and 9D, and described in the Examples herein. Example 13 In vivo mouse studies using coronavirus constructs 1

Eight- to ten-week-old female Balb/C mice received secondary IM (gastrocnemius) immunizations 21 days apart with one of the following five constructs: Cov0064, Cov0199, Cov0200, Cov0208, and Cov0211. The design of these structures is illustrated in Figure 36.

Constructs were administered at 0.1 µg, 0.3 µg, 0.9 µg, 2.7 µg and 8.1 µg and formulated with AS03 adjuvant (alpha-tocopherol and squalene in an oil-in-water emulsion). Each dose of each construct was administered to six animals. Another control group of six animals received injections of NaCl without construct. Blood samples for further serum preparation were collected 14 days after the first and second immunizations, and spleens were collected 14 days after the second immunization for animals dosed with 0.1 μg, 0.9 μg, or 8.1 μg constructs. . Mice were finally euthanized by intraperitoneal injection of pentobarbital. Based on fake virus neutralization analysis

In a vesicular stomatitis virus/coronavirus pseudovirus (VSV/CoV PV)-based neutralization assay, mouse sera collected 14 days after the second immunization were tested against ARS-Cov2-Wuhan-Hu-1, -B.1.351 (β), -B.1.617.2 (δ), SARSCov1, MERS-CoV and only for Cov0064 and Cov0199, in vitro neutralizing activity against SARS-Cov2-B.1.1.529 (o), as the primary study endpoint.

Vero-E6 TMPRSS2 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 50 U/mL penicillin, 50 μg/mL streptomycin, 8 μg/mL puromycin and 10% fetal calf serum- Cultured in high glucose. The infectious potency of VSV/CoV PV was further tested by tissue culture infectious dose 50 (TCID50) analysis. Vero-E6 TMPRSS2 cells were seeded into 96-well plates at a density of 20,000 cells/well. Twenty-four hours later, approximately 11,000 VSV/CoV PV TCID50/well were mixed with equal volumes of heat-inactivated and 3-fold serially diluted serum to achieve final serum dilutions ranked from 1:30 to 1:65610. The virus/serum mixture was then incubated at 37°C-5% CO2 with gentle shaking for 1 hour, then transferred to the previously inoculated Vero-E6 TMPRSS2 cells, and further incubated at 37°C-5% CO2 with gentle shaking for 1 hour. hours. The virus/serum mixture was then removed, replaced with fresh cell culture medium, and cells were incubated for a further 24 hours at 37°C - 5% CO2. After washing with PBS, Steadylite Substrate (PerkinElmer Cat. No. ORT0569) was added and the Luc signal was read using a Synergy reader. Neutralization curves were then generated and analyzed using GraphPad Prism 9.2. Nonlinear regression fit with a sigmoidal dose-response (variable slope) was used to determine the effective dilution corresponding to the reciprocal serum dilution associated with a 50% reduction in Luc activity when compared to VSV/CoV PV alone 50 (ED50). In the case where no neutralizing activity was detected, the corresponding sample was assigned an arbitrary titer corresponding to one-third of the initial dilution, that is, 10.

The measured coronavirus neutralizing antibody (nAb) titers are shown in Figure 37 and Tables 37A-37E. Table 37a. Geometric mean neutralizing antibody titers (ED50) in response to Cov0199 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 641 2465 8703 4591 7398 β 14064 43625 49650 55008 61365 δ 171 2465 2431 3802 4320 o 2466 1035 6948 3534 6473 SARS-Cov1 10 10 14 10 13 MERS-Cov 10 10 10 10 10 Table 37b. Geometric mean neutralizing antibody titers (ED50) in response to Cov0064 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 1940 3508 10709 15196 30225 β 1236 3350 7033 10097 25760 δ 433 684 2082 2948 5485 o 199 371 495 1527 1833 SARS-Cov1 33 157 283 643 889 MERS-Cov 10 10 10 10 10 Table 37c. Geometric mean neutralizing antibody titers (ED50) in response to Cov0200 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 27 33 75 87 200 β 14 15 29 37 102 δ 10 16 43 57 78 SARS-Cov1 10 13 18 80 36 MERS-Cov 10 10 10 10 10 Table 37d. Geometric mean neutralizing antibody titers (ED50) in response to Cov0211 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 61 twenty three 31 133 142 β 13 14 15 69 138 δ 16 14 56 93 91 SARS-Cov1 34 10 10 15 41 MERS-Cov 10 10 10 10 10 Table 37e. Geometric mean neutralizing antibody titers (ED50) in response to Cov0208 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 638 5666 3079 6814 15230 β 24707 58307 53231 70611 65782 δ 234 1555 2170 5592 11846 SARS-Cov1 19 10 10 10 25 MERS-Cov 10 10 10 10 10

No MERS-CoV neutralizing activity was detected using any of the five test constructs.

All CoV S-based constructs evaluated (i.e., Cov0199, Cov0208, Cov0200, and Cov0211) detected no or very low SARS-CoV1 neutralizing activity, while multiple RBD-based constructs, Cov0064, detected SARS-CoV1-nAb responses, although the titers were lower than those against SARS-CoV2 variants.

Figure 38 shows a radar representation of the measured ED50 GMT of the CoV-nAb distribution associated with Cov0199 relative to Cov0064. As observed in Figure 38, Cov0199 and Cov0064 elicited similar nAb responses against SARS-Cov2-Wuhan-Hu-1 and -B.1.617.2 (delta variants). In contrast, Cov0199 induced higher neutralizing antibody (nAbs) responses against ARS-Cov2-B.1.351 (beta variant) and -B.1.1.529 (o variant) when compared to Cov0064 .

Of the five test constructs, three elicited either low SARS-CoV-nAb responses (Cov0200 and Cov0211) or increased/broader SARS-CoV-nAb responses when compared to the parental construct (Cov0208 vs. Cov0199) The response is irrelevant. In contrast, two SARS-Cov2-B.1.351-based S constructs Cov0199 and multiple RBD-based constructs Cov0064 elicited high SARS-CoV2-nAb responses against all tested variants. Although Cov0199 elicited a broad SARS-CoV2-nAb response, Cov0064 elicited an undetected SARS-Cov1-nAb response after immunization with Cov0199. CoV binding antibody response

Mouse sera collected 14 days after the second immunization were further tested using two commercially available panels covering a wide range of SARS-Cov2 variants, as well as SARS-Cov1, SARS-MERS and four human endemic coronaviruses. Cov-binding antibody titer, expressed in ECL units.

Two commercial panels from MesoScale Discovery (MSD) are used to assess CoV-binding Ab responses, a panel that covers all human CoVs, including SARS-Cov1, SARS-MERS, and four endemic human CoVs (“V -plex Covid19 Panel 3", catalog number 5397A-1), and a panel specific for different SARS-CoV2 variants ("V-plex SARS-CoV2 Panel 23", catalog number K15567). Importantly, these panels were originally developed to measure CoV-binding Ab titers in human serum. The supplier then modified the kit to allow detection of mouse antibodies (instead of secondary antibodies). However, human-specific standards and positive controls cannot be modified. Therefore, the measured antibody titers are expressed here in electrochemiluminescence (ECL) units rather than relative to standards in μg/mL. Follow the provider's instructions for analysis. Briefly, after an initial blocking step using set blocking buffer for 30 min at room temperature with shaking, the plates were washed thoroughly and added in duplicate at 1:125000 (CoV Serum samples were diluted 1:500000 (SARS-CoV2 analysis) or 1:500000 (SARS-CoV2 analysis) and incubated for 2 hours at room temperature with shaking. The plates were then washed and detection antibody (Sulfo-Tag™) diluted in set diluent buffer was added and incubated for 1 hour at room temperature with shaking. The plates were then washed and read buffer added before luminescence was measured using an MSD reader.

Radar representations of CoV-binding Ab responses elicited by Cov0199 and Cov0064 are illustrated in Figures 39A-39B. The dose for each construct and the geometric mean ECL determined for each test construct are shown. Figure 39A shows the results obtained for: SARS-Cov2-B.1.351 spike protein (β); SARS-Cov2-Wuhan-Hu-1 spike protein (Wuhan); SARS-Cov2-B.1.1.7. spike protein Protein (α); SARS-Cov2-P1 spike protein (γ); SARS-Cov2-B.1.1.529 spike protein (o); and SARS-Cov2-B.1.617.2 Seq1 (δ-Seq1), AY. 4 (δ-AY4) and AY.4.2 (δ-AY42) spike proteins. Figure 39B shows the results obtained for: SARS-Cov2-Wuhan-Hu-1 spike protein (Cov2-S); SARS-Cov2-Wuhan-Hu-1 recombinant RBD (Cov2-sRBD); SARS-Cov2-Wuhan -Hu-1 nucleocapsid (Cov2-N); SARS-Cov1 spike protein (Cov1-S); MERS-CoV spike protein (MERS); NL63-CoV spike protein (NL63); 229E-CoV spike protein (229E) ; OC43-CoV spike protein (OC43); and HKU1-CoV spike protein (HKU1).

SARS-CoV2 binding antibody responses were detected with all test constructs and against all tested SARS-CoV2 variants. When comparing different constructs, the levels of binding antibody responses to a given SARS-Cov2 variant were similar, but slightly higher SARS-Cov2 (o)-( was detected with Cov0199 relative to Cov0064 at the two highest construct doses Bottom) and SARS-Cov2 (β) binding antibody response.

When looking further at global CoV binding antibody responses, Cov0199, Cov0208, Cov0200 and Cov0211 elicited binding antibody responses against all CoVs tested, including SARS-Cov1 and MERS-CoV. In contrast, the RBD-based construct Cov0064 did not elicit binding antibody responses against any of the four endemic human CoVs (NL63, 229E, OC43, HKU1) or against SARS-MERS (low detection signal Non-specific signal measured in an assay against the negative control BSA protein). However, Cov0064 elicited highly binding antibody responses to both SARS-Cov1 and SARS-Cov2 (Wuhan) compared to Cov0199, which tended to be higher at all construct doses tested. CoV-specific B and T cell responses

Construct-elicited immunity was then further assessed as follows: by self-immunizing the lowest (0.1 μg), middle (0.9 μg), and highest (8.1 μg) construct dose groups plus NaCl 14 days after the second immunization. Characterization of SARS-Cov2-B.1.351 (β) S and SARS-Cov1 S-specific B cell responses in spleen-derived cells collected from the control group, and type 1 and type 2 after restimulation with CoV-specific peptide pools T helper (Th1 and Th2) CD4+ and CD8+ T cell responses. All cellular responses were measured by flow cytometry.

Assessment of vaccine-elicited B and T cell responses was performed on spleen-derived cells. Spleens were collected and placed in a culture medium supplemented with glutamine 2 mM, penicillin 50 U/mL, streptomycin 50 μg/mL, sodium pyruvate 1 mM, 1:100 non-essential amino acids (Life Technologies catalog number 11140-035 ) and 2-mercaptoethanol 0.05 mM in RPMI1640 medium (Gibco Cat. No. 31870-025) (also called complete medium). A cell suspension was prepared from each spleen using a tissue grinder. The spleen cell suspension was filtered (cell strainer 100 μm, BD Cat. No. 352360) and washed with 35 mL of cold PBS-EDTA 2 mM. After centrifugation (335g, 10 min at 4°C), cells were resuspended in cold PBS-EDTA 2 mM and filtered again. Cells were further centrifuged (335 g, 10 min at 4°C) and resuspended in 2 mL of complete medium-5% heat-inactivated fetal bovine serum (Serana Cat. No. S-FBS-SA-021). Cells were then counted using MACSQUANT.

T cell stimulation is then performed as follows. Freshly collected cells were transferred to a round-bottom 96-well plate at a density of 1 million cells/well. Splenocytes were then stimulated for 6 hours (37°C, 5% CO2) with: 1 μg/mL anti-CD28 (clone 37.51, BD catalog no. 553294), 1 μg/mL anti-CD49d (clone 9C10 MFR4.B, BD catalog no. 553313), 1:500 anti-CD107a (pure line 1D4B, Biolegend catalog number 121606), with or without 1 μg/mL peptide pool (MERS-CoV, SARS-CoV, SARS-CoV-2 spike protein B.1.351, SARS-CoV -2 spike protein, SARS-CoV-2 spike protein B.1.429, SARS-CoV-2 spike protein B.1.1.7, SARS-CoV-2 S-RBD, SARSCoV-2 S-RBD B.1.429, SARS- CoV-2 S-RBD B.1.351 or SARS-CoV-2 S-RBD B.1.1.7, all from JPT). After 2 hours, brefeldin A (BD Cat. No. 555029) diluted 1:1000 and monensin (BD Cat. No. 51-2092KZ) diluted 1:500 in complete medium were added and maintained for another 4 hours. The plates were then stored at 4°C overnight. Intracellular filtration was then performed as follows. Transfer cells to a V-bottom 96-well plate, centrifuge at 189 g for 5 minutes at 4°C, and resuspend in 50 μL containing 1:50 anti-CD16/32 (pure line 2.4G2, BD Cat. No. 553142) at 4°C. Brillant Staining Buffer (BD Cat. No. 563794) for 10 minutes. Next, add 50 μL of Brillant staining buffer containing the following for 30 minutes at 4°C: 1:100 anti-CD4-Alexa700 (pure line RM4-5, BD catalog number 557956), 1:50 anti-CD8-BUV805 (pure line 53-6.7, BD catalog number 564920), 1:50 anti-CD44-BUV563 (pure line IM7, BD catalog number 741227), 1:100 anti-ICOS-BUV 737 (pure line 7E17G9, BD catalog number 624286), 1:50 anti-CD127 -BV421 (pure line A7R34, BD catalog number 566377), 1:800 anti-CD62L-BV786 (pure line MEL-14, BD catalog number 564109), and 1:500 Live/dead-near-IR (Invitrogen catalog number L10119). Cells were then centrifuged (189 g, 5 min at 4°C) and washed with 200 μL of FACS buffer (PBS-1% heat-inactivated FBS). Cells were then fixed and permeabilized by adding 200 μL of Cytofix/Cytoperm solution (BD Cat. No. 554722) for 15 min at 4°C. Cells were then centrifuged (500 g, 5 min at 4°C) and washed with 200 μL of Perm/Wash buffer (BD Cat. No. 554723). After an additional centrifugation step, cells were stained for 1 hour at 4°C using 50 μL of Perm/Wash buffer containing: 1:200 anti-IL2-PE-CF594 (pure line JES6-5H4, BD Cat. No. 562483), 1 :100 anti-IFNγ-BV480 (pure line XMG1.2, BD catalog number 566097), 1:700 anti-TNFα-PE (pure line MP6-XT22, BD catalog number 554419), 1:50 anti-IL5-APC (pure line TRFK5, BD catalog number No. 554396), 1:50 anti-IL13-PE-Cy7 (pure line eBio13A, eBiosciences catalog number 25-7/33-80) and 1:100 anti-IL17-BV605 (pure line TC11-18H10, BD catalog number 564169) antibodies. Then 100 μL FACS buffer was added, and the cells were washed twice with Perm/Wash buffer, and finally resuspended in 220 μL PBS. The percentage of stained cells was then determined by flow cytometry using BD FACSymphony and FlowJo software.

B cell staining was performed as follows. Fresh splenocytes were added to V-bottom 96-well plates in duplicate at 2 million cells/well. Cells were centrifuged at 189 g for 5 min at 4°C and resuspended in 50 μL of PBS-1% FBS containing 1:50 anti-CD16/32 (clone 2.4G2, BD Cat. No. 553142) at 4°C. Incubate for 10 minutes. Next, 50 μL of PBS-1% FBS containing 2 μg/mL biotinylated-S (SARS-Cov1 S or SARS-CoV2 B1.351 S) was added and maintained at 4°C for 30 minutes. 100 μL of PBS-1% FBS was added, then the cells were centrifuged at 189 g for 5 min at 4°C, and then washed with 200 μL of FACS buffer. Next, add 50 μL of Brillant Staining Buffer (BD Cat. No. 563794) containing the following for 30 minutes at 4°C: 1:100 anti-CD38 BB700/Percp Cy5.5 (pure line 90/CD38, BD Cat. No. 742132 ), 1:100 anti-CD45R B220 BUV661 (pure line RA3-6B2, BD catalog number 565077), 1:50 anti-CD138 PE (pure line 281-2, BD catalog number 553714), 1:25 anti-IgM BV421 (pure line R6-60.2 , BD catalog number 562595), 1:200 anti-IgD BV786 (pure line 11-26c2a, BD catalog number 563618), 1:25 anti-CD95 PECy7 (pure line JO2, BD catalog number 557653), 1:400 anti-CD19 BV650 (pure line 1D3 , BD catalog number 563235), 1:100 anti-F4/80 APCCy7 (pure line BM8, Biolegend cat. 123118), 1:200 anti-TER-119 APC-Cy7 (pure line TER-119, BD catalog number 560509), 1:100 Anti-NK1.1 APC-Cy7 (pure line PK136, BD catalog number 560618), 1:100 anti-CD3e APC-Cy7 (pure line 1452c11, BD catalog number 557596), 1:25 anti-GL7 FITC (pure line GL7, BD catalog number 553666) , 1:50 anti-CD27 BUV395 (pure line LG.3A10, BD catalog number 740247) and 1:500 Live & dead Far red (APC, Molecular Probes catalog number L10120). Add 100 μL of FACS buffer, centrifuge cells at 189 g for 5 min at 4°C, and resuspend in 50 μL of Streptavidin PE-CF594 (BD Cat. No. 562284) containing 1:250 at room temperature. PBS-1% FBS for 20 minutes. 100 μL of FACS buffer was added, cells were centrifuged at 189 g for 5 min at 4°C, and resuspended in 200 μL of Cytofix/Cytoperm solution (BD Cat. No. 554722) for 15 min at room temperature. The cells were then centrifuged again at 189 g for 5 min at 4°C and subsequently washed with 200 μL FACS buffer. After an additional centrifugation step, cells were finally resuspended in 200 μL PBS. The stained cells were then analyzed by flow cytometry using BD FACSymphony and FlowJo software.

Tables 38a-38b represent Cov S-specific germinal center (GC) B cell responses as the percentage of SARS-Cov2-B.1.351 (β) S and SARS-Cov1 S-specific GC B cells in the total GC B cell population. Table 38a. Geometric mean percentage of SARS-Cov2-B.1.351 (β) S-specific GC B cells in the total GC B cell population in response to the indicated constructs at the indicated doses. construct 0.1 (µg) 0.9 (µg) 8.1 (µg) Cov0199 6.3 6.7 13.2 Cov0208 5.4 7.0 6.3 Cov0200 2.1 4.0 6.4 Cov0211 3.0 3.9 3.2 Cov0064 3.3 3.1 7.2 Table 38b. Geometric mean percentage of SARS-Cov1 S-specific GC B cells among the total GC B cell population responding to the indicated constructs at the indicated doses. construct 0.1 (µg) 0.9 (µg) 8.1 (µg) Cov0199 2.2 3.6 6.0 Cov0208 3.6 2.9 3.9 Cov0200 2.1 2.8 5.1 Cov0211 1.8 2.7 2.8 Cov0064 4.3 2.0 3.4

GC B cells specific for both SARSCov1 and SARS-Cov1-B.1.351 (Beta) were detected with all test constructs at higher frequencies than the NaCl control. Although the frequency of SARS-Cov1-specific GC B cells was very similar in all constructs tested, the SARS-Cov2-B.1.351 (β)-specific GC B cells of Cov0199 were significantly lower when compared to other constructs tested, including Cov0064. Cells tend to be numerically higher.

Characterization of Th1 and Th2 CD4+ and CD8+ T cell responses after restimulation of spleen-derived cells with a pool of peptides specific for different SARS-CoV2 variants as well as SARS-Cov1 and MERSCoV.

Figures 51A-51B show the percentage of Th1 CD4+ T cells (51A) and Th2 CD4+ T cells (51B). Figures 52A-52B show the percentage of Th1 CD8+ T cells (52A) and Th2 CD8+ T cells (52B). As shown in Figures 51A-52A, for constructs other than Cov0064, stimulation with the Cov-2 holospike peptide produced higher frequencies of Th1 CD4+ T cells, Th2 CD4+ T cells, and Th1 CD8+ T cells, and stimulation with the RBD peptide produced lower frequencies, and stimulation with the CoV-1 holospike protein peptide produced frequencies in between. For Cov0064, stimulation with the CoV-2 holospike protein peptide produced similar results to stimulation with the CoV-2 RBD peptide.

Broad CD4+ and CD8+ T cell responses were detected against all SARS-CoV2 variants tested and, albeit at lower levels, against SARS-Cov1. Th1 and Th2 CD4+ and CD8+ T cell responses both detected a Th1-biased distribution (CD8+ T cell responses were particularly strong). No MERS-Cov-specific CD4+ or CD8+ T cell responses were detected.

When further comparing Cov0199 to Cov0064, both constructs elicited similar levels of CD4+ T cell responses, although RBD-based Cov0064 detected a slightly higher frequency of RBD-specific CD4+ T cell responses when compared to Cov0199. Cov0199 detected a numerically higher frequency of SARS-Cov2-specific CD8+ T cell responses compared to Cov0064, while both constructs elicited similar levels of SARS-Cov1-specific CD8+ T cell responses.

All constructs tested elicited broad Cov-binding antibody and specific CD4+/CD8+ T cell responses. Cov0200, Cov0208 and Cov0211 elicited low SARS-CoV2-nAb responses when compared to the parental construct Cov0199. Both Cov0064 and Cov0199 elicited extensive and high SARS-CoV2-nAb responses. When compared to Cov0064, Cov0199 elicited broader CoV-binding Ab and CD8+ T cell responses, as well as higher nAb responses against SARS-Cov2-B.1.351 (β) and -B.1.1.529 (o). Cov0064 also triggered SARS-Cov1-nAb response. Example 14 In vivo mouse studies using coronavirus constructs 2

Female Balb/C mice aged eight to ten weeks were treated with one of six constructs or a combination of two or more constructs (Cov0242; Cov0184; Cov0184+combination of Cov0192; Cov0184+combination of Cov0196; Cov0184+ Combination of Cov0192+Cov0196; and Cov0177) or using Cov199 as a control for secondary IM (gastrocnemius) immunization 21 days apart. These constructs and combinations are illustrated in Figure 40.

Constructs were administered at 0.1 µg, 0.3 µg, 0.9 µg, 2.7 µg and 8.1 µg and formulated with AS03 adjuvant (alpha-tocopherol and squalene in an oil-in-water emulsion). Each dose of each construct was administered to six animals. Another control group of six animals received injections of NaCl without construct. Blood samples for further serum preparation were collected 14 days after the first and second immunizations, and spleens were collected 14 days after the second immunization for animals dosed with 0.1 μg, 0.9 μg, or 8.1 μg constructs. . Mice were finally euthanized by intraperitoneal injection of pentobarbital. Based on fake virus neutralization analysis

In a vesicular stomatitis virus/coronavirus pseudovirus (VSV/CoV PV)-based neutralization assay, mouse sera collected 14 days after the second immunization were tested against SARS-Cov2-Wuhan-Hu-1, The in vitro neutralizing activity of -B.1.351 (β), -B.1.617.2 (δ), -B.1.1.529 (o), SARS-Cov1 and MERS-CoV was used as the main research endpoint.

Pseudovirus-based neutralization analysis was performed as described in Example 13.

The measured CoV-nAb titers are shown in Figure 41 and Tables 39a-39g. Table 39a. Geometric mean neutralizing antibody titers (ED50) in response to Cov0199 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 946 1754 3570 5777 5708 β 34647 46167 56034 36001 54203 δ 743 1348 2122 2457 3861 ο 414 16334 1360 10144 9473 SARS-Cov1 10 10 16 10 13 MERS-Cov 10 10 10 10 10 Table 39b. Geometric mean neutralizing antibody titers (ED50) in response to Cov0242 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 3459 6208 7471 9489 11043 β 49166 51226 47497 50856 40614 δ 3135 8118 5893 5451 4340 ο 6132 4236 3948 2594 5264 SARS-Cov1 12 29 twenty three 28 31 MERS-Cov 10 10 10 10 10 Table 39c. Geometric mean neutralizing antibody titers (ED50) in response to Cov0177 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 61 191 199 242 181 β 28 123 661 470 745 δ twenty one 60 138 153 114 ο 13 34 79 358 236 SARS-Cov1 16 35 36 108 135 MERS-Cov 10 10 10 10 10 Table 39d. Geometric mean neutralizing antibody titers (ED50) in response to Cov0184 at indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 93 787 420 485 594 β 167 2077 631 1747 1934 δ 36 215 370 340 665 ο 89 172 505 567 1463 SARS-Cov1 12 twenty three 69 64 238 MERS-Cov 10 10 10 10 10 Table 39e. Geometric mean neutralizing antibody titers (ED50) in response to Cov0184+Cov0192 at the indicated doses. Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 29 31 94 131 181 β 49 42 84 186 373 δ 25 39 87 121 204 ο 40 18 twenty three 88 147 SARS-Cov1 923 2695 2770 4261 7793 MERS-Cov 10 10 10 10 10 Table 39f. Geometric mean neutralizing antibody titers (ED50) in response to Cov0184+Cov0196 at the indicated doses Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 54 266 148 404 318 β 35 588 399 874 706 δ 20 173 128 257 241 ο 17 458 122 1162 232 SARS-Cov1 17 30 43 25 138 MERS-Cov 10 10 10 10 10 Table 39g. Geometric mean neutralizing antibody titers (ED50) in response to Cov0184+Cov0192+Cov0196 at the indicated doses. Virus 0.1 (µg) 0.3 (µg) 0.9 (µg) 2.7 (µg) 8.1 (µg) SARS-Cov2-Wuhan-Hu-1 132 140 56 116 237 β 71 218 72 264 189 δ 60 114 43 124 182 ο 17 649 58 132 60 SARS-Cov1 985 1716 2966 5162 5247 MERS-Cov 10 10 10 10 10

Radar representation of the CoV-nAb response elicited by Cov0199 versus Cov0242 is shown in Figure 42A; Cov0199 versus Cov0184 versus Cov0177 is shown in Figure 42B; and Cov0184 versus Cov0184+Cov0192 versus Cov0184+Cov0196 versus Cov0184+CoV0192 +Cov0196 is shown in Figure 42C.

No MERS-CoV neutralizing activity was detected for any of the six test constructs, or for the control construct Cov0199 (already observed in Example 13).

Cov0199 and Cov0242 induced similar SARS-Cov2-B.1.351 (β)-nAb responses. Cov0242 induced slightly higher nAb responses against the 3 other tested SARS-CoV2 variants when compared to Cov0199 (only at the lowest test construct dose, i.e. for SARS-Cov2-B.1.1.529 (o) That is, observed at 0.1 μg/mouse) and approximately twice the SARS-Cov1-nAb titer compared to Cov0199.

When compared to Cov0199, Cov0177 and Cov0184 elicited much lower nAb titers against all SARS-CoV2 variants tested, but much higher SARS-Cov1-nAb titers. Cov0184 elicited slightly higher nAb responses against all viruses tested when compared to Cov0184+Cov0196, indicating that combining Cov0196 with Cov0184 has no added value. Compared with Cov0184+Cov0192 and Cov0184+Cov0192+Cov0196, Cov0184 elicited higher SARS-CoV2 and lower SARS-Cov1-nAb responses. Although not formally compared, SARS-Cov1-nAb titers measured with Cov0184+Cov0192 and Cov0184+Cov0192+Cov0196 were comparable at the highest tested construct doses to those of Cov0199 or Cov0242 against SARS-Cov2-B.1.351 (β) All variants except SARS-CoV-2-nAb titers were detected in the same range. CoV binding antibody response

Mouse sera collected 14 days after the second immunization were further tested using two commercially available panels covering a wide range of SARS-Cov2 variants, as well as SARS-Cov1, SARS-MERS and four human endemic coronaviruses. Cov-binding antibody titer, expressed in ECL units.

Multiplex electrochemiluminescence analysis was performed as in Example 13. Figures 53A and 53B show comparative radar representations of SARS-Cov2 binding (53A) and CoV binding (53B) antibody responses measured from sera of mice vaccinated with Cov0242 or Cov0199. Figures 54A and 54B show comparative radar representations of SARS-Cov2 binding (54A) and CoV binding (54B) antibody responses measured from sera of mice vaccinated with Cov0199, Cov0184 or Cov0177. Figures 55A and 55B show comparative radar representations of SARS-Cov2 binding (55A) and CoV binding (55B) antibody responses measured from sera of mice vaccinated with Cov0184+Cov0196, Cov0184+Cov0192, Cov0184+Cov0192+Cov0196, or Cov0184. Figures 53A, 54A, and 55A show the relationship between SARS-Cov2-B.1.351 spike protein (β); SARS-Cov2-Wuhan-Hu-1 spike protein (Wuhan); SARS-Cov2-B.1.1.7. spike protein (α ); SARS-Cov2-P1 spike protein (γ); SARS-Cov2-B.1.1.529 spike protein (o); and SARS-Cov2-B.1.617.2 Seq1 (δ-Seq1), AY.4 (δ -AY4) and AY.4.2 (δ-AY42) spike protein binding results. Figures 53B, 54B, and 55B show recombinant RBD with SARS-Cov2-Wuhan-Hu-1 spike protein (Cov2-S); SARS-Cov2-Wuhan-Hu-1 (Cov2-sRBD); SARS-Cov2-Wuhan-Hu- 1 Nucleocapsid (Cov2-N); SARS-Cov1 spike protein (Cov1-S); MERS-CoV spike protein (MERS); NL63-CoV spike protein (NL63); 229E-CoV spike protein (229E); OC43- The result of the combination of CoV spike protein (OC43); and HKU1-CoV spike protein (HKU1).

All constructs produced similar SARS-CoV2 and SARS-Cov1 binding antibody responses. Only Cov0199 and Cov0242 elicited binding Ab responses against non-SARS-CoV, that is, against MERS-CoV and human endemic CoV. The non-SARS-CoV binding Ab response of Cov0199 was higher than that of Cov0242. CoV-specific B and T cell responses

Immunity elicited by the vaccine candidate was then further assessed as follows: by collecting data from substudy 1 and from the groups immunized with the middle (0.9 μg) and highest (8.1 μg) construct doses 14 days after the second immunization. Characterization of B cell responses in spleen-derived cells or T cell responses in spleen-derived cells collected from groups immunized with the lowest (0.1 μg), middle (0.9 μg), and highest (8.1 μg) construct doses (and from the NaCl control group), SARSCov2- B.1.351 (β)S and SARS-Cov1 S-specific B cell responses, and after restimulation with CoV-specific peptide pools, characterizing type 1 and type 2 T helper (Th1 and Th2 ) CD4+ and CD8+ T cell responses. All cellular responses were measured by flow cytometry as in Example 13.

Tables 40a-40b represent Cov S-specific germinal center (GC) B cell responses as the percentage of SARS-Cov2-B.1.351 (β) S and SARS-Cov1 S-specific GC B cells in the total GC B cell population. Table 40a. Geometric mean percentage of SARS-Cov2-B.1.351 (β) S-specific GC B cells in the total GC B cell population in response to the indicated constructs/combinations at the indicated doses. construct 0.9 (µg) 8.1 (µg) Cov0199 5.8 8.4 Cov0242 2.5 4.1 Cov0177 13.3 25.0 Cov0184 2.9 11.1 Cov0184+Cov0192 6.6 5.5 Cov0184+Cov0199 6.5 5.8 Cov0184+Cov0192+Cov0196 3.6 4.0 Table 40b. Geometric mean percentage of SARS-Cov1 S-specific GC B cells among the total GC B cell population in response to the indicated constructs/combinations at the indicated doses. construct 0.9 (µg) 8.1 (µg) Cov0199 3.6 4.9 Cov0242 1.7 2.1 Cov0177 5.1 10.7 Cov0184 4.5 4.5 Cov0184+Cov0192 7.8 7.7 Cov0184+Cov0199 5.6 3.3 Cov0184+Cov0192+Cov0196 3.9 3.4

Cov0177 was produced at higher frequencies in SARS-CoV2- and SARS-Cov1-specific GC B cells compared to other test constructs. Otherwise, the construct produced similar frequencies in antigen-specific GC B cells among all GC B cells examined.

Characterization of Th1 and Th2 CD4+ and CD8+ T cell responses after restimulation of spleen-derived cells with a pool of peptides specific for different SARS-CoV2 variants as well as SARS-Cov1 and MERSCoV. Figure 56 shows a comparative radar representation of the percentage of Th1 CD4+ T cell (top) and Th2 CD4+ T cell (bottom) responses measured from sera of mice immunized with NaCl, Cov0242 or Cov0199. Figure 57 shows a comparative radar representation of the percentage of Th1 CD4+ T cell (top) and Th2 CD4+ T cell (bottom) responses measured from sera of mice immunized with NaCl, Cov0199, Cov0184 or Cov0177. Figure 58 shows a comparison of Th1 CD4+ T cell (top) and Th2 CD4+ T cell (bottom) response percentages measured in sera from mice immunized with NaCl, Cov0184+Cov0196, Cov0184+Cov0192, Cov0184+Cov0192+Cov0196 or Cov0184 Radar said. Figure 59 shows a comparative radar representation of the percentage of Th1 CD8+ T cell (top) and Th2 CD8+ T cell (bottom) responses measured from sera of mice immunized with NaCl, Cov0242 or Cov0199. Figure 60 shows a comparative radar representation of the percentage of Th1 CD8+ T cell (top) and Th2 CD8+ T cell (bottom) responses measured from sera of mice immunized with NaCl, Cov0199, Cov0184 or Cov0177. Figure 61 shows a comparison of Th1 CD8+ T cell (top) and Th2 CD8+ T cell (bottom) response percentages measured in sera from mice immunized with NaCl, Cov0184+Cov0196, Cov0184+Cov0192, Cov0184+Cov0192+Cov0196 or Cov0184 Radar said.

Broad CD4+ and CD8+ T cell responses were detected against all SARS-CoV2 variants tested, and, albeit at lower levels, against SARS-Cov1, without clear differences between constructs. Th1 and Th2 CD4+ and CD8+ T cell responses both detected a Th1-biased distribution (CD8+ T cell responses were particularly strong). For each construct candidate tested, no or only low MERS-Cov-specific CD4+ or CD8+ T cell responses were detected.

The results reported here support the improved immunogenicity profile of Cov0242 compared to the control Ag Cov0199, and the ability of Cov0192 to elicit high SARS-Cov1-cross-nAb titers. Example 15 BLI verification of constructs

Biolayer interferometry (BLI) was used to evaluate the binding between coronavirus constructs and anti-SARS-CoV2 monoclonal antibodies. Antibodies tested included S2P6 as well as five RBD-binding mAbs: S2E12 (which binds to site Ia); S2K146; S2X259 (which binds to site II); S309 (which binds to site IV); and S2H97 (which binds to site IV). to site V), and two mAbs that bind to the N-terminal domain (NTD) of spikein: S2L20 (which binds to site iv) and S2X333 (which binds to site i).

Biolayer interference was performed using Octet Red96 (ForteBio). Prepare all reagents in kinetic buffer (PBS 0.01% BSA) at the indicated concentrations. S2P6-rIgG was prepared at 3 µg/ml and loaded on a prehydrated protein A biosensor (Sartorius) for at least 10 minutes. The biosensor was then moved into a solution containing the subject antigen and association was recorded for 7 minutes (for holosphin-based antigens) or 2 minutes (for RBD-based antigens prepared at 5 µg/ml). A second association step was then performed in a 20 μg/ml solution of an irrelevant mAb (as a control) or one of the analyzed mAbs and recorded for 5 min (for holosphin-based antigens) or 2 min (for RBD-based antigens). antigen). Reaction values were output and plotted using GraphPad Prism 9.1.0.

Figure 43A shows holosphin-based constructs Cov0211; Cov0208; Cov0200 analyzed against S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; S2X333-rFab; S2H97-rFab; and unrelated mAbs. ; and BLI information of Cov0199. S2X333-rFab served as a negative control. As shown in Figure 43A and summarized in Figure 43B, each construct showed binding to S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; and S2H97-rFab, but not to S2X333-rFab; Combination of rFab or irrelevant mAb controls. All constructs showed binding to S2P6-rIgG.

Figure 44A shows RBD concatemer-based constructs Cov0064; Cov0196; Cov0184; and Cov0192 analyzed against S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; S2H97-rFab; and irrelevant mAbs. BLI information. S2L20-rFab served as a negative control. As shown in Figure 44A and summarized in Figure 44B, Cov0064 and Cov0184 demonstrate binding to S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; ; S309-Fab; and S2H97-rFab binding; and Cov0196 showed binding to S2E12-rFab; S2K146-rFab; S309-Fab; and S2H97-rFab. No construct showed binding to S2L20-rFab or the irrelevant mAb control. All constructs showed binding to S2P6-rIgG.

Figure 45A shows BLI data for RBD monomer-based constructs Cov0046; Cov0047; and Cov0049 analyzed for S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; S2L20-rFab; S2H97-rFab; and unrelated mAbs . S2L20-rFab served as a negative control. As shown in Figure 45A and summarized in Figure 45B, each construct exhibited binding to S2E12-rFab; S2K146-rFab; S2X259-rFab; S309-Fab; and S2H97-rFab. No construct showed binding to S2L20-rFab or the irrelevant mAb control. All constructs showed binding to S2P6-rIgG. Example 16 Vaccination of mice with RBD concatemer-enhanced COV2 spike protein mRNA

Eight- to ten-week-old female Balb/C mice were subjected to secondary IM (gastrocnemius) immunization with the mRNA SARS-CoV2 spike protein vaccine on days 0 and 15. On day 60, boost mice with one of: 1) PBS (negative control), 2) mRNA SARS-CoV2 spike protein vaccine, or 3) Cov0064 plus AddaS03 adjuvant. Sera were obtained on days 15, 21, and 67 for analysis of neutralizing and binding antibody responses.

Mouse sera collected on day 67 after the second immunization were tested against SARS-Cov2-Wuhan-Hu-1 (Wu), -B.1.351 (BA1), -B.1.617 using a VSV-based pseudovirus neutralization assay. In vitro neutralizing activity of .2 (BA2), -B.1.1.529 (BA5) and SARSCov1. Figures 46 and 48 present the results of these analyses. Each point represents an individual mouse, the bar represents the geometric mean, and the error bars represent the geometric standard deviation. Statistical significance was determined using the Kruskal-Wallis test and noted using the following: ns = not significant; * = p < 0.05; ** = p < 0.01, *** = p < 0.001; And ****=p<0.0001. The analysis showed that boosting with Cov0064 produced similar CoV2o neutralizing antibodies (nAbs) as boosting with the mRNA spike vaccine, but produced higher Cov1 nAbs than boosting with the mRNA spike vaccine. Pre-existing anti-spike antibodies from previous immunizations with the mRNA vaccine did not disrupt the induction of anti-SARS-CoV-1 nAbs by CoV0064. Enhancement with CoV0064 increased nAb responses against SARS-CoV-2, SARS-CoV-2o and SARS-CoV-1.

Collected sera were also tested using ELISA analysis for antibody binding to engineered S2P6 linker peptides and RBDs from the following viruses: SARS-Cov2-Wuhan-Hu-1 (Wu), -B.1.351 (β), SARS- Cov1, Wiv-1, RatG13, PangGD, PangGx, Anlog112, YN2013, SX2001, SC2018, ZC45, BTK72 and BGR2008. As shown in Figure 30, these represent viruses from each of the Sabey coronavirus clade. Figures 47 and 49A-49D present the results of these analyses. Each point represents an individual mouse, the bar represents the geometric mean, and the error bars represent the geometric standard deviation. Statistical significance was determined using the Kraska-Wallis test and noted using the following: ns = not significant; * = p < 0.05; ** = p < 0.01, *** = p < 0.001; and **** = p<0.0001.

The analysis showed that Cov0064 enhanced binding antibodies against multiple Sabey coronaviruses from clades 1, 2, and 3 to a higher extent than the mRNA spike protein vaccine. Notably, Cov0064 enhanced binding to RBD over the five viruses represented in the concatemer. Example 17 Behavior of certain protein constructs

For concatemer constructs containing various linkers, protein performance and the ability of selected anti-SARS-CoV-2 antibodies to bind to the expressed constructs were evaluated. The results are summarized in Tables 41 and 42; higher numbers under the "Adjusted Concentration (mg/ml)" row header correlate with higher protein performance, and "Correct BLI Response to Protein" row headings compare High numbers correlate with the presence of the epitope detected by the selected antibody. Table 41. Analysis of protein expression and epitope presence in certain concatenated constructs concatemer linker Adjusted concentration (mg/ml) Correct BLI response to protein All information Remove individual RBDs All information Remove individual RBDs GSGSGSGSG (SEQ ID NO.:711) -0.82 -0.73 -0.59 -1.82 GSGSGS (SEQ ID NO.:710) -1.14 -1.25 -0.51 -1.54 GPPSPPG (SEQ ID NO.:709) 0.00 0.31 0.81 0.88 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) 0.87 1.67 1.67 2.48 Table 42. Analysis of protein expression and epitope presence in certain other concatenated constructs concatemer linker Adjusted concentration (mg/ml) Correct BLI response to protein All information Remove individual RBDs All information Remove individual RBDs GSGSGS (SEQ ID NO.:710) -1.45 -0.02 -0.24 -0.91 GPPSPPG (SEQ ID NO.:709) -1.18 0.80 -0.13 -0.71 GSGSGSGSG (SEQ ID NO.:711) -2.24 -2.02 -0.01 -0.59 PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) -1.06 1.24 1.89 2.21

Of all the concatenated constructs tested, the construct carrying the engineered S2P6 epitope linker (PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701)) performed best.

In additional characterization studies, constructs including Cov0061-Cov0070 (see Table 5) were expressed in host cells and inter alia evaluated: protein concentration; adjusted concentration (mg/mL); and selected anti-SARS-CoV-2 The reaction of an antibody to a protein (as binding measured by BLI). The results for Cov0061-Cov0070 are summarized in Table 43. Table 43. Performance and identification of SARS-CoV-2 antibodies in constructs Cov0061-Cov0070 construct Protein concentration (AdjOD280) Adjusted concentration (mg/ml) BLI response to protein Cov0061 0.549 0.17 0.30097659 Cov0062 0.02 0.03 0.04178145 Cov0063 0.546 0.83 0.18465285 Cov0064 0.82 1.25 0.29843019 Cov0065 0.48 0.73 0.00282981 Cov0066 0.772 1.18 0.02833697 Cov0067 0.077 0.12 0.45220567 Cov0068 1.137 1.73 0.13533677 Cov0069 0.638 0.97 --- Cov0070 0.683 1.04 --- Example 18 Design of additional protein constructs

Additional protein constructs were designed as summarized in Table 44. Constructs Cov0746-Cov0751 were designed using Cov0064 (also shown in Table 44 for reference) as a starting point. Constructs Cov0758, Cov0759, Cov0761 and Cov0762 are constructs based on the extracellular domain of spinin. Table 44. Overview of constructs Cov0064 , Cov0746-Cov0751 , Cov0758 , Cov0759 , Cov0761 and Cov0762 RBDs CoV- 1 2 3 4 5 Connector label 0064 β RsSCH014 PCoV GX-P4L MP789 RatG13 S2P6 His 0746 β RsSCH014 ο MP789 RatG13 S2P6 -- 0747 ο RsSCH014 PCoV GX-P4L MP789 RatG13 S2P6 His 0748 δ RsSCH014 ο MP789 RatG13 S2P6 His 0749 β RsSCH014 ο MP789 RatG13 S2P6 His 0750 ο RsSCH014 PCoV GX-P4L MP789 RatG13 S2P6 -- 0751 δ RsSCH014 ο MP789 RatG13 S2P6 -- spike protein label 0758 ο His 0759 ο -- 0761 οHexaPro -- 0762 οHexaPro His

In Table 44, “β” is SARS-CoV-2 B.1.351, “o” is SARS-CoV-2 B1.1.529, and “δ” is SARS-CoV-2 B.1.617.2. "S2P6" is the engineered linker sequence SEQ ID NO.:701. This linker is placed between two consecutive RBDs, that is, connecting RBD1 and RBD2, RBD2 and RBD3, RBD3 and RBD4, and RBD4 and RBD5. "His" = C-terminal His tag (after RBD5 or at the C terminus of the spike protein construct), and "--" = no His tag present.

Constructs Cov0064 and Cov0746-Cov0751 contain the N-terminal signal peptide MAPLLLLLPLLWAGALA (SEQ ID NO.:706). Constructs Cov0758, Cov0759, Cov0761, and Cov0762 contain the N-terminal signal peptide MFVFLVLLLPLVSS.

The amino acid sequences of the constructs in Table 44 are as follows: Cov0064 = SEQ ID NO.:218; Cov0746 = SEQ ID NO.:712; Cov0747 = SEQ ID NO.:713; Cov0748 = SEQ ID NO.:714; Cov0749 = SEQ ID NO.:715; Cov0750 = SEQ ID NO.:716; Cov0751 = SEQ ID NO.:717; Cov0758 = SEQ ID NO.:718; Cov0759 = SEQ ID NO.:719; Cov0761 = SEQ ID NO. :720; Cov0762 = SEQ ID NO.:721.

The various embodiments described above may be combined to provide further embodiments. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications mentioned in this specification, including U.S. Provisional Application No. 63 filed on August 27, 2021 /238,078 are incorporated by reference in their entirety. If necessary, the embodiments may be modified to adopt concepts from various patents, applications, and publications to provide other embodiments.

These and other changes may be made to the embodiments in light of the above. Generally speaking, the terms used in the following patent application should not be construed to limit the patent application to the specific embodiments disclosed in this specification and the patent application, but should be construed to include all possible embodiments and the application. The scope of the patent covers the entire scope of equivalents to which one is entitled to claim. Therefore, the patentable scope is not limited by the present invention.

without

Figures 1A-1C show certain embodiments of coronavirus spike protein extracellular domain fusions of the present disclosure. (1A) Spinin extracellular domain fusions associate to form a trimer; each fusion monomer of the trimer contains a foldon at the C terminus of the spinin extracellular domain. (1B) The C-terminus of the foldon is a Townsend linker, followed by a SpyTag peptide (for example, including the amino acid sequence AHIVMVDAYKPTK (SEQ ID NO.:700)). (1C) The C-terminus of the foldon is a linker (for example, GSG or GPP ), followed by a stem-helix polypeptide (e.g., comprising the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) from the SARS-CoV-2 sequence recognized by antibody S2P6 as described herein site engineering). In some embodiments, one to three copies of [linker-stem-helix polypeptide] are arranged in a series, where each linker can be the same or different (e.g., each can independently be a GS linker, GSG linker, GPP linker, (Gly _x Ser _y ) _n linker, Townsend linker or similar linker).

In certain drawings of the invention, receptor binding domains (RBDs) are shown as containing lighter portions and shaded or darker portions, and the darker portions may be designated as "epitope" or "RBD epitope" . This is for illustrative purposes only and does not limit any embodiment of the present disclosure to necessarily include a particular epitope. Certain constructs are described in further detail herein.

Figures 2A-2C show certain embodiments of RBD monolithic constructs of the present disclosure. (2A) RBD polypeptide isolated from the S extracellular domain of the SARS-CoV-2 South African variant. (2B) The SpyTag peptide is linked to the RBD polypeptide (N-terminus and/or C-terminus of the RBD polypeptide) via a Townsend linker (GSGGSGGSGGTG; SEQ ID NO.:702). (2C) The SpyTag peptide is fused at the N-terminus of the RBD polypeptide and the stem-helix polypeptide ("S2P6") is fused at the C-terminus of the RBD polypeptide.

Figures 3A and 3B show certain embodiments of spinin ectodomain:foldon:RBD fusion constructs of the present disclosure. The spike protein ectodomain trimer may comprise a foldon at the C-terminus of each spike protein ectodomain of the trimer. Each of the three foldons can be linked to an RBD polypeptide (two RBD polypeptides are shown connected in series, but one, two, three or more RBD polypeptides can be present in the chain extending from the foldon). In Figure 3A , a linker (comprising a non-stem-helical polypeptide; such as a Townsend, GSG, GS or GPP linker) is disposed between each foldon and the corresponding first RBD polypeptide, and each first RBD polypeptide and the corresponding second between RBD polypeptides. Another linker is placed between each second RBD polypeptide and the stem-helix polypeptide ("C-ter S2P6"). Another embodiment is shown in Figure 3B , in which a stem-helix polypeptide is disposed between each foldon and the corresponding first RBD polypeptide, and between each first RBD polypeptide and the corresponding second RBD polypeptide. The stem-helix polypeptide is also linked (via a non-stem-helix polypeptide, such as a Townsend, GS, GSG or GPP linker) to each second RBD polypeptide.

Figures 4A and 4B show certain embodiments of RBD concatemers of the present disclosure. The concatemer may comprise, for example, three ( 4A ) or five ( 4B ) RBD polypeptides. The RBD polypeptides shown in Figures 4A and 4B are heterotypic (each derived from a different coronavirus or strain of coronavirus), but one or more of the RBD polypeptides in the concatemer may alternatively be homotypic. In the upper concatemer in each of Figures 4A and 4B, a non-stem-helix polypeptide linker (such as a Townsend, GS, GSG, or GPP linker) connects consecutive RBD polypeptides to form a single-chain fusion protein. In the lower construct shown in each of Figures 4A and 4B, the stem-helix polypeptide acts as a linker to join consecutive RBD polypeptides to form a single-chain fusion protein. In other embodiments (not shown), the concatemers include tags, such as SpyTag, and optionally purification tags, such as His tags.

Figures 5A-5G summarize the procedures performed in the RBD of the SARS-CoV-2 S protein backbone (South African variant) to generate certain protein constructs of the present disclosure (under the header labeled "Constructs" in each figure "251"-"382") mutations, as described in Example 4. Amino acid numbers (top column in each figure) are referenced to the Wuhan-1 S protein sequence. The corresponding wild-type amino acid sequences of each region are shown in Figures 5A, 5C and 5E. Dashes ("-") indicate that the wild-type residue at the indicated position is retained.

Figure 6 shows (left) certain embodiments of a sequence-engineered RBD:SpyTag fusion protein and (right) an S-ectodomain:foldon:SpyTag fusion comprising a sequence-engineered RBD of the present disclosure. In some embodiments, the engineered RBD is selected from those summarized in Figures 5A-5G; see also Examples 4 and 8, and Tables 1 and 2. In the figure, the Townsend linker connects the RBD or foldon to the SPyTag.

Figure 7 shows another embodiment of the spinin ectodomain:foldon:SpyTag fusion of the present disclosure. Shown is a spike protein ectodomain fusion (assembled as a trimer) based on the backbone of the SARS-CoV-2 South African variant, fused to the foldon and SpyTag. The two RBDs of the trimer are in the "upward" configuration. The fusion of the foldon and SpyTag is via a linker.

Figures 8A and 8B show certain embodiments of extraspinal ectodomain:foldon:RBD fusion constructs of the present disclosure. Spinin ectodomain trimers are shown; one or more monomers may contain the RBD in an "up" or "open" configuration. The foldon is fused to each spinin extracellular domain monomer. Each of the three foldons is linked to one ( 8A ) or two consecutive ( 8B ) RBD monomeric polypeptides (also referred to as "isolated" RBD polypeptides). In some embodiments, all RBD monomeric polypeptides are different from one or more of the three RBDs contained in the trimer of the extracellular domain of spinin, and may be different from all three. In other words, the RBD in the spike protein ectodomain portion of the fusion may be different from one or more of the isolated RBDs disposed at the C-terminus of the foldon. For example, each spike protein ectodomain of the trimer can be derived from the South African variant of SARS-CoV-2, and each RBD monomeric polypeptide can be from or derived from another coronavirus or another coronavirus variant. In each of the two constructs shown in Figure 8A, all three RBD monomer polypeptides are identical to each other and different from one or more of the RBDs contained in the spinin ectodomain trimer. In Figure 8B, all three (first) RBD monomeric polypeptides directly linked to the fold codon are identical to each other, and all three (second) RBD monomeric polypeptides linked to the (first) RBD monomeric polypeptide are identical to each other. same. All RBD monomeric polypeptides are different from one or more RBDs of the S ectodomain trimer.

Figures 9A-11 show the general organizational flow of certain constructs of the present disclosure, as described in Example 8.

Figure 12 shows the binding of monoclonal antibody S2P6 (recombinantly expressed as human IgG1) to the spike (S) protein of different human beta-coronaviruses as measured by enzyme-linked immunosorbent assay (ELISA). The antibody includes the VH of SEQ ID NO.:26 (CDRH1, CDRH2 and CDRH3 of SEQ ID NOs.:27-29, respectively) and the VL of SEQ ID NO.:30 (CDRL1 of SEQ ID NOs.:31-33, respectively). , CDRL2 and CDRL3). Prefusion stable from SARS-CoV (Urbani strain, AAP13441), SARS-CoV-2 (BetaCoV/Wuhan-Hu-1/2019), MERS (London1/2012), OC43 and HKU1 coated at 1 µg/ml S protein. Only PBS was used as a negative control. Half maximum effective concentration (EC50) is reported in ng/ml.

Figure 13 shows an alignment of part of the S2 segment from human beta-coronavirus spike protein. The linker region in the C-terminal part of the prefusion ectodomain is indicated by a square.

Figures 14A-14C illustrate the partially conserved linker region in the C-terminal portion of the prefusion ectodomain of human betacoronavirus spike protein. Figure 14A shows an alignment of partial spike protein amino acid sequences from different human beta-coronaviruses. Figure 14B shows the SARS-CoV-2 spike protein and identifies the linker region (the region inside the square, containing the N1158 glycan). Figure 14C shows a detailed view of the linker region shown in Figure 14B, with certain amino acid residues indicated (numbered according to pre-fusion configuration).

Figures 15A-15C show the structure of the SARS-CoV-2 S protein (Figure 15A) and a detailed view of the conserved linker region and certain amino acid residues and the N1158 glycan (Figure 15B). In Figure 15C, the residues are shown in pre-fusion (bottom) and post-fusion (top) configurations. The numbering of residues in the fused image does not take into account the signal peptide.

Figure 16 shows the binding of S2P6 to the prefusion spike proteins of betacoronavirus MERS, HKU1, OC43, SARS-CoV and SARS-CoV-2. The calculated EC50 value is shown on the right side of the graph.

Figure 17 shows the results of a peptide scan using the ^PEPperCHIP® pan-coronavirus spike protein microarray to identify antibodies S2P6 (represented by recombinant IgG1 with M428L and N434S Fc mutations) within each of the seven coronavirus spike proteins. Binding coronavirus spike protein motif. Microarrays include SARS-CoV-2 (UniProt ID P0DTC2), SARS-CoV (UniProt ID P59594), MERS-CoV (UniProt ID A0A140AYZ5), HCoV-OC43 (UniProt ID P36334), HCoV-HKU1 (UniProt ID U3NAI2), The spike protein of HCoV-NL63 (UniProt ID Q6Q1S2) and HCoV-229E (UniProt ID P15423). Each spike protein sequence is converted into a 15 amino acid peptide with a peptide-peptide overlap of 13 amino acids. The array contained 4,564 different peptides printed in duplicate. Antibody S2P6, representing recombinant IgG1 with M428L and N434S ("MLNS") Fc mutations, was incubated with the array at a concentration of 10 µg/ml. A common motif FKEELDKYF (found in SARS-CoV-2 and SARS-CoV; SEQ ID NO:57) and similar motifs GIDFQDELDEFFK (found in MERS-CoV; SEQ ID NO:58) and DFKEELDQWFK (found in MERS-CoV; SEQ ID NO:58) were observed. Reactions with adjacent peptides found in HCoV-OC43; SEQ ID NO:59). These motifs are located in the surface-exposed linker region at the tail of the prefusion ectodomain.

Figure 18 shows the results of prophylactic administration of antibody S2P6 (expressed as hamster IgG2a) to Syrian hamsters prior to intranasal challenge with SARS-CoV-2 Wuhan Hu-1. Viral RNA (left panel) and viral titer (right panel) were measured in the lungs after infection.

Figure 19 shows the divergence diagram of representative α-coronavirus and β-coronavirus S glycoprotein amino acid sequences inferred by maximum likelihood analysis.

Figure 20 shows antibody S2P6 binding (10 to 0.22 µg/ml) to a set of 26 S glycoproteins (left) and 8 SARS-CoV-2 variants (right) representing all sarbecovirus clades. ), shown as a logarithmic-MFI (geometric mean fluorescence intensity) heat map.

Figure 21 shows binding of antibody S2P6 to a linear peptide (a 15-mer peptide overlapping by 13 residues) spanning the SARS-CoV/SARS-CoV-2 S, OC43 S and MERS-CoV S sequences.

Figure 22 shows an alignment of the beta-coronavirus stem-helix region of multiple beta-coronaviruses and the boxed antibody S2P6 epitope region. Residue numbers are shown according to SARS-CoV-2 S. The N-linked glycosylation sequon is surrounded by a dashed line.

Figure 23 shows analysis of binding of memory B cells to beta-coronavirus stem-helical peptides from 21 COVID-19 convalescent individuals. Each point represents an individual culture containing oligohomogeneous B cells screened for stem-helical peptides in an ELISA (left panel). The cutoff value (0.4) is indicated by the dashed line. Shown are pairwise reactivity comparisons of SARS-CoV/-2 and OC43 (middle panel) and SARS-CoV/-2 and HKU1 (right panel).

Figure 24 shows analysis of binding of memory B cells to beta-coronavirus stem-helical peptides from 16 vaccinees. Each point represents an individual culture containing oligohomogeneous B cells screened for stem-helical peptides in an ELISA (left panel). The cutoff value (0.4) is indicated by the dashed line. Shown are pairwise reactivity comparisons of SARS-CoV/-2 and OC43 (middle panel) and SARS-CoV/-2 and HKU1 (right panel).

Figure 25 shows longitudinal analysis of binding of plasma antibodies to beta-coronavirus stem-helical peptides in vaccinees.

Figure 26 shows the results of testing in Syrian hamsters administered the indicated amounts of antibody S2P6 containing hamster (Hm) or human (Hu) constant regions prior to intranasal challenge with prototype SARS-CoV-2 (Wuhan-1 related). Viral RNA load is shown in the left panel and replicating virus titer in the right panel. *P<0.05, Mann-Whitney test.

Figure 27 shows the results in Syrian hamsters after prophylactic administration of 20 mg/kg human antibody S2P6. Hamsters were challenged with SARS-CoV-2 B.1.351 VOC following antibody administration. Viral RNA load is shown in the left panel and replicating virus titer in the right panel.

Figure 28 shows the binding of antibody S2P6 (left panel) and antibody S2S43 (right panel) to the prefusion β-coronavirus S extracellular domain trimer measured by ELISA.

Figures 29A-29C show the geometric mean fluorescence of antibody S2P6 binding to a panel of 26 S glycoproteins and 8 SARS-CoV-2 variants representing all Sabey coronavirus clades, as measured by flow cytometry. light intensity.

Figure 30 shows the phylogenetic tree of Sabey coronavirus as inferred by maximum likelihood analysis of the spike protein amino acid sequence.

Figure 31 shows the binding (fluorescence) of antibody S2P6 to a stem-helix peptide (amino acid sequence at the bottom of the heat map) containing each possible amino acid substitution (along the left side of the heat map) at the indicated stem-helix peptide amino acid position. intensity) heat map. The white to dark gradient indicates the extent of binding loss compared to the native residues shown as crossed squares (bounded in white). Squares surrounded by dashed lines indicate substitutions that enhance binding compared to native residues. Asterisks highlight substitutions found in antibody S2P6 viral escape.

Figure 32 shows epitope conservation between beta-coronavirus sequences with human and animal hosts as extracted from GISAID. Consensus sequences for SARS-CoV-2 are reported on the x-axis and major substitutions are indicated by bold letters.

Figures 33A-33F show binding of beta-coronavirus stem-helix peptide to IgG memory B cells from convalescent individuals for each individual tested. The cutoff value (OD=0.4) is indicated by the dashed line, and the frequency of scoring positive cultures for each antigen is reported.

Figures 34A-34D show binding of beta-coronavirus stem-helix peptide to IgG memory B cells from vaccine recipients for each individual tested. The cutoff value (OD=0.4) is indicated by the dashed line, and the frequency of scoring positive cultures for each antigen is reported.

Figure 35 shows β-coronavirus with IgG memory B cells from an immune individual (top left panel) and two pre-pandemic individuals (top right panel and bottom panel) after the first vaccine dose demonstrated a high response to SARS-CoV2. Binding of stem-helical peptides.

Figure 36 illustrates the design of five coronavirus constructs of the present disclosure tested in an in vivo mouse model, as described in Example 13.

Figure 37 shows in vitro neutralizing antibody titers against the indicated coronaviruses in mouse sera following immunization of mice with the indicated constructs (CoV0199, CoV0064, CoV0200, CoV0211, CoV0208), as described in Example 13.

Figure 38 shows a comparative radar plot of coronavirus neutralizing antibody ED50 GMT measured from sera of mice immunized with the indicated constructs, as described in Example 13.

Figures 39A-39B show comparative radar representations of coronavirus-binding antibodies (reported as ECL geometric mean) measured from sera of mice immunized with the indicated constructs, as described in Example 13.

Figure 40 illustrates the design of six coronavirus constructs and combinations of coronavirus constructs (groups 1-6 in the figure) of the present disclosure tested in an in vivo mouse model, as described in Example 14.

Figures 41A-41B show in vitro neutralizing antibody titers against designated coronaviruses in mouse sera following immunization of mice with a designated construct or combination of constructs, as described in Example 14.

Figures 42A-42C show comparative radar representations of coronavirus neutralizing antibody responses measured from sera of mice vaccinated with the indicated construct or combination of constructs, as described in Example 14.

Figures 43A-45B show results from biolayer interferometry (BLI) assays that assess binding of certain anti-SARS-CoV-2 antibodies and designated constructs of the present disclosure, as described in Example 15.

Figure 46 shows (top) neutralizing antibody titers against indicated coronaviruses in the sera of mice that received a secondary immunization with the mRNA SARS-CoV2 spike vaccine, followed by either Cov0064 or the mRNA spike vaccine (including PBS As control) boost immunization, and (bottom) Fold change in neutralizing antibody titers against each coronavirus compared to titers achieved using the mRNA spike protein vaccine boost (1.0), as described in Example 16.

Figure 47 shows the binding breadth of antibodies elicited by immunizing mice as described in Example 16 to Sabey coronavirus. ELISA data showing fold changes in binding antibody titers against the indicated antigens (engineered S2P6 peptide; RBD from clade 1 viruses SARS-CoV-1 and Wiv1; RBD from clade 2 viruses YN2013 and S2X2011; and RBD from clade 3 viruses BTKY72 and BGR2008).

Figure 48 shows the breadth of anti-Sabe coronavirus neutralizing antibodies elicited by immunizing mice as described in Example 16. Each data point represents sera from individual mice in a VSV-based pseudovirus neutralization assay.

Figures 49A-49D show the breadth of binding of antibodies to Sabey coronavirus elicited by immunizing mice as described in Example 16. ELISA data show binding EC50 of antibodies against the indicated antigens (engineered S2P6 peptide; from SARS-Cov2-Wuhan-Hu-1 (Wu), -B.1.351 (β), SARS-Cov1, Wiv-1, RatG13, RBDs of PangGD, PangGx, Anlog112, YN2013, SX2001, SC2018, ZC45, BTK72 and BGR2008.

Figures 50A-50B show partial sequence alignments of constructs Cov0204-Cov0233.

Figures 51A-51B show the percentage of Th1 CD4+ T cells (51A) and Th2 CD4+ T cells (51B) in mice following administration of the indicated constructs as described in Example 13.

Figures 52A-52B show the percentage of Th1 CD8+ T cells (52A) and Th2 CD8+ T cells (52B) in mice after administration of the indicated constructs, as described in Example 13.

Figures 53A-55B show comparative radar representations of SARS-CoV2 and SARS-CoV binding antibody responses measured from sera of mice vaccinated with the indicated constructs or combinations of constructs, as described in Example 14.

Figures 56-58 show comparative radar representations of CD4+ T cell responses measured from sera of mice immunized with the indicated constructs or combinations of constructs, as described in Example 14.

Figures 59-61 show comparative radar representations of CD8+ T cell responses measured from sera of mice immunized with the indicated constructs or combinations of constructs, as described in Example 14.

TW202315895A_111132369_SEQL.xml

Claims (76)

A fusion protein comprising a first coronavirus RBD polypeptide linked to a second coronavirus receptor binding domain (RBD) polypeptide, wherein optionally, the first RBD polypeptide and/or The second RBD polypeptide is from a betacoronavirus, and wherein further optionally, the first RBD polypeptide and the second RBD polypeptide are from different betacoronaviruses. Such as the fusion protein of claim 1, which includes the first RBD polypeptide, the second RBD polypeptide and a third coronavirus (such as beta coronavirus) RBD polypeptide, and the first RBD polypeptide is connected by a linker (1) to the second RBD polypeptide, and the second RBD polypeptide is connected to the third RBD polypeptide through a linker (2). The fusion protein of claim 2, wherein the linker (1) and the linker (2) comprise the same amino acid sequence, essentially consist of the same amino acid sequence, or consist of the same amino acid sequence. The fusion protein of claim 2, wherein the linker (1) and the linker (2) have different amino acid sequences from each other. The fusion protein of any one of claims 1 to 4, wherein the linker, the linker (1) and/or the linker (2) comprise a stem-helix polypeptide. The fusion protein of any one of claims 2 to 5, wherein the linker (1) and the linker (2) each comprise a stem-helix polypeptide. Such as the fusion protein of any one of claims 1 to 6, which includes an RBD polypeptide from any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2β variant (also known as B.1.351); the SARS-CoV-2 delta variant (also known as B.1.617.2); and the SARS-CoV-2o variant (also known as B.1.1.529). Such as the fusion protein of any one of claims 1 to 7, which includes an RBD polypeptide, and the RBD polypeptide includes the amino acid sequence of any one of SEQ ID NO.: 2 and 722-729. The fusion protein of any one of claims 1 to 8, which includes an RBD polypeptide consisting of the amino acid sequence of any one of SEQ ID NO.: 2 and 722-729. The fusion protein of any one of claims 1 to 9, which includes an RBD polypeptide from any one or more of the following: PANG/GX; MP789; RaTG13; and RsSHC014. The fusion protein of any one of claims 1 to 10, which includes an RBD polypeptide comprising the amino acid sequence of any one of SEQ ID NO.:730-737 or consisting of SEQ ID NO.:730 The amino acid sequence of any one of -737. Such as the fusion protein of any one of claims 1 to 11, which includes three RBD polypeptides, wherein the three RBD polypeptides are from: MP789; RaTG13; and RsSHC014. The fusion protein of any one of claims 1 to 12, which includes three RBD polypeptides, wherein the three RBD polypeptides respectively include the amino acid sequences set forth in: (i) SEQ ID NO.: 734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731. The fusion protein of any one of claims 1 to 13, which includes three RBD polypeptides, wherein the three RBD polypeptides respectively consist of the amino acid sequences set forth in the following: (i) SEQ ID NO.:734 or 735; (ii) SEQ ID NO.:736 or 737; and (iii) SEQ ID NO.:730 or 731. The fusion protein of any one of claims 5 to 14, wherein the stem-helix polypeptide comprises an amino acid sequence according to any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 or is composed of Composed according to the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59. The fusion protein of any one of claims 5 to 15, wherein the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). . The fusion protein of any one of claims 2 to 16, further comprising a fourth coronavirus (such as β-coronavirus) RBD polypeptide and a fifth coronavirus (such as β-coronavirus) RBD polypeptide, wherein the fourth RBD The polypeptide is linked to the third RBD polypeptide via a linker (3) and the fifth RBD polypeptide is linked to the fourth RBD polypeptide via a linker (4). Such as the fusion protein of claim 17, wherein two, three or all four of the linkers (1)-(4) contain the same amino acid sequence, essentially consist of the same amino acid sequence, or consist of the same Amino acid sequence composition. The fusion protein of claim 17 or 18, wherein two or more of the linkers (1)-(4) have different amino acid sequences from each other. The fusion protein of any one of claims 17 to 19, wherein one or more of the linkers (1)-(4) includes or consists of a stem-helix polypeptide, wherein optionally Preferably, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). The fusion protein of claim 20, wherein each of the peptide linkers (1)-(4) comprises or consists of a stem-helix polypeptide, wherein optionally, the stem-helix polypeptide Comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). The fusion protein of any one of claims 17 to 21, comprising an RBD polypeptide from: (i) SARS-CoV-2β variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (ii) SARS-CoV-2β variant; SARS-CoV-2o variant; MP789; RaTG13; and RsSHC014; or (iii) SARS-CoV-2o variant; PANG/GX; MP789; RaTG13; and RsSHC014; or (iv) SARS-CoV-2δ variant; SARS-CoV-2o variant; MP789; RaTG13; and RsSHC014. The fusion protein of any one of claims 17 to 22, comprising five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequences set forth in the following SEQ ID NO.: (i) respectively, 725 , 731, 733, 735 and 737; or (ii) respectively, 725, 731, 729, 735 and 737; or (iii) respectively, 729, 731, 733, 735 and 737; or (iv) respectively, 727, 731, 729, 735 and 737. The fusion protein of claim 23, wherein: (1) the RBD polypeptide including SEQ ID NO.:725 includes or consists of SEQ ID NO.:724; (2) includes SEQ ID NO.: The RBD polypeptide of 727 comprises SEQ ID NO.:726 or consists of SEQ ID NO.:726; (3) the RBD polypeptide comprising SEQ ID NO.:729 comprises SEQ ID NO.:728 or consists of SEQ ID NO.: 728; (4) the RBD polypeptide comprising SEQ ID NO.:731 comprises or consists of SEQ ID NO.:730; (5) the RBD polypeptide comprising SEQ ID NO.:733 comprises SEQ ID NO.:730 ID NO.:732 or consists of SEQ ID NO.:732; (6) the RBD polypeptide comprising SEQ ID NO.:735 comprises or consists of SEQ ID NO.:734; and/or ( 7) The RBD polypeptide comprising SEQ ID NO.:737 comprises or consists of SEQ ID NO.:736. The fusion protein of any one of claims 17 to 24, which includes five RBD polypeptides, wherein the five RBD polypeptides comprise the amino acid sequences set forth in the following SEQ ID NO. or are composed of the following SEQ ID NO. The set forth amino acid sequence consists of: (i) 724, 732, 734, 736, and 730, respectively; or (ii) 724, 728, 734, 736, and 730, respectively; or (iii) 728, respectively , 732, 734, 736 and 730; or (iv) 726, 728, 735, 736 and 730 respectively. Such as the fusion protein of any one of claims 17 to 25, which includes along the N-terminal to C-terminal direction of the fusion protein: or (ii) One RBD polypeptide from a SARS-CoV-2 beta variant; one RBD polypeptide from RsSHC014; one RBD polypeptide from a SARS-CoV-2o variant; one RBD polypeptide from MP789; and one RBD polypeptide from RatG13 ;or (iii) An RBD polypeptide from a SARS-CoV-2o variant; an RBD polypeptide from RsSHC014; an RBD polypeptide from PANG/GX; an RBD polypeptide from MP789; and an RBD polypeptide from RatG13; or (iv) One RBD polypeptide from a SARS-CoV-2 delta variant; one RBD polypeptide from RsSHC014; one RBD polypeptide from a SARS-CoV-2o variant; one RBD polypeptide from MP789; and one RBD polypeptide from RatG13 . Such as the fusion protein of any one of claims 17 to 26, which includes along the N-terminal to C-terminal direction of the fusion protein: (i) An RBD polypeptide comprising one of SEQ ID NO.:725; an RBD polypeptide comprising one of SEQ ID NO.:731; an RBD polypeptide comprising one of SEQ ID NO.:733; an RBD polypeptide comprising one of SEQ ID NO.:735 ; and an RBD polypeptide comprising one of SEQ ID NO.:737; or (ii) An RBD polypeptide comprising one of SEQ ID NO.:725; an RBD polypeptide comprising one of SEQ ID NO.:731; an RBD polypeptide comprising one of SEQ ID NO.:729; an RBD polypeptide comprising one of SEQ ID NO.:735 ; and an RBD polypeptide comprising one of SEQ ID NO.:737; or (iii) An RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:733; an RBD polypeptide comprising SEQ ID NO.:735 ; and an RBD polypeptide comprising one of SEQ ID NO.:737; or (iv) An RBD polypeptide comprising SEQ ID NO.:727; an RBD polypeptide comprising SEQ ID NO.:731; an RBD polypeptide comprising SEQ ID NO.:729; an RBD polypeptide comprising SEQ ID NO.:735 ; And an RBD polypeptide comprising one of SEQ ID NO.:737. Such as the fusion protein of any one of claims 17 to 27, which includes along the N-terminal to C-terminal direction of the fusion protein: (i) Comprises SEQ ID NO.:724 or an RBD polypeptide consisting of SEQ ID NO.:724; Comprises SEQ ID NO.:730 or an RBD polypeptide consisting of SEQ ID NO.:730; Comprises SEQ ID NO. :732 or an RBD polypeptide consisting of SEQ ID NO.:732; an RBD polypeptide comprising SEQ ID NO.:734 or consisting of SEQ ID NO.:734; and comprising SEQ ID NO.:736 or consisting of SEQ ID NO. .: One of the RBD polypeptides consisting of 736; or (ii) Comprise SEQ ID NO.:724 or an RBD polypeptide consisting of SEQ ID NO.:724; Comprise SEQ ID NO.:730 or an RBD polypeptide consisting of SEQ ID NO.:730; Comprise SEQ ID NO. :728 or an RBD polypeptide consisting of SEQ ID NO.:728; an RBD polypeptide comprising SEQ ID NO.:734 or consisting of SEQ ID NO.:734; and comprising SEQ ID NO.:736 or consisting of SEQ ID NO. .: One of the RBD polypeptides consisting of 736; or (iii) An RBD polypeptide comprising SEQ ID NO.:728 or consisting of SEQ ID NO.:728; comprising SEQ ID NO.:730 or an RBD polypeptide consisting of SEQ ID NO.:730; comprising SEQ ID NO. :732 or an RBD polypeptide consisting of SEQ ID NO.:732; an RBD polypeptide comprising SEQ ID NO.:734 or consisting of SEQ ID NO.:734; and comprising SEQ ID NO.:736 or consisting of SEQ ID NO. .: One of the RBD polypeptides consisting of 736; or (iv) An RBD polypeptide comprising SEQ ID NO.:726 or consisting of SEQ ID NO.:726; comprising SEQ ID NO.:730 or an RBD polypeptide consisting of SEQ ID NO.:730; comprising SEQ ID NO. :728 or an RBD polypeptide consisting of SEQ ID NO.:728; an RBD polypeptide comprising SEQ ID NO.:734 or consisting of SEQ ID NO.:734; and comprising SEQ ID NO.:736 or consisting of SEQ ID NO. .: One of the 736 components of RBD polypeptide. The fusion protein of any one of claims 26 to 28, which includes the third RBD disposed between the first RBD polypeptide and the second RBD polypeptide, between the second RBD polypeptide and the third RBD polypeptide, The amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701) between the polypeptide and the fourth RBD polypeptide and between the fourth RBD polypeptide and the fifth RBD polypeptide, wherein the first RBD polypeptide is the N of the fusion protein terminal RBD polypeptide and the fifth RBD polypeptide is the C-terminal RBD polypeptide of the fusion protein. The fusion protein of any one of claims 1 to 29, further comprising a peptide tag, wherein optionally, the peptide tag is placed at a C-terminus of the fusion protein, preferably fused to a C-terminus of the fusion protein One C terminus of RBD polypeptide. The fusion protein of claim 30, wherein the peptide tag is placed at the C-terminus of the fusion protein. Such as the fusion protein of claim 30 or 31, wherein the peptide tag includes a SpyTag and/or a His tag. The fusion protein of any one of claims 1 to 32, wherein the fusion protein does not include a peptide tag disposed at a C-terminus of the fusion protein, optionally at the C-terminus of the C-terminal RBD polypeptide. The fusion protein of any one of claims 1 to 33, wherein the fusion protein does not include a His tag placed at one of the C termini of the fusion protein. The fusion protein of any one of claims 1 to 34, which includes a signal peptide, wherein optionally, the signal peptide is placed at one N-terminus of the fusion protein, and is preferably fused to the N-terminal RBD polypeptide. N terminus. Such as the fusion protein of claim 35, wherein the signal peptide includes or consists of the following: amino acid sequence MAPLLLLLPLLWAGALA (SEQ ID NO.:706), amino acid sequence MNTQILVFALIAIIIPTNADKI (SEQ ID NO.:705), amino acid sequence The sequence MFVFLVLLPLVS (SEQ ID NO.:707) or the amino acid sequence MFVFLVLLPLVSS (SEQ ID NO.:708), and preferably consists of SEQ ID NO.:706. The fusion protein of any one of claims 1 to 36, which is administered to a mammal (eg, a mouse, such as a female BALB/c mouse, optionally administered twice via intramuscular injection, wherein These second doses (20 or 21 days apart) elicited, optionally, neutralizing antibodies against any one or more of the following: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV- 2 B.1.351; SARS-CoV-2 B.1.617.2; SARS-CoV-2 B.1.1.529; and SARS-CoV-1, optionally using 14 days after the second immunization. Sera collected from mammals were evaluated for neutralizing antibodies in a vesicular stomatitis virus/coronavirus pseudovirus system, optionally using Vero-E6 TMPRSS cells. The fusion protein of any one of claims 1 to 37, when administered to a mammal that has previously received an mRNA SARS-CoV-2 spike protein vaccine, causes: (i) Against any one or more of the following, optionally possessing neutralizing antibodies: SARS-CoV-2 Wuhan-Hu-1; SARS-CoV-2 BA1; SARS-CoV-2 BA2; SARS -CoV-2 BA5; and SARS-CoV-1, optionally to a degree that is greater than that elicited by a third administration of one of the mRNA SARS-CoV-2 spike protein vaccines, wherein optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered intramuscularly and/or once on day 60, and the mammal has received the mRNA spike protein vaccine and received the vaccine again on day 14; and/or assessed neutralizing antibodies in a vesicular stomatitis virus/coronavirus pseudovirus system on day 67 using serum collected from the mammal; and /or (ii) Antibodies that bind to an RBD from any one or more of the following: SARS-Cov2-Wuhan-Hu-1 (Wu); -B.1.351 (β); SARS-Cov1; Wiv-1; RatG13 ; PangGD; PANG/GX; Anlog112; to the extent, wherein optionally: the mammal is a mouse, such as a female BALB/c mouse; the fusion protein is administered intramuscularly and/or once on day 60, and the mammal has received the mRNA spike protein vaccine and receive the vaccine again on day 14; and/or assess binding antibodies by ELISA on day 67 using serum collected from the mammal. Such as the fusion protein of any one of claims 1 to 38, which can bind to any one or more of the following antibodies: S2P6; S2E12; S2K146; S2X259; S309; and S2H97 or one of its antigen-binding fragments, any of which Preferably, the antigen-binding fragment comprises a Fab comprising the VH and VL of the antibody, and further comprising an IgG1 CH1 and an IgG kappa CL or an IgG lambda CL. An isolated polypeptide comprising: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.: 218 without SEQ ID NO.: 706; (iii) SEQ ID NO.: 712; (iv) none SEQ ID NO.:712 of SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii) SEQ ID NO.: 714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:715 without SEQ ID NO.:706; (xi ) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) SEQ ID NO.:706 without .:717; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO. .:742; or (xx) SEQ ID NO.:743. Such as the polypeptide of claim 40, which consists of: (i) SEQ ID NO.: 218; (ii) SEQ ID NO.: 218 without SEQ ID NO.: 706; (iii) SEQ ID NO.: 712; (iv) SEQ ID NO.:712 without SEQ ID NO.:706; (v) SEQ ID NO.:713; (vi) SEQ ID NO.:713 without SEQ ID NO.:706; (vii ) SEQ ID NO.:714; (viii) SEQ ID NO.:714 without SEQ ID NO.:706; (ix) SEQ ID NO.:715; (x) SEQ ID NO.:706 without .:715; (xi) SEQ ID NO.:716; (xii) SEQ ID NO.:716 without SEQ ID NO.:706; (xiii) SEQ ID NO.:717; (xiv) Without SEQ ID NO.:706. :706 of SEQ ID NO.:717; (xv) SEQ ID NO.:738; (xvi) SEQ ID NO.:739; (xvii) SEQ ID NO.:740; (xviii) SEQ ID NO.:741; (xix) SEQ ID NO.:742; or (xx) SEQ ID NO.:743. A fusion protein comprising a coronavirus receptor binding domain (RBD) polypeptide and one or both of (i) and (ii): (i) One or more peptide tags; (ii) One or more stem-helix polypeptides, wherein optionally the one or more stem-helix polypeptides comprise or consist of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). :701) composition. Such as the fusion protein of claim 42, which contains: (a) a peptide tag linked or fused to a first end of the RBD polypeptide, wherein the first end optionally includes an N-terminus of the RBD polypeptide; (b) a peptide tag linked or fused to a second end of the RBD polypeptide, wherein the second end optionally includes a C-terminus of the RBD polypeptide; (c) a stem-helix polypeptide linked or fused to a first end of the RBD polypeptide, wherein the first end optionally includes the N-terminus of the RBD polypeptide; (d) a stem-helix polypeptide linked or fused to a second end of the RBD polypeptide, wherein the first end optionally includes the C terminus of the RBD polypeptide; or (e) Any combination of (a)-(d). The fusion protein of claim 42 or 43, wherein the peptide tag includes a His tag, wherein optionally, the His tag includes the amino acid sequence HHHHHHHH (SEQ ID NO.:704) or consists of the amino acid sequence HHHHHHHH (SEQ ID NO.:704). The fusion protein of claim 44, wherein the peptide tag includes a SpyTag. The fusion protein of any one of claims 42 to 45, which includes a peptide tag disposed between (1) the RBD polypeptide and (2) one of the one or more peptide tags and connecting (1) to (2) of a connector. The fusion protein of claim 46, which contains two or more linkers containing the same amino acid sequence as each other. The fusion protein of claim 46 or 47, wherein the linker or one or more of the two or more linkers comprises the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.: 702) or consists of the amino acid sequence GSGGSGGSGGTG (SEQ ID NO.: 702). It consists of the sequence GSGGSGGSGGTG (SEQ ID NO.:702). The fusion protein of any one of claims 42 to 48, which includes disposed between (1) the RBD polypeptide and (2) one of the one or more stem-helix polypeptides and combining (1) and (2) ) is connected by a connector. The fusion protein of any one of claims 42 to 49, which includes a structure PT1—L1—RBD—L2—SHP—PT2, Wherein: PT1 and PT2 are each an optional peptide tag; L1 and L2 are each an optional linker; RBD is an RBD polypeptide; and SHP is a stem-helix polypeptide. Such as the fusion protein of claim 50, wherein: PT1 has the amino acid sequence of SEQ ID NO.:700 when present; L1 has the amino acid sequence of SEQ ID NO.:702 when present; L2 is absent or present When present, it has the amino acid sequence GSG, GPP, GS or PGP; SHP has the amino acid sequence of SEQ ID NO.:701; and PT2, when present, has the amino acid sequence of SEQ ID NO.:704. For example, the fusion protein of claim 51, wherein: (i) PT1, L1, SHP, L2 and PT2 exist; (ii) PT1, L1, SHP and PT2 exist; (iii) L2, SHP and PT2 exist; (iv) SHP and PT2 is present; (v) SHP and optionally L2 are present; or (vi) L2, SHP and PT2 are present. Such as the fusion protein of any one of claims 42 to 52, which includes: (i) A signal peptide fused to or linked to the N-terminus of the RBD polypeptide; and (ii) A stem-helix polypeptide fused to or linked to one of the C-termini of the RBD polypeptide. Such as the fusion protein of claim 53, which includes a signal peptide (optionally MAPLLLLLPLLWAGALA (SEQ ID NO.: 706)), an optional linker, an RBD, and an optional linker along the N-terminal to C-terminal direction. And a stem-helix polypeptide, wherein optionally, the stem-helix polypeptide comprises or consists of the amino acid sequence PGSFKEELDKYFKNHTSDAASKAGP (SEQ ID NO.:701). Such as the fusion protein of any one of claims 42 to 54, wherein the RBD polypeptide is from any of the following: SARS-CoV-2-Wuhan-Hu-1; SARS-CoV-2β variant; SARS-CoV- 2o variant; SARS-CoV-2δ variant; PANG_GX; MP789; RatG13; RsSCH014; RmYN02; BM48-31/BGR/2008; PC4-241; Rf1/2004; and Rp/Shaanxi 2011. The fusion protein of any one of claims 42 to 55, wherein the RBD polypeptide comprises the amino acid sequence of any one of SEQ ID NO.:724-737 or consists of any one of SEQ ID NO.:724-737. Composed of an amino acid sequence. An isolated polypeptide comprising a structure: RBD1 - L1 - RBD2 - L2 - RBD3 - L3 - RBD4 - L4 - RBD5 Wherein RBD1, RBD2, RBD3, RBD4 and RBD5 are each a different RBD polypeptide selected from the group consisting of: SARS-CoV-2β variant; SARS-CoV-2o variant; SARS-CoV-2δ variant; PANG/ GX; MP789; RaTG13; and RsSHC014, Wherein RBD1 is the N-terminal RBD polypeptide of the fusion protein and/or RBD5 is the C-terminal RBD polypeptide of the fusion protein, And each of L1, L2, L3 and L4 is a linker. The isolated polypeptide of claim 57, wherein one or more of L1, L2, L3 and L4 comprise the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 Or consist of the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59, and optionally, L1, L2, L3 and L4 each independently comprise SEQ ID NOs .: The amino acid sequence of any one of 701, 4-19, 46 and 57-59 or the amino acid sequence of any one of SEQ ID NOs.: 701, 4-19, 46 and 57-59 sequence composition. The isolated polypeptide of claim 57 or 58, wherein L1, L2, L3 and L4 are the same, and L1, L2, L3 and L4 are preferably SEQ ID NO.:701. The isolated polypeptide of any one of claims 57 to 59, wherein RBD1, RBD2, RBD3, RBD4 and RBD5 are independently selected from the group consisting of: (i) SEQ ID NO.: 724 or 725; (ii) ) SEQ ID NO.: 726 or 727; (iii) SEQ ID NO.: 728 or 729; (iv) SEQ ID NO.: 730 or 731; (v) SEQ ID NO.: 732 or 733; (vi) SEQ ID NO.: 734 or 735; and (vii) SEQ ID NO.: 736 or 737, preferably, five of (i)-(vii) are present. The isolated polypeptide of any one of claims 57 to 60, wherein RBD1, RBD2, RBD3, RBD4 and RBD5 are from: (i) Respectively, SARS-CoV-2 beta variant; RsSHC014; PANG/GX; MP789; and RaTG13; or (ii) respectively, SARS-CoV-2 beta variant; RsSHC014; SARS-CoV-2o variant; MP789; and RaTG13; or (iii) respectively, SARS-CoV-2o variants; RsSHC014; PANG/GX; MP789; and RaTG13; or (iv) Respectively, SARS-CoV-2δ variant; RsSHC014; SARS-CoV-2o variant; MP789; RaTG13. The isolated polypeptide of any one of claims 57 to 61, wherein RBD1, RBD2, RBD3, RBD4 and RBD5 comprise the amino acid sequence set forth in the following SEQ ID NO.: (i) respectively, 725, 731, 733, 735 and 737; or (ii) respectively, 725, 731, 729, 735 and 737; or (iii) respectively, 729, 731, 733, 735 and 737; or (iv) respectively, 727, 731, 729, 735 and 737, Optionally, RBD1, RBD2, RBD3, RBD4 and RBD5 comprise or consist of the amino acid sequence set forth in the following SEQ ID NO.: (1) Respectively, 724, 730, 732, 734 and 736; or (2) Respectively, 724, 730, 728, 734 and 736; or (3) respectively, 728, 730, 732, 734 and 736; or (4) Respectively, 726, 730, 728, 734 and 736. An isolated polypeptide comprising the amino acid sequence of any one of SEQ ID NOs.:701, 4-19, 46 and 57-59 or consisting of SEQ ID NOs.:701, 4-19, 46 and 57- Composed of the amino acid sequence of any one of 59. An isolated polypeptide comprising or consisting of the following: the amino acid sequence of SEQ ID NO.:701, the amino acid sequence of SEQ ID NO.:14, the amino group of SEQ ID NO.:15 The acid sequence, the amino acid sequence of SEQ ID NO.:16 or the amino acid sequence of SEQ ID NO.:17. An isolated polynucleotide encoding a fusion protein according to any one of claims 1 to 39 and 42 to 56 or a polypeptide according to any one of claims 40, 41 and 57 to 64. For example, the polynucleotide of claim 65 includes ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA). The polynucleotide of claim 65 or 66, which includes mRNA. A vector comprising the polynucleotide of any one of claims 65 to 67, wherein optionally the vector is a living vector. A host cell comprising the polynucleotide of any one of claims 65 to 67 and/or the vector of claim 68. A composition comprising: (i) the fusion protein of any one of claims 1 to 39 and 42 to 56; and/or (ii) the polypeptide of any one of claims 40, 41 and 57 to 64 ; and/or (i) the polynucleotide of any one of claims 65 to 67; and/or (ii) the vector of claim 68; and/or (iii) the host cell of claim 69, and A pharmaceutically acceptable carrier, excipient or diluent. The composition of claim 70, further comprising an adjuvant. A method of treating a coronavirus infection in an individual or inducing an immune response against the coronavirus infection, the method comprising administering to the individual an effective amount of: any one of claims 1 to 39 and 42 to 56 Fusion protein; such as the polypeptide of any one of claims 40, 41 and 57 to 64; such as the polynucleotide of any one of claims 65 to 67; such as the vector of claim 68; such as the host cell of claim 69; or a composition as claimed in claim 70 or 71, Optionally, the coronavirus infection includes a sarbecovirus infection. Such as the fusion protein of any one of claims 1 to 39 and 42 to 56; such as the polypeptide of any one of claims 40, 41 and 57 to 64; such as the polynucleotide of any one of claims 65 to 67; For example, the vector of claim 68; the host cell of claim 69; or the composition of claim 70 or 71 for use in treating a coronavirus infection in an individual or inducing an immune response against the coronavirus infection, Optionally, the coronavirus infection includes a Sabey coronavirus infection. Such as the fusion protein of any one of claims 1 to 39 and 42 to 56; such as the polypeptide of any one of claims 40, 41 and 57 to 64; such as the polynucleotide of any one of claims 65 to 67; A vector as claimed in claim 68; a host cell as claimed in claim 69; or a composition as claimed in claim 70 or 71 for use in the manufacture of a material for treating a coronavirus infection in a subject or inducing immunity against the coronavirus infection. An agent for reacting, wherein optionally, the coronavirus infection includes a Sabey coronavirus infection. The method of claim 72 or the fusion protein, polypeptide, polynucleotide, vector, host cell or composition of claim 73 or 74, wherein: (i) Treatment includes pre-exposure prophylaxis; (ii) Treatment includes post-exposure prophylaxis; (iii) the individual has previously received one or more, two or more, three or more, four or more or five or more doses of one of the coronavirus vaccine compositions, wherein Optionally: (1) the individual has received two or more different coronavirus vaccine compositions; (2) the coronavirus vaccine composition includes: at least a portion of a SARS-CoV-2 spike protein (e.g., a RBD polypeptide or a whole spike protein), a polynucleotide (e.g., mRNA) encoding at least a portion of a SARS-CoV-2 spike protein (e.g., encoding an RBD polypeptide, or encoding a whole spike protein), or a living, Attenuated or inactivated (e.g., heat inactivated or inactivated with beta-propiolactone) virus; and/or (3) the coronavirus vaccine composition includes Comirnaty (Pfizer-BioNTech), Spikevax (Moderna), Janssen coronavirus Vaccines (Johnson & Johnson), Nuvoxovid/Covavax (Novavax), Vaxzevria (Oxford-AstraZeneca), Coronavac, also known as BBIBP-CorV, also known as BBIBP (Sinovac), Covaxin, also known as BBV152 (Bharat Biotech), Convidecia , also known as AD5-nCOV (CanSino Biologics), Sputnik V, also known as Gam-COVID-Vac, Sinopharm WIBP, also known as WIBP-CorV (Sinovac), Abdala, Soberana 2, Soberana Plus, ZF2001, also known as Anhui Zhifei Longcom ZifiVax ZF2001, also known as ZF-UZ-VAC-2001, also known as Zifivax (Anhui Zhifei Longcom Biopharmaceutical), Corbevax (Texas Children's Hospital/Baylor College of Medicine/Dynavax), COVIran Barekat (Sifa Pharmed Industrial Group), VAT00002 or VAT00008 (Sanofi-GSK), SCB-2019 (Clover Biopharmaceuticals), VLA2001 (Valneva), HIPRA SARS-CoV-2, also known as PHH-1V (HIPRA), mRNA-1273.214 (Moderna) and Sputnik V bivalent ( L452R; Gamaleya National Research Center for Epidemiology and Microbiology) or any combination thereof; (iv) The fusion protein, polypeptide, polynucleotide, vector, host cell or composition is administered once every twelve months or once every six months; (v) The coronavirus infection is or includes a SARS-CoV-2 infection. A method comprising introducing into a host cell a polynucleotide as claimed in any one of claims 65 to 67 or a vector as claimed in claim 68, and optionally in a state sufficient to express an encoded fusion protein or polypeptide or to produce a polynucleoside The host cell is cultured for a period of time and under conditions such as acid (e.g., mRNA), and the fusion protein, polypeptide, or resulting polynucleotide is further optionally isolated.

Images